{
  "agent": "ProfitabilityConstraintAgent",
  "timestamp": "2025-09-15T12:03:14.628492",
  "portfolio_summary": {
    "total_drugs_analyzed": 1184,
    "total_projected_annual_profit": 569900342.8656707,
    "average_expected_margin": 0.3336578676288786,
    "risk_distribution": {
      "high": 231,
      "low": 667,
      "medium": 286
    }
  },
  "pricing_recommendations": [
    {
      "drug_id": "ndc_2322730",
      "drug_name": "STRATTERA 10 MG CAPSULE",
      "ndc": 2322730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          10.999935266666666,
          11.964773859999998
        ],
        "expected_margin": 0.28915458936815486,
        "estimated_acquisition_cost": 8.24995145,
        "profit_projections": {
          "gross_profit_per_unit": 3.7148224099999982,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18574.112049999992,
          "annual_profit_projection": 222889.3445999999,
          "margin_percentage": 31.04799516871102
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.999935266666666,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.79"
        ]
      }
    },
    {
      "drug_id": "ndc_2322830",
      "drug_name": "STRATTERA 25 MG CAPSULE",
      "ndc": 2322830,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          10.927157800000002,
          11.964773859999998
        ],
        "expected_margin": 0.29385766506117095,
        "estimated_acquisition_cost": 8.19536835,
        "profit_projections": {
          "gross_profit_per_unit": 3.769405509999997,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18847.027549999984,
          "annual_profit_projection": 226164.3305999998,
          "margin_percentage": 31.504193510933582
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.927157800000002,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.69"
        ]
      }
    },
    {
      "drug_id": "ndc_2322930",
      "drug_name": "STRATTERA 40 MG CAPSULE",
      "ndc": 2322930,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.872328866666665,
        "feasible_range": [
          11.872328866666665,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 8.90424665,
        "profit_projections": {
          "gross_profit_per_unit": 3.0605272099999983,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15302.636049999992,
          "annual_profit_projection": 183631.6325999999,
          "margin_percentage": 25.579482285342575
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.872328866666665,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.88"
        ]
      }
    },
    {
      "drug_id": "ndc_2323560",
      "drug_name": "CYMBALTA 20 MG CAPSULE",
      "ndc": 2323560,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.669690249999999,
        "feasible_range": [
          6.935752199999999,
          9.243223604999999
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.201814149999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.4678761,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 26009.07075,
          "annual_profit_projection": 312108.849,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.935752199999999,
        "regulatory_headroom": 3.295083609999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_2323830",
      "drug_name": "STRATTERA 18 MG CAPSULE",
      "ndc": 2323830,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          10.965876566666665,
          11.964773859999998
        ],
        "expected_margin": 0.2913555541920527,
        "estimated_acquisition_cost": 8.224407424999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.7403664349999985,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18701.832174999992,
          "annual_profit_projection": 224421.98609999992,
          "margin_percentage": 31.261488756629113
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.965876566666665,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.74"
        ]
      }
    },
    {
      "drug_id": "ndc_2323930",
      "drug_name": "STRATTERA 60 MG CAPSULE",
      "ndc": 2323930,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.870357633333333,
        "feasible_range": [
          11.870357633333333,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 8.902768224999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.0620056349999984,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15310.028174999992,
          "annual_profit_projection": 183720.3380999999,
          "margin_percentage": 25.59183876626983
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.870357633333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.87"
        ]
      }
    },
    {
      "drug_id": "ndc_2324030",
      "drug_name": "CYMBALTA 30 MG CAPSULE",
      "ndc": 2324030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.72065141666667,
        "feasible_range": [
          7.776521133333335,
          10.363709895000003
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.832390850000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.888260566666668,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29161.95425000001,
          "annual_profit_projection": 349943.4510000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.776521133333335,
        "regulatory_headroom": 2.244122443333328,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_2324090",
      "drug_name": "CYMBALTA 30 MG CAPSULE",
      "ndc": 2324090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.72065141666667,
        "feasible_range": [
          7.776521133333335,
          10.363709895000003
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.832390850000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.888260566666668,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29161.95425000001,
          "annual_profit_projection": 349943.4510000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.776521133333335,
        "regulatory_headroom": 2.244122443333328,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_2325030",
      "drug_name": "STRATTERA 80 MG CAPSULE",
      "ndc": 2325030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.805305933333331,
        "feasible_range": [
          12.805305933333331,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.603979449999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.2013264833333324,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16006.632416666662,
          "annual_profit_projection": 192079.58899999995,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.805305933333331,
        "regulatory_headroom": -0.8405320733333337,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.04"
        ]
      }
    },
    {
      "drug_id": "ndc_2325130",
      "drug_name": "STRATTERA 100 MG CAPSULE",
      "ndc": 2325130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.7930322,
        "feasible_range": [
          12.7930322,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.594774150000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.1982580499999997,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15991.290249999998,
          "annual_profit_projection": 191895.48299999998,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.7930322,
        "regulatory_headroom": -0.8282583400000032,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.03"
        ]
      }
    },
    {
      "drug_id": "ndc_2327030",
      "drug_name": "CYMBALTA 60 MG CAPSULE",
      "ndc": 2327030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.711202583333332,
        "feasible_range": [
          7.768962066666666,
          10.353635984999999
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 5.826721549999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.8844810333333326,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29133.607749999996,
          "annual_profit_projection": 349603.29299999995,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.768962066666666,
        "regulatory_headroom": 2.2535712766666656,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_2411230",
      "drug_name": "ZYPREXA 2.5 MG TABLET",
      "ndc": 2411230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.109973333333336,
          11.964773859999998
        ],
        "expected_margin": 0.28204363345900185,
        "estimated_acquisition_cost": 8.332480000000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.6322938599999954,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18161.46929999998,
          "annual_profit_projection": 217937.63159999973,
          "margin_percentage": 30.358232445523182
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.109973333333336,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.92"
        ]
      }
    },
    {
      "drug_id": "ndc_2411530",
      "drug_name": "ZYPREXA 5 MG TABLET",
      "ndc": 2411530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.135128933333334,
        "feasible_range": [
          13.135128933333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.8513467,
        "profit_projections": {
          "gross_profit_per_unit": 3.2837822333333335,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16418.91116666667,
          "annual_profit_projection": 197026.934,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.135128933333334,
        "regulatory_headroom": -1.1703550733333365,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.45"
        ]
      }
    },
    {
      "drug_id": "ndc_2411630",
      "drug_name": "ZYPREXA 7.5 MG TABLET",
      "ndc": 2411630,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.894371133333337,
        "feasible_range": [
          15.894371133333337,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.920778350000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.973592783333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19867.96391666667,
          "annual_profit_projection": 238415.56700000004,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.894371133333337,
        "regulatory_headroom": -3.9295972733333393,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.90"
        ]
      }
    },
    {
      "drug_id": "ndc_2411730",
      "drug_name": "ZYPREXA 10 MG TABLET",
      "ndc": 2411730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.7553824,
        "feasible_range": [
          19.7553824,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 14.8165368,
        "profit_projections": {
          "gross_profit_per_unit": 4.938845599999999,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 24694.227999999992,
          "annual_profit_projection": 296330.7359999999,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.7553824,
        "regulatory_headroom": -7.790608540000001,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.73"
        ]
      }
    },
    {
      "drug_id": "ndc_2418430",
      "drug_name": "EVISTA 60 MG TABLET",
      "ndc": 2418430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.9987650200000004,
        "feasible_range": [
          5.489227466666667,
          7.31545122
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 4.1169206,
        "profit_projections": {
          "gross_profit_per_unit": 2.744613733333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 27446.13733333334,
          "annual_profit_projection": 329353.64800000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.489227466666667,
        "regulatory_headroom": 5.1032395266666635,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_2441530",
      "drug_name": "ZYPREXA 15 MG TABLET",
      "ndc": 2441530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 29.71987763333334,
        "feasible_range": [
          29.71987763333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 22.289908225000005,
        "profit_projections": {
          "gross_profit_per_unit": 7.429969408333335,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 37149.847041666675,
          "annual_profit_projection": 445798.1645000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 29.71987763333334,
        "regulatory_headroom": -17.755103773333342,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $25.19"
        ]
      }
    },
    {
      "drug_id": "ndc_2442030",
      "drug_name": "ZYPREXA 20 MG TABLET",
      "ndc": 2442030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 43.15453133333333,
        "feasible_range": [
          43.15453133333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 32.3658985,
        "profit_projections": {
          "gross_profit_per_unit": 10.788632833333331,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 53943.164166666655,
          "annual_profit_projection": 647317.9699999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 43.15453133333333,
        "regulatory_headroom": -31.189757473333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $41.98"
        ]
      }
    },
    {
      "drug_id": "ndc_2445301",
      "drug_name": "ZYPREXA ZYDIS 5 MG TABLET",
      "ndc": 2445301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.968647333333331,
        "feasible_range": [
          13.968647333333331,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 10.476485499999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.4921618333333324,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17460.809166666662,
          "annual_profit_projection": 209529.70999999996,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.968647333333331,
        "regulatory_headroom": -2.003873473333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.50"
        ]
      }
    },
    {
      "drug_id": "ndc_2445385",
      "drug_name": "ZYPREXA ZYDIS 5 MG TABLET",
      "ndc": 2445385,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.968647333333331,
        "feasible_range": [
          13.968647333333331,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 10.476485499999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.4921618333333324,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17460.809166666662,
          "annual_profit_projection": 209529.70999999996,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.968647333333331,
        "regulatory_headroom": -2.003873473333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.50"
        ]
      }
    },
    {
      "drug_id": "ndc_2446230",
      "drug_name": "CIALIS 5 MG TABLET",
      "ndc": 2446230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.206052935000002,
        "feasible_range": [
          8.004747400000001,
          10.667865285000005
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.003560550000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.0023737000000015,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 40023.737000000016,
          "annual_profit_projection": 480284.84400000016,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.004747400000001,
        "regulatory_headroom": 1.9588396099999947,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_2446430",
      "drug_name": "CIALIS 20 MG TABLET",
      "ndc": 2446430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 46.94313563333335,
        "feasible_range": [
          46.94313563333335,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 35.20735172500001,
        "profit_projections": {
          "gross_profit_per_unit": 11.735783908333339,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 117357.83908333338,
          "annual_profit_projection": 1408294.0690000006,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 46.94313563333335,
        "regulatory_headroom": -34.97836177333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $46.71"
        ]
      }
    },
    {
      "drug_id": "ndc_2840001",
      "drug_name": "FORTEO 560 MCG/2.24 ML PEN INJ",
      "ndc": 2840001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": NaN,
        "feasible_range": [
          NaN,
          11.964773859999998
        ],
        "expected_margin": 0.0,
        "estimated_acquisition_cost": NaN,
        "profit_projections": {
          "gross_profit_per_unit": NaN,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": NaN,
          "annual_profit_projection": 0.0,
          "margin_percentage": 0.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": NaN,
        "regulatory_headroom": NaN,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_3029305",
      "drug_name": "KENALOG-40 40 MG/ML VIAL",
      "ndc": 3029305,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.757243166666669,
        "feasible_range": [
          7.8057945333333345,
          10.402722330000003
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.854345900000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.9028972666666677,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29271.72950000001,
          "annual_profit_projection": 351260.7540000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.8057945333333345,
        "regulatory_headroom": 2.2075306933333287,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_3029320",
      "drug_name": "KENALOG-40 200 MG/5 ML VIAL",
      "ndc": 3029320,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.973305333333329,
        "feasible_range": [
          7.978644266666663,
          10.633077839999997
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.983983199999997,
        "profit_projections": {
          "gross_profit_per_unit": 3.9893221333333315,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29919.915999999987,
          "annual_profit_projection": 359038.99199999985,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.978644266666663,
        "regulatory_headroom": 1.9914685266666687,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_3029328",
      "drug_name": "KENALOG-40 400 MG/10 ML VIAL",
      "ndc": 3029328,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.391932166666668,
        "feasible_range": [
          5.913545733333334,
          7.880936910000001
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.4351593000000005,
        "profit_projections": {
          "gross_profit_per_unit": 2.9567728666666673,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 22175.796500000004,
          "annual_profit_projection": 266109.5580000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.913545733333334,
        "regulatory_headroom": 4.57284169333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_3161112",
      "drug_name": "BARACLUDE 0.5 MG TABLET",
      "ndc": 3161112,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 38.21215796666667,
        "feasible_range": [
          38.21215796666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 28.659118475000003,
        "profit_projections": {
          "gross_profit_per_unit": 9.55303949166667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 95530.3949166667,
          "annual_profit_projection": 1146364.7390000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 38.21215796666667,
        "regulatory_headroom": -26.247384106666676,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $35.80"
        ]
      }
    },
    {
      "drug_id": "ndc_4025901",
      "drug_name": "CELLCEPT 250 MG CAPSULE",
      "ndc": 4025901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.402916250000002,
        "feasible_range": [
          7.522333000000002,
          10.024955325000004
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 5.641749750000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.7611665000000007,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28208.748750000006,
          "annual_profit_projection": 338504.9850000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.522333000000002,
        "regulatory_headroom": 2.5618576099999952,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_4025943",
      "drug_name": "CELLCEPT 250 MG CAPSULE",
      "ndc": 4025943,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.402916250000002,
        "feasible_range": [
          7.522333000000002,
          10.024955325000004
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 5.641749750000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.7611665000000007,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28208.748750000006,
          "annual_profit_projection": 338504.9850000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.522333000000002,
        "regulatory_headroom": 2.5618576099999952,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_4026001",
      "drug_name": "CELLCEPT 500 MG TABLET",
      "ndc": 4026001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.015993200000004,
        "feasible_range": [
          15.015993200000004,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.261994900000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.753998300000001,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28154.98725000001,
          "annual_profit_projection": 337859.8470000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.015993200000004,
        "regulatory_headroom": -3.0512193400000065,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.81"
        ]
      }
    },
    {
      "drug_id": "ndc_4026043",
      "drug_name": "CELLCEPT 500 MG TABLET",
      "ndc": 4026043,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.015993200000004,
        "feasible_range": [
          15.015993200000004,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.261994900000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.753998300000001,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28154.98725000001,
          "annual_profit_projection": 337859.8470000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.015993200000004,
        "regulatory_headroom": -3.0512193400000065,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.81"
        ]
      }
    },
    {
      "drug_id": "ndc_4026129",
      "drug_name": "CELLCEPT 200 MG/ML ORAL SUSP",
      "ndc": 4026129,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.015978833333337,
        "feasible_range": [
          7.2127830666666695,
          9.612420510000003
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.409587300000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.606391533333335,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 27047.936500000014,
          "annual_profit_projection": 324575.2380000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.2127830666666695,
        "regulatory_headroom": 2.9487950266666605,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_4080085",
      "drug_name": "TAMIFLU 75 MG CAPSULE",
      "ndc": 4080085,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.660626333333338,
        "feasible_range": [
          12.660626333333338,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.495469750000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.165156583333335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 31651.565833333352,
          "annual_profit_projection": 379818.7900000002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.660626333333338,
        "regulatory_headroom": -0.6958524733333409,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.86"
        ]
      }
    },
    {
      "drug_id": "ndc_4082205",
      "drug_name": "TAMIFLU 6 MG/ML SUSPENSION",
      "ndc": 4082205,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.686224305555556,
        "feasible_range": [
          2.1068425925925927,
          2.807772916666667
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 1.5801319444444446,
        "profit_projections": {
          "gross_profit_per_unit": 1.0534212962962965,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 10534.212962962965,
          "annual_profit_projection": 126410.55555555559,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.1068425925925927,
        "regulatory_headroom": 9.331220619259255,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_6003220",
      "drug_name": "STROMECTOL 3 MG TABLET",
      "ndc": 6003220,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.9036143,
        "feasible_range": [
          3.8459719999999997,
          5.125497299999999
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.884479,
        "profit_projections": {
          "gross_profit_per_unit": 1.9229859999999999,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 19229.859999999997,
          "annual_profit_projection": 230758.31999999995,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.8459719999999997,
        "regulatory_headroom": 7.157308859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_6046102",
      "drug_name": "EMEND 80 MG CAPSULE",
      "ndc": 6046102,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 181.11860000000004,
        "feasible_range": [
          181.11860000000004,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 135.83895000000004,
        "profit_projections": {
          "gross_profit_per_unit": 45.279650000000004,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 452796.50000000006,
          "annual_profit_projection": 5433558.000000001,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 181.11860000000004,
        "regulatory_headroom": -169.15382614000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $214.43"
        ]
      }
    },
    {
      "drug_id": "ndc_8083321",
      "drug_name": "EFFEXOR XR 75 MG CAPSULE",
      "ndc": 8083321,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.376915533333335,
        "feasible_range": [
          16.376915533333335,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.282686650000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.094228883333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12282.686649999998,
          "annual_profit_projection": 147392.23979999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.376915533333335,
        "regulatory_headroom": -4.412141673333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.51"
        ]
      }
    },
    {
      "drug_id": "ndc_8083322",
      "drug_name": "EFFEXOR XR 75 MG CAPSULE",
      "ndc": 8083322,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.376915533333335,
        "feasible_range": [
          16.376915533333335,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.282686650000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.094228883333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12282.686649999998,
          "annual_profit_projection": 147392.23979999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.376915533333335,
        "regulatory_headroom": -4.412141673333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.51"
        ]
      }
    },
    {
      "drug_id": "ndc_8083621",
      "drug_name": "EFFEXOR XR 150 MG CAPSULE",
      "ndc": 8083621,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.809430600000002,
        "feasible_range": [
          17.809430600000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.357072950000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.4523576500000015,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13357.072950000005,
          "annual_profit_projection": 160284.87540000008,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.809430600000002,
        "regulatory_headroom": -5.844656740000005,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.30"
        ]
      }
    },
    {
      "drug_id": "ndc_8083622",
      "drug_name": "EFFEXOR XR 150 MG CAPSULE",
      "ndc": 8083622,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.809430600000002,
        "feasible_range": [
          17.809430600000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.357072950000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.4523576500000015,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13357.072950000005,
          "annual_profit_projection": 160284.87540000008,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.809430600000002,
        "regulatory_headroom": -5.844656740000005,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.30"
        ]
      }
    },
    {
      "drug_id": "ndc_8083721",
      "drug_name": "EFFEXOR XR 37.5 MG CAPSULE",
      "ndc": 8083721,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.58510386666667,
        "feasible_range": [
          14.58510386666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 10.938827900000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.6462759666666678,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10938.827900000004,
          "annual_profit_projection": 131265.93480000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.58510386666667,
        "regulatory_headroom": -2.6203300066666717,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.27"
        ]
      }
    },
    {
      "drug_id": "ndc_8083722",
      "drug_name": "EFFEXOR XR 37.5 MG CAPSULE",
      "ndc": 8083722,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.58510386666667,
        "feasible_range": [
          14.58510386666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 10.938827900000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.6462759666666678,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10938.827900000004,
          "annual_profit_projection": 131265.93480000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.58510386666667,
        "regulatory_headroom": -2.6203300066666717,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.27"
        ]
      }
    },
    {
      "drug_id": "ndc_8084181",
      "drug_name": "PROTONIX DR 40 MG TABLET",
      "ndc": 8084181,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.053132866666667,
        "feasible_range": [
          12.053132866666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.03984965,
        "profit_projections": {
          "gross_profit_per_unit": 3.0132832166666663,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 22599.624125,
          "annual_profit_projection": 271195.48949999997,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.053132866666667,
        "regulatory_headroom": -0.08835900666666952,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.10"
        ]
      }
    },
    {
      "drug_id": "ndc_8084381",
      "drug_name": "PROTONIX DR 20 MG TABLET",
      "ndc": 8084381,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.044445833333336,
        "feasible_range": [
          12.044445833333336,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.033334375000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.0111114583333336,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 22583.335937500004,
          "annual_profit_projection": 271000.03125000006,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.044445833333336,
        "regulatory_headroom": -0.07967197333333864,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.09"
        ]
      }
    },
    {
      "drug_id": "ndc_8084401",
      "drug_name": "PROTONIX 40 MG SUSPENSION",
      "ndc": 8084401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.930221333333336,
          11.964773859999998
        ],
        "expected_margin": 0.25216589091471525,
        "estimated_acquisition_cost": 8.947666000000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.017107859999996,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 22628.30894999997,
          "annual_profit_projection": 271539.7073999996,
          "margin_percentage": 25.216589091471526
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.930221333333336,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.95"
        ]
      }
    },
    {
      "drug_id": "ndc_8084402",
      "drug_name": "PROTONIX 40 MG SUSPENSION",
      "ndc": 8084402,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.930221333333336,
          11.964773859999998
        ],
        "expected_margin": 0.25216589091471525,
        "estimated_acquisition_cost": 8.947666000000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.017107859999996,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 22628.30894999997,
          "annual_profit_projection": 271539.7073999996,
          "margin_percentage": 25.216589091471526
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.930221333333336,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.95"
        ]
      }
    },
    {
      "drug_id": "ndc_8103004",
      "drug_name": "RAPAMUNE 1 MG/ML ORAL SOLN",
      "ndc": 8103004,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 27.519665333333336,
        "feasible_range": [
          27.519665333333336,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 20.639749000000002,
        "profit_projections": {
          "gross_profit_per_unit": 6.879916333333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 68799.16333333334,
          "annual_profit_projection": 825589.9600000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 27.519665333333336,
        "regulatory_headroom": -15.554891473333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $22.43"
        ]
      }
    },
    {
      "drug_id": "ndc_8103006",
      "drug_name": "RAPAMUNE 1 MG/ML ORAL SOLN",
      "ndc": 8103006,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 27.519665333333336,
        "feasible_range": [
          27.519665333333336,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 20.639749000000002,
        "profit_projections": {
          "gross_profit_per_unit": 6.879916333333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 68799.16333333334,
          "annual_profit_projection": 825589.9600000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 27.519665333333336,
        "regulatory_headroom": -15.554891473333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $22.43"
        ]
      }
    },
    {
      "drug_id": "ndc_8121030",
      "drug_name": "PRISTIQ ER 25 MG TABLET",
      "ndc": 8121030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.100078033333332,
        "feasible_range": [
          12.100078033333332,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.075058525,
        "profit_projections": {
          "gross_profit_per_unit": 3.025019508333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15125.097541666666,
          "annual_profit_projection": 181501.1705,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.100078033333332,
        "regulatory_headroom": -0.1353041733333349,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.16"
        ]
      }
    },
    {
      "drug_id": "ndc_8121101",
      "drug_name": "PRISTIQ ER 50 MG TABLET",
      "ndc": 8121101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.097627100000002,
        "feasible_range": [
          12.097627100000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.073220325000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.024406775000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15122.033875000005,
          "annual_profit_projection": 181464.40650000004,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.097627100000002,
        "regulatory_headroom": -0.13285324000000465,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.16"
        ]
      }
    },
    {
      "drug_id": "ndc_8121114",
      "drug_name": "PRISTIQ ER 50 MG TABLET",
      "ndc": 8121114,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.097627100000002,
        "feasible_range": [
          12.097627100000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.073220325000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.024406775000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15122.033875000005,
          "annual_profit_projection": 181464.40650000004,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.097627100000002,
        "regulatory_headroom": -0.13285324000000465,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.16"
        ]
      }
    },
    {
      "drug_id": "ndc_8121130",
      "drug_name": "PRISTIQ ER 50 MG TABLET",
      "ndc": 8121130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.097627100000002,
        "feasible_range": [
          12.097627100000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.073220325000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.024406775000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15122.033875000005,
          "annual_profit_projection": 181464.40650000004,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.097627100000002,
        "regulatory_headroom": -0.13285324000000465,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.16"
        ]
      }
    },
    {
      "drug_id": "ndc_8122201",
      "drug_name": "PRISTIQ ER 100 MG TABLET",
      "ndc": 8122201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.106984500000003,
        "feasible_range": [
          12.106984500000003,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.080238375000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.0267461250000007,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15133.730625000004,
          "annual_profit_projection": 181604.76750000005,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.106984500000003,
        "regulatory_headroom": -0.14221064000000538,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.17"
        ]
      }
    },
    {
      "drug_id": "ndc_8122214",
      "drug_name": "PRISTIQ ER 100 MG TABLET",
      "ndc": 8122214,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.106984500000003,
        "feasible_range": [
          12.106984500000003,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.080238375000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.0267461250000007,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15133.730625000004,
          "annual_profit_projection": 181604.76750000005,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.106984500000003,
        "regulatory_headroom": -0.14221064000000538,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.17"
        ]
      }
    },
    {
      "drug_id": "ndc_8122230",
      "drug_name": "PRISTIQ ER 100 MG TABLET",
      "ndc": 8122230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.106984500000003,
        "feasible_range": [
          12.106984500000003,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.080238375000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.0267461250000007,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15133.730625000004,
          "annual_profit_projection": 181604.76750000005,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.106984500000003,
        "regulatory_headroom": -0.14221064000000538,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.17"
        ]
      }
    },
    {
      "drug_id": "ndc_9001201",
      "drug_name": "CORTEF 5 MG TABLET",
      "ndc": 9001201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.0633752025000003,
        "feasible_range": [
          0.8340197666666668,
          1.1114917275000005
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.6255148250000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.41700988333333344,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 4170.098833333334,
          "annual_profit_projection": 50041.186000000016,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8340197666666668,
        "regulatory_headroom": 10.922249151666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9002901",
      "drug_name": "XANAX 0.25 MG TABLET",
      "ndc": 9002901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.644304304166666,
        "feasible_range": [
          4.655096333333333,
          6.203811075
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 3.4913222499999996,
        "profit_projections": {
          "gross_profit_per_unit": 2.3275481666666664,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 11637.740833333331,
          "annual_profit_projection": 139652.88999999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.655096333333333,
        "regulatory_headroom": 6.1459034433333315,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9002902",
      "drug_name": "XANAX 0.25 MG TABLET",
      "ndc": 9002902,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.644304304166666,
        "feasible_range": [
          4.655096333333333,
          6.203811075
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 3.4913222499999996,
        "profit_projections": {
          "gross_profit_per_unit": 2.3275481666666664,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 11637.740833333331,
          "annual_profit_projection": 139652.88999999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.655096333333333,
        "regulatory_headroom": 6.1459034433333315,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9003101",
      "drug_name": "CORTEF 10 MG TABLET",
      "ndc": 9003101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.7883507850000002,
        "feasible_range": [
          1.4026280666666668,
          1.869271635
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 1.0519710500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.7013140333333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 7013.140333333335,
          "annual_profit_projection": 84157.68400000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4026280666666668,
        "regulatory_headroom": 10.211488776666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9005501",
      "drug_name": "XANAX 0.5 MG TABLET",
      "ndc": 9005501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.030303030833335,
        "feasible_range": [
          5.798188066666668,
          7.727200635000003
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 4.348641050000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.899094033333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 14495.470166666672,
          "annual_profit_projection": 173945.64200000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.798188066666668,
        "regulatory_headroom": 4.717038776666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9005503",
      "drug_name": "XANAX 0.5 MG TABLET",
      "ndc": 9005503,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.030303030833335,
        "feasible_range": [
          5.798188066666668,
          7.727200635000003
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 4.348641050000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.899094033333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 14495.470166666672,
          "annual_profit_projection": 173945.64200000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.798188066666668,
        "regulatory_headroom": 4.717038776666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9005604",
      "drug_name": "MEDROL 4 MG DOSEPAK",
      "ndc": 9005604,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.2974206949999999,
        "feasible_range": [
          0.23327113333333327,
          0.31087864499999995
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 0.17495334999999995,
        "profit_projections": {
          "gross_profit_per_unit": 0.11663556666666663,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 1166.3556666666664,
          "annual_profit_projection": 13996.267999999996,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.23327113333333327,
        "regulatory_headroom": 11.67318494333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9008510",
      "drug_name": "DEPO-TESTOSTERONE 1,000 MG/10 ML",
      "ndc": 9008510,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.910543759166666,
        "feasible_range": [
          5.699417533333333,
          7.5955699050000005
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 4.27456315,
        "profit_projections": {
          "gross_profit_per_unit": 2.8497087666666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 14248.543833333333,
          "annual_profit_projection": 170982.526,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.699417533333333,
        "regulatory_headroom": 4.840501943333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9008601",
      "drug_name": "DEPO-TESTOSTERONE 200 MG/ML VL",
      "ndc": 9008601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          9.972467700000001,
          11.964773859999998
        ],
        "expected_margin": 0.3555523077757645,
        "estimated_acquisition_cost": 7.479350775,
        "profit_projections": {
          "gross_profit_per_unit": 4.485423084999997,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 22427.115424999985,
          "annual_profit_projection": 269125.38509999984,
          "margin_percentage": 37.48857385424916
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.972467700000001,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.50"
        ]
      }
    },
    {
      "drug_id": "ndc_9008610",
      "drug_name": "DEPO-TESTOSTERONE 200 MG/ML VL",
      "ndc": 9008610,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.648304333333334,
        "feasible_range": [
          8.782106666666666,
          11.703845999999999
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.58658,
        "profit_projections": {
          "gross_profit_per_unit": 4.391053333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21955.26666666667,
          "annual_profit_projection": 263463.20000000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.782106666666666,
        "regulatory_headroom": 0.9871405266666642,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9009001",
      "drug_name": "XANAX 1 MG TABLET",
      "ndc": 9009001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.383768279166668,
        "feasible_range": [
          7.739190333333334,
          10.313959425000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.804392750000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.8695951666666675,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19347.975833333338,
          "annual_profit_projection": 232175.71000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.739190333333334,
        "regulatory_headroom": 2.2907859433333293,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9009004",
      "drug_name": "XANAX 1 MG TABLET",
      "ndc": 9009004,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.383768279166668,
        "feasible_range": [
          7.739190333333334,
          10.313959425000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.804392750000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.8695951666666675,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19347.975833333338,
          "annual_profit_projection": 232175.71000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.739190333333334,
        "regulatory_headroom": 2.2907859433333293,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9009401",
      "drug_name": "XANAX 2 MG TABLET",
      "ndc": 9009401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.143657800000002,
        "feasible_range": [
          13.143657800000002,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.857743350000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.28591445,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16429.57225,
          "annual_profit_projection": 197154.86700000003,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.143657800000002,
        "regulatory_headroom": -1.178883940000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.46"
        ]
      }
    },
    {
      "drug_id": "ndc_9028003",
      "drug_name": "DEPO-MEDROL 400 MG/10 ML VIAL",
      "ndc": 9028003,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.85421666666667,
        "feasible_range": [
          7.883373333333335,
          10.506111000000002
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 5.912530000000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.9416866666666683,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 26606.385000000013,
          "annual_profit_projection": 319276.62000000017,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.883373333333335,
        "regulatory_headroom": 2.110557193333328,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9030602",
      "drug_name": "DEPO-MEDROL 400 MG/5 ML VIAL",
      "ndc": 9030602,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.814935708333339,
        "feasible_range": [
          9.45194856666667,
          11.964773859999998
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 7.088961425000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.725974283333336,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 31900.32641250002,
          "annual_profit_projection": 382803.9169500002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.45194856666667,
        "regulatory_headroom": 0.1498381516666587,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9034702",
      "drug_name": "DEPO-TESTOSTERONE 1,000 MG/10 ML",
      "ndc": 9034702,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.910543759166666,
        "feasible_range": [
          5.699417533333333,
          7.5955699050000005
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 4.27456315,
        "profit_projections": {
          "gross_profit_per_unit": 2.8497087666666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 14248.543833333333,
          "annual_profit_projection": 170982.526,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.699417533333333,
        "regulatory_headroom": 4.840501943333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9041701",
      "drug_name": "DEPO-TESTOSTERONE 200 MG/ML",
      "ndc": 9041701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          9.972467700000001,
          11.964773859999998
        ],
        "expected_margin": 0.3555523077757645,
        "estimated_acquisition_cost": 7.479350775,
        "profit_projections": {
          "gross_profit_per_unit": 4.485423084999997,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 22427.115424999985,
          "annual_profit_projection": 269125.38509999984,
          "margin_percentage": 37.48857385424916
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.972467700000001,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.50"
        ]
      }
    },
    {
      "drug_id": "ndc_9041702",
      "drug_name": "DEPO-TESTOSTERONE 200 MG/ML",
      "ndc": 9041702,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.648304333333334,
        "feasible_range": [
          8.782106666666666,
          11.703845999999999
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.58658,
        "profit_projections": {
          "gross_profit_per_unit": 4.391053333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21955.26666666667,
          "annual_profit_projection": 263463.20000000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.782106666666666,
        "regulatory_headroom": 0.9871405266666642,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9045003",
      "drug_name": "COLESTID 1 GM TABLET",
      "ndc": 9045003,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.3717278000000004,
        "feasible_range": [
          1.8601786666666669,
          2.4790458
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 1.395134,
        "profit_projections": {
          "gross_profit_per_unit": 0.9300893333333335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 9300.893333333335,
          "annual_profit_projection": 111610.72000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.8601786666666669,
        "regulatory_headroom": 9.639550526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9074630",
      "drug_name": "DEPO-PROVERA 150 MG/ML VIAL",
      "ndc": 9074630,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 43.803066666666666,
        "feasible_range": [
          43.803066666666666,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 32.8523,
        "profit_projections": {
          "gross_profit_per_unit": 10.950766666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 109507.66666666667,
          "annual_profit_projection": 1314092.0,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 43.803066666666666,
        "regulatory_headroom": -31.83829280666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $42.79"
        ]
      }
    },
    {
      "drug_id": "ndc_9082501",
      "drug_name": "SOLU-CORTEF 100 MG VIAL",
      "ndc": 9082501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.07803266666667,
        "feasible_range": [
          15.07803266666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.308524500000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.769508166666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 37695.08166666668,
          "annual_profit_projection": 452340.98000000016,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.07803266666667,
        "regulatory_headroom": -3.113258806666673,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.88"
        ]
      }
    },
    {
      "drug_id": "ndc_9307301",
      "drug_name": "DEPO-MEDROL 40 MG/ML VIAL",
      "ndc": 9307301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.0825657500000005,
        "feasible_range": [
          5.6660526,
          7.551104715
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.24953945,
        "profit_projections": {
          "gross_profit_per_unit": 2.8330263,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 21247.69725,
          "annual_profit_projection": 254972.36700000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.6660526,
        "regulatory_headroom": 4.882208109999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9307322",
      "drug_name": "DEPO-MEDROL 40 MG/ML VIAL",
      "ndc": 9307322,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.0825657500000005,
        "feasible_range": [
          5.6660526,
          7.551104715
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.24953945,
        "profit_projections": {
          "gross_profit_per_unit": 2.8330263,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 21247.69725,
          "annual_profit_projection": 254972.36700000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.6660526,
        "regulatory_headroom": 4.882208109999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9332901",
      "drug_name": "CLEOCIN T 1% LOTION",
      "ndc": 9332901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.8442863000000004,
        "feasible_range": [
          0.6621853333333335,
          0.8824893000000003
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.49663900000000016,
        "profit_projections": {
          "gross_profit_per_unit": 0.3310926666666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 3310.926666666668,
          "annual_profit_projection": 39731.12000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.6621853333333335,
        "regulatory_headroom": 11.13704219333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9344801",
      "drug_name": "CLEOCIN 2% VAGINAL CREAM",
      "ndc": 9344801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.9386954275000001,
        "feasible_range": [
          1.5205454333333333,
          2.0264192025
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 1.140409075,
        "profit_projections": {
          "gross_profit_per_unit": 0.7602727166666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 7602.7271666666675,
          "annual_profit_projection": 91232.72600000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.5205454333333333,
        "regulatory_headroom": 10.06409206833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9347501",
      "drug_name": "DEPO-MEDROL 80 MG/ML VIAL",
      "ndc": 9347501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.811972,
        "feasible_range": [
          7.0495776,
          9.394917840000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.2871832,
        "profit_projections": {
          "gross_profit_per_unit": 3.5247888000000005,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 26435.916000000005,
          "annual_profit_projection": 317230.9920000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.0495776,
        "regulatory_headroom": 3.1528018599999967,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_9519102",
      "drug_name": "DETROL LA 4 MG CAPSULE",
      "ndc": 9519102,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.469006466666668,
          11.964773859999998
        ],
        "expected_margin": 0.2810766880637055,
        "estimated_acquisition_cost": 8.60175485,
        "profit_projections": {
          "gross_profit_per_unit": 3.363019009999997,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 25222.642574999976,
          "annual_profit_projection": 302671.7108999997,
          "margin_percentage": 28.10766880637055
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.469006466666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.37"
        ]
      }
    },
    {
      "drug_id": "ndc_9737611",
      "drug_name": "DEPO-PROVERA 150 MG/ML SYRINGE",
      "ndc": 9737611,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 45.95969689999999,
        "feasible_range": [
          45.95969689999999,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 34.469772674999994,
        "profit_projections": {
          "gross_profit_per_unit": 11.489924224999996,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 114899.24224999995,
          "annual_profit_projection": 1378790.9069999994,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 45.95969689999999,
        "regulatory_headroom": -33.99492303999999,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $45.48"
        ]
      }
    },
    {
      "drug_id": "ndc_9766304",
      "drug_name": "AROMASIN 25 MG TABLET",
      "ndc": 9766304,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 31.78309333333334,
        "feasible_range": [
          31.78309333333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 23.837320000000005,
        "profit_projections": {
          "gross_profit_per_unit": 7.945773333333335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 79457.73333333335,
          "annual_profit_projection": 953492.8000000003,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 31.78309333333334,
        "regulatory_headroom": -19.818319473333343,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $27.76"
        ]
      }
    },
    {
      "drug_id": "ndc_13830304",
      "drug_name": "XALATAN 0.005% EYE DROPS",
      "ndc": 13830304,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 89.73711586666668,
        "feasible_range": [
          89.73711586666668,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 67.30283690000002,
        "profit_projections": {
          "gross_profit_per_unit": 22.434278966666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 224342.78966666668,
          "annual_profit_projection": 2692113.4760000003,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 89.73711586666668,
        "regulatory_headroom": -77.77234200666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $100.21"
        ]
      }
    },
    {
      "drug_id": "ndc_23024004",
      "drug_name": "REFRESH P.M. OINTMENT",
      "ndc": 23024004,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 2.572674861249999,
        "feasible_range": [
          2.121793699999999,
          2.8276981424999996
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 1.5913452749999994,
        "profit_projections": {
          "gross_profit_per_unit": 1.0608968499999996,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 5304.484249999998,
          "annual_profit_projection": 63653.81099999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.121793699999999,
        "regulatory_headroom": 9.312531734999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23040330",
      "drug_name": "REFRESH PLUS 0.5% EYE DROPS",
      "ndc": 23040330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.31161621833333336,
        "feasible_range": [
          0.25700306666666667,
          0.34250601
        ],
        "expected_margin": 0.38144329896907225,
        "estimated_acquisition_cost": 0.1927523,
        "profit_projections": {
          "gross_profit_per_unit": 0.12850153333333336,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 578.2569000000001,
          "annual_profit_projection": 6939.082800000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.25700306666666667,
        "regulatory_headroom": 11.643520026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23040370",
      "drug_name": "REFRESH PLUS 0.5% EYE DROPS",
      "ndc": 23040370,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.2727080633333333,
        "feasible_range": [
          0.22491386666666666,
          0.29974098
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.16868539999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.11245693333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 562.2846666666667,
          "annual_profit_projection": 6747.416,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.22491386666666666,
        "regulatory_headroom": 11.683631526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23066704",
      "drug_name": "REFRESH P.M. OINTMENT",
      "ndc": 23066704,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 2.572674861249999,
        "feasible_range": [
          2.121793699999999,
          2.8276981424999996
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 1.5913452749999994,
        "profit_projections": {
          "gross_profit_per_unit": 1.0608968499999996,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 5304.484249999998,
          "annual_profit_projection": 63653.81099999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.121793699999999,
        "regulatory_headroom": 9.312531734999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23079801",
      "drug_name": "REFRESH TEARS 0.5% EYE DROP",
      "ndc": 23079801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.43228498625000006,
        "feasible_range": [
          0.35652370000000005,
          0.47513639250000006
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 0.267392775,
        "profit_projections": {
          "gross_profit_per_unit": 0.17826185000000005,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 891.3092500000002,
          "annual_profit_projection": 10695.711000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.35652370000000005,
        "regulatory_headroom": 11.519119234999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23079815",
      "drug_name": "REFRESH TEARS 0.5% EYE DROP",
      "ndc": 23079815,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.5830307058333332,
        "feasible_range": [
          0.4808500666666666,
          0.6408251849999999
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.3606375499999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.24042503333333326,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 1202.1251666666662,
          "annual_profit_projection": 14425.501999999995,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.4808500666666666,
        "regulatory_headroom": 11.363711276666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23218105",
      "drug_name": "ACULAR 0.5% EYE DROPS",
      "ndc": 23218105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 46.015840000000004,
        "feasible_range": [
          46.015840000000004,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 34.511880000000005,
        "profit_projections": {
          "gross_profit_per_unit": 11.50396,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 115039.59999999999,
          "annual_profit_projection": 1380475.2,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 46.015840000000004,
        "regulatory_headroom": -34.05106614,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $45.56"
        ]
      }
    },
    {
      "drug_id": "ndc_23361605",
      "drug_name": "LATISSE 0.03% EYELASH SOLUTION",
      "ndc": 23361605,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 27.29640029999999,
        "feasible_range": [
          27.29640029999999,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 20.472300224999994,
        "profit_projections": {
          "gross_profit_per_unit": 6.824100074999997,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 68241.00074999996,
          "annual_profit_projection": 818892.0089999996,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 27.29640029999999,
        "regulatory_headroom": -15.331626439999994,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $22.16"
        ]
      }
    },
    {
      "drug_id": "ndc_23361670",
      "drug_name": "LATISSE 0.03% EYELASH SOLUTION",
      "ndc": 23361670,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 35.56011203333334,
        "feasible_range": [
          35.56011203333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 26.670084025000005,
        "profit_projections": {
          "gross_profit_per_unit": 8.890028008333335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 88900.28008333335,
          "annual_profit_projection": 1066803.361,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 35.56011203333334,
        "regulatory_headroom": -23.595338173333342,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $32.49"
        ]
      }
    },
    {
      "drug_id": "ndc_23585318",
      "drug_name": "DELZICOL DR 400 MG CAPSULE",
      "ndc": 23585318,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.123528500000001,
        "feasible_range": [
          3.2341400000000005,
          4.310113500000001
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 2.4256050000000005,
        "profit_projections": {
          "gross_profit_per_unit": 1.6170700000000005,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 16170.700000000004,
          "annual_profit_projection": 194048.40000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.2341400000000005,
        "regulatory_headroom": 7.922098859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23586228",
      "drug_name": "TAYTULLA 1 MG-20 MCG CAPSULE",
      "ndc": 23586228,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.463430502500003,
        "feasible_range": [
          7.422298433333335,
          9.891640027500003
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.566723825000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.7111492166666684,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 33400.34295000001,
          "annual_profit_projection": 400804.1154000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.422298433333335,
        "regulatory_headroom": 2.686900818333328,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23586230",
      "drug_name": "TAYTULLA 1 MG-20 MCG CAPSULE",
      "ndc": 23586230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.463430502500003,
        "feasible_range": [
          7.422298433333335,
          9.891640027500003
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.566723825000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.7111492166666684,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 33400.34295000001,
          "annual_profit_projection": 400804.1154000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.422298433333335,
        "regulatory_headroom": 2.686900818333328,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23611803",
      "drug_name": "CONDYLOX 0.5% GEL",
      "ndc": 23611803,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 149.51211990000004,
        "feasible_range": [
          149.51211990000004,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 112.13408992500004,
        "profit_projections": {
          "gross_profit_per_unit": 37.378029975000004,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 373780.29975000006,
          "annual_profit_projection": 4485363.597000001,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 149.51211990000004,
        "regulatory_headroom": -137.54734604000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $174.93"
        ]
      }
    },
    {
      "drug_id": "ndc_23614230",
      "drug_name": "RAPAFLO 8 MG CAPSULE",
      "ndc": 23614230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.280688917500004,
        "feasible_range": [
          7.278971700000003,
          9.700629592500004
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.459228775000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.6394858500000025,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 32755.372650000023,
          "annual_profit_projection": 393064.4718000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.278971700000003,
        "regulatory_headroom": 2.8660592349999927,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23614730",
      "drug_name": "RAPAFLO 4 MG CAPSULE",
      "ndc": 23614730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.332686350000005,
        "feasible_range": [
          7.319754000000003,
          9.754979850000003
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.489815500000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.6598770000000016,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 36598.77000000002,
          "annual_profit_projection": 439185.2400000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.319754000000003,
        "regulatory_headroom": 2.8150813599999935,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23916330",
      "drug_name": "RESTASIS 0.05% EYE EMULSION",
      "ndc": 23916330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.406796765000005,
        "feasible_range": [
          8.94650726666667,
          11.922941415000004
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 6.709880450000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.473253633333336,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 40259.28270000002,
          "annual_profit_projection": 483111.39240000024,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.94650726666667,
        "regulatory_headroom": 0.7816397766666601,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23916360",
      "drug_name": "RESTASIS 0.05% EYE EMULSION",
      "ndc": 23916360,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.417844002500003,
        "feasible_range": [
          8.955171766666668,
          11.934488527500003
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.716378825000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.477585883333335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44775.85883333335,
          "annual_profit_projection": 537310.3060000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.955171766666668,
        "regulatory_headroom": 0.7708091516666613,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23917705",
      "drug_name": "ALPHAGAN P 0.15% EYE DROPS",
      "ndc": 23917705,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 34.54583903333333,
        "feasible_range": [
          34.54583903333333,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 25.909379274999996,
        "profit_projections": {
          "gross_profit_per_unit": 8.636459758333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 43182.29879166667,
          "annual_profit_projection": 518187.58550000004,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 34.54583903333333,
        "regulatory_headroom": -22.581065173333332,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $31.22"
        ]
      }
    },
    {
      "drug_id": "ndc_23917710",
      "drug_name": "ALPHAGAN P 0.15% EYE DROPS",
      "ndc": 23917710,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 34.609370033333335,
        "feasible_range": [
          34.609370033333335,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 25.957027525,
        "profit_projections": {
          "gross_profit_per_unit": 8.652342508333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 43261.71254166667,
          "annual_profit_projection": 519140.5505,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 34.609370033333335,
        "regulatory_headroom": -22.644596173333337,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $31.30"
        ]
      }
    },
    {
      "drug_id": "ndc_23917715",
      "drug_name": "ALPHAGAN P 0.15% EYE DROPS",
      "ndc": 23917715,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 34.72756906666667,
        "feasible_range": [
          34.72756906666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 26.045676800000003,
        "profit_projections": {
          "gross_profit_per_unit": 8.681892266666665,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 43409.461333333325,
          "annual_profit_projection": 520913.5359999999,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 34.72756906666667,
        "regulatory_headroom": -22.76279520666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $31.44"
        ]
      }
    },
    {
      "drug_id": "ndc_23921105",
      "drug_name": "COMBIGAN 0.2%-0.5% EYE DROPS",
      "ndc": 23921105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 33.96038706666667,
        "feasible_range": [
          33.96038706666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 25.470290300000002,
        "profit_projections": {
          "gross_profit_per_unit": 8.490096766666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 63675.725750000005,
          "annual_profit_projection": 764108.709,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 33.96038706666667,
        "regulatory_headroom": -21.995613206666672,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $30.49"
        ]
      }
    },
    {
      "drug_id": "ndc_23921110",
      "drug_name": "COMBIGAN 0.2%-0.5% EYE DROPS",
      "ndc": 23921110,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 33.96483176666667,
        "feasible_range": [
          33.96483176666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 25.473623825,
        "profit_projections": {
          "gross_profit_per_unit": 8.49120794166667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 63684.05956250002,
          "annual_profit_projection": 764208.7147500003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 33.96483176666667,
        "regulatory_headroom": -22.000057906666672,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $30.49"
        ]
      }
    },
    {
      "drug_id": "ndc_23921115",
      "drug_name": "COMBIGAN 0.2%-0.5% EYE DROPS",
      "ndc": 23921115,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 33.9781546,
        "feasible_range": [
          33.9781546,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 25.48361595,
        "profit_projections": {
          "gross_profit_per_unit": 8.494538650000003,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 63709.03987500002,
          "annual_profit_projection": 764508.4785000002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 33.9781546,
        "regulatory_headroom": -22.013380740000006,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $30.51"
        ]
      }
    },
    {
      "drug_id": "ndc_23932105",
      "drug_name": "ALPHAGAN P 0.1% DROPS",
      "ndc": 23932105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 32.36791696666666,
        "feasible_range": [
          32.36791696666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 24.275937725,
        "profit_projections": {
          "gross_profit_per_unit": 8.091979241666664,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 40459.89620833332,
          "annual_profit_projection": 485518.7544999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 32.36791696666666,
        "regulatory_headroom": -20.403143106666665,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $28.50"
        ]
      }
    },
    {
      "drug_id": "ndc_23932110",
      "drug_name": "ALPHAGAN P 0.1% DROPS",
      "ndc": 23932110,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 32.35498629999999,
        "feasible_range": [
          32.35498629999999,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 24.266239724999995,
        "profit_projections": {
          "gross_profit_per_unit": 8.088746574999998,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 40443.732874999994,
          "annual_profit_projection": 485324.79449999996,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 32.35498629999999,
        "regulatory_headroom": -20.390212439999996,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $28.48"
        ]
      }
    },
    {
      "drug_id": "ndc_23932115",
      "drug_name": "ALPHAGAN P 0.1% DROPS",
      "ndc": 23932115,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 32.3866985,
        "feasible_range": [
          32.3866985,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 24.290023875,
        "profit_projections": {
          "gross_profit_per_unit": 8.096674625000002,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 40483.37312500001,
          "annual_profit_projection": 485800.47750000015,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 32.3866985,
        "regulatory_headroom": -20.421924640000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $28.52"
        ]
      }
    },
    {
      "drug_id": "ndc_24117190",
      "drug_name": "PLAVIX 75 MG TABLET",
      "ndc": 24117190,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.890941052499999,
        "feasible_range": [
          6.973287099999998,
          9.2932460775
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 5.229965324999998,
        "profit_projections": {
          "gross_profit_per_unit": 3.48664355,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 31379.791950000003,
          "annual_profit_projection": 376557.50340000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.973287099999998,
        "regulatory_headroom": 3.248164984999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24540131",
      "drug_name": "AMBIEN 5 MG TABLET",
      "ndc": 24540131,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.872417766666672,
        "feasible_range": [
          17.872417766666672,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 13.404313325000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.468104441666668,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33510.78331250001,
          "annual_profit_projection": 402129.3997500001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.872417766666672,
        "regulatory_headroom": -5.907643906666674,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.38"
        ]
      }
    },
    {
      "drug_id": "ndc_24542131",
      "drug_name": "AMBIEN 10 MG TABLET",
      "ndc": 24542131,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.835628633333332,
        "feasible_range": [
          17.835628633333332,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.376721474999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.458907158333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33441.8036875,
          "annual_profit_projection": 401301.64425,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.835628633333332,
        "regulatory_headroom": -5.870854773333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.33"
        ]
      }
    },
    {
      "drug_id": "ndc_24550131",
      "drug_name": "AMBIEN CR 6.25 MG TABLET",
      "ndc": 24550131,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.901380900000007,
        "feasible_range": [
          17.901380900000007,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 13.426035675000005,
        "profit_projections": {
          "gross_profit_per_unit": 4.475345225000002,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33565.08918750001,
          "annual_profit_projection": 402781.0702500001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.901380900000007,
        "regulatory_headroom": -5.936607040000009,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.41"
        ]
      }
    },
    {
      "drug_id": "ndc_24552131",
      "drug_name": "AMBIEN CR 12.5 MG TABLET",
      "ndc": 24552131,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.8831185,
        "feasible_range": [
          17.8831185,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.412338874999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.4707796250000005,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33530.8471875,
          "annual_profit_projection": 402370.16625,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.8831185,
        "regulatory_headroom": -5.918344640000001,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.39"
        ]
      }
    },
    {
      "drug_id": "ndc_24583701",
      "drug_name": "FLOMAX 0.4 MG CAPSULE",
      "ndc": 24583701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.354447805,
        "feasible_range": [
          8.121135533333332,
          10.822974854999998
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.090851649999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.060567766666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 40605.67766666667,
          "annual_profit_projection": 487268.13200000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.121135533333332,
        "regulatory_headroom": 1.8133544433333313,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24585090",
      "drug_name": "AVAPRO 75 MG TABLET",
      "ndc": 24585090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.570311666666666,
        "feasible_range": [
          6.056249333333333,
          8.071116899999998
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.542186999999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.028124666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 22710.935,
          "annual_profit_projection": 272531.22000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.056249333333333,
        "regulatory_headroom": 4.394462193333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24585130",
      "drug_name": "AVAPRO 150 MG TABLET",
      "ndc": 24585130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.971750583333335,
        "feasible_range": [
          6.377400466666668,
          8.499112545000001
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.783050350000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.188700233333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23915.251750000003,
          "annual_profit_projection": 286983.02100000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.377400466666668,
        "regulatory_headroom": 3.993023276666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24585230",
      "drug_name": "AVAPRO 300 MG TABLET",
      "ndc": 24585230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.551242458333334,
        "feasible_range": [
          7.640993966666667,
          10.1830938825
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 5.730745475,
        "profit_projections": {
          "gross_profit_per_unit": 3.820496983333334,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 25788.354637500004,
          "annual_profit_projection": 309460.25565000006,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.640993966666667,
        "regulatory_headroom": 2.4135314016666634,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24585630",
      "drug_name": "AVALIDE 300-12.5 MG TABLET",
      "ndc": 24585630,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.73227935,
        "feasible_range": [
          8.417474,
          11.21790285
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.3131055,
        "profit_projections": {
          "gross_profit_per_unit": 4.208737,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 42087.37,
          "annual_profit_projection": 505048.44000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.417474,
        "regulatory_headroom": 1.4429313599999976,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_25006131",
      "drug_name": "LOMOTIL 2.5-0.025 MG TABLET",
      "ndc": 25006131,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.2292674699999995,
        "feasible_range": [
          2.5327587999999994,
          3.375388169999999
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 1.8995690999999995,
        "profit_projections": {
          "gross_profit_per_unit": 1.2663794,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 11397.4146,
          "annual_profit_projection": 136768.9752,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.5327587999999994,
        "regulatory_headroom": 8.798825359999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_25142160",
      "drug_name": "ARTHROTEC 75 MG-200 MCG TAB",
      "ndc": 25142160,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.3207551125,
        "feasible_range": [
          7.310396166666666,
          9.7425087375
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 5.482797124999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.6551980833333335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 36551.980833333335,
          "annual_profit_projection": 438623.77,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.310396166666666,
        "regulatory_headroom": 2.8267786516666646,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_25152031",
      "drug_name": "CELEBREX 100 MG CAPSULE",
      "ndc": 25152031,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.844821539583332,
        "feasible_range": [
          8.290376033333333,
          11.048520367499998
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.217782024999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.145188016666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12435.564049999999,
          "annual_profit_projection": 149226.76859999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.290376033333333,
        "regulatory_headroom": 1.601803818333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_25152034",
      "drug_name": "CELEBREX 100 MG CAPSULE",
      "ndc": 25152034,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.844821539583332,
        "feasible_range": [
          8.290376033333333,
          11.048520367499998
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.217782024999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.145188016666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12435.564049999999,
          "annual_profit_projection": 149226.76859999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.290376033333333,
        "regulatory_headroom": 1.601803818333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_25152051",
      "drug_name": "CELEBREX 100 MG CAPSULE",
      "ndc": 25152051,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.844821539583332,
        "feasible_range": [
          8.290376033333333,
          11.048520367499998
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.217782024999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.145188016666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12435.564049999999,
          "annual_profit_projection": 149226.76859999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.290376033333333,
        "regulatory_headroom": 1.601803818333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_25152531",
      "drug_name": "CELEBREX 200 MG CAPSULE",
      "ndc": 25152531,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.628605033333336,
        "feasible_range": [
          13.628605033333336,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.221453775000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.407151258333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10221.453775000002,
          "annual_profit_projection": 122657.44530000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.628605033333336,
        "regulatory_headroom": -1.6638311733333389,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.07"
        ]
      }
    },
    {
      "drug_id": "ndc_25152534",
      "drug_name": "CELEBREX 200 MG CAPSULE",
      "ndc": 25152534,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.628605033333336,
        "feasible_range": [
          13.628605033333336,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.221453775000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.407151258333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10221.453775000002,
          "annual_profit_projection": 122657.44530000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.628605033333336,
        "regulatory_headroom": -1.6638311733333389,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.07"
        ]
      }
    },
    {
      "drug_id": "ndc_25152551",
      "drug_name": "CELEBREX 200 MG CAPSULE",
      "ndc": 25152551,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.628605033333336,
        "feasible_range": [
          13.628605033333336,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.221453775000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.407151258333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10221.453775000002,
          "annual_profit_projection": 122657.44530000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.628605033333336,
        "regulatory_headroom": -1.6638311733333389,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.07"
        ]
      }
    },
    {
      "drug_id": "ndc_25171001",
      "drug_name": "INSPRA 25 MG TABLET",
      "ndc": 25171001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.279704666666667,
        "feasible_range": [
          12.279704666666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.2097785,
        "profit_projections": {
          "gross_profit_per_unit": 3.069926166666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 30699.26166666667,
          "annual_profit_projection": 368391.14,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.279704666666667,
        "regulatory_headroom": -0.31493080666666984,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.38"
        ]
      }
    },
    {
      "drug_id": "ndc_37024523",
      "drug_name": "DYMISTA NASAL SPRAY",
      "ndc": 37024523,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.072204284999998,
        "feasible_range": [
          7.899768066666666,
          10.527960134999999
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 5.924826049999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.9498840333333325,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 39498.840333333326,
          "annual_profit_projection": 473986.0839999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.899768066666666,
        "regulatory_headroom": 2.090063776666666,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_37043001",
      "drug_name": "FELBATOL 400 MG TABLET",
      "ndc": 37043001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.7039588,
        "feasible_range": [
          12.7039588,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.5279691,
        "profit_projections": {
          "gross_profit_per_unit": 3.1759897000000006,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 31759.897000000004,
          "annual_profit_projection": 381118.7640000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.7039588,
        "regulatory_headroom": -0.739184940000003,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.92"
        ]
      }
    },
    {
      "drug_id": "ndc_37043101",
      "drug_name": "FELBATOL 600 MG TABLET",
      "ndc": 37043101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.566492199999999,
        "feasible_range": [
          14.566492199999999,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.92486915,
        "profit_projections": {
          "gross_profit_per_unit": 3.6416230499999998,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 36416.2305,
          "annual_profit_projection": 436994.76599999995,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.566492199999999,
        "regulatory_headroom": -2.6017183400000015,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.24"
        ]
      }
    },
    {
      "drug_id": "ndc_37067896",
      "drug_name": "GASTROCROM 100 MG/5 ML CONC",
      "ndc": 37067896,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.5714631800000007,
        "feasible_range": [
          2.016833866666667,
          2.6878189800000003
        ],
        "expected_margin": 0.4117647058823531,
        "estimated_acquisition_cost": 1.5126254000000001,
        "profit_projections": {
          "gross_profit_per_unit": 1.0084169333333337,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 9075.752400000003,
          "annual_profit_projection": 108909.02880000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.016833866666667,
        "regulatory_headroom": 9.443731526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_37200101",
      "drug_name": "SOMA 350 MG TABLET",
      "ndc": 37200101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.933258545,
        "feasible_range": [
          9.359418466666666,
          11.964773859999998
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 7.01956385,
        "profit_projections": {
          "gross_profit_per_unit": 4.679709233333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 46797.09233333333,
          "annual_profit_projection": 561565.1079999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.359418466666666,
        "regulatory_headroom": 0.2655007766666646,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49005001",
      "drug_name": "ZOLOFT 20 MG/ML ORAL CONC",
      "ndc": 49005001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.779788975,
        "feasible_range": [
          3.9420939999999995,
          5.253598350000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.9565704999999998,
        "profit_projections": {
          "gross_profit_per_unit": 1.9710470000000004,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 8869.711500000001,
          "annual_profit_projection": 106436.53800000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.9420939999999995,
        "regulatory_headroom": 7.037156359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49017402",
      "drug_name": "GLUCOTROL XL 5 MG TABLET",
      "ndc": 49017402,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.4062175000000002,
        "feasible_range": [
          0.32497400000000015,
          0.43309035000000023
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.2437305000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.16248700000000008,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 1218.6525000000006,
          "annual_profit_projection": 14623.830000000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.32497400000000015,
        "regulatory_headroom": 11.558556359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49017403",
      "drug_name": "GLUCOTROL XL 5 MG TABLET",
      "ndc": 49017403,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.4062175000000002,
        "feasible_range": [
          0.32497400000000015,
          0.43309035000000023
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.2437305000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.16248700000000008,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 1218.6525000000006,
          "annual_profit_projection": 14623.830000000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.32497400000000015,
        "regulatory_headroom": 11.558556359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49017807",
      "drug_name": "GLUCOTROL XL 10 MG TABLET",
      "ndc": 49017807,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.7354966666666667,
        "feasible_range": [
          0.5883973333333333,
          0.7841526000000001
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 0.44129799999999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.2941986666666667,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 1985.8410000000003,
          "annual_profit_projection": 23830.092000000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.5883973333333333,
        "regulatory_headroom": 11.229277193333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49017808",
      "drug_name": "GLUCOTROL XL 10 MG TABLET",
      "ndc": 49017808,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.7354966666666667,
        "feasible_range": [
          0.5883973333333333,
          0.7841526000000001
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 0.44129799999999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.2941986666666667,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 1985.8410000000003,
          "annual_profit_projection": 23830.092000000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.5883973333333333,
        "regulatory_headroom": 11.229277193333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49035260",
      "drug_name": "GEODON 20 MG CAPSULE",
      "ndc": 49035260,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 21.10199346666667,
        "feasible_range": [
          21.10199346666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 15.826495100000002,
        "profit_projections": {
          "gross_profit_per_unit": 5.2754983666666675,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 52754.983666666674,
          "annual_profit_projection": 633059.8040000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 21.10199346666667,
        "regulatory_headroom": -9.137219606666672,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $14.41"
        ]
      }
    },
    {
      "drug_id": "ndc_49035860",
      "drug_name": "GEODON 80 MG CAPSULE",
      "ndc": 49035860,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 25.573364266666662,
        "feasible_range": [
          25.573364266666662,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 19.180023199999997,
        "profit_projections": {
          "gross_profit_per_unit": 6.393341066666665,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 63933.41066666665,
          "annual_profit_projection": 767200.9279999998,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 25.573364266666662,
        "regulatory_headroom": -13.608590406666664,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $20.00"
        ]
      }
    },
    {
      "drug_id": "ndc_49233045",
      "drug_name": "RELPAX 20 MG TABLET",
      "ndc": 49233045,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 67.24511039999997,
        "feasible_range": [
          67.24511039999997,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 50.43383279999998,
        "profit_projections": {
          "gross_profit_per_unit": 16.81127759999999,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 84056.38799999995,
          "annual_profit_projection": 1008676.6559999994,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 67.24511039999997,
        "regulatory_headroom": -55.28033653999998,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $72.09"
        ]
      }
    },
    {
      "drug_id": "ndc_49233079",
      "drug_name": "RELPAX 20 MG TABLET",
      "ndc": 49233079,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 67.24511039999997,
        "feasible_range": [
          67.24511039999997,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 50.43383279999998,
        "profit_projections": {
          "gross_profit_per_unit": 16.81127759999999,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 84056.38799999995,
          "annual_profit_projection": 1008676.6559999994,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 67.24511039999997,
        "regulatory_headroom": -55.28033653999998,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $72.09"
        ]
      }
    },
    {
      "drug_id": "ndc_49234005",
      "drug_name": "RELPAX 40 MG TABLET",
      "ndc": 49234005,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 67.01014536666668,
        "feasible_range": [
          67.01014536666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 50.25760902500001,
        "profit_projections": {
          "gross_profit_per_unit": 16.75253634166667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 83762.68170833334,
          "annual_profit_projection": 1005152.1805000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 67.01014536666668,
        "regulatory_headroom": -55.04537150666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $71.80"
        ]
      }
    },
    {
      "drug_id": "ndc_49234045",
      "drug_name": "RELPAX 40 MG TABLET",
      "ndc": 49234045,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 67.01014536666668,
        "feasible_range": [
          67.01014536666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 50.25760902500001,
        "profit_projections": {
          "gross_profit_per_unit": 16.75253634166667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 83762.68170833334,
          "annual_profit_projection": 1005152.1805000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 67.01014536666668,
        "regulatory_headroom": -55.04537150666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $71.80"
        ]
      }
    },
    {
      "drug_id": "ndc_49234079",
      "drug_name": "RELPAX 40 MG TABLET",
      "ndc": 49234079,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 67.01014536666668,
        "feasible_range": [
          67.01014536666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 50.25760902500001,
        "profit_projections": {
          "gross_profit_per_unit": 16.75253634166667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 83762.68170833334,
          "annual_profit_projection": 1005152.1805000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 67.01014536666668,
        "regulatory_headroom": -55.04537150666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $71.80"
        ]
      }
    },
    {
      "drug_id": "ndc_49342030",
      "drug_name": "DIFLUCAN 100 MG TABLET",
      "ndc": 49342030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.2074777,
        "feasible_range": [
          0.9470413333333333,
          1.2621147
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.7102809999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.4735206666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 4735.206666666667,
          "annual_profit_projection": 56822.48,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9470413333333333,
        "regulatory_headroom": 10.78097219333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49342041",
      "drug_name": "DIFLUCAN 100 MG TABLET",
      "ndc": 49342041,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.2074777,
        "feasible_range": [
          0.9470413333333333,
          1.2621147
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.7102809999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.4735206666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 4735.206666666667,
          "annual_profit_projection": 56822.48,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9470413333333333,
        "regulatory_headroom": 10.78097219333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49490030",
      "drug_name": "ZOLOFT 50 MG TABLET",
      "ndc": 49490030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.351011399999999,
        "feasible_range": [
          12.351011399999999,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.26325855,
        "profit_projections": {
          "gross_profit_per_unit": 3.0877528499999993,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15438.764249999997,
          "annual_profit_projection": 185265.17099999997,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.351011399999999,
        "regulatory_headroom": -0.38623754000000154,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.47"
        ]
      }
    },
    {
      "drug_id": "ndc_49490041",
      "drug_name": "ZOLOFT 50 MG TABLET",
      "ndc": 49490041,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.351011399999999,
        "feasible_range": [
          12.351011399999999,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.26325855,
        "profit_projections": {
          "gross_profit_per_unit": 3.0877528499999993,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15438.764249999997,
          "annual_profit_projection": 185265.17099999997,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.351011399999999,
        "regulatory_headroom": -0.38623754000000154,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.47"
        ]
      }
    },
    {
      "drug_id": "ndc_49491030",
      "drug_name": "ZOLOFT 100 MG TABLET",
      "ndc": 49491030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.319540133333335,
        "feasible_range": [
          12.319540133333335,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.239655100000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.0798850333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15399.425166666668,
          "annual_profit_projection": 184793.102,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.319540133333335,
        "regulatory_headroom": -0.3547662733333379,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.43"
        ]
      }
    },
    {
      "drug_id": "ndc_49491041",
      "drug_name": "ZOLOFT 100 MG TABLET",
      "ndc": 49491041,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.319540133333335,
        "feasible_range": [
          12.319540133333335,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.239655100000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.0798850333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15399.425166666668,
          "annual_profit_projection": 184793.102,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.319540133333335,
        "regulatory_headroom": -0.3547662733333379,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.43"
        ]
      }
    },
    {
      "drug_id": "ndc_49496030",
      "drug_name": "ZOLOFT 25 MG TABLET",
      "ndc": 49496030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.394581333333337,
        "feasible_range": [
          12.394581333333337,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.295936000000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.0986453333333337,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15493.22666666667,
          "annual_profit_projection": 185918.72000000003,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.394581333333337,
        "regulatory_headroom": -0.429807473333339,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.53"
        ]
      }
    },
    {
      "drug_id": "ndc_51846233",
      "drug_name": "ANDROGEL 1.62% GEL PUMP",
      "ndc": 51846233,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.735323350000002,
        "feasible_range": [
          6.851234000000001,
          9.13058685
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 5.1384255,
        "profit_projections": {
          "gross_profit_per_unit": 3.425617000000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 34256.170000000006,
          "annual_profit_projection": 411074.04000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.851234000000001,
        "regulatory_headroom": 3.4007313599999964,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65042636",
      "drug_name": "GENTEAL TEARS 0.1%-0.2%-0.3%",
      "ndc": 65042636,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.52943525,
        "feasible_range": [
          0.41524333333333335,
          0.5533915961538463
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.3114325,
        "profit_projections": {
          "gross_profit_per_unit": 0.2076216666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 2076.216666666667,
          "annual_profit_projection": 24914.600000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.41524333333333335,
        "regulatory_headroom": 11.44571969333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65042915",
      "drug_name": "SYSTANE 0.4-0.3% EYE DROP",
      "ndc": 65042915,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.7517748333333335,
        "feasible_range": [
          0.6014198666666668,
          0.8015076300000001
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.4510649000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.3007099333333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 2255.3245000000006,
          "annual_profit_projection": 27063.894000000008,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.6014198666666668,
        "regulatory_headroom": 11.212999026666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65043133",
      "drug_name": "SYSTANE 0.3-0.4% EYE DROP",
      "ndc": 65043133,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.39706116666666663,
        "feasible_range": [
          0.31764893333333327,
          0.42332829
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.23823669999999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.15882446666666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 1191.1834999999999,
          "annual_profit_projection": 14294.201999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.31764893333333327,
        "regulatory_headroom": 11.56771269333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65143206",
      "drug_name": "SYSTANE ULTRA 0.4-0.3% EYE DRP",
      "ndc": 65143206,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.47715416666666677,
        "feasible_range": [
          0.3817233333333334,
          0.5087197500000001
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.28629250000000006,
        "profit_projections": {
          "gross_profit_per_unit": 0.1908616666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 1431.4625000000003,
          "annual_profit_projection": 17177.550000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.3817233333333334,
        "regulatory_headroom": 11.48761969333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65143704",
      "drug_name": "SYSTANE HYDRATION PF 0.4-0.3%",
      "ndc": 65143704,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.39706116666666663,
        "feasible_range": [
          0.31764893333333327,
          0.42332829
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.23823669999999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.15882446666666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 1191.1834999999999,
          "annual_profit_projection": 14294.201999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.31764893333333327,
        "regulatory_headroom": 11.56771269333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65401105",
      "drug_name": "ZADITOR 0.025% (0.035%) DROPS",
      "ndc": 65401105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 2.4834167800000015,
        "feasible_range": [
          1.9477778666666679,
          2.5957885800000016
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 1.460833400000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.973888933333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 9738.88933333334,
          "annual_profit_projection": 116866.67200000008,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.9477778666666679,
        "regulatory_headroom": 9.530051526666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65427401",
      "drug_name": "PATADAY TWICE DAILY 0.1% DROPS",
      "ndc": 65427401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 2.73780325,
        "feasible_range": [
          2.147296666666666,
          2.86168575
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 1.6104724999999998,
        "profit_projections": {
          "gross_profit_per_unit": 1.0736483333333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 10736.483333333334,
          "annual_profit_projection": 128837.8,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.147296666666666,
        "regulatory_headroom": 9.280653026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65815001",
      "drug_name": "PATADAY ONCE DAILY 0.2% DROPS",
      "ndc": 65815001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 6.516838055000002,
        "feasible_range": [
          5.111245533333334,
          6.811717605000001
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 3.8334341500000004,
        "profit_projections": {
          "gross_profit_per_unit": 2.5556227666666675,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 23000.60490000001,
          "annual_profit_projection": 276007.2588000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.111245533333334,
        "regulatory_headroom": 5.57571694333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69024230",
      "drug_name": "TOVIAZ ER 4 MG TABLET",
      "ndc": 69024230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.239353767499999,
        "feasible_range": [
          8.0308657,
          10.702672942500001
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.023149275,
        "profit_projections": {
          "gross_profit_per_unit": 4.01543285,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 40154.328499999996,
          "annual_profit_projection": 481851.9419999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.0308657,
        "regulatory_headroom": 1.926191734999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69024430",
      "drug_name": "TOVIAZ ER 8 MG TABLET",
      "ndc": 69024430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.240201302499996,
        "feasible_range": [
          8.03153043333333,
          10.703558827499997
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.023647824999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.015765216666665,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 40157.65216666665,
          "annual_profit_projection": 481891.8259999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.03153043333333,
        "regulatory_headroom": 1.9253608183333348,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69033621",
      "drug_name": "REVATIO 10 MG/ML ORAL SUSP",
      "ndc": 69033621,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 76.460852,
        "feasible_range": [
          76.460852,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 57.345639,
        "profit_projections": {
          "gross_profit_per_unit": 19.115213000000004,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 191152.13000000003,
          "annual_profit_projection": 2293825.5600000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 76.460852,
        "regulatory_headroom": -64.49607814000001,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $83.61"
        ]
      }
    },
    {
      "drug_id": "ndc_69152068",
      "drug_name": "NORVASC 2.5 MG TABLET",
      "ndc": 69152068,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.460675220833338,
        "feasible_range": [
          7.124779133333337,
          9.495138345000004
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 5.343584350000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.5623895666666687,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10687.168700000006,
          "annual_profit_projection": 128246.02440000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.124779133333337,
        "regulatory_headroom": 3.0587999433333266,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69153041",
      "drug_name": "NORVASC 5 MG TABLET",
      "ndc": 69153041,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.533506258333333,
        "feasible_range": [
          7.1861105333333315,
          9.576874229999998
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 5.389582899999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.593055266666667,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 9701.249220000002,
          "annual_profit_projection": 116414.99064000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.1861105333333315,
        "regulatory_headroom": 2.9821356933333316,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69153068",
      "drug_name": "NORVASC 5 MG TABLET",
      "ndc": 69153068,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.533506258333333,
        "feasible_range": [
          7.1861105333333315,
          9.576874229999998
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 5.389582899999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.593055266666667,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 9701.249220000002,
          "annual_profit_projection": 116414.99064000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.1861105333333315,
        "regulatory_headroom": 2.9821356933333316,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69153072",
      "drug_name": "NORVASC 5 MG TABLET",
      "ndc": 69153072,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.533506258333333,
        "feasible_range": [
          7.1861105333333315,
          9.576874229999998
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 5.389582899999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.593055266666667,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 9701.249220000002,
          "annual_profit_projection": 116414.99064000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.1861105333333315,
        "regulatory_headroom": 2.9821356933333316,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69154041",
      "drug_name": "NORVASC 10 MG TABLET",
      "ndc": 69154041,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.784606962962961,
          11.964773859999998
        ],
        "expected_margin": 0.3543806345202132,
        "estimated_acquisition_cost": 7.338455222222221,
        "profit_projections": {
          "gross_profit_per_unit": 4.626318637777777,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13878.95591333333,
          "annual_profit_projection": 166547.47095999995,
          "margin_percentage": 38.666160279420254
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.784606962962961,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.27"
        ]
      }
    },
    {
      "drug_id": "ndc_69154068",
      "drug_name": "NORVASC 10 MG TABLET",
      "ndc": 69154068,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.808158533333332,
          11.964773859999998
        ],
        "expected_margin": 0.35282662729476943,
        "estimated_acquisition_cost": 7.356118899999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.608654959999998,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13825.964879999994,
          "annual_profit_projection": 165911.57855999994,
          "margin_percentage": 38.518529593003095
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.808158533333332,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.30"
        ]
      }
    },
    {
      "drug_id": "ndc_69306075",
      "drug_name": "ZITHROMAX 250 MG Z-PAK TABLET",
      "ndc": 69306075,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.251714291666666,
        "feasible_range": [
          1.801371433333333,
          2.4006738524999998
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 1.3510285749999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.9006857166666664,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 6755.142874999998,
          "annual_profit_projection": 81061.71449999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.801371433333333,
        "regulatory_headroom": 9.713059568333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69406101",
      "drug_name": "ZITHROMAX 250 MG TABLET",
      "ndc": 69406101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.251714291666666,
        "feasible_range": [
          1.801371433333333,
          2.4006738524999998
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 1.3510285749999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.9006857166666664,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 6755.142874999998,
          "annual_profit_projection": 81061.71449999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.801371433333333,
        "regulatory_headroom": 9.713059568333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69406189",
      "drug_name": "ZITHROMAX 250 MG TABLET",
      "ndc": 69406189,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.251714291666666,
        "feasible_range": [
          1.801371433333333,
          2.4006738524999998
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 1.3510285749999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.9006857166666664,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 6755.142874999998,
          "annual_profit_projection": 81061.71449999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.801371433333333,
        "regulatory_headroom": 9.713059568333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69421030",
      "drug_name": "VIAGRA 50 MG TABLET",
      "ndc": 69421030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 73.29353200000001,
        "feasible_range": [
          73.29353200000001,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 54.97014900000001,
        "profit_projections": {
          "gross_profit_per_unit": 18.323383,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 137425.3725,
          "annual_profit_projection": 1649104.47,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 73.29353200000001,
        "regulatory_headroom": -61.32875814000002,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $79.65"
        ]
      }
    },
    {
      "drug_id": "ndc_69421066",
      "drug_name": "VIAGRA 50 MG TABLET",
      "ndc": 69421066,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 73.29353200000001,
        "feasible_range": [
          73.29353200000001,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 54.97014900000001,
        "profit_projections": {
          "gross_profit_per_unit": 18.323383,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 137425.3725,
          "annual_profit_projection": 1649104.47,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 73.29353200000001,
        "regulatory_headroom": -61.32875814000002,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $79.65"
        ]
      }
    },
    {
      "drug_id": "ndc_69422030",
      "drug_name": "VIAGRA 100 MG TABLET",
      "ndc": 69422030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 72.66535856666665,
        "feasible_range": [
          72.66535856666665,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 54.499018924999994,
        "profit_projections": {
          "gross_profit_per_unit": 18.16633964166666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 136247.54731249996,
          "annual_profit_projection": 1634970.5677499995,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 72.66535856666665,
        "regulatory_headroom": -60.70058470666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $78.87"
        ]
      }
    },
    {
      "drug_id": "ndc_69422066",
      "drug_name": "VIAGRA 100 MG TABLET",
      "ndc": 69422066,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 72.66535856666665,
        "feasible_range": [
          72.66535856666665,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 54.499018924999994,
        "profit_projections": {
          "gross_profit_per_unit": 18.16633964166666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 136247.54731249996,
          "annual_profit_projection": 1634970.5677499995,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 72.66535856666665,
        "regulatory_headroom": -60.70058470666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $78.87"
        ]
      }
    },
    {
      "drug_id": "ndc_69582043",
      "drug_name": "TIKOSYN 500 MCG CAPSULE",
      "ndc": 69582043,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.645530000000003,
        "feasible_range": [
          9.316424000000001,
          11.964773859999998
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.987318000000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.658212000000002,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 34936.59000000001,
          "annual_profit_projection": 419239.08000000013,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.316424000000001,
        "regulatory_headroom": 0.31924385999999494,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69582060",
      "drug_name": "TIKOSYN 500 MCG CAPSULE",
      "ndc": 69582060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.662860625000006,
        "feasible_range": [
          9.330288500000004,
          11.964773859999998
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.997716375000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.665144250000003,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 34988.58187500002,
          "annual_profit_projection": 419862.9825000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.330288500000004,
        "regulatory_headroom": 0.3019132349999918,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69582061",
      "drug_name": "TIKOSYN 500 MCG CAPSULE",
      "ndc": 69582061,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.662860625000006,
        "feasible_range": [
          9.330288500000004,
          11.964773859999998
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.997716375000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.665144250000003,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 34988.58187500002,
          "annual_profit_projection": 419862.9825000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.330288500000004,
        "regulatory_headroom": 0.3019132349999918,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71000724",
      "drug_name": "DILANTIN 50 MG INFATAB",
      "ndc": 71000724,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.5895955833333335,
        "feasible_range": [
          1.3110066666666669,
          1.7471685000000006
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.9832550000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.6555033333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 3277.5166666666673,
          "annual_profit_projection": 39330.20000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3110066666666669,
        "regulatory_headroom": 10.326015526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71000740",
      "drug_name": "DILANTIN 50 MG INFATAB",
      "ndc": 71000740,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.5895955833333335,
        "feasible_range": [
          1.3110066666666669,
          1.7471685000000006
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.9832550000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.6555033333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 3277.5166666666673,
          "annual_profit_projection": 39330.20000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3110066666666669,
        "regulatory_headroom": 10.326015526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71015523",
      "drug_name": "LIPITOR 10 MG TABLET",
      "ndc": 71015523,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.060003066666667,
          11.964773859999998
        ],
        "expected_margin": 0.28527284652861795,
        "estimated_acquisition_cost": 8.2950023,
        "profit_projections": {
          "gross_profit_per_unit": 3.6697715599999974,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18348.857799999987,
          "annual_profit_projection": 220186.29359999986,
          "margin_percentage": 30.67146611327594
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.060003066666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.86"
        ]
      }
    },
    {
      "drug_id": "ndc_71015623",
      "drug_name": "LIPITOR 20 MG TABLET",
      "ndc": 71015623,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.81416026666667,
        "feasible_range": [
          15.81416026666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.860620200000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.953540066666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19767.700333333334,
          "annual_profit_projection": 237212.404,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.81416026666667,
        "regulatory_headroom": -3.8493864066666728,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.80"
        ]
      }
    },
    {
      "drug_id": "ndc_71015723",
      "drug_name": "LIPITOR 40 MG TABLET",
      "ndc": 71015723,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.848492400000005,
        "feasible_range": [
          15.848492400000005,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.886369300000004,
        "profit_projections": {
          "gross_profit_per_unit": 3.9621231000000012,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19810.615500000007,
          "annual_profit_projection": 237727.3860000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.848492400000005,
        "regulatory_headroom": -3.8837185400000074,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.85"
        ]
      }
    },
    {
      "drug_id": "ndc_71015823",
      "drug_name": "LIPITOR 80 MG TABLET",
      "ndc": 71015823,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.902466666666667,
        "feasible_range": [
          15.902466666666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.92685,
        "profit_projections": {
          "gross_profit_per_unit": 3.9756166666666672,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19878.083333333336,
          "annual_profit_projection": 238537.00000000003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.902466666666667,
        "regulatory_headroom": -3.9376928066666697,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.91"
        ]
      }
    },
    {
      "drug_id": "ndc_71035060",
      "drug_name": "NARDIL 15 MG TABLET",
      "ndc": 71035060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.7249846975,
        "feasible_range": [
          2.1372429,
          2.8482871724999996
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 1.6029321749999998,
        "profit_projections": {
          "gross_profit_per_unit": 1.0686214500000002,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 9617.593050000001,
          "annual_profit_projection": 115411.11660000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.1372429,
        "regulatory_headroom": 9.293220234999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71036924",
      "drug_name": "DILANTIN 100 MG CAPSULE",
      "ndc": 71036924,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.7400454933333336,
        "feasible_range": [
          1.4350890666666667,
          1.91253216
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 1.0763168,
        "profit_projections": {
          "gross_profit_per_unit": 0.7175445333333335,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 3587.7226666666675,
          "annual_profit_projection": 43052.672000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4350890666666667,
        "regulatory_headroom": 10.170912526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71036932",
      "drug_name": "DILANTIN 100 MG CAPSULE",
      "ndc": 71036932,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.7400454933333336,
        "feasible_range": [
          1.4350890666666667,
          1.91253216
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 1.0763168,
        "profit_projections": {
          "gross_profit_per_unit": 0.7175445333333335,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 3587.7226666666675,
          "annual_profit_projection": 43052.672000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4350890666666667,
        "regulatory_headroom": 10.170912526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71036940",
      "drug_name": "DILANTIN 100 MG CAPSULE",
      "ndc": 71036940,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.7400454933333336,
        "feasible_range": [
          1.4350890666666667,
          1.91253216
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 1.0763168,
        "profit_projections": {
          "gross_profit_per_unit": 0.7175445333333335,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 3587.7226666666675,
          "annual_profit_projection": 43052.672000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4350890666666667,
        "regulatory_headroom": 10.170912526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71040124",
      "drug_name": "NEURONTIN 800 MG TABLET",
      "ndc": 71040124,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.936993199999998,
        "feasible_range": [
          13.936993199999998,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 10.452744899999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.484248299999999,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 26131.862249999995,
          "annual_profit_projection": 313582.34699999995,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.936993199999998,
        "regulatory_headroom": -1.9722193400000005,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.46"
        ]
      }
    },
    {
      "drug_id": "ndc_71041813",
      "drug_name": "NITROSTAT 0.4 MG TABLET SL",
      "ndc": 71041813,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6797625000000005,
        "feasible_range": [
          1.3438100000000004,
          1.7908852500000005
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.0078575000000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.6719050000000002,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 5039.287500000001,
          "annual_profit_projection": 60471.45000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3438100000000004,
        "regulatory_headroom": 10.285011359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71051324",
      "drug_name": "NEURONTIN 600 MG TABLET",
      "ndc": 71051324,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.630809666666666,
          11.964773859999998
        ],
        "expected_margin": 0.2709342147148612,
        "estimated_acquisition_cost": 8.72310725,
        "profit_projections": {
          "gross_profit_per_unit": 3.2416666099999976,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 24312.499574999983,
          "annual_profit_projection": 291749.9948999998,
          "margin_percentage": 27.093421471486117
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.630809666666666,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.57"
        ]
      }
    },
    {
      "drug_id": "ndc_71080324",
      "drug_name": "NEURONTIN 100 MG CAPSULE",
      "ndc": 71080324,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.063105499999999,
        "feasible_range": [
          2.4504843999999992,
          3.2657417099999995
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.8378632999999993,
        "profit_projections": {
          "gross_profit_per_unit": 1.2252421999999996,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 9189.316499999997,
          "annual_profit_projection": 110271.79799999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.4504843999999992,
        "regulatory_headroom": 8.901668359999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71080524",
      "drug_name": "NEURONTIN 300 MG CAPSULE",
      "ndc": 71080524,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.632125583333335,
        "feasible_range": [
          6.105700466666668,
          8.137020045000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.5792753500000005,
        "profit_projections": {
          "gross_profit_per_unit": 3.0528502333333343,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 22896.376750000007,
          "annual_profit_projection": 274756.52100000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.105700466666668,
        "regulatory_headroom": 4.332648276666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71080624",
      "drug_name": "NEURONTIN 400 MG CAPSULE",
      "ndc": 71080624,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.125319666666668,
        "feasible_range": [
          7.3002557333333336,
          9.728994660000001
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 5.4751918,
        "profit_projections": {
          "gross_profit_per_unit": 3.6501278666666677,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 24638.363100000006,
          "annual_profit_projection": 295660.3572000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.3002557333333336,
        "regulatory_headroom": 2.8394541933333297,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101268",
      "drug_name": "LYRICA 25 MG CAPSULE",
      "ndc": 71101268,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.978872041666666,
        "feasible_range": [
          8.403260666666666,
          11.198960849999999
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.302445499999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.201630333333334,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 11344.401900000003,
          "annual_profit_projection": 136132.82280000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.403260666666666,
        "regulatory_headroom": 1.4606980266666643,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101341",
      "drug_name": "LYRICA 50 MG CAPSULE",
      "ndc": 71101341,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.990559258333333,
        "feasible_range": [
          8.413102533333332,
          11.21207703
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.309826899999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.206551266666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12619.6538,
          "annual_profit_projection": 151435.8456,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.413102533333332,
        "regulatory_headroom": 1.4483956933333317,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101368",
      "drug_name": "LYRICA 50 MG CAPSULE",
      "ndc": 71101368,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.990559258333333,
        "feasible_range": [
          8.413102533333332,
          11.21207703
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.309826899999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.206551266666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12619.6538,
          "annual_profit_projection": 151435.8456,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.413102533333332,
        "regulatory_headroom": 1.4483956933333317,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101441",
      "drug_name": "LYRICA 75 MG CAPSULE",
      "ndc": 71101441,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.983287166666667,
        "feasible_range": [
          8.406978666666667,
          11.2039158
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.3052340000000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.203489333333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12610.468,
          "annual_profit_projection": 151325.616,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.406978666666667,
        "regulatory_headroom": 1.4560505266666635,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101468",
      "drug_name": "LYRICA 75 MG CAPSULE",
      "ndc": 71101468,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.983287166666667,
        "feasible_range": [
          8.406978666666667,
          11.2039158
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.3052340000000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.203489333333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12610.468,
          "annual_profit_projection": 151325.616,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.406978666666667,
        "regulatory_headroom": 1.4560505266666635,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101541",
      "drug_name": "LYRICA 100 MG CAPSULE",
      "ndc": 71101541,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.97824270625,
        "feasible_range": [
          8.402730700000001,
          11.198254567500003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.302048025,
        "profit_projections": {
          "gross_profit_per_unit": 4.2013653500000006,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12604.096050000002,
          "annual_profit_projection": 151249.15260000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.402730700000001,
        "regulatory_headroom": 1.4613604849999966,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101568",
      "drug_name": "LYRICA 100 MG CAPSULE",
      "ndc": 71101568,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.97824270625,
        "feasible_range": [
          8.402730700000001,
          11.198254567500003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.302048025,
        "profit_projections": {
          "gross_profit_per_unit": 4.2013653500000006,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12604.096050000002,
          "annual_profit_projection": 151249.15260000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.402730700000001,
        "regulatory_headroom": 1.4613604849999966,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101641",
      "drug_name": "LYRICA 150 MG CAPSULE",
      "ndc": 71101641,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.970644883333332,
        "feasible_range": [
          8.396332533333332,
          11.189727779999998
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.297249399999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.198166266666667,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 11335.048920000001,
          "annual_profit_projection": 136020.58704,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.396332533333332,
        "regulatory_headroom": 1.4693581933333313,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101668",
      "drug_name": "LYRICA 150 MG CAPSULE",
      "ndc": 71101668,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.970644883333332,
        "feasible_range": [
          8.396332533333332,
          11.189727779999998
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.297249399999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.198166266666667,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 11335.048920000001,
          "annual_profit_projection": 136020.58704,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.396332533333332,
        "regulatory_headroom": 1.4693581933333313,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101768",
      "drug_name": "LYRICA 200 MG CAPSULE",
      "ndc": 71101768,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.981672918750004,
        "feasible_range": [
          8.405619300000003,
          11.202104182500003
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.304214475000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.2028096500000025,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 11347.586055000007,
          "annual_profit_projection": 136171.03266000008,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.405619300000003,
        "regulatory_headroom": 1.457749734999993,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101868",
      "drug_name": "LYRICA 300 MG CAPSULE",
      "ndc": 71101868,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.973635127083337,
        "feasible_range": [
          8.398850633333337,
          11.193083632500004
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.2991379750000025,
        "profit_projections": {
          "gross_profit_per_unit": 4.1994253166666695,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 11338.448355000008,
          "annual_profit_projection": 136061.3802600001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.398850633333337,
        "regulatory_headroom": 1.4662105683333255,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_71101968",
      "drug_name": "LYRICA 225 MG CAPSULE",
      "ndc": 71101968,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.98196108541667,
        "feasible_range": [
          8.405861966666668,
          11.202427582500004
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.304396475000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.202930983333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12608.792950000003,
          "annual_profit_projection": 151305.51540000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.405861966666668,
        "regulatory_headroom": 1.4574464016666617,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74234030",
      "drug_name": "NORVIR 100 MG TABLET",
      "ndc": 74234030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.2144187525,
        "feasible_range": [
          7.2269951,
          9.6313607775
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.420246325,
        "profit_projections": {
          "gross_profit_per_unit": 3.613497550000001,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 32521.477950000008,
          "annual_profit_projection": 390257.7354000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.2269951,
        "regulatory_headroom": 2.931029984999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74310832",
      "drug_name": "GENGRAF 25 MG CAPSULE",
      "ndc": 74310832,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.9584638775000007,
        "feasible_range": [
          1.5360501000000004,
          2.0470821525000003
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 1.1520375750000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.7680250500000003,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 7680.250500000003,
          "annual_profit_projection": 92163.00600000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.5360501000000004,
        "regulatory_headroom": 10.044711234999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74310932",
      "drug_name": "GENGRAF 100 MG CAPSULE",
      "ndc": 74310932,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.791298092500002,
        "feasible_range": [
          6.110822033333334,
          8.1438455175
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 4.583116525,
        "profit_projections": {
          "gross_profit_per_unit": 3.0554110166666675,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 30554.110166666676,
          "annual_profit_projection": 366649.3220000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.110822033333334,
        "regulatory_headroom": 4.32624631833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74316290",
      "drug_name": "TRILIPIX DR 135 MG CAPSULE",
      "ndc": 74316290,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.537453900000001,
        "feasible_range": [
          7.4803560000000004,
          9.969012900000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.610267,
        "profit_projections": {
          "gross_profit_per_unit": 3.7401780000000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 37401.78,
          "annual_profit_projection": 448821.36,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.4803560000000004,
        "regulatory_headroom": 2.614328859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74318990",
      "drug_name": "TRICOR 145 MG TABLET",
      "ndc": 74318990,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1027198325000005,
        "feasible_range": [
          0.8648783000000003,
          1.1526166575000003
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.6486587250000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.4324391500000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 4324.391500000002,
          "annual_profit_projection": 51892.69800000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8648783000000003,
        "regulatory_headroom": 10.883675984999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74372719",
      "drug_name": "SYNTHROID 137 MCG TABLET",
      "ndc": 74372719,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.630373414583333,
        "feasible_range": [
          1.3729460333333332,
          1.8297146175
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 1.029709525,
        "profit_projections": {
          "gross_profit_per_unit": 0.6864730166666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.41905,
          "annual_profit_projection": 24713.028599999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3729460333333332,
        "regulatory_headroom": 10.24859131833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74372790",
      "drug_name": "SYNTHROID 137 MCG TABLET",
      "ndc": 74372790,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.630373414583333,
        "feasible_range": [
          1.3729460333333332,
          1.8297146175
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 1.029709525,
        "profit_projections": {
          "gross_profit_per_unit": 0.6864730166666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.41905,
          "annual_profit_projection": 24713.028599999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3729460333333332,
        "regulatory_headroom": 10.24859131833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74382611",
      "drug_name": "DEPAKOTE ER 250 MG TABLET",
      "ndc": 74382611,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.6903974141666662,
        "feasible_range": [
          3.043626733333333,
          4.056217934999999
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.2827200499999996,
        "profit_projections": {
          "gross_profit_per_unit": 1.5218133666666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 7609.066833333333,
          "annual_profit_projection": 91308.802,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.043626733333333,
        "regulatory_headroom": 8.16024044333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74401412",
      "drug_name": "KALETRA 200-50 MG TABLET",
      "ndc": 74401412,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.176030500000005,
        "feasible_range": [
          7.196886666666669,
          9.591235500000003
        ],
        "expected_margin": 0.4117647058823531,
        "estimated_acquisition_cost": 5.397665000000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.5984433333333357,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 32385.99000000002,
          "annual_profit_projection": 388631.88000000024,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.196886666666669,
        "regulatory_headroom": 2.96866552666666,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74434119",
      "drug_name": "SYNTHROID 25 MCG TABLET",
      "ndc": 74434119,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.630106345833333,
        "feasible_range": [
          1.3727211333333331,
          1.829414895
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 1.0295408499999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.6863605666666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.0816999999997,
          "annual_profit_projection": 24708.980399999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3727211333333331,
        "regulatory_headroom": 10.248872443333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74434190",
      "drug_name": "SYNTHROID 25 MCG TABLET",
      "ndc": 74434190,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.630106345833333,
        "feasible_range": [
          1.3727211333333331,
          1.829414895
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 1.0295408499999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.6863605666666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.0816999999997,
          "annual_profit_projection": 24708.980399999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3727211333333331,
        "regulatory_headroom": 10.248872443333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74455211",
      "drug_name": "SYNTHROID 50 MCG TABLET",
      "ndc": 74455211,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6301253854166668,
        "feasible_range": [
          1.3727371666666668,
          1.8294362625000005
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.029552875,
        "profit_projections": {
          "gross_profit_per_unit": 0.6863685833333335,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1853.1951750000005,
          "annual_profit_projection": 22238.342100000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3727371666666668,
        "regulatory_headroom": 10.248852401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74455219",
      "drug_name": "SYNTHROID 50 MCG TABLET",
      "ndc": 74455219,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6301253854166668,
        "feasible_range": [
          1.3727371666666668,
          1.8294362625000005
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.029552875,
        "profit_projections": {
          "gross_profit_per_unit": 0.6863685833333335,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1853.1951750000005,
          "annual_profit_projection": 22238.342100000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3727371666666668,
        "regulatory_headroom": 10.248852401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74455290",
      "drug_name": "SYNTHROID 50 MCG TABLET",
      "ndc": 74455290,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6301253854166668,
        "feasible_range": [
          1.3727371666666668,
          1.8294362625000005
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.029552875,
        "profit_projections": {
          "gross_profit_per_unit": 0.6863685833333335,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1853.1951750000005,
          "annual_profit_projection": 22238.342100000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3727371666666668,
        "regulatory_headroom": 10.248852401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74518211",
      "drug_name": "SYNTHROID 75 MCG TABLET",
      "ndc": 74518211,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6308972604166672,
        "feasible_range": [
          1.373387166666667,
          1.8303025125000005
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.0300403750000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.6866935833333336,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1854.0726750000008,
          "annual_profit_projection": 22248.872100000008,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.373387166666667,
        "regulatory_headroom": 10.248039901666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74518219",
      "drug_name": "SYNTHROID 75 MCG TABLET",
      "ndc": 74518219,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6308972604166672,
        "feasible_range": [
          1.373387166666667,
          1.8303025125000005
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.0300403750000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.6866935833333336,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1854.0726750000008,
          "annual_profit_projection": 22248.872100000008,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.373387166666667,
        "regulatory_headroom": 10.248039901666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74518290",
      "drug_name": "SYNTHROID 75 MCG TABLET",
      "ndc": 74518290,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6308972604166672,
        "feasible_range": [
          1.373387166666667,
          1.8303025125000005
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.0300403750000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.6866935833333336,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1854.0726750000008,
          "annual_profit_projection": 22248.872100000008,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.373387166666667,
        "regulatory_headroom": 10.248039901666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74611413",
      "drug_name": "DEPAKOTE DR 125 MG SPRINKLE CP",
      "ndc": 74611413,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.9724787929166676,
        "feasible_range": [
          1.626786633333334,
          2.168006032500001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 1.2200899750000005,
        "profit_projections": {
          "gross_profit_per_unit": 0.8133933166666671,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 4066.9665833333356,
          "annual_profit_projection": 48803.59900000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.626786633333334,
        "regulatory_headroom": 9.93129056833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74621413",
      "drug_name": "DEPAKOTE DR 250 MG TABLET",
      "ndc": 74621413,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.052943320833334,
        "feasible_range": [
          3.3426336666666665,
          4.4547021749999995
        ],
        "expected_margin": 0.3814432989690723,
        "estimated_acquisition_cost": 2.50697525,
        "profit_projections": {
          "gross_profit_per_unit": 1.671316833333334,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 7520.925750000003,
          "annual_profit_projection": 90251.10900000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.3426336666666665,
        "regulatory_headroom": 7.786481776666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74621453",
      "drug_name": "DEPAKOTE DR 250 MG TABLET",
      "ndc": 74621453,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.052943320833334,
        "feasible_range": [
          3.3426336666666665,
          4.4547021749999995
        ],
        "expected_margin": 0.3814432989690723,
        "estimated_acquisition_cost": 2.50697525,
        "profit_projections": {
          "gross_profit_per_unit": 1.671316833333334,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 7520.925750000003,
          "annual_profit_projection": 90251.10900000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.3426336666666665,
        "regulatory_headroom": 7.786481776666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74621553",
      "drug_name": "DEPAKOTE DR 500 MG TABLET",
      "ndc": 74621553,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.460910887083332,
        "feasible_range": [
          6.153328566666666,
          8.2004936475
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 4.614996424999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.076664283333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15383.321416666664,
          "annual_profit_projection": 184599.85699999996,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.153328566666666,
        "regulatory_headroom": 4.273113151666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74659419",
      "drug_name": "SYNTHROID 88 MCG TABLET",
      "ndc": 74659419,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6308149270833334,
        "feasible_range": [
          1.3733178333333333,
          1.8302101125000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 1.029988375,
        "profit_projections": {
          "gross_profit_per_unit": 0.6866589166666668,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.9767500000003,
          "annual_profit_projection": 24719.721000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3733178333333333,
        "regulatory_headroom": 10.24812656833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74659490",
      "drug_name": "SYNTHROID 88 MCG TABLET",
      "ndc": 74659490,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6308149270833334,
        "feasible_range": [
          1.3733178333333333,
          1.8302101125000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 1.029988375,
        "profit_projections": {
          "gross_profit_per_unit": 0.6866589166666668,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.9767500000003,
          "annual_profit_projection": 24719.721000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3733178333333333,
        "regulatory_headroom": 10.24812656833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74662411",
      "drug_name": "SYNTHROID 100 MCG TABLET",
      "ndc": 74662411,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6301361916666672,
        "feasible_range": [
          1.372746266666667,
          1.8294483900000007
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.0295597000000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.6863731333333336,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.119400000001,
          "annual_profit_projection": 24709.43280000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.372746266666667,
        "regulatory_headroom": 10.248841026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74662419",
      "drug_name": "SYNTHROID 100 MCG TABLET",
      "ndc": 74662419,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6301361916666672,
        "feasible_range": [
          1.372746266666667,
          1.8294483900000007
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.0295597000000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.6863731333333336,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.119400000001,
          "annual_profit_projection": 24709.43280000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.372746266666667,
        "regulatory_headroom": 10.248841026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74662490",
      "drug_name": "SYNTHROID 100 MCG TABLET",
      "ndc": 74662490,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6301361916666672,
        "feasible_range": [
          1.372746266666667,
          1.8294483900000007
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.0295597000000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.6863731333333336,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.119400000001,
          "annual_profit_projection": 24709.43280000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.372746266666667,
        "regulatory_headroom": 10.248841026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74679922",
      "drug_name": "KALETRA 200-50 MG TABLET",
      "ndc": 74679922,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.176030500000005,
        "feasible_range": [
          7.196886666666669,
          9.591235500000003
        ],
        "expected_margin": 0.4117647058823531,
        "estimated_acquisition_cost": 5.397665000000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.5984433333333357,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 32385.99000000002,
          "annual_profit_projection": 388631.88000000024,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.196886666666669,
        "regulatory_headroom": 2.96866552666666,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74706811",
      "drug_name": "SYNTHROID 125 MCG TABLET",
      "ndc": 74706811,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6310413437500002,
        "feasible_range": [
          1.3735085,
          1.8304642125000004
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.030131375,
        "profit_projections": {
          "gross_profit_per_unit": 0.6867542500000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2060.2627500000003,
          "annual_profit_projection": 24723.153000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3735085,
        "regulatory_headroom": 10.247888234999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74706819",
      "drug_name": "SYNTHROID 125 MCG TABLET",
      "ndc": 74706819,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6310413437500002,
        "feasible_range": [
          1.3735085,
          1.8304642125000004
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.030131375,
        "profit_projections": {
          "gross_profit_per_unit": 0.6867542500000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2060.2627500000003,
          "annual_profit_projection": 24723.153000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3735085,
        "regulatory_headroom": 10.247888234999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74706890",
      "drug_name": "SYNTHROID 125 MCG TABLET",
      "ndc": 74706890,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6310413437500002,
        "feasible_range": [
          1.3735085,
          1.8304642125000004
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.030131375,
        "profit_projections": {
          "gross_profit_per_unit": 0.6867542500000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2060.2627500000003,
          "annual_profit_projection": 24723.153000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3735085,
        "regulatory_headroom": 10.247888234999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74706911",
      "drug_name": "SYNTHROID 150 MCG TABLET",
      "ndc": 74706911,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6303327625000001,
        "feasible_range": [
          1.3729118,
          1.8296689950000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.02968385,
        "profit_projections": {
          "gross_profit_per_unit": 0.6864559000000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.3677000000002,
          "annual_profit_projection": 24712.4124,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3729118,
        "regulatory_headroom": 10.248634109999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74706919",
      "drug_name": "SYNTHROID 150 MCG TABLET",
      "ndc": 74706919,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6303327625000001,
        "feasible_range": [
          1.3729118,
          1.8296689950000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.02968385,
        "profit_projections": {
          "gross_profit_per_unit": 0.6864559000000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.3677000000002,
          "annual_profit_projection": 24712.4124,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3729118,
        "regulatory_headroom": 10.248634109999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74706990",
      "drug_name": "SYNTHROID 150 MCG TABLET",
      "ndc": 74706990,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6303327625000001,
        "feasible_range": [
          1.3729118,
          1.8296689950000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.02968385,
        "profit_projections": {
          "gross_profit_per_unit": 0.6864559000000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2059.3677000000002,
          "annual_profit_projection": 24712.4124,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3729118,
        "regulatory_headroom": 10.248634109999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74707019",
      "drug_name": "SYNTHROID 175 MCG TABLET",
      "ndc": 74707019,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.627426395833334,
        "feasible_range": [
          1.3704643333333337,
          1.8264072750000007
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.0278482500000004,
        "profit_projections": {
          "gross_profit_per_unit": 0.685232166666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2055.696500000001,
          "annual_profit_projection": 24668.35800000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3704643333333337,
        "regulatory_headroom": 10.25169344333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74707090",
      "drug_name": "SYNTHROID 175 MCG TABLET",
      "ndc": 74707090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.627426395833334,
        "feasible_range": [
          1.3704643333333337,
          1.8264072750000007
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.0278482500000004,
        "profit_projections": {
          "gross_profit_per_unit": 0.685232166666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2055.696500000001,
          "annual_profit_projection": 24668.35800000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3704643333333337,
        "regulatory_headroom": 10.25169344333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74714811",
      "drug_name": "SYNTHROID 200 MCG TABLET",
      "ndc": 74714811,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6293159458333333,
        "feasible_range": [
          1.3720555333333333,
          1.8285278550000001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.02904165,
        "profit_projections": {
          "gross_profit_per_unit": 0.6860277666666668,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1852.2749700000002,
          "annual_profit_projection": 22227.29964,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3720555333333333,
        "regulatory_headroom": 10.24970444333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74714819",
      "drug_name": "SYNTHROID 200 MCG TABLET",
      "ndc": 74714819,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6293159458333333,
        "feasible_range": [
          1.3720555333333333,
          1.8285278550000001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.02904165,
        "profit_projections": {
          "gross_profit_per_unit": 0.6860277666666668,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1852.2749700000002,
          "annual_profit_projection": 22227.29964,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3720555333333333,
        "regulatory_headroom": 10.24970444333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74714890",
      "drug_name": "SYNTHROID 200 MCG TABLET",
      "ndc": 74714890,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6293159458333333,
        "feasible_range": [
          1.3720555333333333,
          1.8285278550000001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.02904165,
        "profit_projections": {
          "gross_profit_per_unit": 0.6860277666666668,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1852.2749700000002,
          "annual_profit_projection": 22227.29964,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3720555333333333,
        "regulatory_headroom": 10.24970444333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74714919",
      "drug_name": "SYNTHROID 300 MCG TABLET",
      "ndc": 74714919,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.623343691666667,
        "feasible_range": [
          1.3670262666666668,
          1.82182539
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.0252697000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.6835131333333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2050.5394000000006,
          "annual_profit_projection": 24606.472800000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3670262666666668,
        "regulatory_headroom": 10.255991026666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74714990",
      "drug_name": "SYNTHROID 300 MCG TABLET",
      "ndc": 74714990,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.623343691666667,
        "feasible_range": [
          1.3670262666666668,
          1.82182539
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 1.0252697000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.6835131333333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2050.5394000000006,
          "annual_profit_projection": 24606.472800000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3670262666666668,
        "regulatory_headroom": 10.255991026666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74732513",
      "drug_name": "DEPAKOTE DR 125 MG TABLET",
      "ndc": 74732513,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.0720899116666667,
        "feasible_range": [
          1.7089401333333332,
          2.27749137
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 1.2817051,
        "profit_projections": {
          "gross_profit_per_unit": 0.8544700666666669,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 3845.1153000000013,
          "annual_profit_projection": 46141.383600000016,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.7089401333333332,
        "regulatory_headroom": 9.82859869333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74732613",
      "drug_name": "DEPAKOTE DR 250 MG TABLET",
      "ndc": 74732613,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.052943320833334,
        "feasible_range": [
          3.3426336666666665,
          4.4547021749999995
        ],
        "expected_margin": 0.3814432989690723,
        "estimated_acquisition_cost": 2.50697525,
        "profit_projections": {
          "gross_profit_per_unit": 1.671316833333334,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 7520.925750000003,
          "annual_profit_projection": 90251.10900000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.3426336666666665,
        "regulatory_headroom": 7.786481776666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74732713",
      "drug_name": "DEPAKOTE DR 500 MG TABLET",
      "ndc": 74732713,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.460910887083332,
        "feasible_range": [
          6.153328566666666,
          8.2004936475
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 4.614996424999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.076664283333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15383.321416666664,
          "annual_profit_projection": 184599.85699999996,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.153328566666666,
        "regulatory_headroom": 4.273113151666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74740113",
      "drug_name": "DEPAKOTE ER 250 MG TABLET",
      "ndc": 74740113,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.6903974141666662,
        "feasible_range": [
          3.043626733333333,
          4.056217934999999
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.2827200499999996,
        "profit_projections": {
          "gross_profit_per_unit": 1.5218133666666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 7609.066833333333,
          "annual_profit_projection": 91308.802,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.043626733333333,
        "regulatory_headroom": 8.16024044333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74740213",
      "drug_name": "DEPAKOTE ER 500 MG TABLET",
      "ndc": 74740213,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.484673585000001,
        "feasible_range": [
          5.348184400000001,
          7.127484210000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 4.011138300000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.6740922000000005,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 13370.461000000003,
          "annual_profit_projection": 160445.53200000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.348184400000001,
        "regulatory_headroom": 5.279543359999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74929619",
      "drug_name": "SYNTHROID 112 MCG TABLET",
      "ndc": 74929619,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6298789,
        "feasible_range": [
          1.3725296,
          1.82915964
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 1.0293972,
        "profit_projections": {
          "gross_profit_per_unit": 0.6862648,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2058.7944,
          "annual_profit_projection": 24705.5328,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3725296,
        "regulatory_headroom": 10.249111859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_74929690",
      "drug_name": "SYNTHROID 112 MCG TABLET",
      "ndc": 74929690,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6298789,
        "feasible_range": [
          1.3725296,
          1.82915964
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 1.0293972,
        "profit_projections": {
          "gross_profit_per_unit": 0.6862648,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 2058.7944,
          "annual_profit_projection": 24705.5328,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3725296,
        "regulatory_headroom": 10.249111859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_75062040",
      "drug_name": "LOVENOX 40 MG/0.4 ML SYRINGE",
      "ndc": 75062040,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.234299666666669,
        "feasible_range": [
          6.587439733333334,
          8.779030260000004
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.940579800000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.2937198666666676,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 24702.89900000001,
          "annual_profit_projection": 296434.7880000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.587439733333334,
        "regulatory_headroom": 3.730474193333329,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_75062280",
      "drug_name": "LOVENOX 80 MG/0.8 ML SYRINGE",
      "ndc": 75062280,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.721291666666668,
        "feasible_range": [
          7.777033333333335,
          10.364392500000001
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 5.832775000000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.888516666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29163.875,
          "annual_profit_projection": 349966.5,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.777033333333335,
        "regulatory_headroom": 2.24348219333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_75801410",
      "drug_name": "LOVENOX 40 MG/0.4 ML SYRINGE",
      "ndc": 75801410,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.234299666666669,
        "feasible_range": [
          6.587439733333334,
          8.779030260000004
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.940579800000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.2937198666666676,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 24702.89900000001,
          "annual_profit_projection": 296434.7880000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.587439733333334,
        "regulatory_headroom": 3.730474193333329,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_75801810",
      "drug_name": "LOVENOX 80 MG/0.8 ML SYRINGE",
      "ndc": 75801810,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.721291666666668,
        "feasible_range": [
          7.777033333333335,
          10.364392500000001
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 5.832775000000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.888516666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29163.875,
          "annual_profit_projection": 349966.5,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.777033333333335,
        "regulatory_headroom": 2.24348219333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78024015",
      "drug_name": "SANDIMMUNE 25 MG CAPSULE",
      "ndc": 78024015,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.7281530075000004,
        "feasible_range": [
          3.7083552999999996,
          4.9420965825
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 2.781266475,
        "profit_projections": {
          "gross_profit_per_unit": 1.8541776500000005,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 16687.598850000006,
          "annual_profit_projection": 200251.18620000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.7083552999999996,
        "regulatory_headroom": 7.329329734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78024061",
      "drug_name": "SANDIMMUNE 25 MG CAPSULE",
      "ndc": 78024061,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.7281530075000004,
        "feasible_range": [
          3.7083552999999996,
          4.9420965825
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 2.781266475,
        "profit_projections": {
          "gross_profit_per_unit": 1.8541776500000005,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 16687.598850000006,
          "annual_profit_projection": 200251.18620000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.7083552999999996,
        "regulatory_headroom": 7.329329734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78024615",
      "drug_name": "NEORAL 25 MG GELATIN CAPSULE",
      "ndc": 78024615,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.022707458333333,
        "feasible_range": [
          2.4181659666666664,
          3.2226711825
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 1.813624475,
        "profit_projections": {
          "gross_profit_per_unit": 1.2090829833333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 9068.122374999999,
          "annual_profit_projection": 108817.46849999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.4181659666666664,
        "regulatory_headroom": 8.942066401666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78024661",
      "drug_name": "NEORAL 25 MG GELATIN CAPSULE",
      "ndc": 78024661,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.022707458333333,
        "feasible_range": [
          2.4181659666666664,
          3.2226711825
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 1.813624475,
        "profit_projections": {
          "gross_profit_per_unit": 1.2090829833333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 9068.122374999999,
          "annual_profit_projection": 108817.46849999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.4181659666666664,
        "regulatory_headroom": 8.942066401666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78024815",
      "drug_name": "NEORAL 100 MG GELATIN CAPSULE",
      "ndc": 78024815,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          9.681496933333335,
          11.964773859999998
        ],
        "expected_margin": 0.39312495288565336,
        "estimated_acquisition_cost": 7.261122700000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.703651159999996,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 35277.38369999997,
          "annual_profit_projection": 423328.6043999996,
          "margin_percentage": 39.31249528856534
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.681496933333335,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.14"
        ]
      }
    },
    {
      "drug_id": "ndc_78024861",
      "drug_name": "NEORAL 100 MG GELATIN CAPSULE",
      "ndc": 78024861,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          9.681496933333335,
          11.964773859999998
        ],
        "expected_margin": 0.39312495288565336,
        "estimated_acquisition_cost": 7.261122700000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.703651159999996,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 35277.38369999997,
          "annual_profit_projection": 423328.6043999996,
          "margin_percentage": 39.31249528856534
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.681496933333335,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.14"
        ]
      }
    },
    {
      "drug_id": "ndc_78024915",
      "drug_name": "FEMARA 2.5 MG TABLET",
      "ndc": 78024915,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 22.694676766666674,
        "feasible_range": [
          22.694676766666674,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 17.021007575000006,
        "profit_projections": {
          "gross_profit_per_unit": 5.673669191666669,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 56736.691916666685,
          "annual_profit_projection": 680840.3030000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 22.694676766666674,
        "regulatory_headroom": -10.729902906666677,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $16.40"
        ]
      }
    },
    {
      "drug_id": "ndc_78031434",
      "drug_name": "DIOVAN HCT 80-12.5 MG TABLET",
      "ndc": 78031434,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.739048520416668,
        "feasible_range": [
          8.856947233333335,
          11.803585447500003
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.642710425000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.428473616666668,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 19928.131275000007,
          "annual_profit_projection": 239137.57530000008,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.856947233333335,
        "regulatory_headroom": 0.8935898183333286,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78031534",
      "drug_name": "DIOVAN HCT 160-12.5 MG TAB",
      "ndc": 78031534,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          9.630648733333333,
          11.964773859999998
        ],
        "expected_margin": 0.37764156901516743,
        "estimated_acquisition_cost": 7.222986549999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.7417873099999985,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23708.93654999999,
          "annual_profit_projection": 284507.2385999999,
          "margin_percentage": 39.631232194471245
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.630648733333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.07"
        ]
      }
    },
    {
      "drug_id": "ndc_78033705",
      "drug_name": "TRILEPTAL 300 MG TABLET",
      "ndc": 78033705,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.026261458333336,
        "feasible_range": [
          8.821009166666668,
          11.7556910625
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 6.615756875000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.410504583333335,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 29770.90593750001,
          "annual_profit_projection": 357250.87125000014,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.821009166666668,
        "regulatory_headroom": 0.9385124016666619,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78034442",
      "drug_name": "VIVELLE-DOT 0.05 MG PATCH",
      "ndc": 78034442,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.963533733333335,
        "feasible_range": [
          15.963533733333335,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.972650300000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.990883433333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11972.650300000001,
          "annual_profit_projection": 143671.8036,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.963533733333335,
        "regulatory_headroom": -3.998759873333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.99"
        ]
      }
    },
    {
      "drug_id": "ndc_78034542",
      "drug_name": "VIVELLE-DOT 0.075 MG PATCH",
      "ndc": 78034542,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.931248666666662,
        "feasible_range": [
          15.931248666666662,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.948436499999996,
        "profit_projections": {
          "gross_profit_per_unit": 3.9828121666666654,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11948.436499999996,
          "annual_profit_projection": 143381.23799999995,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.931248666666662,
        "regulatory_headroom": -3.966474806666664,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.95"
        ]
      }
    },
    {
      "drug_id": "ndc_78034642",
      "drug_name": "VIVELLE-DOT 0.1 MG PATCH",
      "ndc": 78034642,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.030750666666663,
        "feasible_range": [
          16.030750666666663,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 12.023062999999997,
        "profit_projections": {
          "gross_profit_per_unit": 4.007687666666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12023.062999999996,
          "annual_profit_projection": 144276.75599999996,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.030750666666663,
        "regulatory_headroom": -4.065976806666665,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.07"
        ]
      }
    },
    {
      "drug_id": "ndc_78035415",
      "drug_name": "LESCOL XL 80 MG TABLET",
      "ndc": 78035415,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.358091333333334,
          11.964773859999998
        ],
        "expected_margin": 0.2880292933509733,
        "estimated_acquisition_cost": 8.5185685,
        "profit_projections": {
          "gross_profit_per_unit": 3.446205359999997,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 34462.05359999997,
          "annual_profit_projection": 413544.64319999964,
          "margin_percentage": 28.802929335097332
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.358091333333334,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.23"
        ]
      }
    },
    {
      "drug_id": "ndc_78035752",
      "drug_name": "TRILEPTAL 300 MG/5 ML SUSP",
      "ndc": 78035752,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.033133916666667,
        "feasible_range": [
          1.6265071333333332,
          2.1676335449999997
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 1.21988035,
        "profit_projections": {
          "gross_profit_per_unit": 0.8132535666666669,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 5489.461575000002,
          "annual_profit_projection": 65873.53890000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.6265071333333332,
        "regulatory_headroom": 9.93163994333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78035834",
      "drug_name": "DIOVAN 80 MG TABLET",
      "ndc": 78035834,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.530384223750005,
        "feasible_range": [
          7.8601107000000034,
          10.475109067500004
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.895083025000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.9300553500000026,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 17685.24907500001,
          "annual_profit_projection": 212222.9889000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.8601107000000034,
        "regulatory_headroom": 2.1396354849999923,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78035934",
      "drug_name": "DIOVAN 160 MG TABLET",
      "ndc": 78035934,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.22928086375,
        "feasible_range": [
          8.4365203,
          11.243285707500002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.327390225,
        "profit_projections": {
          "gross_profit_per_unit": 4.218260150000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21091.300750000002,
          "annual_profit_projection": 253095.60900000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.4365203,
        "regulatory_headroom": 1.4191234849999965,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78036034",
      "drug_name": "DIOVAN 320 MG TABLET",
      "ndc": 78036034,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          10.70474253333333,
          11.964773859999998
        ],
        "expected_margin": 0.30823073796856915,
        "estimated_acquisition_cost": 8.028556899999998,
        "profit_projections": {
          "gross_profit_per_unit": 3.9362169599999994,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19681.084799999997,
          "annual_profit_projection": 236173.01759999996,
          "margin_percentage": 32.89838158295121
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.70474253333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.42"
        ]
      }
    },
    {
      "drug_id": "ndc_78037005",
      "drug_name": "RITALIN LA 20 MG CAPSULE",
      "ndc": 78037005,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          10.48275843333333,
          11.964773859999998
        ],
        "expected_margin": 0.3225759477259769,
        "estimated_acquisition_cost": 7.862068824999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.102705035,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20513.525175,
          "annual_profit_projection": 246162.30209999997,
          "margin_percentage": 34.289866929419766
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.48275843333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.14"
        ]
      }
    },
    {
      "drug_id": "ndc_78037105",
      "drug_name": "RITALIN LA 30 MG CAPSULE",
      "ndc": 78037105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          10.754805099999999,
          11.964773859999998
        ],
        "expected_margin": 0.3049955602246336,
        "estimated_acquisition_cost": 8.066103824999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.8986700349999985,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19493.350174999992,
          "annual_profit_projection": 233920.2020999999,
          "margin_percentage": 32.58456934178946
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.754805099999999,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.48"
        ]
      }
    },
    {
      "drug_id": "ndc_78037205",
      "drug_name": "RITALIN LA 40 MG CAPSULE",
      "ndc": 78037205,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.002352833333338,
          11.964773859999998
        ],
        "expected_margin": 0.2889983597060487,
        "estimated_acquisition_cost": 8.251764625000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.713009234999994,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18565.04617499997,
          "annual_profit_projection": 222780.55409999966,
          "margin_percentage": 31.032840891486728
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.002352833333338,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.79"
        ]
      }
    },
    {
      "drug_id": "ndc_78037905",
      "drug_name": "LOTREL 10-40 MG CAPSULE",
      "ndc": 78037905,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.568074000000001,
        "feasible_range": [
          13.568074000000001,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 10.1760555,
        "profit_projections": {
          "gross_profit_per_unit": 3.3920185000000007,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 25440.138750000006,
          "annual_profit_projection": 305281.66500000004,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.568074000000001,
        "regulatory_headroom": -1.6033001400000035,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.00"
        ]
      }
    },
    {
      "drug_id": "ndc_78038005",
      "drug_name": "FOCALIN 2.5 MG TABLET",
      "ndc": 78038005,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.6666427083333335,
        "feasible_range": [
          0.5613833333333335,
          0.7481512500000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.42103750000000006,
        "profit_projections": {
          "gross_profit_per_unit": 0.2806916666666668,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 757.8675000000003,
          "annual_profit_projection": 9094.410000000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.5613833333333335,
        "regulatory_headroom": 11.263044693333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78038105",
      "drug_name": "FOCALIN 5 MG TABLET",
      "ndc": 78038105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9530134791666668,
        "feasible_range": [
          0.8025376666666668,
          1.0695357750000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.6019032500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.4012688333333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1203.8065000000001,
          "annual_profit_projection": 14445.678000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8025376666666668,
        "regulatory_headroom": 10.961601776666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78038205",
      "drug_name": "FOCALIN 10 MG TABLET",
      "ndc": 78038205,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.3673950874999996,
        "feasible_range": [
          1.1514905999999996,
          1.5345826649999996
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.8636179499999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.5757452999999998,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1727.2358999999994,
          "annual_profit_projection": 20726.830799999992,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.1514905999999996,
        "regulatory_headroom": 10.525410609999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78038334",
      "drug_name": "DIOVAN HCT 160-25 MG TABLET",
      "ndc": 78038334,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          10.93792916666667,
          11.964773859999998
        ],
        "expected_margin": 0.29316159036840095,
        "estimated_acquisition_cost": 8.203446875000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.761326984999995,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18806.634924999973,
          "annual_profit_projection": 225679.61909999966,
          "margin_percentage": 31.436674265734894
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.93792916666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.71"
        ]
      }
    },
    {
      "drug_id": "ndc_78038566",
      "drug_name": "MYFORTIC 180 MG TABLET",
      "ndc": 78038566,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.8483227225,
        "feasible_range": [
          6.155547233333333,
          8.2034504475
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 4.616660425,
        "profit_projections": {
          "gross_profit_per_unit": 3.0777736166666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 30777.736166666666,
          "annual_profit_projection": 369332.834,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.155547233333333,
        "regulatory_headroom": 4.270339818333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78038666",
      "drug_name": "MYFORTIC 360 MG TABLET",
      "ndc": 78038666,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.310845733333338,
        "feasible_range": [
          12.310845733333338,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.233134300000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.0777114333333344,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 30777.114333333346,
          "annual_profit_projection": 369325.37200000015,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.310845733333338,
        "regulatory_headroom": -0.3460718733333401,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.42"
        ]
      }
    },
    {
      "drug_id": "ndc_78040505",
      "drug_name": "LOTREL 5-10 MG CAPSULE",
      "ndc": 78040505,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.016116740740742,
          11.964773859999998
        ],
        "expected_margin": 0.37214964165185166,
        "estimated_acquisition_cost": 7.512087555555556,
        "profit_projections": {
          "gross_profit_per_unit": 4.452686304444441,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33395.14728333331,
          "annual_profit_projection": 400741.7673999997,
          "margin_percentage": 37.214964165185165
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.016116740740742,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.56"
        ]
      }
    },
    {
      "drug_id": "ndc_78040605",
      "drug_name": "LOTREL 5-20 MG CAPSULE",
      "ndc": 78040605,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.596369333333335,
          11.964773859999998
        ],
        "expected_margin": 0.3357770825432046,
        "estimated_acquisition_cost": 7.9472770000000015,
        "profit_projections": {
          "gross_profit_per_unit": 4.017496859999996,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30131.22644999997,
          "annual_profit_projection": 361574.7173999996,
          "margin_percentage": 33.57770825432046
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.596369333333335,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.28"
        ]
      }
    },
    {
      "drug_id": "ndc_78042315",
      "drug_name": "DIOVAN 40 MG TABLET",
      "ndc": 78042315,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.9771653379166665,
        "feasible_range": [
          6.579105433333333,
          8.7679232025
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 4.934329075,
        "profit_projections": {
          "gross_profit_per_unit": 3.289552716666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16447.763583333333,
          "annual_profit_projection": 197373.163,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.579105433333333,
        "regulatory_headroom": 3.7408920683333307,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78042405",
      "drug_name": "RITALIN LA 10 MG CAPSULE",
      "ndc": 78042405,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          10.493522433333336,
          11.964773859999998
        ],
        "expected_margin": 0.3218803490870257,
        "estimated_acquisition_cost": 7.870141825000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.094632034999996,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20473.16017499998,
          "annual_profit_projection": 245677.92209999973,
          "margin_percentage": 34.22239386144149
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.493522433333336,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.15"
        ]
      }
    },
    {
      "drug_id": "ndc_78043005",
      "drug_name": "FOCALIN XR 5 MG CAPSULE",
      "ndc": 78043005,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.847866427083333,
        "feasible_range": [
          4.082413833333333,
          5.4406015125
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 3.061810375,
        "profit_projections": {
          "gross_profit_per_unit": 2.0412069166666664,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 6123.620749999999,
          "annual_profit_projection": 73483.449,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.082413833333333,
        "regulatory_headroom": 6.861756568333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78043105",
      "drug_name": "FOCALIN XR 10 MG CAPSULE",
      "ndc": 78043105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.91886451875,
        "feasible_range": [
          4.1422017,
          5.520280342500001
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 3.1066512750000004,
        "profit_projections": {
          "gross_profit_per_unit": 2.07110085,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 6213.30255,
          "annual_profit_projection": 74559.6306,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.1422017,
        "regulatory_headroom": 6.787021734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78043205",
      "drug_name": "FOCALIN XR 20 MG CAPSULE",
      "ndc": 78043205,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.04703281875,
        "feasible_range": [
          4.2501329,
          5.6641194225
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 3.1875996749999995,
        "profit_projections": {
          "gross_profit_per_unit": 2.1250664500000003,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 5737.6794150000005,
          "annual_profit_projection": 68852.15298000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.2501329,
        "regulatory_headroom": 6.652107734999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78043305",
      "drug_name": "FOCALIN XR 30 MG CAPSULE",
      "ndc": 78043305,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.865767752083333,
        "feasible_range": [
          4.097488633333334,
          5.460691582500001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 3.073116475,
        "profit_projections": {
          "gross_profit_per_unit": 2.0487443166666672,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 5531.609655000001,
          "annual_profit_projection": 66379.31586000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.097488633333334,
        "regulatory_headroom": 6.84291306833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78043405",
      "drug_name": "FOCALIN XR 40 MG CAPSULE",
      "ndc": 78043405,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.558660899999998,
        "feasible_range": [
          4.6809775999999985,
          6.2383028399999985
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 3.510733199999999,
        "profit_projections": {
          "gross_profit_per_unit": 2.3404887999999993,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 7021.4663999999975,
          "annual_profit_projection": 84257.59679999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.6809775999999985,
        "regulatory_headroom": 6.113551859999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78043905",
      "drug_name": "RITALIN 5 MG TABLET",
      "ndc": 78043905,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.8392921766666664,
        "feasible_range": [
          0.6921997333333332,
          0.9224892599999999
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.5191497999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.3460998666666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 1730.499333333333,
          "annual_profit_projection": 20765.991999999995,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.6921997333333332,
        "regulatory_headroom": 11.09952419333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78044005",
      "drug_name": "RITALIN 10 MG TABLET",
      "ndc": 78044005,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1950496999999998,
        "feasible_range": [
          0.9856079999999999,
          1.3135122000000001
        ],
        "expected_margin": 0.3814432989690721,
        "estimated_acquisition_cost": 0.7392059999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.4928039999999999,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 2464.0199999999995,
          "annual_profit_projection": 29568.239999999994,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9856079999999999,
        "regulatory_headroom": 10.732763859999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78044105",
      "drug_name": "RITALIN 20 MG TABLET",
      "ndc": 78044105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.7238080166666672,
        "feasible_range": [
          1.4216973333333336,
          1.8946851000000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 1.0662730000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.7108486666666669,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 3554.2433333333347,
          "annual_profit_projection": 42650.92000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4216973333333336,
        "regulatory_headroom": 10.18765219333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78045605",
      "drug_name": "TRILEPTAL 150 MG TABLET",
      "ndc": 78045605,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.038719374999999,
        "feasible_range": [
          4.830975499999998,
          6.438203887499999
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.623231624999999,
        "profit_projections": {
          "gross_profit_per_unit": 2.4154877499999996,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 18116.158124999998,
          "annual_profit_projection": 217393.89749999996,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.830975499999998,
        "regulatory_headroom": 5.926054484999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78045705",
      "drug_name": "TRILEPTAL 600 MG TABLET",
      "ndc": 78045705,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.229302699999998,
        "feasible_range": [
          16.229302699999998,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 12.171977024999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.0573256749999995,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30429.942562499997,
          "annual_profit_projection": 365159.31074999995,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.229302699999998,
        "regulatory_headroom": -4.2645288400000005,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.32"
        ]
      }
    },
    {
      "drug_id": "ndc_78047234",
      "drug_name": "DIOVAN HCT 320-25 MG TABLET",
      "ndc": 78047234,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.829751433333335,
        "feasible_range": [
          13.829751433333335,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.372313575000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.457437858333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17287.18929166667,
          "annual_profit_projection": 207446.27150000003,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.829751433333335,
        "regulatory_headroom": -1.8649775733333378,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.32"
        ]
      }
    },
    {
      "drug_id": "ndc_78048915",
      "drug_name": "EXFORGE 10-160 MG TABLET",
      "ndc": 78048915,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.166689866666665,
          11.964773859999998
        ],
        "expected_margin": 0.36271111437454273,
        "estimated_acquisition_cost": 7.625017399999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.3397564599999985,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 32548.173449999987,
          "annual_profit_projection": 390578.08139999985,
          "margin_percentage": 36.27111143745427
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.166689866666665,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.74"
        ]
      }
    },
    {
      "drug_id": "ndc_78049115",
      "drug_name": "EXFORGE 10-320 MG TABLET",
      "ndc": 78049115,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.905655100000002,
        "feasible_range": [
          12.905655100000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.679241325000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.226413775000001,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 24198.103312500007,
          "annual_profit_projection": 290377.23975000007,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.905655100000002,
        "regulatory_headroom": -0.9408812400000048,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.17"
        ]
      }
    },
    {
      "drug_id": "ndc_78049305",
      "drug_name": "FOCALIN XR 15 MG CAPSULE",
      "ndc": 78049305,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.053895816666666,
        "feasible_range": [
          4.255912266666666,
          5.67182154
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 3.1919341999999995,
        "profit_projections": {
          "gross_profit_per_unit": 2.127956133333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 6383.868399999999,
          "annual_profit_projection": 76606.42079999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.255912266666666,
        "regulatory_headroom": 6.644883526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78050115",
      "drug_name": "EXELON 4.6 MG/24HR PATCH",
      "ndc": 78050115,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.0498425,
        "feasible_range": [
          19.0498425,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 14.287381875,
        "profit_projections": {
          "gross_profit_per_unit": 4.762460625000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23812.303125000006,
          "annual_profit_projection": 285747.63750000007,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.0498425,
        "regulatory_headroom": -7.085068640000003,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.85"
        ]
      }
    },
    {
      "drug_id": "ndc_78050161",
      "drug_name": "EXELON 4.6 MG/24HR PATCH",
      "ndc": 78050161,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.0498425,
        "feasible_range": [
          19.0498425,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 14.287381875,
        "profit_projections": {
          "gross_profit_per_unit": 4.762460625000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23812.303125000006,
          "annual_profit_projection": 285747.63750000007,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.0498425,
        "regulatory_headroom": -7.085068640000003,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.85"
        ]
      }
    },
    {
      "drug_id": "ndc_78050215",
      "drug_name": "EXELON 9.5 MG/24HR PATCH",
      "ndc": 78050215,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.006493999999996,
        "feasible_range": [
          19.006493999999996,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 14.254870499999997,
        "profit_projections": {
          "gross_profit_per_unit": 4.751623499999999,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23758.117499999997,
          "annual_profit_projection": 285097.41,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.006493999999996,
        "regulatory_headroom": -7.041720139999999,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.79"
        ]
      }
    },
    {
      "drug_id": "ndc_78050261",
      "drug_name": "EXELON 9.5 MG/24HR PATCH",
      "ndc": 78050261,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.006493999999996,
        "feasible_range": [
          19.006493999999996,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 14.254870499999997,
        "profit_projections": {
          "gross_profit_per_unit": 4.751623499999999,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23758.117499999997,
          "annual_profit_projection": 285097.41,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.006493999999996,
        "regulatory_headroom": -7.041720139999999,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.79"
        ]
      }
    },
    {
      "drug_id": "ndc_78050315",
      "drug_name": "EXELON 13.3 MG/24HR PATCH",
      "ndc": 78050315,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.04926226666667,
        "feasible_range": [
          19.04926226666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 14.286946700000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.7623155666666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23811.577833333333,
          "annual_profit_projection": 285738.934,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.04926226666667,
        "regulatory_headroom": -7.084488406666672,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.85"
        ]
      }
    },
    {
      "drug_id": "ndc_78050361",
      "drug_name": "EXELON 13.3 MG/24HR PATCH",
      "ndc": 78050361,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.04926226666667,
        "feasible_range": [
          19.04926226666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 14.286946700000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.7623155666666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23811.577833333333,
          "annual_profit_projection": 285738.934,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.04926226666667,
        "regulatory_headroom": -7.084488406666672,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.85"
        ]
      }
    },
    {
      "drug_id": "ndc_78050883",
      "drug_name": "TEGRETOL 100 MG/5 ML SUSP",
      "ndc": 78050883,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.4570280000000001,
        "feasible_range": [
          0.36562240000000007,
          0.4872621600000001
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.27421680000000004,
        "profit_projections": {
          "gross_profit_per_unit": 0.18281120000000006,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 1371.0840000000005,
          "annual_profit_projection": 16453.008000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.36562240000000007,
        "regulatory_headroom": 11.507745859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78050905",
      "drug_name": "TEGRETOL 200 MG TABLET",
      "ndc": 78050905,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.196295916666667,
        "feasible_range": [
          2.5570367333333337,
          3.4077431850000006
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.9177775500000003,
        "profit_projections": {
          "gross_profit_per_unit": 1.2785183666666669,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 9588.887750000002,
          "annual_profit_projection": 115066.65300000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.5570367333333337,
        "regulatory_headroom": 8.76847794333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78051005",
      "drug_name": "TEGRETOL XR 100 MG TABLET",
      "ndc": 78051005,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.712679583333333,
        "feasible_range": [
          1.3701436666666664,
          1.825979925
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.0276077499999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.6850718333333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 5138.038749999999,
          "annual_profit_projection": 61656.46499999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3701436666666664,
        "regulatory_headroom": 10.252094276666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78051105",
      "drug_name": "TEGRETOL XR 200 MG TABLET",
      "ndc": 78051105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.4162716250000003,
        "feasible_range": [
          2.7330173,
          3.6422711324999995
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.049762975,
        "profit_projections": {
          "gross_profit_per_unit": 1.36650865,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 10248.814875,
          "annual_profit_projection": 122985.7785,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.7330173,
        "regulatory_headroom": 8.548502234999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78051205",
      "drug_name": "TEGRETOL XR 400 MG TABLET",
      "ndc": 78051205,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.831322333333335,
        "feasible_range": [
          5.465057866666668,
          7.283240580000002
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 4.098793400000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.7325289333333345,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 18444.570300000007,
          "annual_profit_projection": 221334.84360000008,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.465057866666668,
        "regulatory_headroom": 5.133451526666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78056315",
      "drug_name": "EXFORGE HCT 10-320-25 MG TAB",
      "ndc": 78056315,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.950539333333333,
        "feasible_range": [
          12.950539333333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.7129045,
        "profit_projections": {
          "gross_profit_per_unit": 3.237634833333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 24282.261249999996,
          "annual_profit_projection": 291387.13499999995,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.950539333333333,
        "regulatory_headroom": -0.9857654733333359,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.22"
        ]
      }
    },
    {
      "drug_id": "ndc_78060715",
      "drug_name": "GILENYA 0.5 MG CAPSULE",
      "ndc": 78060715,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 322.62027156666676,
        "feasible_range": [
          322.62027156666676,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 241.96520367500005,
        "profit_projections": {
          "gross_profit_per_unit": 80.6550678916667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 806550.678916667,
          "annual_profit_projection": 9678608.147000004,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 322.62027156666676,
        "regulatory_headroom": -310.6554977066668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $391.31"
        ]
      }
    },
    {
      "drug_id": "ndc_78060805",
      "drug_name": "FOCALIN XR 25 MG CAPSULE",
      "ndc": 78060805,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.324267677083333,
        "feasible_range": [
          4.483593833333333,
          5.975251012499999
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 3.3626953749999995,
        "profit_projections": {
          "gross_profit_per_unit": 2.241796916666667,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 6052.851675000001,
          "annual_profit_projection": 72634.2201,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.483593833333333,
        "regulatory_headroom": 6.360281568333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78060905",
      "drug_name": "FOCALIN XR 35 MG CAPSULE",
      "ndc": 78060905,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.596824458333334,
        "feasible_range": [
          4.7131153333333335,
          6.281132550000001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 3.5348365,
        "profit_projections": {
          "gross_profit_per_unit": 2.356557666666667,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 6362.705700000001,
          "annual_profit_projection": 76352.46840000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.7131153333333335,
        "regulatory_headroom": 6.07337969333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78064913",
      "drug_name": "GLEEVEC 400 MG TABLET",
      "ndc": 78064913,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 284.2963239999999,
        "feasible_range": [
          284.2963239999999,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 213.22224299999993,
        "profit_projections": {
          "gross_profit_per_unit": 71.07408099999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 533055.6074999998,
          "annual_profit_projection": 6396667.289999997,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 284.2963239999999,
        "regulatory_headroom": -272.33155013999993,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $343.41"
        ]
      }
    },
    {
      "drug_id": "ndc_78064926",
      "drug_name": "GLEEVEC 400 MG TABLET",
      "ndc": 78064926,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 284.2963239999999,
        "feasible_range": [
          284.2963239999999,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 213.22224299999993,
        "profit_projections": {
          "gross_profit_per_unit": 71.07408099999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 533055.6074999998,
          "annual_profit_projection": 6396667.289999997,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 284.2963239999999,
        "regulatory_headroom": -272.33155013999993,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $343.41"
        ]
      }
    },
    {
      "drug_id": "ndc_78064930",
      "drug_name": "GLEEVEC 400 MG TABLET",
      "ndc": 78064930,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 284.2963239999999,
        "feasible_range": [
          284.2963239999999,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 213.22224299999993,
        "profit_projections": {
          "gross_profit_per_unit": 71.07408099999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 533055.6074999998,
          "annual_profit_projection": 6396667.289999997,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 284.2963239999999,
        "regulatory_headroom": -272.33155013999993,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $343.41"
        ]
      }
    },
    {
      "drug_id": "ndc_78072210",
      "drug_name": "AZOPT 1% EYE DROPS",
      "ndc": 78072210,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.481344399999998,
        "feasible_range": [
          30.481344399999998,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 22.861008299999998,
        "profit_projections": {
          "gross_profit_per_unit": 7.620336099999999,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 57152.520749999996,
          "annual_profit_projection": 685830.249,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.481344399999998,
        "regulatory_headroom": -18.51657054,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $26.14"
        ]
      }
    },
    {
      "drug_id": "ndc_78072215",
      "drug_name": "AZOPT 1% EYE DROPS",
      "ndc": 78072215,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.589849333333333,
        "feasible_range": [
          30.589849333333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 22.942387,
        "profit_projections": {
          "gross_profit_per_unit": 7.647462333333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 57355.9675,
          "annual_profit_projection": 688271.61,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.589849333333333,
        "regulatory_headroom": -18.625075473333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $26.27"
        ]
      }
    },
    {
      "drug_id": "ndc_78086225",
      "drug_name": "DUREZOL 0.05% EYE DROPS",
      "ndc": 78086225,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 36.87333866666667,
        "feasible_range": [
          36.87333866666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 27.655004,
        "profit_projections": {
          "gross_profit_per_unit": 9.218334666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 92183.34666666668,
          "annual_profit_projection": 1106200.1600000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 36.87333866666667,
        "regulatory_headroom": -24.90856480666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $34.13"
        ]
      }
    },
    {
      "drug_id": "ndc_78093926",
      "drug_name": "VIGAMOX 0.5% EYE DROPS",
      "ndc": 78093926,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 27.314516666666666,
        "feasible_range": [
          27.314516666666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 20.4858875,
        "profit_projections": {
          "gross_profit_per_unit": 6.828629166666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 68286.29166666666,
          "annual_profit_projection": 819435.4999999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 27.314516666666666,
        "regulatory_headroom": -15.349742806666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $22.18"
        ]
      }
    },
    {
      "drug_id": "ndc_78094625",
      "drug_name": "TRAVATAN Z 0.004% EYE DROP",
      "ndc": 78094625,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 81.79181659999999,
        "feasible_range": [
          81.79181659999999,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 61.343862449999996,
        "profit_projections": {
          "gross_profit_per_unit": 20.447954149999994,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 153359.65612499995,
          "annual_profit_projection": 1840315.8734999993,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 81.79181659999999,
        "regulatory_headroom": -69.82704274,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $90.27"
        ]
      }
    },
    {
      "drug_id": "ndc_78094640",
      "drug_name": "TRAVATAN Z 0.004% EYE DROP",
      "ndc": 78094640,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 81.56124946666668,
        "feasible_range": [
          81.56124946666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 61.17093710000001,
        "profit_projections": {
          "gross_profit_per_unit": 20.39031236666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 152927.34275000004,
          "annual_profit_projection": 1835128.1130000004,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 81.56124946666668,
        "regulatory_headroom": -69.59647560666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $89.99"
        ]
      }
    },
    {
      "drug_id": "ndc_113172002",
      "drug_name": "NASONEX 24HR ALLERGY 50 MCG NASAL SPRAY",
      "ndc": 113172002,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 1.3591782388888893,
        "feasible_range": [
          1.0660221481481484,
          1.420679516666667
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.7995166111111113,
        "profit_projections": {
          "gross_profit_per_unit": 0.5330110740740742,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 5330.110740740743,
          "annual_profit_projection": 63961.32888888891,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.0660221481481484,
        "regulatory_headroom": 10.632246174814812,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_113600203",
      "drug_name": "PREVACID 24HR DR 15 MG CAPSULE",
      "ndc": 113600203,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.5843463491666667,
        "feasible_range": [
          0.4819351333333333,
          0.642271245
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 0.36145135,
        "profit_projections": {
          "gross_profit_per_unit": 0.2409675666666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 1204.8378333333335,
          "annual_profit_projection": 14458.054000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.4819351333333333,
        "regulatory_headroom": 11.362354943333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_116106104",
      "drug_name": "DYNA-HEX 4% LIQUID",
      "ndc": 116106104,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.027408874999999996,
        "feasible_range": [
          0.021927099999999995,
          0.0292220775
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.016445324999999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.010963549999999999,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 82.226625,
          "annual_profit_projection": 986.7194999999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.021927099999999995,
        "regulatory_headroom": 11.937364984999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_116106108",
      "drug_name": "DYNA-HEX 4% LIQUID",
      "ndc": 116106108,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.02672800000000001,
        "feasible_range": [
          0.021382400000000006,
          0.02849616000000001
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 0.016036800000000004,
        "profit_projections": {
          "gross_profit_per_unit": 0.010691200000000005,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 72.16560000000003,
          "annual_profit_projection": 865.9872000000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.021382400000000006,
        "regulatory_headroom": 11.938045859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_116106116",
      "drug_name": "DYNA-HEX 4% LIQUID",
      "ndc": 116106116,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.022190458333333336,
        "feasible_range": [
          0.01775236666666667,
          0.023658442500000005
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 0.013314275000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.008876183333333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 66.571375,
          "annual_profit_projection": 798.8565000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.01775236666666667,
        "regulatory_headroom": 11.942583401666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_116106140",
      "drug_name": "DYNA-HEX 4% LIQUID",
      "ndc": 116106140,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.027408874999999996,
        "feasible_range": [
          0.021927099999999995,
          0.0292220775
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.016445324999999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.010963549999999999,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 82.226625,
          "annual_profit_projection": 986.7194999999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.021927099999999995,
        "regulatory_headroom": 11.937364984999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_131247735",
      "drug_name": "VIMPAT 50 MG TABLET",
      "ndc": 131247735,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          10.017826866666669,
          11.964773859999998
        ],
        "expected_margin": 0.3526210763936315,
        "estimated_acquisition_cost": 7.513370150000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.451403709999997,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 22257.018549999982,
          "annual_profit_projection": 267084.2225999998,
          "margin_percentage": 37.204244410182255
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.017826866666669,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.56"
        ]
      }
    },
    {
      "drug_id": "ndc_131247760",
      "drug_name": "VIMPAT 50 MG TABLET",
      "ndc": 131247760,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          10.017826866666669,
          11.964773859999998
        ],
        "expected_margin": 0.3526210763936315,
        "estimated_acquisition_cost": 7.513370150000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.451403709999997,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 22257.018549999982,
          "annual_profit_projection": 267084.2225999998,
          "margin_percentage": 37.204244410182255
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.017826866666669,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.56"
        ]
      }
    },
    {
      "drug_id": "ndc_131247835",
      "drug_name": "VIMPAT 100 MG TABLET",
      "ndc": 131247835,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.637023566666665,
        "feasible_range": [
          15.637023566666665,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.727767674999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.9092558916666658,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19546.279458333327,
          "annual_profit_projection": 234555.3534999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.637023566666665,
        "regulatory_headroom": -3.6722497066666673,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.58"
        ]
      }
    },
    {
      "drug_id": "ndc_131247860",
      "drug_name": "VIMPAT 100 MG TABLET",
      "ndc": 131247860,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.637023566666665,
        "feasible_range": [
          15.637023566666665,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.727767674999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.9092558916666658,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19546.279458333327,
          "annual_profit_projection": 234555.3534999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.637023566666665,
        "regulatory_headroom": -3.6722497066666673,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.58"
        ]
      }
    },
    {
      "drug_id": "ndc_131247935",
      "drug_name": "VIMPAT 150 MG TABLET",
      "ndc": 131247935,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.593202166666668,
        "feasible_range": [
          16.593202166666668,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.444901625000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.148300541666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20741.50270833333,
          "annual_profit_projection": 248898.03249999997,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.593202166666668,
        "regulatory_headroom": -4.62842830666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.78"
        ]
      }
    },
    {
      "drug_id": "ndc_131247960",
      "drug_name": "VIMPAT 150 MG TABLET",
      "ndc": 131247960,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.593202166666668,
        "feasible_range": [
          16.593202166666668,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.444901625000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.148300541666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20741.50270833333,
          "annual_profit_projection": 248898.03249999997,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.593202166666668,
        "regulatory_headroom": -4.62842830666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.78"
        ]
      }
    },
    {
      "drug_id": "ndc_131248035",
      "drug_name": "VIMPAT 200 MG TABLET",
      "ndc": 131248035,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.576955200000004,
        "feasible_range": [
          16.576955200000004,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.432716400000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.1442388,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20721.194,
          "annual_profit_projection": 248654.32799999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.576955200000004,
        "regulatory_headroom": -4.6121813400000065,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.76"
        ]
      }
    },
    {
      "drug_id": "ndc_131248060",
      "drug_name": "VIMPAT 200 MG TABLET",
      "ndc": 131248060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.576955200000004,
        "feasible_range": [
          16.576955200000004,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.432716400000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.1442388,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20721.194,
          "annual_profit_projection": 248654.32799999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.576955200000004,
        "regulatory_headroom": -4.6121813400000065,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.76"
        ]
      }
    },
    {
      "drug_id": "ndc_131541072",
      "drug_name": "VIMPAT 10 MG/ML SOLUTION",
      "ndc": 131541072,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.3548045354166667,
        "feasible_range": [
          1.9421068333333336,
          2.5882308375000003
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 1.4565801250000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.9710534166666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 4855.267083333333,
          "annual_profit_projection": 58263.205,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.9421068333333336,
        "regulatory_headroom": 9.53714031833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_132007900",
      "drug_name": "FLEET GLYCERIN 2 GM ADULT SUPP",
      "ndc": 132007900,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.06313143958333334,
        "feasible_range": [
          0.05206716666666667,
          0.06938951250000001
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.039050375000000005,
        "profit_projections": {
          "gross_profit_per_unit": 0.02603358333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 130.16791666666668,
          "annual_profit_projection": 1562.0150000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.05206716666666667,
        "regulatory_headroom": 11.899689901666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_132007912",
      "drug_name": "FLEET GLYCERIN 2 GM ADULT SUPP",
      "ndc": 132007912,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.10520943333333335,
        "feasible_range": [
          0.08677066666666668,
          0.11563860000000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 0.06507800000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.043385333333333345,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 216.92666666666673,
          "annual_profit_projection": 2603.120000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.08677066666666668,
        "regulatory_headroom": 11.856310526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_132007924",
      "drug_name": "FLEET GLYCERIN 2 GM ADULT SUPP",
      "ndc": 132007924,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.084026735,
        "feasible_range": [
          0.0693004,
          0.09235611000000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 0.0519753,
        "profit_projections": {
          "gross_profit_per_unit": 0.034650200000000006,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 173.25100000000003,
          "annual_profit_projection": 2079.0120000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.0693004,
        "regulatory_headroom": 11.878148359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_132007950",
      "drug_name": "FLEET GLYCERIN 2 GM ADULT SUPP",
      "ndc": 132007950,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.06313143958333334,
        "feasible_range": [
          0.05206716666666667,
          0.06938951250000001
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.039050375000000005,
        "profit_projections": {
          "gross_profit_per_unit": 0.02603358333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 130.16791666666668,
          "annual_profit_projection": 1562.0150000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.05206716666666667,
        "regulatory_headroom": 11.899689901666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_132020140",
      "drug_name": "FLEET ENEMA",
      "ndc": 132020140,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.008606325,
        "feasible_range": [
          0.007098,
          0.00945945
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.0053235,
        "profit_projections": {
          "gross_profit_per_unit": 0.003549,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17.745,
          "annual_profit_projection": 212.94,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.007098,
        "regulatory_headroom": 11.955901359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_132020142",
      "drug_name": "FLEET ENEMA",
      "ndc": 132020142,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.007664252916666667,
        "feasible_range": [
          0.006321033333333333,
          0.0084239925
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 0.004740775,
        "profit_projections": {
          "gross_profit_per_unit": 0.0031605166666666675,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 14.222325000000003,
          "annual_profit_projection": 170.66790000000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.006321033333333333,
        "regulatory_headroom": 11.956872568333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_132030140",
      "drug_name": "FLEET MINERAL OIL ENEMA",
      "ndc": 132030140,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.015541299583333333,
        "feasible_range": [
          0.012817566666666667,
          0.0170818725
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.009613175,
        "profit_projections": {
          "gross_profit_per_unit": 0.006408783333333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 32.04391666666666,
          "annual_profit_projection": 384.52699999999993,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.012817566666666667,
        "regulatory_headroom": 11.948751901666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_169406012",
      "drug_name": "VICTOZA 2-PAK 18 MG/3 ML PEN",
      "ndc": 169406012,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 75.78705636666669,
        "feasible_range": [
          75.78705636666669,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 56.84029227500002,
        "profit_projections": {
          "gross_profit_per_unit": 18.946764091666672,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 189467.6409166667,
          "annual_profit_projection": 2273611.6910000006,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 75.78705636666669,
        "regulatory_headroom": -63.822282506666696,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $82.77"
        ]
      }
    },
    {
      "drug_id": "ndc_169406013",
      "drug_name": "VICTOZA 3-PAK 18 MG/3 ML PEN",
      "ndc": 169406013,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 75.80414790000002,
        "feasible_range": [
          75.80414790000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 56.85311092500001,
        "profit_projections": {
          "gross_profit_per_unit": 18.951036975000008,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 189510.36975000007,
          "annual_profit_projection": 2274124.437000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 75.80414790000002,
        "regulatory_headroom": -63.839374040000024,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $82.79"
        ]
      }
    },
    {
      "drug_id": "ndc_169517603",
      "drug_name": "VAGIFEM 10 MCG VAGINAL TAB",
      "ndc": 169517603,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.683049800000006,
        "feasible_range": [
          17.683049800000006,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 13.262287350000005,
        "profit_projections": {
          "gross_profit_per_unit": 4.420762450000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44207.62450000001,
          "annual_profit_projection": 530491.4940000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.683049800000006,
        "regulatory_headroom": -5.718275940000009,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.14"
        ]
      }
    },
    {
      "drug_id": "ndc_169517604",
      "drug_name": "VAGIFEM 10 MCG VAGINAL TAB",
      "ndc": 169517604,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.683049800000006,
        "feasible_range": [
          17.683049800000006,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 13.262287350000005,
        "profit_projections": {
          "gross_profit_per_unit": 4.420762450000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44207.62450000001,
          "annual_profit_projection": 530491.4940000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.683049800000006,
        "regulatory_headroom": -5.718275940000009,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.14"
        ]
      }
    },
    {
      "drug_id": "ndc_173013555",
      "drug_name": "WELLBUTRIN SR 150 MG TABLET",
      "ndc": 173013555,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.9203846095833335,
        "feasible_range": [
          6.532275966666667,
          8.7055139325
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 4.899206975,
        "profit_projections": {
          "gross_profit_per_unit": 3.2661379833333335,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16330.689916666668,
          "annual_profit_projection": 195968.279,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.532275966666667,
        "regulatory_headroom": 3.799428901666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173047800",
      "drug_name": "IMITREX 6 MG/0.5 ML CARTRIDGES",
      "ndc": 173047800,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 379.16123483333337,
        "feasible_range": [
          379.16123483333337,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 284.37092612500004,
        "profit_projections": {
          "gross_profit_per_unit": 94.79030870833333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 710927.3153125,
          "annual_profit_projection": 8531127.78375,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 379.16123483333337,
        "regulatory_headroom": -367.1964609733334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $461.99"
        ]
      }
    },
    {
      "drug_id": "ndc_173047900",
      "drug_name": "IMITREX 6 MG/0.5 ML PEN INJECT",
      "ndc": 173047900,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 400.28484470000006,
        "feasible_range": [
          400.28484470000006,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 300.21363352500003,
        "profit_projections": {
          "gross_profit_per_unit": 100.07121117500003,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 750534.0838125002,
          "annual_profit_projection": 9006409.005750002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 400.28484470000006,
        "regulatory_headroom": -388.3200708400001,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $488.39"
        ]
      }
    },
    {
      "drug_id": "ndc_173052700",
      "drug_name": "LAMICTAL 25 MG DISPER TABLET",
      "ndc": 173052700,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.778404566666666,
          11.964773859999998
        ],
        "expected_margin": 0.3547898882773059,
        "estimated_acquisition_cost": 7.333803424999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.630970434999998,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13892.911304999994,
          "annual_profit_projection": 166714.93565999993,
          "margin_percentage": 38.70503938634406
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.778404566666666,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.26"
        ]
      }
    },
    {
      "drug_id": "ndc_173056504",
      "drug_name": "VALTREX 1 GM CAPLET",
      "ndc": 173056504,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.60436080000001,
        "feasible_range": [
          17.60436080000001,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 13.203270600000007,
        "profit_projections": {
          "gross_profit_per_unit": 4.401090200000002,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33008.176500000016,
          "annual_profit_projection": 396098.1180000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.60436080000001,
        "regulatory_headroom": -5.639586940000012,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.04"
        ]
      }
    },
    {
      "drug_id": "ndc_173056510",
      "drug_name": "VALTREX 1 GM CAPLET",
      "ndc": 173056510,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.60436080000001,
        "feasible_range": [
          17.60436080000001,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 13.203270600000007,
        "profit_projections": {
          "gross_profit_per_unit": 4.401090200000002,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33008.176500000016,
          "annual_profit_projection": 396098.1180000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.60436080000001,
        "regulatory_headroom": -5.639586940000012,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.04"
        ]
      }
    },
    {
      "drug_id": "ndc_173060002",
      "drug_name": "FLOVENT 50 MCG DISKUS",
      "ndc": 173060002,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.2537057583333335,
        "feasible_range": [
          2.6834686666666667,
          3.5762380500000006
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 2.0126015,
        "profit_projections": {
          "gross_profit_per_unit": 1.3417343333333336,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 6708.671666666668,
          "annual_profit_projection": 80504.06000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.6834686666666667,
        "regulatory_headroom": 8.610438026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173060102",
      "drug_name": "FLOVENT 250 MCG DISKUS",
      "ndc": 173060102,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.593844016666667,
        "feasible_range": [
          3.7887373333333336,
          5.049221100000001
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 2.841553,
        "profit_projections": {
          "gross_profit_per_unit": 1.8943686666666668,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 9471.843333333334,
          "annual_profit_projection": 113662.12000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.7887373333333336,
        "regulatory_headroom": 7.2288521933333305,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173060202",
      "drug_name": "FLOVENT 100 MCG DISKUS",
      "ndc": 173060202,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.4326942000000007,
        "feasible_range": [
          2.8310880000000007,
          3.772969200000001
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 2.1233160000000004,
        "profit_projections": {
          "gross_profit_per_unit": 1.4155440000000006,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 6369.948000000003,
          "annual_profit_projection": 76439.37600000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.8310880000000007,
        "regulatory_headroom": 8.425913859999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173063302",
      "drug_name": "LAMICTAL 25 MG TABLET",
      "ndc": 173063302,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.59408420416667,
        "feasible_range": [
          8.921334066666669,
          11.889393285000004
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.691000550000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.460667033333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13382.001100000005,
          "annual_profit_projection": 160584.01320000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.921334066666669,
        "regulatory_headroom": 0.8131062766666606,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173064255",
      "drug_name": "LAMICTAL 100 MG TABLET",
      "ndc": 173064255,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.242182872916668,
        "feasible_range": [
          9.467101366666668,
          11.964773859999998
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 7.100326025000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.733550683333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 14200.652050000002,
          "annual_profit_projection": 170407.82460000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.467101366666668,
        "regulatory_headroom": 0.13089715166666238,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173064360",
      "drug_name": "LAMICTAL 150 MG TABLET",
      "ndc": 173064360,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.9581885,
          11.964773859999998
        ],
        "expected_margin": 0.342927174792596,
        "estimated_acquisition_cost": 7.468641375,
        "profit_projections": {
          "gross_profit_per_unit": 4.496132484999998,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13488.397454999993,
          "annual_profit_projection": 161860.76945999992,
          "margin_percentage": 37.57808160529662
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.9581885,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.48"
        ]
      }
    },
    {
      "drug_id": "ndc_173064460",
      "drug_name": "LAMICTAL 200 MG TABLET",
      "ndc": 173064460,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.480499033333336,
          11.964773859999998
        ],
        "expected_margin": 0.30846347110061206,
        "estimated_acquisition_cost": 7.8603742750000025,
        "profit_projections": {
          "gross_profit_per_unit": 4.104399584999995,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12313.198754999985,
          "annual_profit_projection": 147758.38505999983,
          "margin_percentage": 34.30402975455815
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.480499033333336,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.14"
        ]
      }
    },
    {
      "drug_id": "ndc_173067501",
      "drug_name": "MALARONE 250-100 MG TABLET",
      "ndc": 173067501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.3046025000000006,
        "feasible_range": [
          5.7291,
          7.635127500000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 4.296825,
        "profit_projections": {
          "gross_profit_per_unit": 2.8645500000000004,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 28645.500000000004,
          "annual_profit_projection": 343746.00000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.7291,
        "regulatory_headroom": 4.803398859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173067502",
      "drug_name": "MALARONE 250-100 MG TABLET",
      "ndc": 173067502,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.3046025000000006,
        "feasible_range": [
          5.7291,
          7.635127500000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 4.296825,
        "profit_projections": {
          "gross_profit_per_unit": 2.8645500000000004,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 28645.500000000004,
          "annual_profit_projection": 343746.00000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.7291,
        "regulatory_headroom": 4.803398859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173068220",
      "drug_name": "VENTOLIN HFA 90 MCG INHALER",
      "ndc": 173068220,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.3583088174999998,
        "feasible_range": [
          2.6339677,
          3.5102684925
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 1.9754757749999998,
        "profit_projections": {
          "gross_profit_per_unit": 1.31698385,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 13169.8385,
          "annual_profit_projection": 158038.062,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.6339677,
        "regulatory_headroom": 8.672314234999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173069500",
      "drug_name": "ADVAIR 100-50 DISKUS",
      "ndc": 173069500,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.621050499166666,
        "feasible_range": [
          2.161691133333333,
          2.8808691449999997
        ],
        "expected_margin": 0.3814432989690721,
        "estimated_acquisition_cost": 1.6212683499999998,
        "profit_projections": {
          "gross_profit_per_unit": 1.0808455666666665,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 5404.2278333333325,
          "annual_profit_projection": 64850.73399999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.161691133333333,
        "regulatory_headroom": 9.26265994333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173069600",
      "drug_name": "ADVAIR 250-50 DISKUS",
      "ndc": 173069600,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.288829862500001,
        "feasible_range": [
          2.712437000000001,
          3.6148439250000015
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.0343277500000005,
        "profit_projections": {
          "gross_profit_per_unit": 1.3562185000000007,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 6102.983250000003,
          "annual_profit_projection": 73235.79900000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.712437000000001,
        "regulatory_headroom": 8.574227609999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173069700",
      "drug_name": "ADVAIR 500-50 DISKUS",
      "ndc": 173069700,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.45440684,
        "feasible_range": [
          3.6737375999999995,
          4.89596184
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.7553031999999997,
        "profit_projections": {
          "gross_profit_per_unit": 1.8368688,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 9184.344,
          "annual_profit_projection": 110212.128,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.6737375999999995,
        "regulatory_headroom": 7.372601859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173071520",
      "drug_name": "ADVAIR HFA 45-21 MCG INHALER",
      "ndc": 173071520,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.355346666666673,
        "feasible_range": [
          17.355346666666673,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.016510000000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.338836666666669,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21694.183333333345,
          "annual_profit_projection": 260330.20000000013,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.355346666666673,
        "regulatory_headroom": -5.390572806666675,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $9.73"
        ]
      }
    },
    {
      "drug_id": "ndc_173071620",
      "drug_name": "ADVAIR HFA 115-21 MCG INHALER",
      "ndc": 173071620,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 22.086374699999997,
        "feasible_range": [
          22.086374699999997,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 16.564781025,
        "profit_projections": {
          "gross_profit_per_unit": 5.521593674999998,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 27607.968374999993,
          "annual_profit_projection": 331295.6204999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 22.086374699999997,
        "regulatory_headroom": -10.12160084,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $15.64"
        ]
      }
    },
    {
      "drug_id": "ndc_173071720",
      "drug_name": "ADVAIR HFA 230-21 MCG INHALER",
      "ndc": 173071720,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.441099000000005,
        "feasible_range": [
          30.441099000000005,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 22.830824250000003,
        "profit_projections": {
          "gross_profit_per_unit": 7.610274750000002,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 38051.37375000001,
          "annual_profit_projection": 456616.48500000016,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.441099000000005,
        "regulatory_headroom": -18.476325140000007,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $26.09"
        ]
      }
    },
    {
      "drug_id": "ndc_173071820",
      "drug_name": "FLOVENT HFA 44 MCG INHALER",
      "ndc": 173071820,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.032094,
        "feasible_range": [
          16.032094,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 12.0240705,
        "profit_projections": {
          "gross_profit_per_unit": 4.0080235,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20040.1175,
          "annual_profit_projection": 240481.41,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.032094,
        "regulatory_headroom": -4.067320140000003,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.08"
        ]
      }
    },
    {
      "drug_id": "ndc_173071920",
      "drug_name": "FLOVENT HFA 110 MCG INHALER",
      "ndc": 173071920,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 18.959260666666665,
        "feasible_range": [
          18.959260666666665,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 14.219445499999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.739815166666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23699.075833333332,
          "annual_profit_projection": 284388.91,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 18.959260666666665,
        "regulatory_headroom": -6.994486806666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.73"
        ]
      }
    },
    {
      "drug_id": "ndc_173072020",
      "drug_name": "FLOVENT HFA 220 MCG INHALER",
      "ndc": 173072020,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 29.43773733333334,
        "feasible_range": [
          29.43773733333334,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 22.078303000000005,
        "profit_projections": {
          "gross_profit_per_unit": 7.359434333333336,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 36797.17166666668,
          "annual_profit_projection": 441566.0600000002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 29.43773733333334,
        "regulatory_headroom": -17.472963473333344,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $24.83"
        ]
      }
    },
    {
      "drug_id": "ndc_173072200",
      "drug_name": "WELLBUTRIN SR 200 MG TABLET",
      "ndc": 173072200,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.141871299999998,
        "feasible_range": [
          12.141871299999998,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.106403474999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.0354678249999996,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15177.339124999999,
          "annual_profit_projection": 182128.06949999998,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.141871299999998,
        "regulatory_headroom": -0.17709744000000072,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.21"
        ]
      }
    },
    {
      "drug_id": "ndc_173073601",
      "drug_name": "IMITREX 50 MG TABLET",
      "ndc": 173073601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 63.32573866666667,
        "feasible_range": [
          63.32573866666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 47.49430400000001,
        "profit_projections": {
          "gross_profit_per_unit": 15.831434666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 118735.76,
          "annual_profit_projection": 1424829.1199999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 63.32573866666667,
        "regulatory_headroom": -51.36096480666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $67.19"
        ]
      }
    },
    {
      "drug_id": "ndc_173073701",
      "drug_name": "IMITREX 100 MG TABLET",
      "ndc": 173073701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 62.98943689999998,
        "feasible_range": [
          62.98943689999998,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 47.24207767499998,
        "profit_projections": {
          "gross_profit_per_unit": 15.747359224999997,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 118105.19418749998,
          "annual_profit_projection": 1417262.3302499996,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 62.98943689999998,
        "regulatory_headroom": -51.02466303999998,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $66.77"
        ]
      }
    },
    {
      "drug_id": "ndc_173075400",
      "drug_name": "LAMICTAL XR 25 MG TABLET",
      "ndc": 173075400,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.942236366666668,
        "feasible_range": [
          11.942236366666668,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 8.956677275,
        "profit_projections": {
          "gross_profit_per_unit": 3.008096584999997,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 9024.28975499999,
          "annual_profit_projection": 108291.47705999989,
          "margin_percentage": 25.14127404494043
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.942236366666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.96"
        ]
      }
    },
    {
      "drug_id": "ndc_173075500",
      "drug_name": "LAMICTAL XR 50 MG TABLET",
      "ndc": 173075500,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 23.922291033333337,
        "feasible_range": [
          23.922291033333337,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 17.941718275000003,
        "profit_projections": {
          "gross_profit_per_unit": 5.980572758333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 17941.718275000003,
          "annual_profit_projection": 215300.61930000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 23.922291033333337,
        "regulatory_headroom": -11.95751717333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $17.94"
        ]
      }
    },
    {
      "drug_id": "ndc_173075600",
      "drug_name": "LAMICTAL XR 100 MG TABLET",
      "ndc": 173075600,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 25.57125003333334,
        "feasible_range": [
          25.57125003333334,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 19.178437525000003,
        "profit_projections": {
          "gross_profit_per_unit": 6.392812508333336,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 19178.43752500001,
          "annual_profit_projection": 230141.2503000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 25.57125003333334,
        "regulatory_headroom": -13.606476173333341,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $20.00"
        ]
      }
    },
    {
      "drug_id": "ndc_173075700",
      "drug_name": "LAMICTAL XR 200 MG TABLET",
      "ndc": 173075700,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 27.297394366666662,
        "feasible_range": [
          27.297394366666662,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 20.473045774999996,
        "profit_projections": {
          "gross_profit_per_unit": 6.824348591666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 20473.045775,
          "annual_profit_projection": 245676.54929999998,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 27.297394366666662,
        "regulatory_headroom": -15.332620506666665,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $22.16"
        ]
      }
    },
    {
      "drug_id": "ndc_173076100",
      "drug_name": "LAMICTAL XR 300 MG TABLET",
      "ndc": 173076100,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 41.0778017,
        "feasible_range": [
          41.0778017,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 30.808351275,
        "profit_projections": {
          "gross_profit_per_unit": 10.269450425000002,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 30808.351275000008,
          "annual_profit_projection": 369700.2153000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 41.0778017,
        "regulatory_headroom": -29.113027840000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $39.38"
        ]
      }
    },
    {
      "drug_id": "ndc_173077202",
      "drug_name": "LAMICTAL ODT 25 MG TABLET",
      "ndc": 173077202,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          11.05487326666667,
          11.964773859999998
        ],
        "expected_margin": 0.27056443954254605,
        "estimated_acquisition_cost": 8.291154950000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.6736189099999947,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11020.856729999985,
          "annual_profit_projection": 132250.28075999982,
          "margin_percentage": 30.703621756541878
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.05487326666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.85"
        ]
      }
    },
    {
      "drug_id": "ndc_173077402",
      "drug_name": "LAMICTAL ODT 50 MG TABLET",
      "ndc": 173077402,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.915291700000003,
        "feasible_range": [
          11.915291700000003,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 8.936468775000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.028305084999996,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 9084.915254999987,
          "annual_profit_projection": 109018.98305999985,
          "margin_percentage": 25.310174019452774
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.915291700000003,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.93"
        ]
      }
    },
    {
      "drug_id": "ndc_173077602",
      "drug_name": "LAMICTAL ODT 100 MG TABLET",
      "ndc": 173077602,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.704878766666667,
        "feasible_range": [
          12.704878766666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.528659075,
        "profit_projections": {
          "gross_profit_per_unit": 3.1762196916666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 9528.659075,
          "annual_profit_projection": 114343.9089,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.704878766666667,
        "regulatory_headroom": -0.7401049066666694,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.92"
        ]
      }
    },
    {
      "drug_id": "ndc_173077702",
      "drug_name": "LAMICTAL ODT 200 MG TABLET",
      "ndc": 173077702,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.167723566666671,
        "feasible_range": [
          15.167723566666671,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.375792675000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.7919308916666683,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11375.792675000004,
          "annual_profit_projection": 136509.51210000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.167723566666671,
        "regulatory_headroom": -3.202949706666674,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.99"
        ]
      }
    },
    {
      "drug_id": "ndc_173078100",
      "drug_name": "LAMICTAL XR 250 MG TABLET",
      "ndc": 173078100,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 37.20497820000001,
        "feasible_range": [
          37.20497820000001,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 27.90373365000001,
        "profit_projections": {
          "gross_profit_per_unit": 9.301244550000003,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 27903.73365000001,
          "annual_profit_projection": 334844.8038000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 37.20497820000001,
        "regulatory_headroom": -25.240204340000016,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $34.54"
        ]
      }
    },
    {
      "drug_id": "ndc_173085910",
      "drug_name": "BREO ELLIPTA 100-25 MCG INHALR",
      "ndc": 173085910,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.194993130000001,
        "feasible_range": [
          5.643131866666668,
          7.520558430000001
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 4.232348900000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.821565933333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 28215.659333333337,
          "annual_profit_projection": 338587.912,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.643131866666668,
        "regulatory_headroom": 4.910859026666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173088210",
      "drug_name": "BREO ELLIPTA 200-25 MCG INHALR",
      "ndc": 173088210,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.194605827500001,
        "feasible_range": [
          5.6428281,
          7.5201536025
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 4.232121075,
        "profit_projections": {
          "gross_profit_per_unit": 2.8214140500000005,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 28214.140500000005,
          "annual_profit_projection": 338569.68600000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.6428281,
        "regulatory_headroom": 4.911238734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_173093308",
      "drug_name": "VALTREX 500 MG CAPLET",
      "ndc": 173093308,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.175109399999998,
          11.964773859999998
        ],
        "expected_margin": 0.29949933462428174,
        "estimated_acquisition_cost": 8.38133205,
        "profit_projections": {
          "gross_profit_per_unit": 3.5834418099999983,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 26875.813574999986,
          "annual_profit_projection": 322509.76289999986,
          "margin_percentage": 29.949933462428174
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.175109399999998,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.00"
        ]
      }
    },
    {
      "drug_id": "ndc_173093310",
      "drug_name": "VALTREX 500 MG CAPLET",
      "ndc": 173093310,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.175109399999998,
          11.964773859999998
        ],
        "expected_margin": 0.29949933462428174,
        "estimated_acquisition_cost": 8.38133205,
        "profit_projections": {
          "gross_profit_per_unit": 3.5834418099999983,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 26875.813574999986,
          "annual_profit_projection": 322509.76289999986,
          "margin_percentage": 29.949933462428174
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.175109399999998,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.00"
        ]
      }
    },
    {
      "drug_id": "ndc_173094755",
      "drug_name": "WELLBUTRIN SR 100 MG TABLET",
      "ndc": 173094755,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.399747658333334,
        "feasible_range": [
          6.102884666666667,
          8.133267450000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 4.5771635,
        "profit_projections": {
          "gross_profit_per_unit": 3.051442333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15257.21166666667,
          "annual_profit_projection": 183086.54000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.102884666666667,
        "regulatory_headroom": 4.336168026666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186037020",
      "drug_name": "SYMBICORT 160-4.5 MCG INHALER",
      "ndc": 186037020,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.10918793333333,
        "feasible_range": [
          19.10918793333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 14.331890949999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.777296983333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 47772.96983333333,
          "annual_profit_projection": 573275.6379999999,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.10918793333333,
        "regulatory_headroom": -7.1444140733333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.92"
        ]
      }
    },
    {
      "drug_id": "ndc_186037220",
      "drug_name": "SYMBICORT 80-4.5 MCG INHALER",
      "ndc": 186037220,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.716436966666667,
        "feasible_range": [
          16.716436966666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 12.537327724999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.1791092416666675,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 41791.092416666674,
          "annual_profit_projection": 501493.10900000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.716436966666667,
        "regulatory_headroom": -4.751663106666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.93"
        ]
      }
    },
    {
      "drug_id": "ndc_186198804",
      "drug_name": "PULMICORT 0.25 MG/2 ML RESPUL",
      "ndc": 186198804,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.541405374999999,
        "feasible_range": [
          3.633124299999999,
          4.8418368075
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.7248432249999994,
        "profit_projections": {
          "gross_profit_per_unit": 1.8165621499999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 13624.216124999999,
          "annual_profit_projection": 163490.5935,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.633124299999999,
        "regulatory_headroom": 7.423368484999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186198904",
      "drug_name": "PULMICORT 0.5 MG/2 ML RESPULE",
      "ndc": 186198904,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.339941208333336,
        "feasible_range": [
          4.271952966666668,
          5.693198857500002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.2039647250000014,
        "profit_projections": {
          "gross_profit_per_unit": 2.1359764833333346,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 16019.82362500001,
          "annual_profit_projection": 192237.8835000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.271952966666668,
        "regulatory_headroom": 6.624832651666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186199004",
      "drug_name": "PULMICORT 1 MG/2 ML RESPULE",
      "ndc": 186199004,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.660129458333339,
        "feasible_range": [
          8.52810356666667,
          11.365338022500005
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 6.396077675000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.264051783333336,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 28782.34953750002,
          "annual_profit_projection": 345388.19445000024,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.52810356666667,
        "regulatory_headroom": 1.3046444016666587,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186401001",
      "drug_name": "NEXIUM DR 10 MG PACKET",
      "ndc": 186401001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.653210877916665,
        "feasible_range": [
          7.961411033333332,
          10.610111242499999
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.971058274999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.980705516666667,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 17913.174825000002,
          "annual_profit_projection": 214958.09790000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.961411033333332,
        "regulatory_headroom": 2.0130100683333314,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186402001",
      "drug_name": "NEXIUM DR 20 MG PACKET",
      "ndc": 186402001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.643565804166666,
        "feasible_range": [
          7.953456333333333,
          10.599510075000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.96509225,
        "profit_projections": {
          "gross_profit_per_unit": 3.9767281666666676,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 17895.276750000005,
          "annual_profit_projection": 214743.32100000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.953456333333333,
        "regulatory_headroom": 2.0229534433333303,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186404001",
      "drug_name": "NEXIUM DR 40 MG PACKET",
      "ndc": 186404001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.639824837500003,
        "feasible_range": [
          7.950371000000001,
          10.595398275000004
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.962778250000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.975185500000002,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 17888.33475000001,
          "annual_profit_projection": 214660.0170000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.950371000000001,
        "regulatory_headroom": 2.0268101099999942,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186405001",
      "drug_name": "NEXIUM DR 5 MG PACKET",
      "ndc": 186405001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.645157816666668,
        "feasible_range": [
          7.954769333333334,
          10.601259900000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.966077,
        "profit_projections": {
          "gross_profit_per_unit": 3.9773846666666675,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19886.923333333336,
          "annual_profit_projection": 238643.08000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.954769333333334,
        "regulatory_headroom": 2.02131219333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186502031",
      "drug_name": "NEXIUM DR 20 MG CAPSULE",
      "ndc": 186502031,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.269346190000002,
        "feasible_range": [
          7.644821600000001,
          10.188194940000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.733616200000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.822410800000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19112.054000000004,
          "annual_profit_projection": 229344.64800000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.644821600000001,
        "regulatory_headroom": 2.4087468599999955,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186502054",
      "drug_name": "NEXIUM DR 20 MG CAPSULE",
      "ndc": 186502054,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.269346190000002,
        "feasible_range": [
          7.644821600000001,
          10.188194940000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.733616200000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.822410800000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19112.054000000004,
          "annual_profit_projection": 229344.64800000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.644821600000001,
        "regulatory_headroom": 2.4087468599999955,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186504031",
      "drug_name": "NEXIUM DR 40 MG CAPSULE",
      "ndc": 186504031,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.257618364583333,
        "feasible_range": [
          7.6351491666666655,
          10.1753045625
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.726361874999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.817574583333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19087.872916666667,
          "annual_profit_projection": 229054.475,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.6351491666666655,
        "regulatory_headroom": 2.420837401666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_186504054",
      "drug_name": "NEXIUM DR 40 MG CAPSULE",
      "ndc": 186504054,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.257618364583333,
        "feasible_range": [
          7.6351491666666655,
          10.1753045625
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.726361874999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.817574583333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19087.872916666667,
          "annual_profit_projection": 229054.475,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.6351491666666655,
        "regulatory_headroom": 2.420837401666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187006301",
      "drug_name": "ATIVAN 0.5 MG TABLET",
      "ndc": 187006301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.59774813333333,
        "feasible_range": [
          30.59774813333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 22.948311099999998,
        "profit_projections": {
          "gross_profit_per_unit": 7.6494370333333315,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 57370.77774999999,
          "annual_profit_projection": 688449.3329999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.59774813333333,
        "regulatory_headroom": -18.632974273333332,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $26.28"
        ]
      }
    },
    {
      "drug_id": "ndc_187006401",
      "drug_name": "ATIVAN 1 MG TABLET",
      "ndc": 187006401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 41.03869380000001,
        "feasible_range": [
          41.03869380000001,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 30.77902035000001,
        "profit_projections": {
          "gross_profit_per_unit": 10.259673450000001,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 76947.55087500002,
          "annual_profit_projection": 923370.6105000002,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 41.03869380000001,
        "regulatory_headroom": -29.073919940000014,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $39.33"
        ]
      }
    },
    {
      "drug_id": "ndc_187006410",
      "drug_name": "ATIVAN 1 MG TABLET",
      "ndc": 187006410,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 41.03869380000001,
        "feasible_range": [
          41.03869380000001,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 30.77902035000001,
        "profit_projections": {
          "gross_profit_per_unit": 10.259673450000001,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 76947.55087500002,
          "annual_profit_projection": 923370.6105000002,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 41.03869380000001,
        "regulatory_headroom": -29.073919940000014,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $39.33"
        ]
      }
    },
    {
      "drug_id": "ndc_187006501",
      "drug_name": "ATIVAN 2 MG TABLET",
      "ndc": 187006501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 65.58837653333332,
        "feasible_range": [
          65.58837653333332,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 49.19128239999999,
        "profit_projections": {
          "gross_profit_per_unit": 16.397094133333326,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 122978.20599999995,
          "annual_profit_projection": 1475738.4719999994,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 65.58837653333332,
        "regulatory_headroom": -53.62360267333332,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $70.02"
        ]
      }
    },
    {
      "drug_id": "ndc_187073030",
      "drug_name": "WELLBUTRIN XL 150 MG TABLET",
      "ndc": 187073030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 60.473335866666694,
        "feasible_range": [
          60.473335866666694,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 45.35500190000002,
        "profit_projections": {
          "gross_profit_per_unit": 15.118333966666675,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 75591.66983333338,
          "annual_profit_projection": 907100.0380000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 60.473335866666694,
        "regulatory_headroom": -48.50856200666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $63.63"
        ]
      }
    },
    {
      "drug_id": "ndc_187073090",
      "drug_name": "WELLBUTRIN XL 150 MG TABLET",
      "ndc": 187073090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 60.473335866666694,
        "feasible_range": [
          60.473335866666694,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 45.35500190000002,
        "profit_projections": {
          "gross_profit_per_unit": 15.118333966666675,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 75591.66983333338,
          "annual_profit_projection": 907100.0380000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 60.473335866666694,
        "regulatory_headroom": -48.50856200666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $63.63"
        ]
      }
    },
    {
      "drug_id": "ndc_187073130",
      "drug_name": "WELLBUTRIN XL 300 MG TABLET",
      "ndc": 187073130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 79.93728036666668,
        "feasible_range": [
          79.93728036666668,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 59.95296027500002,
        "profit_projections": {
          "gross_profit_per_unit": 19.984320091666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 99921.60045833334,
          "annual_profit_projection": 1199059.2055000002,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 79.93728036666668,
        "regulatory_headroom": -67.97250650666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $87.96"
        ]
      }
    },
    {
      "drug_id": "ndc_187079530",
      "drug_name": "CARDIZEM CD 120 MG CAPSULE",
      "ndc": 187079530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 23.60005266666667,
        "feasible_range": [
          23.60005266666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 17.700039500000003,
        "profit_projections": {
          "gross_profit_per_unit": 5.9000131666666675,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 29500.065833333338,
          "annual_profit_projection": 354000.79000000004,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 23.60005266666667,
        "regulatory_headroom": -11.635278806666673,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $17.54"
        ]
      }
    },
    {
      "drug_id": "ndc_187079542",
      "drug_name": "CARDIZEM CD 120 MG CAPSULE",
      "ndc": 187079542,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 23.60005266666667,
        "feasible_range": [
          23.60005266666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 17.700039500000003,
        "profit_projections": {
          "gross_profit_per_unit": 5.9000131666666675,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 29500.065833333338,
          "annual_profit_projection": 354000.79000000004,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 23.60005266666667,
        "regulatory_headroom": -11.635278806666673,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $17.54"
        ]
      }
    },
    {
      "drug_id": "ndc_187079730",
      "drug_name": "CARDIZEM CD 240 MG CAPSULE",
      "ndc": 187079730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 40.44098066666667,
        "feasible_range": [
          40.44098066666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 30.330735500000003,
        "profit_projections": {
          "gross_profit_per_unit": 10.110245166666665,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 50551.22583333332,
          "annual_profit_projection": 606614.7099999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 40.44098066666667,
        "regulatory_headroom": -28.47620680666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $38.59"
        ]
      }
    },
    {
      "drug_id": "ndc_187079742",
      "drug_name": "CARDIZEM CD 240 MG CAPSULE",
      "ndc": 187079742,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 40.44098066666667,
        "feasible_range": [
          40.44098066666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 30.330735500000003,
        "profit_projections": {
          "gross_profit_per_unit": 10.110245166666665,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 50551.22583333332,
          "annual_profit_projection": 606614.7099999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 40.44098066666667,
        "regulatory_headroom": -28.47620680666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $38.59"
        ]
      }
    },
    {
      "drug_id": "ndc_187099395",
      "drug_name": "ZOVIRAX 5% OINTMENT",
      "ndc": 187099395,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.3018104425000026,
        "feasible_range": [
          4.158282700000002,
          5.541711367500002
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 3.118712025000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.079141350000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 20791.41350000001,
          "annual_profit_projection": 249496.96200000012,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.158282700000002,
        "regulatory_headroom": 6.7669204849999955,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187099445",
      "drug_name": "ZOVIRAX 5% CREAM",
      "ndc": 187099445,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 33.22372256666666,
        "feasible_range": [
          33.22372256666666,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 24.917791924999992,
        "profit_projections": {
          "gross_profit_per_unit": 8.305930641666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 83059.30641666666,
          "annual_profit_projection": 996711.6769999999,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 33.22372256666666,
        "regulatory_headroom": -21.25894870666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $29.56"
        ]
      }
    },
    {
      "drug_id": "ndc_187149605",
      "drug_name": "TIMOPTIC 0.5% OCUDOSE DROP",
      "ndc": 187149605,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.442316437499999,
        "feasible_range": [
          8.974365833333332,
          11.960068312499999
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.730774374999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.487182916666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44871.82916666667,
          "annual_profit_projection": 538461.9500000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.974365833333332,
        "regulatory_headroom": 0.7468165683333314,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187204530",
      "drug_name": "CARDIZEM LA 120 MG TABLET",
      "ndc": 187204530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.8403092975000015,
        "feasible_range": [
          3.167265400000001,
          4.220990235000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.3754490500000007,
        "profit_projections": {
          "gross_profit_per_unit": 1.5836327000000008,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 7918.163500000004,
          "annual_profit_projection": 95017.96200000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.167265400000001,
        "regulatory_headroom": 8.005692109999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187204590",
      "drug_name": "CARDIZEM LA 120 MG TABLET",
      "ndc": 187204590,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.8403092975000015,
        "feasible_range": [
          3.167265400000001,
          4.220990235000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.3754490500000007,
        "profit_projections": {
          "gross_profit_per_unit": 1.5836327000000008,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 7918.163500000004,
          "annual_profit_projection": 95017.96200000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.167265400000001,
        "regulatory_headroom": 8.005692109999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187204630",
      "drug_name": "CARDIZEM LA 180 MG TABLET",
      "ndc": 187204630,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.026162833333334,
        "feasible_range": [
          3.320546666666667,
          4.425267000000001
        ],
        "expected_margin": 0.38144329896907225,
        "estimated_acquisition_cost": 2.4904100000000002,
        "profit_projections": {
          "gross_profit_per_unit": 1.660273333333334,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 7471.230000000002,
          "annual_profit_projection": 89654.76000000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.320546666666667,
        "regulatory_headroom": 7.814090526666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187204690",
      "drug_name": "CARDIZEM LA 180 MG TABLET",
      "ndc": 187204690,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.026162833333334,
        "feasible_range": [
          3.320546666666667,
          4.425267000000001
        ],
        "expected_margin": 0.38144329896907225,
        "estimated_acquisition_cost": 2.4904100000000002,
        "profit_projections": {
          "gross_profit_per_unit": 1.660273333333334,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 7471.230000000002,
          "annual_profit_projection": 89654.76000000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.320546666666667,
        "regulatory_headroom": 7.814090526666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187204730",
      "drug_name": "CARDIZEM LA 240 MG TABLET",
      "ndc": 187204730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.563128158333334,
        "feasible_range": [
          3.7634046666666667,
          5.01546045
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.8225535,
        "profit_projections": {
          "gross_profit_per_unit": 1.8817023333333336,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 9408.511666666667,
          "annual_profit_projection": 112902.14000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.7634046666666667,
        "regulatory_headroom": 7.260518026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187204790",
      "drug_name": "CARDIZEM LA 240 MG TABLET",
      "ndc": 187204790,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.563128158333334,
        "feasible_range": [
          3.7634046666666667,
          5.01546045
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.8225535,
        "profit_projections": {
          "gross_profit_per_unit": 1.8817023333333336,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 9408.511666666667,
          "annual_profit_projection": 112902.14000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.7634046666666667,
        "regulatory_headroom": 7.260518026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187301030",
      "drug_name": "MESTINON 60 MG TABLET",
      "ndc": 187301030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.915931366666666,
        "feasible_range": [
          17.915931366666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 13.436948525,
        "profit_projections": {
          "gross_profit_per_unit": 4.4789828416666655,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44789.828416666656,
          "annual_profit_projection": 537477.9409999999,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.915931366666666,
        "regulatory_headroom": -5.951157506666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.43"
        ]
      }
    },
    {
      "drug_id": "ndc_187301330",
      "drug_name": "MESTINON 180 MG TIMESPAN",
      "ndc": 187301330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 33.91116733333333,
        "feasible_range": [
          33.91116733333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 25.4333755,
        "profit_projections": {
          "gross_profit_per_unit": 8.477791833333331,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 84777.9183333333,
          "annual_profit_projection": 1017335.0199999997,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 33.91116733333333,
        "regulatory_headroom": -21.946393473333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $30.42"
        ]
      }
    },
    {
      "drug_id": "ndc_187305050",
      "drug_name": "ONEXTON GEL PUMP",
      "ndc": 187305050,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.023753299999997,
        "feasible_range": [
          12.023753299999997,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.017814974999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.005938324999999,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 30059.383249999988,
          "annual_profit_projection": 360712.5989999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.023753299999997,
        "regulatory_headroom": -0.05897943999999988,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.06"
        ]
      }
    },
    {
      "drug_id": "ndc_187320447",
      "drug_name": "EFUDEX 5% CREAM",
      "ndc": 187320447,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.5951730275000005,
        "feasible_range": [
          1.2511161000000002,
          1.6673528025000002
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.9383370750000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.6255580500000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 6255.580500000002,
          "annual_profit_projection": 75066.96600000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.2511161000000002,
        "regulatory_headroom": 10.400878734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187510001",
      "drug_name": "ELIDEL 1% CREAM",
      "ndc": 187510001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.382675333333331,
        "feasible_range": [
          8.306140266666665,
          11.069529239999998
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 6.229605199999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.153070133333333,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 28033.2234,
          "annual_profit_projection": 336398.6808,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.306140266666665,
        "regulatory_headroom": 1.582098526666666,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187510102",
      "drug_name": "ELIDEL 1% CREAM",
      "ndc": 187510102,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.277691666666668,
        "feasible_range": [
          8.222153333333333,
          10.9576005
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.166615,
        "profit_projections": {
          "gross_profit_per_unit": 4.111076666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30833.075000000004,
          "annual_profit_projection": 369996.9,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.222153333333333,
        "regulatory_headroom": 1.68708219333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187510203",
      "drug_name": "ELIDEL 1% CREAM",
      "ndc": 187510203,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.340015833333336,
        "feasible_range": [
          8.272012666666669,
          11.024047650000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.2040095000000015,
        "profit_projections": {
          "gross_profit_per_unit": 4.136006333333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 31020.047500000008,
          "annual_profit_projection": 372240.57000000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.272012666666669,
        "regulatory_headroom": 1.6247580266666617,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187514850",
      "drug_name": "RETIN-A MICRO PUMP 0.08% GEL",
      "ndc": 187514850,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.024421533333339,
        "feasible_range": [
          15.024421533333339,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.268316150000004,
        "profit_projections": {
          "gross_profit_per_unit": 3.7561053833333347,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11268.316150000004,
          "annual_profit_projection": 135219.79380000004,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.024421533333339,
        "regulatory_headroom": -3.059647673333341,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.82"
        ]
      }
    },
    {
      "drug_id": "ndc_187516020",
      "drug_name": "RETIN-A 0.025% CREAM",
      "ndc": 187516020,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.7405764979166668,
        "feasible_range": [
          0.6236433666666669,
          0.8311247175000004
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 0.4677325250000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.31182168333333343,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 935.4650500000002,
          "annual_profit_projection": 11225.580600000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.6236433666666669,
        "regulatory_headroom": 11.185219651666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187516045",
      "drug_name": "RETIN-A 0.025% CREAM",
      "ndc": 187516045,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.7409238416666667,
        "feasible_range": [
          0.6239358666666667,
          0.8315145300000002
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.46795190000000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.31196793333333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 935.9038,
          "annual_profit_projection": 11230.8456,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.6239358666666667,
        "regulatory_headroom": 11.184854026666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187516220",
      "drug_name": "RETIN-A 0.05% CREAM",
      "ndc": 187516220,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.7414476875,
        "feasible_range": [
          0.6243770000000001,
          0.8321024250000001
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.46828275,
        "profit_projections": {
          "gross_profit_per_unit": 0.31218850000000004,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 936.5655000000002,
          "annual_profit_projection": 11238.786000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.6243770000000001,
        "regulatory_headroom": 11.184302609999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187516245",
      "drug_name": "RETIN-A 0.05% CREAM",
      "ndc": 187516245,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.7408255562500001,
        "feasible_range": [
          0.6238531000000002,
          0.8314042275000002
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.4678898250000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.31192655000000014,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 842.2016850000003,
          "annual_profit_projection": 10106.420220000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.6238531000000002,
        "regulatory_headroom": 11.184957484999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187516420",
      "drug_name": "RETIN-A 0.1% CREAM",
      "ndc": 187516420,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9881641520833337,
        "feasible_range": [
          0.8321382333333337,
          1.1089842225000006
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.6241036750000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.4160691166666669,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1248.2073500000008,
          "annual_profit_projection": 14978.48820000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8321382333333337,
        "regulatory_headroom": 10.924601068333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187516445",
      "drug_name": "RETIN-A 0.1% CREAM",
      "ndc": 187516445,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9875420208333332,
        "feasible_range": [
          0.8316143333333331,
          1.1082860249999997
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.6237107499999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.4158071666666667,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1122.67935,
          "annual_profit_projection": 13472.1522,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8316143333333331,
        "regulatory_headroom": 10.925255943333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187517015",
      "drug_name": "RETIN-A 0.025% GEL",
      "ndc": 187517015,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9883108083333331,
        "feasible_range": [
          0.8322617333333331,
          1.1091488099999998
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.6241962999999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.41613086666666665,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1123.55334,
          "annual_profit_projection": 13482.64008,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8322617333333331,
        "regulatory_headroom": 10.924446693333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187517045",
      "drug_name": "RETIN-A 0.025% GEL",
      "ndc": 187517045,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9881523166666663,
        "feasible_range": [
          0.8321282666666664,
          1.1089709399999996
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.6240961999999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.41606413333333314,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1248.1923999999995,
          "annual_profit_projection": 14978.308799999993,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8321282666666664,
        "regulatory_headroom": 10.924613526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187517215",
      "drug_name": "RETIN-A 0.01% GEL",
      "ndc": 187517215,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9888696458333336,
        "feasible_range": [
          0.8327323333333335,
          1.1097759750000005
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.6245492500000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.4163661666666668,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1249.0985000000005,
          "annual_profit_projection": 14989.182000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8327323333333335,
        "regulatory_headroom": 10.92385844333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187517245",
      "drug_name": "RETIN-A 0.01% GEL",
      "ndc": 187517245,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9839708125,
        "feasible_range": [
          0.828607,
          1.1042781750000001
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.62145525,
        "profit_projections": {
          "gross_profit_per_unit": 0.41430350000000005,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1242.9105000000002,
          "annual_profit_projection": 14914.926000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.828607,
        "regulatory_headroom": 10.929015109999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_187520546",
      "drug_name": "BENZAMYCIN GEL",
      "ndc": 187520546,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.4263284750000003,
        "feasible_range": [
          1.118689,
          1.4908682250000005
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.8390167500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.5593445000000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 5593.4450000000015,
          "annual_profit_projection": 67121.34000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.118689,
        "regulatory_headroom": 10.566412609999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245014401",
      "drug_name": "PACERONE 100 MG TABLET",
      "ndc": 245014401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9176091166666666,
        "feasible_range": [
          0.7727234666666666,
          1.02980262
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.5795425999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.38636173333333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1159.0852,
          "annual_profit_projection": 13909.0224,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7727234666666666,
        "regulatory_headroom": 10.998869526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245014430",
      "drug_name": "PACERONE 100 MG TABLET",
      "ndc": 245014430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9176091166666666,
        "feasible_range": [
          0.7727234666666666,
          1.02980262
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.5795425999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.38636173333333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1159.0852,
          "annual_profit_projection": 13909.0224,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7727234666666666,
        "regulatory_headroom": 10.998869526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245014489",
      "drug_name": "PACERONE 100 MG TABLET",
      "ndc": 245014489,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9176091166666666,
        "feasible_range": [
          0.7727234666666666,
          1.02980262
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.5795425999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.38636173333333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1159.0852,
          "annual_profit_projection": 13909.0224,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7727234666666666,
        "regulatory_headroom": 10.998869526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245014701",
      "drug_name": "PACERONE 200 MG TABLET",
      "ndc": 245014701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.14777003703703703,
        "feasible_range": [
          0.12443792592592594,
          0.1658374666666667
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 0.09332844444444445,
        "profit_projections": {
          "gross_profit_per_unit": 0.06221896296296296,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 186.6568888888889,
          "annual_profit_projection": 2239.8826666666664,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.12443792592592594,
        "regulatory_headroom": 11.80922645259259,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245014715",
      "drug_name": "PACERONE 200 MG TABLET",
      "ndc": 245014715,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.14777003703703703,
        "feasible_range": [
          0.12443792592592594,
          0.1658374666666667
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 0.09332844444444445,
        "profit_projections": {
          "gross_profit_per_unit": 0.06221896296296296,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 186.6568888888889,
          "annual_profit_projection": 2239.8826666666664,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.12443792592592594,
        "regulatory_headroom": 11.80922645259259,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245014760",
      "drug_name": "PACERONE 200 MG TABLET",
      "ndc": 245014760,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.14777003703703703,
        "feasible_range": [
          0.12443792592592594,
          0.1658374666666667
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 0.09332844444444445,
        "profit_projections": {
          "gross_profit_per_unit": 0.06221896296296296,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 186.6568888888889,
          "annual_profit_projection": 2239.8826666666664,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.12443792592592594,
        "regulatory_headroom": 11.80922645259259,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245014789",
      "drug_name": "PACERONE 200 MG TABLET",
      "ndc": 245014789,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.14777003703703703,
        "feasible_range": [
          0.12443792592592594,
          0.1658374666666667
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 0.09332844444444445,
        "profit_projections": {
          "gross_profit_per_unit": 0.06221896296296296,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 186.6568888888889,
          "annual_profit_projection": 2239.8826666666664,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.12443792592592594,
        "regulatory_headroom": 11.80922645259259,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245014790",
      "drug_name": "PACERONE 200 MG TABLET",
      "ndc": 245014790,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.14777003703703703,
        "feasible_range": [
          0.12443792592592594,
          0.1658374666666667
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 0.09332844444444445,
        "profit_projections": {
          "gross_profit_per_unit": 0.06221896296296296,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 186.6568888888889,
          "annual_profit_projection": 2239.8826666666664,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.12443792592592594,
        "regulatory_headroom": 11.80922645259259,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245036001",
      "drug_name": "KLOR-CON 20 MEQ PACKET",
      "ndc": 245036001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.48684420416666685,
        "feasible_range": [
          0.40997406666666675,
          0.5463692850000001
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 0.3074805500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.20498703333333346,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 553.4649900000003,
          "annual_profit_projection": 6641.579880000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.40997406666666675,
        "regulatory_headroom": 11.452306276666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245036030",
      "drug_name": "KLOR-CON 20 MEQ PACKET",
      "ndc": 245036030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.48684420416666685,
        "feasible_range": [
          0.40997406666666675,
          0.5463692850000001
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 0.3074805500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.20498703333333346,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 553.4649900000003,
          "annual_profit_projection": 6641.579880000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.40997406666666675,
        "regulatory_headroom": 11.452306276666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245036089",
      "drug_name": "KLOR-CON 20 MEQ PACKET",
      "ndc": 245036089,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.48684420416666685,
        "feasible_range": [
          0.40997406666666675,
          0.5463692850000001
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 0.3074805500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.20498703333333346,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 553.4649900000003,
          "annual_profit_projection": 6641.579880000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.40997406666666675,
        "regulatory_headroom": 11.452306276666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245087105",
      "drug_name": "VOGELXO 50 MG/5 GRAM GEL",
      "ndc": 245087105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.184543285000002,
        "feasible_range": [
          3.2819947333333346,
          4.373889135000002
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.461496050000001,
        "profit_projections": {
          "gross_profit_per_unit": 1.6409973666666673,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 16409.973666666672,
          "annual_profit_projection": 196919.68400000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.2819947333333346,
        "regulatory_headroom": 7.862280443333329,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245107130",
      "drug_name": "QUDEXY XR 25 MG CAPSULE",
      "ndc": 245107130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.110014166666671,
        "feasible_range": [
          8.088011333333336,
          10.778830488461542
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.066008500000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.044005666666669,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30330.042500000018,
          "annual_profit_projection": 363960.51000000024,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.088011333333336,
        "regulatory_headroom": 1.8547596933333264,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245107330",
      "drug_name": "QUDEXY XR 200 MG CAPSULE",
      "ndc": 245107330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 28.47141396666666,
        "feasible_range": [
          28.47141396666666,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 21.353560474999995,
        "profit_projections": {
          "gross_profit_per_unit": 7.117853491666665,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 53383.901187499985,
          "annual_profit_projection": 640606.8142499998,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 28.47141396666666,
        "regulatory_headroom": -16.506640106666662,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $23.62"
        ]
      }
    },
    {
      "drug_id": "ndc_245107430",
      "drug_name": "QUDEXY XR 100 MG CAPSULE",
      "ndc": 245107430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 20.915646266666673,
        "feasible_range": [
          20.915646266666673,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 15.686734700000004,
        "profit_projections": {
          "gross_profit_per_unit": 5.228911566666669,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 39216.83675000002,
          "annual_profit_projection": 470602.0410000002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 20.915646266666673,
        "regulatory_headroom": -8.950872406666676,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $14.18"
        ]
      }
    },
    {
      "drug_id": "ndc_245107530",
      "drug_name": "QUDEXY XR 150 MG CAPSULE",
      "ndc": 245107530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 25.608132333333344,
        "feasible_range": [
          25.608132333333344,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 19.20609925000001,
        "profit_projections": {
          "gross_profit_per_unit": 6.402033083333336,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 48015.24812500002,
          "annual_profit_projection": 576182.9775000003,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 25.608132333333344,
        "regulatory_headroom": -13.643358473333347,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $20.05"
        ]
      }
    },
    {
      "drug_id": "ndc_245164501",
      "drug_name": "PACERONE 400 MG TABLET",
      "ndc": 245164501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.8739441479166667,
        "feasible_range": [
          0.7359529666666668,
          0.9807988575
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.551964725,
        "profit_projections": {
          "gross_profit_per_unit": 0.36797648333333344,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1103.9294500000003,
          "annual_profit_projection": 13247.153400000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7359529666666668,
        "regulatory_headroom": 11.044832651666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245164530",
      "drug_name": "PACERONE 400 MG TABLET",
      "ndc": 245164530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.8739441479166667,
        "feasible_range": [
          0.7359529666666668,
          0.9807988575
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.551964725,
        "profit_projections": {
          "gross_profit_per_unit": 0.36797648333333344,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1103.9294500000003,
          "annual_profit_projection": 13247.153400000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7359529666666668,
        "regulatory_headroom": 11.044832651666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245164589",
      "drug_name": "PACERONE 400 MG TABLET",
      "ndc": 245164589,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.8739441479166667,
        "feasible_range": [
          0.7359529666666668,
          0.9807988575
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.551964725,
        "profit_projections": {
          "gross_profit_per_unit": 0.36797648333333344,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1103.9294500000003,
          "annual_profit_projection": 13247.153400000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7359529666666668,
        "regulatory_headroom": 11.044832651666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531501",
      "drug_name": "KLOR-CON 8 MEQ TABLET",
      "ndc": 245531501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.24190716874999996,
        "feasible_range": [
          0.20371129999999996,
          0.2714844825
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.15278347499999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.10185564999999999,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 305.56694999999996,
          "annual_profit_projection": 3666.8034,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.20371129999999996,
        "regulatory_headroom": 11.710134734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531511",
      "drug_name": "KLOR-CON 8 MEQ TABLET",
      "ndc": 245531511,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.24190716874999996,
        "feasible_range": [
          0.20371129999999996,
          0.2714844825
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.15278347499999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.10185564999999999,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 305.56694999999996,
          "annual_profit_projection": 3666.8034,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.20371129999999996,
        "regulatory_headroom": 11.710134734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531515",
      "drug_name": "KLOR-CON 8 MEQ TABLET",
      "ndc": 245531515,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.24190716874999996,
        "feasible_range": [
          0.20371129999999996,
          0.2714844825
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.15278347499999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.10185564999999999,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 305.56694999999996,
          "annual_profit_projection": 3666.8034,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.20371129999999996,
        "regulatory_headroom": 11.710134734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531589",
      "drug_name": "KLOR-CON 8 MEQ TABLET",
      "ndc": 245531589,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.24190716874999996,
        "feasible_range": [
          0.20371129999999996,
          0.2714844825
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.15278347499999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.10185564999999999,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 305.56694999999996,
          "annual_profit_projection": 3666.8034,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.20371129999999996,
        "regulatory_headroom": 11.710134734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531601",
      "drug_name": "KLOR-CON 10 MEQ TABLET",
      "ndc": 245531601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.18115340208333336,
        "feasible_range": [
          0.15255023333333334,
          0.2033025225
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.114412675,
        "profit_projections": {
          "gross_profit_per_unit": 0.07627511666666668,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 228.82535000000004,
          "annual_profit_projection": 2745.9042000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.15255023333333334,
        "regulatory_headroom": 11.77408606833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531611",
      "drug_name": "KLOR-CON 10 MEQ TABLET",
      "ndc": 245531611,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.18115340208333336,
        "feasible_range": [
          0.15255023333333334,
          0.2033025225
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.114412675,
        "profit_projections": {
          "gross_profit_per_unit": 0.07627511666666668,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 228.82535000000004,
          "annual_profit_projection": 2745.9042000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.15255023333333334,
        "regulatory_headroom": 11.77408606833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531615",
      "drug_name": "KLOR-CON 10 MEQ TABLET",
      "ndc": 245531615,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.18115340208333336,
        "feasible_range": [
          0.15255023333333334,
          0.2033025225
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.114412675,
        "profit_projections": {
          "gross_profit_per_unit": 0.07627511666666668,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 228.82535000000004,
          "annual_profit_projection": 2745.9042000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.15255023333333334,
        "regulatory_headroom": 11.77408606833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531689",
      "drug_name": "KLOR-CON 10 MEQ TABLET",
      "ndc": 245531689,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.18115340208333336,
        "feasible_range": [
          0.15255023333333334,
          0.2033025225
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.114412675,
        "profit_projections": {
          "gross_profit_per_unit": 0.07627511666666668,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 228.82535000000004,
          "annual_profit_projection": 2745.9042000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.15255023333333334,
        "regulatory_headroom": 11.77408606833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531701",
      "drug_name": "KLOR-CON M10 TABLET",
      "ndc": 245531701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.1517537125,
        "feasible_range": [
          0.1277926,
          0.17030821499999999
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.09584445,
        "profit_projections": {
          "gross_profit_per_unit": 0.06389630000000002,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 172.52001000000004,
          "annual_profit_projection": 2070.2401200000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.1277926,
        "regulatory_headroom": 11.805033109999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531710",
      "drug_name": "KLOR-CON M10 TABLET",
      "ndc": 245531710,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.1517537125,
        "feasible_range": [
          0.1277926,
          0.17030821499999999
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.09584445,
        "profit_projections": {
          "gross_profit_per_unit": 0.06389630000000002,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 172.52001000000004,
          "annual_profit_projection": 2070.2401200000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.1277926,
        "regulatory_headroom": 11.805033109999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531711",
      "drug_name": "KLOR-CON M10 TABLET",
      "ndc": 245531711,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.1517537125,
        "feasible_range": [
          0.1277926,
          0.17030821499999999
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.09584445,
        "profit_projections": {
          "gross_profit_per_unit": 0.06389630000000002,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 172.52001000000004,
          "annual_profit_projection": 2070.2401200000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.1277926,
        "regulatory_headroom": 11.805033109999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531789",
      "drug_name": "KLOR-CON M10 TABLET",
      "ndc": 245531789,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.1517537125,
        "feasible_range": [
          0.1277926,
          0.17030821499999999
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.09584445,
        "profit_projections": {
          "gross_profit_per_unit": 0.06389630000000002,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 172.52001000000004,
          "annual_profit_projection": 2070.2401200000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.1277926,
        "regulatory_headroom": 11.805033109999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531790",
      "drug_name": "KLOR-CON M10 TABLET",
      "ndc": 245531790,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.1517537125,
        "feasible_range": [
          0.1277926,
          0.17030821499999999
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.09584445,
        "profit_projections": {
          "gross_profit_per_unit": 0.06389630000000002,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 172.52001000000004,
          "annual_profit_projection": 2070.2401200000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.1277926,
        "regulatory_headroom": 11.805033109999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531901",
      "drug_name": "KLOR-CON M20 TABLET",
      "ndc": 245531901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.06776393541666668,
        "feasible_range": [
          0.05706436666666668,
          0.07604924250000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.04279827500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.02853218333333335,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 77.03689500000004,
          "annual_profit_projection": 924.4427400000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.05706436666666668,
        "regulatory_headroom": 11.893443401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531910",
      "drug_name": "KLOR-CON M20 TABLET",
      "ndc": 245531910,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.06776393541666668,
        "feasible_range": [
          0.05706436666666668,
          0.07604924250000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.04279827500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.02853218333333335,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 77.03689500000004,
          "annual_profit_projection": 924.4427400000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.05706436666666668,
        "regulatory_headroom": 11.893443401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531911",
      "drug_name": "KLOR-CON M20 TABLET",
      "ndc": 245531911,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.06776393541666668,
        "feasible_range": [
          0.05706436666666668,
          0.07604924250000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.04279827500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.02853218333333335,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 77.03689500000004,
          "annual_profit_projection": 924.4427400000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.05706436666666668,
        "regulatory_headroom": 11.893443401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531915",
      "drug_name": "KLOR-CON M20 TABLET",
      "ndc": 245531915,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.06776393541666668,
        "feasible_range": [
          0.05706436666666668,
          0.07604924250000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.04279827500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.02853218333333335,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 77.03689500000004,
          "annual_profit_projection": 924.4427400000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.05706436666666668,
        "regulatory_headroom": 11.893443401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531989",
      "drug_name": "KLOR-CON M20 TABLET",
      "ndc": 245531989,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.06776393541666668,
        "feasible_range": [
          0.05706436666666668,
          0.07604924250000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.04279827500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.02853218333333335,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 77.03689500000004,
          "annual_profit_projection": 924.4427400000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.05706436666666668,
        "regulatory_headroom": 11.893443401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_245531990",
      "drug_name": "KLOR-CON M20 TABLET",
      "ndc": 245531990,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.06776393541666668,
        "feasible_range": [
          0.05706436666666668,
          0.07604924250000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.04279827500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.02853218333333335,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 77.03689500000004,
          "annual_profit_projection": 924.4427400000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.05706436666666668,
        "regulatory_headroom": 11.893443401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_259050116",
      "drug_name": "CUVPOSA 1 MG/5 ML SOLUTION",
      "ndc": 259050116,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1146284175,
        "feasible_range": [
          0.8742183666666667,
          1.1650640925000002
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 0.6556637750000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.4371091833333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 4371.091833333334,
          "annual_profit_projection": 52453.102000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8742183666666667,
        "regulatory_headroom": 10.872000901666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_299382230",
      "drug_name": "ORACEA 40 MG CAPSULE",
      "ndc": 299382230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 25.308876666666666,
        "feasible_range": [
          25.308876666666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 18.9816575,
        "profit_projections": {
          "gross_profit_per_unit": 6.327219166666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 63272.19166666666,
          "annual_profit_projection": 759266.2999999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 25.308876666666666,
        "regulatory_headroom": -13.344102806666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $19.67"
        ]
      }
    },
    {
      "drug_id": "ndc_299382345",
      "drug_name": "SOOLANTRA 1% CREAM",
      "ndc": 299382345,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.472368000000001,
        "feasible_range": [
          13.472368000000001,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 10.104276,
        "profit_projections": {
          "gross_profit_per_unit": 3.3680920000000008,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 33680.920000000006,
          "annual_profit_projection": 404171.04000000004,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.472368000000001,
        "regulatory_headroom": -1.5075941400000037,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.88"
        ]
      }
    },
    {
      "drug_id": "ndc_299590645",
      "drug_name": "EPIDUO FORTE 0.3-2.5% GEL PUMP",
      "ndc": 299590645,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.974606666666668,
        "feasible_range": [
          12.974606666666668,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.730955000000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.2436516666666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 32436.516666666666,
          "annual_profit_projection": 389238.2,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.974606666666668,
        "regulatory_headroom": -1.0098328066666706,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.25"
        ]
      }
    },
    {
      "drug_id": "ndc_299591545",
      "drug_name": "DIFFERIN 0.1% CREAM",
      "ndc": 299591545,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          9.767870666666665,
          11.964773859999998
        ],
        "expected_margin": 0.38771070095260446,
        "estimated_acquisition_cost": 7.325902999999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.638870859999998,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 46388.70859999998,
          "annual_profit_projection": 556664.5031999998,
          "margin_percentage": 38.77107009526045
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.767870666666665,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.25"
        ]
      }
    },
    {
      "drug_id": "ndc_310008828",
      "drug_name": "DALIRESP 250 MCG TABLET",
      "ndc": 310008828,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.575274833333333,
        "feasible_range": [
          12.575274833333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.431456125,
        "profit_projections": {
          "gross_profit_per_unit": 3.143818708333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23578.640312499996,
          "annual_profit_projection": 282943.68374999997,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.575274833333333,
        "regulatory_headroom": -0.6105009733333358,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.75"
        ]
      }
    },
    {
      "drug_id": "ndc_310008839",
      "drug_name": "DALIRESP 250 MCG TABLET",
      "ndc": 310008839,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.575274833333333,
        "feasible_range": [
          12.575274833333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.431456125,
        "profit_projections": {
          "gross_profit_per_unit": 3.143818708333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23578.640312499996,
          "annual_profit_projection": 282943.68374999997,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.575274833333333,
        "regulatory_headroom": -0.6105009733333358,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.75"
        ]
      }
    },
    {
      "drug_id": "ndc_310009530",
      "drug_name": "DALIRESP 500 MCG TABLET",
      "ndc": 310009530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.63347496666667,
        "feasible_range": [
          12.63347496666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.475106225000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.158368741666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23687.765562500004,
          "annual_profit_projection": 284253.18675000005,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.63347496666667,
        "regulatory_headroom": -0.6687011066666724,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.83"
        ]
      }
    },
    {
      "drug_id": "ndc_310009590",
      "drug_name": "DALIRESP 500 MCG TABLET",
      "ndc": 310009590,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.63347496666667,
        "feasible_range": [
          12.63347496666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.475106225000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.158368741666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23687.765562500004,
          "annual_profit_projection": 284253.18675000005,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.63347496666667,
        "regulatory_headroom": -0.6687011066666724,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.83"
        ]
      }
    },
    {
      "drug_id": "ndc_310027110",
      "drug_name": "SEROQUEL 100 MG TABLET",
      "ndc": 310027110,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.594685418750001,
        "feasible_range": [
          5.553419300000001,
          7.4009991825000006
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 4.165064475,
        "profit_projections": {
          "gross_profit_per_unit": 2.776709650000001,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 7497.116055000002,
          "annual_profit_projection": 89965.39266000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.553419300000001,
        "regulatory_headroom": 5.022999734999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_310027210",
      "drug_name": "SEROQUEL 200 MG TABLET",
      "ndc": 310027210,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.348098799999997,
          11.964773859999998
        ],
        "expected_margin": 0.317199657945685,
        "estimated_acquisition_cost": 7.761074099999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.203699759999999,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12611.099279999999,
          "annual_profit_projection": 151333.19136,
          "margin_percentage": 35.13396750484008
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.348098799999997,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.97"
        ]
      }
    },
    {
      "drug_id": "ndc_310027460",
      "drug_name": "SEROQUEL 300 MG TABLET",
      "ndc": 310027460,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.670666100000004,
        "feasible_range": [
          13.670666100000004,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 10.252999575000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.4176665250000013,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10252.999575000003,
          "annual_profit_projection": 123035.99490000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.670666100000004,
        "regulatory_headroom": -1.705892240000006,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.12"
        ]
      }
    },
    {
      "drug_id": "ndc_310027510",
      "drug_name": "SEROQUEL 25 MG TABLET",
      "ndc": 310027510,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.830772914583334,
        "feasible_range": [
          3.225914033333334,
          4.299150817500002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 2.4194355250000004,
        "profit_projections": {
          "gross_profit_per_unit": 1.6129570166666674,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 4354.983945000002,
          "annual_profit_projection": 52259.80734000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.225914033333334,
        "regulatory_headroom": 7.93238131833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_310027810",
      "drug_name": "SEROQUEL 50 MG TABLET",
      "ndc": 310027810,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.302850287500003,
        "feasible_range": [
          5.307663400000003,
          7.073482185000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 3.980747550000002,
        "profit_projections": {
          "gross_profit_per_unit": 2.6538317000000013,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 7961.495100000004,
          "annual_profit_projection": 95537.94120000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.307663400000003,
        "regulatory_headroom": 5.330194609999994,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_310027910",
      "drug_name": "SEROQUEL 400 MG TABLET",
      "ndc": 310027910,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.117295566666666,
        "feasible_range": [
          16.117295566666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.087971675,
        "profit_projections": {
          "gross_profit_per_unit": 4.029323891666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12087.971674999997,
          "annual_profit_projection": 145055.66009999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.117295566666666,
        "regulatory_headroom": -4.152521706666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.18"
        ]
      }
    },
    {
      "drug_id": "ndc_310028060",
      "drug_name": "SEROQUEL XR 50 MG TABLET",
      "ndc": 310028060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.136400241666665,
        "feasible_range": [
          6.851705466666666,
          9.13121517
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 5.1387791,
        "profit_projections": {
          "gross_profit_per_unit": 3.4258527333333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10277.558200000001,
          "annual_profit_projection": 123330.69840000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.851705466666666,
        "regulatory_headroom": 3.400142026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_310028160",
      "drug_name": "SEROQUEL XR 150 MG TABLET",
      "ndc": 310028160,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.313211733333338,
        "feasible_range": [
          12.313211733333338,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.234908800000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.078302933333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 9234.908800000005,
          "annual_profit_projection": 110818.90560000006,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.313211733333338,
        "regulatory_headroom": -0.3484378733333404,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.43"
        ]
      }
    },
    {
      "drug_id": "ndc_310028260",
      "drug_name": "SEROQUEL XR 200 MG TABLET",
      "ndc": 310028260,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.452200666666668,
        "feasible_range": [
          13.452200666666668,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 10.0891505,
        "profit_projections": {
          "gross_profit_per_unit": 3.3630501666666675,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10089.150500000002,
          "annual_profit_projection": 121069.80600000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.452200666666668,
        "regulatory_headroom": -1.4874268066666705,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.85"
        ]
      }
    },
    {
      "drug_id": "ndc_310028360",
      "drug_name": "SEROQUEL XR 300 MG TABLET",
      "ndc": 310028360,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.7495448,
        "feasible_range": [
          17.7495448,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 13.3121586,
        "profit_projections": {
          "gross_profit_per_unit": 4.437386199999999,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13312.158599999997,
          "annual_profit_projection": 159745.90319999997,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.7495448,
        "regulatory_headroom": -5.784770940000001,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.22"
        ]
      }
    },
    {
      "drug_id": "ndc_310028460",
      "drug_name": "SEROQUEL XR 400 MG TABLET",
      "ndc": 310028460,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 20.799954933333336,
        "feasible_range": [
          20.799954933333336,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 15.599966200000003,
        "profit_projections": {
          "gross_profit_per_unit": 5.199988733333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 15599.966199999999,
          "annual_profit_projection": 187199.5944,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 20.799954933333336,
        "regulatory_headroom": -8.835181073333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $14.04"
        ]
      }
    },
    {
      "drug_id": "ndc_310610530",
      "drug_name": "ONGLYZA 5 MG TABLET",
      "ndc": 310610530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.446255333333333,
        "feasible_range": [
          13.446255333333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.0846915,
        "profit_projections": {
          "gross_profit_per_unit": 3.3615638333333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 33615.638333333336,
          "annual_profit_projection": 403387.66000000003,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.446255333333333,
        "regulatory_headroom": -1.4814814733333357,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.84"
        ]
      }
    },
    {
      "drug_id": "ndc_310610590",
      "drug_name": "ONGLYZA 5 MG TABLET",
      "ndc": 310610590,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.446255333333333,
        "feasible_range": [
          13.446255333333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.0846915,
        "profit_projections": {
          "gross_profit_per_unit": 3.3615638333333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 33615.638333333336,
          "annual_profit_projection": 403387.66000000003,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.446255333333333,
        "regulatory_headroom": -1.4814814733333357,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.84"
        ]
      }
    },
    {
      "drug_id": "ndc_310620530",
      "drug_name": "FARXIGA 5 MG TABLET",
      "ndc": 310620530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.597117333333333,
        "feasible_range": [
          16.597117333333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.447838,
        "profit_projections": {
          "gross_profit_per_unit": 4.149279333333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 31119.594999999994,
          "annual_profit_projection": 373435.1399999999,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.597117333333333,
        "regulatory_headroom": -4.632343473333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.78"
        ]
      }
    },
    {
      "drug_id": "ndc_310620590",
      "drug_name": "FARXIGA 5 MG TABLET",
      "ndc": 310620590,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.597117333333333,
        "feasible_range": [
          16.597117333333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.447838,
        "profit_projections": {
          "gross_profit_per_unit": 4.149279333333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 31119.594999999994,
          "annual_profit_projection": 373435.1399999999,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.597117333333333,
        "regulatory_headroom": -4.632343473333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.78"
        ]
      }
    },
    {
      "drug_id": "ndc_310621030",
      "drug_name": "FARXIGA 10 MG TABLET",
      "ndc": 310621030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.605018733333335,
        "feasible_range": [
          16.605018733333335,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.453764050000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.151254683333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 31134.410124999995,
          "annual_profit_projection": 373612.92149999994,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.605018733333335,
        "regulatory_headroom": -4.640244873333337,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.79"
        ]
      }
    },
    {
      "drug_id": "ndc_310621039",
      "drug_name": "FARXIGA 10 MG TABLET",
      "ndc": 310621039,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.605018733333335,
        "feasible_range": [
          16.605018733333335,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.453764050000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.151254683333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 31134.410124999995,
          "annual_profit_projection": 373612.92149999994,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.605018733333335,
        "regulatory_headroom": -4.640244873333337,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.79"
        ]
      }
    },
    {
      "drug_id": "ndc_310621090",
      "drug_name": "FARXIGA 10 MG TABLET",
      "ndc": 310621090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.605018733333335,
        "feasible_range": [
          16.605018733333335,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.453764050000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.151254683333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 31134.410124999995,
          "annual_profit_projection": 373612.92149999994,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.605018733333335,
        "regulatory_headroom": -4.640244873333337,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.79"
        ]
      }
    },
    {
      "drug_id": "ndc_310626060",
      "drug_name": "XIGDUO XR 5 MG-1,000 MG TABLET",
      "ndc": 310626060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.584882847500003,
        "feasible_range": [
          8.301868900000002,
          11.063836822500003
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.226401675000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.150934450000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 41509.344500000014,
          "annual_profit_projection": 498112.1340000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.301868900000002,
        "regulatory_headroom": 1.5874377349999946,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_310628030",
      "drug_name": "XIGDUO XR 10 MG-1,000 MG TAB",
      "ndc": 310628030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.5911811,
        "feasible_range": [
          16.5911811,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 12.443385825,
        "profit_projections": {
          "gross_profit_per_unit": 4.147795275,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 41477.95275,
          "annual_profit_projection": 497735.43299999996,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.5911811,
        "regulatory_headroom": -4.6264072400000025,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.77"
        ]
      }
    },
    {
      "drug_id": "ndc_310756090",
      "drug_name": "CRESTOR 5 MG TABLET",
      "ndc": 310756090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.596010125000001,
        "feasible_range": [
          7.6768081,
          10.230823102499999
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 5.757606075,
        "profit_projections": {
          "gross_profit_per_unit": 3.838404050000001,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 25909.227337500008,
          "annual_profit_projection": 310910.7280500001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.6768081,
        "regulatory_headroom": 2.3687637349999964,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_310757090",
      "drug_name": "CRESTOR 10 MG TABLET",
      "ndc": 310757090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.595433249999997,
        "feasible_range": [
          7.676346599999998,
          10.230208065
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.757259949999998,
        "profit_projections": {
          "gross_profit_per_unit": 3.8381732999999993,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28786.299749999995,
          "annual_profit_projection": 345435.59699999995,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.676346599999998,
        "regulatory_headroom": 2.36934061,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_310758090",
      "drug_name": "CRESTOR 20 MG TABLET",
      "ndc": 310758090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.576961333333333,
        "feasible_range": [
          7.661569066666666,
          10.210514159999999
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.7461768,
        "profit_projections": {
          "gross_profit_per_unit": 3.8307845333333335,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28730.884000000002,
          "annual_profit_projection": 344770.608,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.661569066666666,
        "regulatory_headroom": 2.3878125266666643,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_310759030",
      "drug_name": "CRESTOR 40 MG TABLET",
      "ndc": 310759030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.584606958333332,
        "feasible_range": [
          7.667685566666665,
          10.218665572499997
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.750764174999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.833842783333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28753.820874999998,
          "annual_profit_projection": 345045.85049999994,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.667685566666665,
        "regulatory_headroom": 2.380166901666666,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_378972055",
      "drug_name": "DENAVIR 1% CREAM",
      "ndc": 378972055,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 135.12773690000003,
        "feasible_range": [
          135.12773690000003,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 101.34580267500002,
        "profit_projections": {
          "gross_profit_per_unit": 33.781934225000015,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 337819.34225000016,
          "annual_profit_projection": 4053832.1070000017,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 135.12773690000003,
        "regulatory_headroom": -123.16296304000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $156.94"
        ]
      }
    },
    {
      "drug_id": "ndc_430047203",
      "drug_name": "ACTONEL 35 MG TABLET",
      "ndc": 430047203,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 70.76351576666669,
        "feasible_range": [
          70.76351576666669,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 53.07263682500001,
        "profit_projections": {
          "gross_profit_per_unit": 17.690878941666675,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 132681.59206250007,
          "annual_profit_projection": 1592179.1047500009,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 70.76351576666669,
        "regulatory_headroom": -58.79874190666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $76.49"
        ]
      }
    },
    {
      "drug_id": "ndc_430047207",
      "drug_name": "ACTONEL 35 MG TABLET",
      "ndc": 430047207,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 70.76351576666669,
        "feasible_range": [
          70.76351576666669,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 53.07263682500001,
        "profit_projections": {
          "gross_profit_per_unit": 17.690878941666675,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 132681.59206250007,
          "annual_profit_projection": 1592179.1047500009,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 70.76351576666669,
        "regulatory_headroom": -58.79874190666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $76.49"
        ]
      }
    },
    {
      "drug_id": "ndc_430047801",
      "drug_name": "ACTONEL 150 MG TABLET",
      "ndc": 430047801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 306.36493333333334,
        "feasible_range": [
          306.36493333333334,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 229.7737,
        "profit_projections": {
          "gross_profit_per_unit": 76.59123333333335,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 574434.2500000001,
          "annual_profit_projection": 6893211.000000002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 306.36493333333334,
        "regulatory_headroom": -294.40015947333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $370.99"
        ]
      }
    },
    {
      "drug_id": "ndc_430047802",
      "drug_name": "ACTONEL 150 MG TABLET",
      "ndc": 430047802,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 306.36493333333334,
        "feasible_range": [
          306.36493333333334,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 229.7737,
        "profit_projections": {
          "gross_profit_per_unit": 76.59123333333335,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 574434.2500000001,
          "annual_profit_projection": 6893211.000000002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 306.36493333333334,
        "regulatory_headroom": -294.40015947333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $370.99"
        ]
      }
    },
    {
      "drug_id": "ndc_430072124",
      "drug_name": "ESTRACE 1 MG TABLET",
      "ndc": 430072124,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.634329999999999,
        "feasible_range": [
          4.507464,
          6.007062599999999
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.3805979999999995,
        "profit_projections": {
          "gross_profit_per_unit": 2.253732,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 16902.989999999998,
          "annual_profit_projection": 202835.87999999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.507464,
        "regulatory_headroom": 6.330443859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_430072224",
      "drug_name": "ESTRACE 2 MG TABLET",
      "ndc": 430072224,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.301948333333335,
        "feasible_range": [
          5.841558666666668,
          7.785000300000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.381169000000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.920779333333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 21905.845000000005,
          "annual_profit_projection": 262870.1400000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.841558666666668,
        "regulatory_headroom": 4.662825526666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_430097903",
      "drug_name": "ATELVIA DR 35 MG TABLET",
      "ndc": 430097903,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 55.4124857254902,
        "feasible_range": [
          55.4124857254902,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 41.55936429411765,
        "profit_projections": {
          "gross_profit_per_unit": 13.85312143137255,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 138531.2143137255,
          "annual_profit_projection": 1662374.5717647062,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 55.4124857254902,
        "regulatory_headroom": -43.447711865490206,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $57.30"
        ]
      }
    },
    {
      "drug_id": "ndc_430375414",
      "drug_name": "ESTRACE 0.01% CREAM",
      "ndc": 430375414,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.412673750000002,
        "feasible_range": [
          6.730139000000001,
          8.969204475000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.047604250000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.3650695000000006,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 25238.021250000005,
          "annual_profit_projection": 302856.25500000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.730139000000001,
        "regulatory_headroom": 3.552100109999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_456111030",
      "drug_name": "VIIBRYD 10 MG TABLET",
      "ndc": 456111030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.062221433333331,
          11.964773859999998
        ],
        "expected_margin": 0.36925961465685403,
        "estimated_acquisition_cost": 7.546666074999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.418107784999999,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33135.808387499994,
          "annual_profit_projection": 397629.7006499999,
          "margin_percentage": 36.925961465685404
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.062221433333331,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.61"
        ]
      }
    },
    {
      "drug_id": "ndc_456112030",
      "drug_name": "VIIBRYD 20 MG TABLET",
      "ndc": 456112030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.074083933333334,
          11.964773859999998
        ],
        "expected_margin": 0.3685160255924802,
        "estimated_acquisition_cost": 7.5555629500000006,
        "profit_projections": {
          "gross_profit_per_unit": 4.409210909999997,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33069.08182499998,
          "annual_profit_projection": 396828.9818999998,
          "margin_percentage": 36.85160255924802
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.074083933333334,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.63"
        ]
      }
    },
    {
      "drug_id": "ndc_456114030",
      "drug_name": "VIIBRYD 40 MG TABLET",
      "ndc": 456114030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.061988299999998,
          11.964773859999998
        ],
        "expected_margin": 0.36927422838896845,
        "estimated_acquisition_cost": 7.546491224999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.418282634999999,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33137.11976249999,
          "annual_profit_projection": 397645.4371499999,
          "margin_percentage": 36.927422838896845
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.061988299999998,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.61"
        ]
      }
    },
    {
      "drug_id": "ndc_456122830",
      "drug_name": "NAMZARIC 28 MG-10 MG CAPSULE",
      "ndc": 456122830,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.187421333333333,
        "feasible_range": [
          17.187421333333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 12.890566,
        "profit_projections": {
          "gross_profit_per_unit": 4.296855333333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 42968.55333333333,
          "annual_profit_projection": 515622.63999999996,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.187421333333333,
        "regulatory_headroom": -5.2226474733333355,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $9.52"
        ]
      }
    },
    {
      "drug_id": "ndc_456140230",
      "drug_name": "BYSTOLIC 2.5 MG TABLET",
      "ndc": 456140230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.650509125000003,
        "feasible_range": [
          5.320407300000002,
          7.090465882500002
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 3.9903054750000013,
        "profit_projections": {
          "gross_profit_per_unit": 2.6602036500000015,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 17956.37463750001,
          "annual_profit_projection": 215476.4956500001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.320407300000002,
        "regulatory_headroom": 5.314264734999995,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_456140590",
      "drug_name": "BYSTOLIC 5 MG TABLET",
      "ndc": 456140590,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.635234666666666,
        "feasible_range": [
          5.308187733333333,
          7.0741809600000005
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 3.9811408,
        "profit_projections": {
          "gross_profit_per_unit": 2.6540938666666665,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 19905.703999999998,
          "annual_profit_projection": 238868.44799999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.308187733333333,
        "regulatory_headroom": 5.329539193333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_456141090",
      "drug_name": "BYSTOLIC 10 MG TABLET",
      "ndc": 456141090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.626988875,
        "feasible_range": [
          5.3015911000000004,
          7.065389677500002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.976193325,
        "profit_projections": {
          "gross_profit_per_unit": 2.6507955500000002,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 19880.966625,
          "annual_profit_projection": 238571.5995,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.3015911000000004,
        "regulatory_headroom": 5.337784984999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_456142090",
      "drug_name": "BYSTOLIC 20 MG TABLET",
      "ndc": 456142090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.630360750000001,
        "feasible_range": [
          5.3042886000000005,
          7.068984615000001
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.9782164500000006,
        "profit_projections": {
          "gross_profit_per_unit": 2.6521443000000007,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 19891.082250000007,
          "annual_profit_projection": 238692.98700000008,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.3042886000000005,
        "regulatory_headroom": 5.334413109999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_456200501",
      "drug_name": "LEXAPRO 5 MG TABLET",
      "ndc": 456200501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.195046066666665,
        "feasible_range": [
          12.195046066666665,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.146284549999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.0487615166666657,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 22865.71137499999,
          "annual_profit_projection": 274388.53649999993,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.195046066666665,
        "regulatory_headroom": -0.23027220666666715,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.28"
        ]
      }
    },
    {
      "drug_id": "ndc_456201001",
      "drug_name": "LEXAPRO 10 MG TABLET",
      "ndc": 456201001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.754548300000005,
        "feasible_range": [
          12.754548300000005,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.565911225000004,
        "profit_projections": {
          "gross_profit_per_unit": 3.188637075000001,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23914.778062500005,
          "annual_profit_projection": 286977.3367500001,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.754548300000005,
        "regulatory_headroom": -0.7897744400000075,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.98"
        ]
      }
    },
    {
      "drug_id": "ndc_456202001",
      "drug_name": "LEXAPRO 20 MG TABLET",
      "ndc": 456202001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.300709066666668,
        "feasible_range": [
          13.300709066666668,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.9755318,
        "profit_projections": {
          "gross_profit_per_unit": 3.3251772666666675,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 24938.829500000007,
          "annual_profit_projection": 299265.9540000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.300709066666668,
        "regulatory_headroom": -1.3359352066666705,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.66"
        ]
      }
    },
    {
      "drug_id": "ndc_456240206",
      "drug_name": "SAPHRIS 2.5 MG TAB SUBLINGUAL",
      "ndc": 456240206,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.377002066666662,
        "feasible_range": [
          17.377002066666662,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 13.032751549999997,
        "profit_projections": {
          "gross_profit_per_unit": 4.344250516666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21721.252583333327,
          "annual_profit_projection": 260655.03099999993,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.377002066666662,
        "regulatory_headroom": -5.412228206666665,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $9.76"
        ]
      }
    },
    {
      "drug_id": "ndc_456240260",
      "drug_name": "SAPHRIS 2.5 MG TAB SUBLINGUAL",
      "ndc": 456240260,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.377002066666662,
        "feasible_range": [
          17.377002066666662,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 13.032751549999997,
        "profit_projections": {
          "gross_profit_per_unit": 4.344250516666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21721.252583333327,
          "annual_profit_projection": 260655.03099999993,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.377002066666662,
        "regulatory_headroom": -5.412228206666665,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $9.76"
        ]
      }
    },
    {
      "drug_id": "ndc_456240506",
      "drug_name": "SAPHRIS 5 MG TAB SUBLINGUAL",
      "ndc": 456240506,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.400009466666663,
        "feasible_range": [
          17.400009466666663,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.050007099999997,
        "profit_projections": {
          "gross_profit_per_unit": 4.350002366666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21750.011833333334,
          "annual_profit_projection": 261000.142,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.400009466666663,
        "regulatory_headroom": -5.435235606666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $9.79"
        ]
      }
    },
    {
      "drug_id": "ndc_456240560",
      "drug_name": "SAPHRIS 5 MG TAB SUBLINGUAL",
      "ndc": 456240560,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.400009466666663,
        "feasible_range": [
          17.400009466666663,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.050007099999997,
        "profit_projections": {
          "gross_profit_per_unit": 4.350002366666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21750.011833333334,
          "annual_profit_projection": 261000.142,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.400009466666663,
        "regulatory_headroom": -5.435235606666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $9.79"
        ]
      }
    },
    {
      "drug_id": "ndc_456241006",
      "drug_name": "SAPHRIS 10 MG TAB SUBLINGUAL",
      "ndc": 456241006,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.517916000000003,
        "feasible_range": [
          17.517916000000003,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 13.138437000000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.379479,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21897.395,
          "annual_profit_projection": 262768.74,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.517916000000003,
        "regulatory_headroom": -5.553142140000006,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $9.93"
        ]
      }
    },
    {
      "drug_id": "ndc_456241060",
      "drug_name": "SAPHRIS 10 MG TAB SUBLINGUAL",
      "ndc": 456241060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.476206800000003,
        "feasible_range": [
          17.476206800000003,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 13.107155100000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.3690517,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21845.2585,
          "annual_profit_projection": 262143.102,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.476206800000003,
        "regulatory_headroom": -5.511432940000006,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $9.88"
        ]
      }
    },
    {
      "drug_id": "ndc_456342833",
      "drug_name": "NAMENDA XR 28 MG CAPSULE",
      "ndc": 456342833,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.893400000000002,
        "feasible_range": [
          12.893400000000002,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.670050000000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.22335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 32233.5,
          "annual_profit_projection": 386802.0,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.893400000000002,
        "regulatory_headroom": -0.928626140000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.15"
        ]
      }
    },
    {
      "drug_id": "ndc_456402001",
      "drug_name": "CELEXA 20 MG TABLET",
      "ndc": 456402001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.007068955000001,
        "feasible_range": [
          7.848681533333334,
          10.459877505000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.8865111500000005,
        "profit_projections": {
          "gross_profit_per_unit": 3.924340766666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 39243.40766666667,
          "annual_profit_projection": 470920.8920000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.848681533333334,
        "regulatory_headroom": 2.15392194333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_456404001",
      "drug_name": "CELEXA 40 MG TABLET",
      "ndc": 456404001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.478551459999997,
        "feasible_range": [
          8.218471733333331,
          10.952694059999999
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.163853799999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.1092358666666655,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 41092.35866666665,
          "annual_profit_projection": 493108.3039999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.218471733333331,
        "regulatory_headroom": 1.6916841933333338,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_469060773",
      "drug_name": "PROGRAF 0.5 MG CAPSULE",
      "ndc": 469060773,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.841025500000001,
        "feasible_range": [
          3.072820400000001,
          4.09512411
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.3046153000000005,
        "profit_projections": {
          "gross_profit_per_unit": 1.5364102000000006,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 11523.076500000005,
          "annual_profit_projection": 138276.91800000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.072820400000001,
        "regulatory_headroom": 8.123748359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_469061773",
      "drug_name": "PROGRAF 1 MG CAPSULE",
      "ndc": 469061773,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.686333958333333,
        "feasible_range": [
          6.149067166666666,
          8.1948145125
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.611800375,
        "profit_projections": {
          "gross_profit_per_unit": 3.0745335833333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23059.001875,
          "annual_profit_projection": 276708.0225,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.149067166666666,
        "regulatory_headroom": 4.2784399016666645,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_469065773",
      "drug_name": "PROGRAF 5 MG CAPSULE",
      "ndc": 469065773,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.882852,
        "feasible_range": [
          30.882852,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 23.162139,
        "profit_projections": {
          "gross_profit_per_unit": 7.720713,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 57905.347499999996,
          "annual_profit_projection": 694864.1699999999,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.882852,
        "regulatory_headroom": -18.918078140000002,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $26.64"
        ]
      }
    },
    {
      "drug_id": "ndc_469260130",
      "drug_name": "MYRBETRIQ ER 25 MG TABLET",
      "ndc": 469260130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.746915133333337,
        "feasible_range": [
          12.746915133333337,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.560186350000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.1867287833333346,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23900.46587500001,
          "annual_profit_projection": 286805.5905000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.746915133333337,
        "regulatory_headroom": -0.7821412733333393,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.97"
        ]
      }
    },
    {
      "drug_id": "ndc_469260190",
      "drug_name": "MYRBETRIQ ER 25 MG TABLET",
      "ndc": 469260190,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.746915133333337,
        "feasible_range": [
          12.746915133333337,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.560186350000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.1867287833333346,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23900.46587500001,
          "annual_profit_projection": 286805.5905000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.746915133333337,
        "regulatory_headroom": -0.7821412733333393,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.97"
        ]
      }
    },
    {
      "drug_id": "ndc_469260230",
      "drug_name": "MYRBETRIQ ER 50 MG TABLET",
      "ndc": 469260230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.7503857,
        "feasible_range": [
          12.7503857,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.562789275,
        "profit_projections": {
          "gross_profit_per_unit": 3.1875964250000006,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23906.973187500003,
          "annual_profit_projection": 286883.67825000006,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.7503857,
        "regulatory_headroom": -0.7856118400000032,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.97"
        ]
      }
    },
    {
      "drug_id": "ndc_469260290",
      "drug_name": "MYRBETRIQ ER 50 MG TABLET",
      "ndc": 469260290,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.7503857,
        "feasible_range": [
          12.7503857,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.562789275,
        "profit_projections": {
          "gross_profit_per_unit": 3.1875964250000006,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23906.973187500003,
          "annual_profit_projection": 286883.67825000006,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.7503857,
        "regulatory_headroom": -0.7856118400000032,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.97"
        ]
      }
    },
    {
      "drug_id": "ndc_575620030",
      "drug_name": "PROGLYCEM 50 MG/ML ORAL SUSP",
      "ndc": 575620030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.315243933333337,
        "feasible_range": [
          13.315243933333337,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.986432950000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.3288109833333337,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 33288.109833333336,
          "annual_profit_projection": 399457.318,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.315243933333337,
        "regulatory_headroom": -1.350470073333339,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.68"
        ]
      }
    },
    {
      "drug_id": "ndc_597003937",
      "drug_name": "MICARDIS 20 MG TABLET",
      "ndc": 597003937,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.700934441666667,
        "feasible_range": [
          3.8770593333333334,
          5.166927150000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.9077945,
        "profit_projections": {
          "gross_profit_per_unit": 1.9385296666666672,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 8723.383500000002,
          "annual_profit_projection": 104680.60200000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.8770593333333334,
        "regulatory_headroom": 7.11844969333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597004037",
      "drug_name": "MICARDIS 40 MG TABLET",
      "ndc": 597004037,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.7208193608333335,
        "feasible_range": [
          3.893459266666666,
          5.188783215
        ],
        "expected_margin": 0.38144329896907225,
        "estimated_acquisition_cost": 2.9200944499999997,
        "profit_projections": {
          "gross_profit_per_unit": 1.9467296333333337,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 8760.283350000002,
          "annual_profit_projection": 105123.40020000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.893459266666666,
        "regulatory_headroom": 7.097949776666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597004137",
      "drug_name": "MICARDIS 80 MG TABLET",
      "ndc": 597004137,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.710521719583333,
        "feasible_range": [
          3.8849663666666667,
          5.1774647924999995
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.913724775,
        "profit_projections": {
          "gross_profit_per_unit": 1.9424831833333331,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 9712.415916666665,
          "annual_profit_projection": 116548.99099999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.8849663666666667,
        "regulatory_headroom": 7.1085659016666645,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597004237",
      "drug_name": "MICARDIS HCT 80-25 MG TABLET",
      "ndc": 597004237,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.728865066250003,
        "feasible_range": [
          3.9000949000000023,
          5.197626472500003
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.9250711750000016,
        "profit_projections": {
          "gross_profit_per_unit": 1.950047450000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 9750.237250000004,
          "annual_profit_projection": 117002.84700000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.9000949000000023,
        "regulatory_headroom": 7.089655234999995,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597004337",
      "drug_name": "MICARDIS HCT 40-12.5 MG TABLET",
      "ndc": 597004337,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.733733051666667,
        "feasible_range": [
          3.9041097333333337,
          5.202977010000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.9280823000000002,
        "profit_projections": {
          "gross_profit_per_unit": 1.9520548666666673,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 8784.246900000002,
          "annual_profit_projection": 105410.96280000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.9041097333333337,
        "regulatory_headroom": 7.08463669333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597004437",
      "drug_name": "MICARDIS HCT 80-12.5 MG TABLET",
      "ndc": 597004437,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.705161944166665,
        "feasible_range": [
          3.880545933333332,
          5.171573714999998
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.910409449999999,
        "profit_projections": {
          "gross_profit_per_unit": 1.9402729666666665,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 8731.22835,
          "annual_profit_projection": 104774.7402,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.880545933333332,
        "regulatory_headroom": 7.114091443333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597007541",
      "drug_name": "SPIRIVA HANDIHALER 18 MCG CAP",
      "ndc": 597007541,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          9.4618394,
          11.964773859999998
        ],
        "expected_margin": 0.40689396782297377,
        "estimated_acquisition_cost": 7.096379550000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.7309197,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 47309.197,
          "annual_profit_projection": 567710.3640000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.4618394,
        "regulatory_headroom": 0.1374746099999964,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597010854",
      "drug_name": "PRADAXA 110 MG CAPSULE",
      "ndc": 597010854,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.322409241666666,
        "feasible_range": [
          2.740131333333333,
          3.6517519499999995
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 2.0550984999999997,
        "profit_projections": {
          "gross_profit_per_unit": 1.3700656666666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 6850.328333333333,
          "annual_profit_projection": 82203.94,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.740131333333333,
        "regulatory_headroom": 8.53960969333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597010860",
      "drug_name": "PRADAXA 110 MG CAPSULE",
      "ndc": 597010860,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.322409241666666,
        "feasible_range": [
          2.740131333333333,
          3.6517519499999995
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 2.0550984999999997,
        "profit_projections": {
          "gross_profit_per_unit": 1.3700656666666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 6850.328333333333,
          "annual_profit_projection": 82203.94,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.740131333333333,
        "regulatory_headroom": 8.53960969333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597035509",
      "drug_name": "PRADAXA 75 MG CAPSULE",
      "ndc": 597035509,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.332754170416667,
        "feasible_range": [
          2.7486632333333336,
          3.6631223475000003
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 2.061497425,
        "profit_projections": {
          "gross_profit_per_unit": 1.3743316166666668,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 6871.658083333334,
          "annual_profit_projection": 82459.897,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.7486632333333336,
        "regulatory_headroom": 8.528944818333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597035556",
      "drug_name": "PRADAXA 75 MG CAPSULE",
      "ndc": 597035556,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.332754170416667,
        "feasible_range": [
          2.7486632333333336,
          3.6631223475000003
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 2.061497425,
        "profit_projections": {
          "gross_profit_per_unit": 1.3743316166666668,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 6871.658083333334,
          "annual_profit_projection": 82459.897,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.7486632333333336,
        "regulatory_headroom": 8.528944818333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597036055",
      "drug_name": "PRADAXA 150 MG CAPSULE",
      "ndc": 597036055,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.332423683333334,
        "feasible_range": [
          2.7483906666666673,
          3.662759100000001
        ],
        "expected_margin": 0.3814432989690721,
        "estimated_acquisition_cost": 2.0612930000000005,
        "profit_projections": {
          "gross_profit_per_unit": 1.3741953333333337,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 6870.976666666668,
          "annual_profit_projection": 82451.72000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.7483906666666673,
        "regulatory_headroom": 8.529285526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_597036082",
      "drug_name": "PRADAXA 150 MG CAPSULE",
      "ndc": 597036082,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.332423683333334,
        "feasible_range": [
          2.7483906666666673,
          3.662759100000001
        ],
        "expected_margin": 0.3814432989690721,
        "estimated_acquisition_cost": 2.0612930000000005,
        "profit_projections": {
          "gross_profit_per_unit": 1.3741953333333337,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 6870.976666666668,
          "annual_profit_projection": 82451.72000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.7483906666666673,
        "regulatory_headroom": 8.529285526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_713086030",
      "drug_name": "BENICAR 5 MG TABLET",
      "ndc": 713086030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.844321411250002,
        "feasible_range": [
          7.294285700000002,
          9.721038442500005
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 5.4707142750000015,
        "profit_projections": {
          "gross_profit_per_unit": 3.6471428500000007,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18235.714250000005,
          "annual_profit_projection": 218828.57100000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.294285700000002,
        "regulatory_headroom": 2.8469167349999953,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_713086130",
      "drug_name": "BENICAR 20 MG TABLET",
      "ndc": 713086130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.787597545833332,
        "feasible_range": [
          8.896987666666666,
          11.856947025
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.672740749999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.448493833333334,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 20018.222250000003,
          "annual_profit_projection": 240218.66700000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.896987666666666,
        "regulatory_headroom": 0.8435392766666645,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_713086230",
      "drug_name": "BENICAR 40 MG TABLET",
      "ndc": 713086230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.354277000000002,
        "feasible_range": [
          12.354277000000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 9.26570775,
        "profit_projections": {
          "gross_profit_per_unit": 3.088569250000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15442.846250000004,
          "annual_profit_projection": 185314.15500000006,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.354277000000002,
        "regulatory_headroom": -0.38950314000000397,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.48"
        ]
      }
    },
    {
      "drug_id": "ndc_713086330",
      "drug_name": "BENICAR HCT 20-12.5 MG TABLET",
      "ndc": 713086330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.835608019166667,
        "feasible_range": [
          8.936583933333333,
          11.909716665000001
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 6.70243795,
        "profit_projections": {
          "gross_profit_per_unit": 4.468291966666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 22341.459833333338,
          "annual_profit_projection": 268097.51800000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.936583933333333,
        "regulatory_headroom": 0.79404394333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_713086430",
      "drug_name": "BENICAR HCT 40-12.5 MG TABLET",
      "ndc": 713086430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.347208899999998,
        "feasible_range": [
          12.347208899999998,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.260406674999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.0868022249999996,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15434.011124999997,
          "annual_profit_projection": 185208.13349999997,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.347208899999998,
        "regulatory_headroom": -0.3824350400000007,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.47"
        ]
      }
    },
    {
      "drug_id": "ndc_713086530",
      "drug_name": "BENICAR HCT 40-25 MG TABLET",
      "ndc": 713086530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.329926700000003,
        "feasible_range": [
          12.329926700000003,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.247445025000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.0824816750000004,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15412.408375000003,
          "annual_profit_projection": 184948.90050000005,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.329926700000003,
        "regulatory_headroom": -0.3651528400000057,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.45"
        ]
      }
    },
    {
      "drug_id": "ndc_713087030",
      "drug_name": "AZOR 5-20 MG TABLET",
      "ndc": 713087030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.118225733333333,
          11.964773859999998
        ],
        "expected_margin": 0.30306503093406556,
        "estimated_acquisition_cost": 8.3386693,
        "profit_projections": {
          "gross_profit_per_unit": 3.626104559999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 27195.784199999987,
          "annual_profit_projection": 326349.4103999998,
          "margin_percentage": 30.306503093406555
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.118225733333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.93"
        ]
      }
    },
    {
      "drug_id": "ndc_713087330",
      "drug_name": "AZOR 10-40 MG TABLET",
      "ndc": 713087330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.982757966666668,
        "feasible_range": [
          13.982757966666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.487068475000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.495689491666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 26217.671187500004,
          "annual_profit_projection": 314612.05425000004,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.982757966666668,
        "regulatory_headroom": -2.0179841066666704,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.51"
        ]
      }
    },
    {
      "drug_id": "ndc_713087530",
      "drug_name": "TRIBENZOR 40-5-12.5 MG TABLET",
      "ndc": 713087530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.089850666666665,
        "feasible_range": [
          14.089850666666665,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 10.567388,
        "profit_projections": {
          "gross_profit_per_unit": 3.522462666666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 35224.626666666656,
          "annual_profit_projection": 422695.5199999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.089850666666665,
        "regulatory_headroom": -2.1250768066666677,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.65"
        ]
      }
    },
    {
      "drug_id": "ndc_713087830",
      "drug_name": "TRIBENZOR 40-10-25 MG TABLET",
      "ndc": 713087830,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.995626666666668,
        "feasible_range": [
          13.995626666666668,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 10.496720000000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.4989066666666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 34989.066666666666,
          "annual_profit_projection": 419868.8,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.995626666666668,
        "regulatory_headroom": -2.0308528066666707,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.53"
        ]
      }
    },
    {
      "drug_id": "ndc_713087981",
      "drug_name": "WELCHOL 625 MG TABLET",
      "ndc": 713087981,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.220027182500003,
        "feasible_range": [
          4.0941389666666685,
          5.456227507500003
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 3.070604225000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.0470694833333347,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 18423.625350000013,
          "annual_profit_projection": 221083.50420000014,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.0941389666666685,
        "regulatory_headroom": 6.847100151666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_713088230",
      "drug_name": "EFFIENT 10 MG TABLET",
      "ndc": 713088230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.852948666666673,
        "feasible_range": [
          16.852948666666673,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 12.639711500000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.213237166666669,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 42132.371666666695,
          "annual_profit_projection": 505588.4600000003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.852948666666673,
        "regulatory_headroom": -4.888174806666676,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $9.10"
        ]
      }
    },
    {
      "drug_id": "ndc_713088301",
      "drug_name": "EVOXAC 30 MG CAPSULE",
      "ndc": 713088301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.637082711111113,
        "feasible_range": [
          6.7741825185185185,
          9.027900933333333
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 5.080636888888889,
        "profit_projections": {
          "gross_profit_per_unit": 3.38709125925926,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 30483.82133333334,
          "annual_profit_projection": 365805.8560000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.7741825185185185,
        "regulatory_headroom": 3.4970457118518485,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_777310402",
      "drug_name": "PROZAC 10 MG PULVULE",
      "ndc": 777310402,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.828969533333336,
          11.964773859999998
        ],
        "expected_margin": 0.25851275972214627,
        "estimated_acquisition_cost": 8.871727150000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.093046709999996,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23197.85032499997,
          "annual_profit_projection": 278374.2038999996,
          "margin_percentage": 25.851275972214626
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.828969533333336,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.82"
        ]
      }
    },
    {
      "drug_id": "ndc_777310502",
      "drug_name": "PROZAC 20 MG PULVULE",
      "ndc": 777310502,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.1366375,
        "feasible_range": [
          12.1366375,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.102478125000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.0341593749999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 22756.1953125,
          "annual_profit_projection": 273074.34375,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.1366375,
        "regulatory_headroom": -0.17186364000000331,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.21"
        ]
      }
    },
    {
      "drug_id": "ndc_777310530",
      "drug_name": "PROZAC 20 MG PULVULE",
      "ndc": 777310530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.1366375,
        "feasible_range": [
          12.1366375,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.102478125000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.0341593749999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 22756.1953125,
          "annual_profit_projection": 273074.34375,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.1366375,
        "regulatory_headroom": -0.17186364000000331,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.21"
        ]
      }
    },
    {
      "drug_id": "ndc_777310730",
      "drug_name": "PROZAC 40 MG PULVULE",
      "ndc": 777310730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 21.068771100000003,
        "feasible_range": [
          21.068771100000003,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 15.801578325000003,
        "profit_projections": {
          "gross_profit_per_unit": 5.267192775,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 39503.9458125,
          "annual_profit_projection": 474047.34975000005,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 21.068771100000003,
        "regulatory_headroom": -9.103997240000005,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $14.37"
        ]
      }
    },
    {
      "drug_id": "ndc_10019055303",
      "drug_name": "TRANSDERM-SCOP 1 MG/3 DAY PTCH",
      "ndc": 10019055303,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.622326366666666,
        "feasible_range": [
          17.622326366666666,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.216744774999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.405581591666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44055.815916666674,
          "annual_profit_projection": 528669.7910000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.622326366666666,
        "regulatory_headroom": -5.6575525066666685,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.06"
        ]
      }
    },
    {
      "drug_id": "ndc_10019055304",
      "drug_name": "TRANSDERM-SCOP 1 MG/3 DAY PTCH",
      "ndc": 10019055304,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.622326366666666,
        "feasible_range": [
          17.622326366666666,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.216744774999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.405581591666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44055.815916666674,
          "annual_profit_projection": 528669.7910000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.622326366666666,
        "regulatory_headroom": -5.6575525066666685,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.06"
        ]
      }
    },
    {
      "drug_id": "ndc_10631011631",
      "drug_name": "ABSORICA 20 MG CAPSULE",
      "ndc": 10631011631,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.910266399999994,
        "feasible_range": [
          30.910266399999994,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 23.182699799999995,
        "profit_projections": {
          "gross_profit_per_unit": 7.727566599999999,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 38637.833,
          "annual_profit_projection": 463653.996,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.910266399999994,
        "regulatory_headroom": -18.945492539999996,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $26.67"
        ]
      }
    },
    {
      "drug_id": "ndc_10631011669",
      "drug_name": "ABSORICA 20 MG CAPSULE",
      "ndc": 10631011669,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.910266399999994,
        "feasible_range": [
          30.910266399999994,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 23.182699799999995,
        "profit_projections": {
          "gross_profit_per_unit": 7.727566599999999,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 38637.833,
          "annual_profit_projection": 463653.996,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.910266399999994,
        "regulatory_headroom": -18.945492539999996,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $26.67"
        ]
      }
    },
    {
      "drug_id": "ndc_10631011731",
      "drug_name": "ABSORICA 30 MG CAPSULE",
      "ndc": 10631011731,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 33.30217973333334,
        "feasible_range": [
          33.30217973333334,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 24.976634800000006,
        "profit_projections": {
          "gross_profit_per_unit": 8.325544933333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 41627.72466666667,
          "annual_profit_projection": 499532.696,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 33.30217973333334,
        "regulatory_headroom": -21.337405873333342,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $29.66"
        ]
      }
    },
    {
      "drug_id": "ndc_10631011769",
      "drug_name": "ABSORICA 30 MG CAPSULE",
      "ndc": 10631011769,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 33.30217973333334,
        "feasible_range": [
          33.30217973333334,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 24.976634800000006,
        "profit_projections": {
          "gross_profit_per_unit": 8.325544933333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 41627.72466666667,
          "annual_profit_projection": 499532.696,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 33.30217973333334,
        "regulatory_headroom": -21.337405873333342,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $29.66"
        ]
      }
    },
    {
      "drug_id": "ndc_10631011831",
      "drug_name": "ABSORICA 40 MG CAPSULE",
      "ndc": 10631011831,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 32.81035853333333,
        "feasible_range": [
          32.81035853333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 24.607768899999996,
        "profit_projections": {
          "gross_profit_per_unit": 8.202589633333332,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 41012.94816666666,
          "annual_profit_projection": 492155.3779999999,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 32.81035853333333,
        "regulatory_headroom": -20.84558467333333,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $29.05"
        ]
      }
    },
    {
      "drug_id": "ndc_10631011869",
      "drug_name": "ABSORICA 40 MG CAPSULE",
      "ndc": 10631011869,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 32.81035853333333,
        "feasible_range": [
          32.81035853333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 24.607768899999996,
        "profit_projections": {
          "gross_profit_per_unit": 8.202589633333332,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 41012.94816666666,
          "annual_profit_projection": 492155.3779999999,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 32.81035853333333,
        "regulatory_headroom": -20.84558467333333,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $29.05"
        ]
      }
    },
    {
      "drug_id": "ndc_10631040701",
      "drug_name": "PROCTOSOL-HC 2.5% CREAM",
      "ndc": 10631040701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.06272491,
        "feasible_range": [
          0.8335097333333333,
          1.11081201
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.6251323,
        "profit_projections": {
          "gross_profit_per_unit": 0.4167548666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 4167.5486666666675,
          "annual_profit_projection": 50010.58400000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8335097333333333,
        "regulatory_headroom": 10.92288669333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_11980018005",
      "drug_name": "PRED FORTE 1% EYE DROPS",
      "ndc": 11980018005,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 26.60418539999999,
        "feasible_range": [
          26.60418539999999,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 19.953139049999994,
        "profit_projections": {
          "gross_profit_per_unit": 6.651046349999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 49882.84762499999,
          "annual_profit_projection": 598594.1714999998,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 26.60418539999999,
        "regulatory_headroom": -14.639411539999994,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $21.29"
        ]
      }
    },
    {
      "drug_id": "ndc_11980018010",
      "drug_name": "PRED FORTE 1% EYE DROPS",
      "ndc": 11980018010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 26.569660866666656,
        "feasible_range": [
          26.569660866666656,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 19.927245649999993,
        "profit_projections": {
          "gross_profit_per_unit": 6.642415216666663,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 49818.11412499997,
          "annual_profit_projection": 597817.3694999997,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 26.569660866666656,
        "regulatory_headroom": -14.604887006666658,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $21.25"
        ]
      }
    },
    {
      "drug_id": "ndc_11980018015",
      "drug_name": "PRED FORTE 1% EYE DROPS",
      "ndc": 11980018015,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 26.77954066666666,
        "feasible_range": [
          26.77954066666666,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 20.084655499999993,
        "profit_projections": {
          "gross_profit_per_unit": 6.6948851666666656,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 50211.63874999999,
          "annual_profit_projection": 602539.6649999999,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 26.77954066666666,
        "regulatory_headroom": -14.814766806666661,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $21.51"
        ]
      }
    },
    {
      "drug_id": "ndc_11980021105",
      "drug_name": "FML LIQUIFILM 0.1% EYE DROP",
      "ndc": 11980021105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 28.014311433333337,
        "feasible_range": [
          28.014311433333337,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 21.010733575000003,
        "profit_projections": {
          "gross_profit_per_unit": 7.003577858333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 70035.77858333333,
          "annual_profit_projection": 840429.343,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 28.014311433333337,
        "regulatory_headroom": -16.04953757333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $23.05"
        ]
      }
    },
    {
      "drug_id": "ndc_12496120201",
      "drug_name": "SUBOXONE 2 MG-0.5 MG SL FILM",
      "ndc": 12496120201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.047960065416667,
        "feasible_range": [
          4.163266033333334,
          5.548352617500001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 3.1224495250000004,
        "profit_projections": {
          "gross_profit_per_unit": 2.0816330166666672,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 10408.165083333337,
          "annual_profit_projection": 124897.98100000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.163266033333334,
        "regulatory_headroom": 6.76069131833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_12496120203",
      "drug_name": "SUBOXONE 2 MG-0.5 MG SL FILM",
      "ndc": 12496120203,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.047960065416667,
        "feasible_range": [
          4.163266033333334,
          5.548352617500001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 3.1224495250000004,
        "profit_projections": {
          "gross_profit_per_unit": 2.0816330166666672,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 10408.165083333337,
          "annual_profit_projection": 124897.98100000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.163266033333334,
        "regulatory_headroom": 6.76069131833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_12496120401",
      "drug_name": "SUBOXONE 4 MG-1 MG SL FILM",
      "ndc": 12496120401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.03603544458333,
        "feasible_range": [
          7.452400366666665,
          9.9317566425
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 5.5893002749999985,
        "profit_projections": {
          "gross_profit_per_unit": 3.726200183333332,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18631.00091666666,
          "annual_profit_projection": 223572.01099999994,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.452400366666665,
        "regulatory_headroom": 2.649273401666667,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_12496120403",
      "drug_name": "SUBOXONE 4 MG-1 MG SL FILM",
      "ndc": 12496120403,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.03603544458333,
        "feasible_range": [
          7.452400366666665,
          9.9317566425
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 5.5893002749999985,
        "profit_projections": {
          "gross_profit_per_unit": 3.726200183333332,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18631.00091666666,
          "annual_profit_projection": 223572.01099999994,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.452400366666665,
        "regulatory_headroom": 2.649273401666667,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_12496120801",
      "drug_name": "SUBOXONE 8 MG-2 MG SL FILM",
      "ndc": 12496120801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.04909099791667,
        "feasible_range": [
          7.463167833333334,
          9.9461063625
        ],
        "expected_margin": 0.3814432989690723,
        "estimated_acquisition_cost": 5.597375875000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.7315839166666684,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 16792.12762500001,
          "annual_profit_projection": 201505.5315000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.463167833333334,
        "regulatory_headroom": 2.635814068333328,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_12496120803",
      "drug_name": "SUBOXONE 8 MG-2 MG SL FILM",
      "ndc": 12496120803,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.04909099791667,
        "feasible_range": [
          7.463167833333334,
          9.9461063625
        ],
        "expected_margin": 0.3814432989690723,
        "estimated_acquisition_cost": 5.597375875000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.7315839166666684,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 16792.12762500001,
          "annual_profit_projection": 201505.5315000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.463167833333334,
        "regulatory_headroom": 2.635814068333328,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_12496121201",
      "drug_name": "SUBOXONE 12 MG-3 MG SL FILM",
      "ndc": 12496121201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.934064600000005,
        "feasible_range": [
          14.934064600000005,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.200548450000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.7335161500000016,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18667.58075000001,
          "annual_profit_projection": 224010.9690000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.934064600000005,
        "regulatory_headroom": -2.969290740000007,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.70"
        ]
      }
    },
    {
      "drug_id": "ndc_12496121203",
      "drug_name": "SUBOXONE 12 MG-3 MG SL FILM",
      "ndc": 12496121203,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.934064600000005,
        "feasible_range": [
          14.934064600000005,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.200548450000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.7335161500000016,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18667.58075000001,
          "annual_profit_projection": 224010.9690000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.934064600000005,
        "regulatory_headroom": -2.969290740000007,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.70"
        ]
      }
    },
    {
      "drug_id": "ndc_13548013250",
      "drug_name": "ACANYA GEL PUMP",
      "ndc": 13548013250,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.242888799999996,
        "feasible_range": [
          8.817951999999996,
          11.751616799999997
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.613463999999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.408975999999998,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44089.75999999998,
          "annual_profit_projection": 529077.1199999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.817951999999996,
        "regulatory_headroom": 0.9423338600000015,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_16781046275",
      "drug_name": "CLINDAGEL 1% GEL",
      "ndc": 16781046275,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.420821333333333,
        "feasible_range": [
          19.420821333333333,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 14.565615999999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.855205333333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 48552.05333333334,
          "annual_profit_projection": 582624.64,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.420821333333333,
        "regulatory_headroom": -7.456047473333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.31"
        ]
      }
    },
    {
      "drug_id": "ndc_17433987603",
      "drug_name": "ENEMEEZ MINI ENEMA",
      "ndc": 17433987603,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.40736101249999995,
        "feasible_range": [
          0.3194988333333333,
          0.4257936375
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.23962412499999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.15974941666666664,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 1597.4941666666664,
          "annual_profit_projection": 19169.929999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.3194988333333333,
        "regulatory_headroom": 11.565400318333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_17772010130",
      "drug_name": "TROKENDI XR 25 MG CAPSULE",
      "ndc": 17772010130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.184671466666666,
          11.964773859999998
        ],
        "expected_margin": 0.361583955586771,
        "estimated_acquisition_cost": 7.6385036,
        "profit_projections": {
          "gross_profit_per_unit": 4.326270259999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 32447.02694999998,
          "annual_profit_projection": 389364.32339999976,
          "margin_percentage": 36.1583955586771
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.184671466666666,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.77"
        ]
      }
    },
    {
      "drug_id": "ndc_17772010230",
      "drug_name": "TROKENDI XR 50 MG CAPSULE",
      "ndc": 17772010230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.260588466666668,
        "feasible_range": [
          13.260588466666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.945441350000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.315147116666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 24863.603375000002,
          "annual_profit_projection": 298363.2405,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.260588466666668,
        "regulatory_headroom": -1.2958146066666707,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.61"
        ]
      }
    },
    {
      "drug_id": "ndc_17772010330",
      "drug_name": "TROKENDI XR 100 MG CAPSULE",
      "ndc": 17772010330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 26.298950599999994,
        "feasible_range": [
          26.298950599999994,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 19.724212949999995,
        "profit_projections": {
          "gross_profit_per_unit": 6.574737649999999,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 49310.532374999995,
          "annual_profit_projection": 591726.3884999999,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 26.298950599999994,
        "regulatory_headroom": -14.334176739999997,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $20.91"
        ]
      }
    },
    {
      "drug_id": "ndc_17772010401",
      "drug_name": "TROKENDI XR 200 MG CAPSULE",
      "ndc": 17772010401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 35.97892393333334,
        "feasible_range": [
          35.97892393333334,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 26.984192950000004,
        "profit_projections": {
          "gross_profit_per_unit": 8.994730983333337,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 67460.48237500002,
          "annual_profit_projection": 809525.7885000003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 35.97892393333334,
        "regulatory_headroom": -24.014150073333344,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $33.01"
        ]
      }
    },
    {
      "drug_id": "ndc_17772010430",
      "drug_name": "TROKENDI XR 200 MG CAPSULE",
      "ndc": 17772010430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 35.97892393333334,
        "feasible_range": [
          35.97892393333334,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 26.984192950000004,
        "profit_projections": {
          "gross_profit_per_unit": 8.994730983333337,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 67460.48237500002,
          "annual_profit_projection": 809525.7885000003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 35.97892393333334,
        "regulatory_headroom": -24.014150073333344,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $33.01"
        ]
      }
    },
    {
      "drug_id": "ndc_17772012101",
      "drug_name": "OXTELLAR XR 150 MG TABLET",
      "ndc": 17772012101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.522735083333336,
        "feasible_range": [
          7.618188066666669,
          10.152700635000004
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.713641050000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.8090940333333343,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28568.205250000006,
          "annual_profit_projection": 342818.4630000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.618188066666669,
        "regulatory_headroom": 2.442038776666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_17772012201",
      "drug_name": "OXTELLAR XR 300 MG TABLET",
      "ndc": 17772012201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.588875266666669,
          11.964773859999998
        ],
        "expected_margin": 0.33624684069039285,
        "estimated_acquisition_cost": 7.941656450000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.023117409999996,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30173.38057499997,
          "annual_profit_projection": 362080.5668999996,
          "margin_percentage": 33.62468406903928
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.588875266666669,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.27"
        ]
      }
    },
    {
      "drug_id": "ndc_17772012301",
      "drug_name": "OXTELLAR XR 600 MG TABLET",
      "ndc": 17772012301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.311553733333334,
        "feasible_range": [
          19.311553733333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 14.4836653,
        "profit_projections": {
          "gross_profit_per_unit": 4.827888433333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 36209.16325,
          "annual_profit_projection": 434509.959,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.311553733333334,
        "regulatory_headroom": -7.346779873333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.17"
        ]
      }
    },
    {
      "drug_id": "ndc_21724070105",
      "drug_name": "PROCENTRA 5 MG/5 ML SOLUTION",
      "ndc": 21724070105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.7982018600000003,
        "feasible_range": [
          1.4103544000000001,
          1.87956846
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 1.0577658,
        "profit_projections": {
          "gross_profit_per_unit": 0.7051772000000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 7051.772000000001,
          "annual_profit_projection": 84621.26400000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4103544000000001,
        "regulatory_headroom": 10.201830859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23594010105",
      "drug_name": "KARBINAL ER 4 MG/5 ML SUSP",
      "ndc": 23594010105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.3217474074999997,
        "feasible_range": [
          1.0366646333333331,
          1.3815549825
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 0.7774984749999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.5183323166666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 5183.323166666666,
          "annual_profit_projection": 62199.878,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.0366646333333331,
        "regulatory_headroom": 10.66894306833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23635050860",
      "drug_name": "AMITIZA 8 MCG CAPSULE",
      "ndc": 23635050860,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.972893416666667,
        "feasible_range": [
          5.578314733333333,
          7.434177135
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.18373605,
        "profit_projections": {
          "gross_profit_per_unit": 2.789157366666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 20918.680250000005,
          "annual_profit_projection": 251024.16300000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.578314733333333,
        "regulatory_headroom": 4.99188044333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23635052460",
      "drug_name": "AMITIZA 24 MCG CAPSULE",
      "ndc": 23635052460,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.977428791666666,
        "feasible_range": [
          5.581943033333332,
          7.4390125425
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.1864572749999995,
        "profit_projections": {
          "gross_profit_per_unit": 2.7909715166666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 20932.286375,
          "annual_profit_projection": 251187.4365,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.581943033333332,
        "regulatory_headroom": 4.987345068333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23635058110",
      "drug_name": "ROXICODONE 15 MG TABLET",
      "ndc": 23635058110,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.515138980000002,
        "feasible_range": [
          4.325599200000002,
          5.764692780000002
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.244199400000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.1627996000000014,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 19465.19640000001,
          "annual_profit_projection": 233582.35680000013,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.325599200000002,
        "regulatory_headroom": 6.557774859999995,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_23635058210",
      "drug_name": "ROXICODONE 30 MG TABLET",
      "ndc": 23635058210,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.865514172499998,
        "feasible_range": [
          8.521971899999999,
          11.357166397499999
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.391478924999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.260985949999999,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 42609.85949999999,
          "annual_profit_projection": 511318.3139999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.521971899999999,
        "regulatory_headroom": 1.3123089849999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24208000401",
      "drug_name": "ISTALOL 0.5% EYE DROPS",
      "ndc": 24208000401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 69.33058210000003,
        "feasible_range": [
          69.33058210000003,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 51.99793657500002,
        "profit_projections": {
          "gross_profit_per_unit": 17.33264552500001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 173326.45525000012,
          "annual_profit_projection": 2079917.4630000014,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 69.33058210000003,
        "regulatory_headroom": -57.365808240000035,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $74.70"
        ]
      }
    },
    {
      "drug_id": "ndc_24208000403",
      "drug_name": "ISTALOL 0.5% EYE DROPS",
      "ndc": 24208000403,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 69.40034053333333,
        "feasible_range": [
          69.40034053333333,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 52.0502554,
        "profit_projections": {
          "gross_profit_per_unit": 17.350085133333337,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 173500.85133333338,
          "annual_profit_projection": 2082010.2160000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 69.40034053333333,
        "regulatory_headroom": -57.43556667333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $74.79"
        ]
      }
    },
    {
      "drug_id": "ndc_24208029905",
      "drug_name": "LOTEMAX 0.5% EYE DROPS",
      "ndc": 24208029905,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 53.67324256666666,
        "feasible_range": [
          53.67324256666666,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 40.254931924999994,
        "profit_projections": {
          "gross_profit_per_unit": 13.418310641666665,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 100637.32981249999,
          "annual_profit_projection": 1207647.9577499998,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 53.67324256666666,
        "regulatory_headroom": -41.708468706666665,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $55.13"
        ]
      }
    },
    {
      "drug_id": "ndc_24208029910",
      "drug_name": "LOTEMAX 0.5% EYE DROPS",
      "ndc": 24208029910,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 53.49193156666667,
        "feasible_range": [
          53.49193156666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 40.118948675000006,
        "profit_projections": {
          "gross_profit_per_unit": 13.372982891666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 100297.3716875,
          "annual_profit_projection": 1203568.46025,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 53.49193156666667,
        "regulatory_headroom": -41.52715770666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $54.90"
        ]
      }
    },
    {
      "drug_id": "ndc_24208035305",
      "drug_name": "ALREX 0.2% EYE DROPS",
      "ndc": 24208035305,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 50.41006576666666,
        "feasible_range": [
          50.41006576666666,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 37.807549325,
        "profit_projections": {
          "gross_profit_per_unit": 12.602516441666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 126025.16441666665,
          "annual_profit_projection": 1512301.9729999998,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 50.41006576666666,
        "regulatory_headroom": -38.44529190666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $51.05"
        ]
      }
    },
    {
      "drug_id": "ndc_24208049968",
      "drug_name": "TIMOPTIC 0.5% OCUDOSE DROP",
      "ndc": 24208049968,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.442316437499999,
        "feasible_range": [
          8.974365833333332,
          11.960068312499999
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.730774374999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.487182916666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44871.82916666667,
          "annual_profit_projection": 538461.9500000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.974365833333332,
        "regulatory_headroom": 0.7468165683333314,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24208050307",
      "drug_name": "LOTEMAX 0.5% OPHTHALMIC GEL",
      "ndc": 24208050307,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 42.94102583333335,
        "feasible_range": [
          42.94102583333335,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 32.20576937500001,
        "profit_projections": {
          "gross_profit_per_unit": 10.735256458333339,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 80514.42343750004,
          "annual_profit_projection": 966173.0812500005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 42.94102583333335,
        "regulatory_headroom": -30.97625197333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $41.71"
        ]
      }
    },
    {
      "drug_id": "ndc_24208060203",
      "drug_name": "PROLENSA 0.07% EYE DROPS",
      "ndc": 24208060203,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 100.37297876666669,
        "feasible_range": [
          100.37297876666669,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 75.27973407500002,
        "profit_projections": {
          "gross_profit_per_unit": 25.09324469166667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 250932.4469166667,
          "annual_profit_projection": 3011189.3630000004,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 100.37297876666669,
        "regulatory_headroom": -88.4082049066667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $113.50"
        ]
      }
    },
    {
      "drug_id": "ndc_24208062901",
      "drug_name": "BEPREVE 1.5% EYE DROPS",
      "ndc": 24208062901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 46.60182106666667,
        "feasible_range": [
          46.60182106666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 34.951365800000005,
        "profit_projections": {
          "gross_profit_per_unit": 11.650455266666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 116504.55266666668,
          "annual_profit_projection": 1398054.6320000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 46.60182106666667,
        "regulatory_headroom": -34.63704720666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $46.29"
        ]
      }
    },
    {
      "drug_id": "ndc_24208062902",
      "drug_name": "BEPREVE 1.5% EYE DROPS",
      "ndc": 24208062902,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 48.5080739,
        "feasible_range": [
          48.5080739,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 36.381055425,
        "profit_projections": {
          "gross_profit_per_unit": 12.127018475,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 121270.18475,
          "annual_profit_projection": 1455242.217,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 48.5080739,
        "regulatory_headroom": -36.543300040000005,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $48.67"
        ]
      }
    },
    {
      "drug_id": "ndc_24338001009",
      "drug_name": "BIDIL 20 MG-37.5 MG TABLET",
      "ndc": 24338001009,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.841739272500001,
        "feasible_range": [
          3.7974425666666676,
          5.060822497500001
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 2.8480819250000007,
        "profit_projections": {
          "gross_profit_per_unit": 1.8987212833333338,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 18987.21283333334,
          "annual_profit_projection": 227846.55400000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.7974425666666676,
        "regulatory_headroom": 7.217970651666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24338001018",
      "drug_name": "BIDIL 20 MG-37.5 MG TABLET",
      "ndc": 24338001018,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.842262373684211,
        "feasible_range": [
          3.797852842105264,
          5.061369268421053
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 2.848389631578948,
        "profit_projections": {
          "gross_profit_per_unit": 1.8989264210526318,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 18989.26421052632,
          "annual_profit_projection": 227871.1705263158,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.797852842105264,
        "regulatory_headroom": 7.217457807368418,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24338002603",
      "drug_name": "EVEKEO 10 MG TABLET",
      "ndc": 24338002603,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.475695312500003,
        "feasible_range": [
          6.647604166666668,
          8.859210937500002
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 4.9857031250000015,
        "profit_projections": {
          "gross_profit_per_unit": 3.3238020833333346,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 33238.02083333334,
          "annual_profit_projection": 398856.2500000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.647604166666668,
        "regulatory_headroom": 3.6552686516666615,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24338002610",
      "drug_name": "EVEKEO 10 MG TABLET",
      "ndc": 24338002610,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.474382252631582,
        "feasible_range": [
          6.646574315789476,
          8.857838463157899
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 4.984930736842107,
        "profit_projections": {
          "gross_profit_per_unit": 3.3232871578947387,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 29909.58442105265,
          "annual_profit_projection": 358915.01305263175,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.646574315789476,
        "regulatory_headroom": 3.656555965263152,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24338013013",
      "drug_name": "ERYPED 400 MG/5 ML SUSPENSION",
      "ndc": 24338013013,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.832843333333336,
        "feasible_range": [
          5.466274666666668,
          7.284862200000003
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.099706000000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.7331373333333344,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 20498.53000000001,
          "annual_profit_projection": 245982.3600000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.466274666666668,
        "regulatory_headroom": 5.131930526666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24338013213",
      "drug_name": "ERYPED 200 MG/5 ML SUSPENSION",
      "ndc": 24338013213,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.905005000000001,
        "feasible_range": [
          3.1240040000000007,
          4.1633361
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.3430030000000004,
        "profit_projections": {
          "gross_profit_per_unit": 1.5620020000000006,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 11715.015000000005,
          "annual_profit_projection": 140580.18000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.1240040000000007,
        "regulatory_headroom": 8.059768859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24338013402",
      "drug_name": "E.E.S. 200 MG/5 ML SUSPENSION",
      "ndc": 24338013402,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.983105100000001,
        "feasible_range": [
          3.1240040000000007,
          4.1633361
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.3430030000000004,
        "profit_projections": {
          "gross_profit_per_unit": 1.5620020000000006,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 15620.020000000006,
          "annual_profit_projection": 187440.24000000008,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.1240040000000007,
        "regulatory_headroom": 8.059768859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24338018504",
      "drug_name": "SKLICE 0.5% LOTION",
      "ndc": 24338018504,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.3296878000000001,
        "feasible_range": [
          0.25857866666666673,
          0.3446058000000001
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 0.19393400000000005,
        "profit_projections": {
          "gross_profit_per_unit": 0.12928933333333337,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 1292.8933333333337,
          "annual_profit_projection": 15514.720000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.25857866666666673,
        "regulatory_headroom": 11.641550526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_24979024407",
      "drug_name": "TENORMIN 25 MG TABLET",
      "ndc": 24979024407,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.052955333333337,
          11.964773859999998
        ],
        "expected_margin": 0.30715644131697745,
        "estimated_acquisition_cost": 8.289716500000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.675057359999995,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 27562.930199999962,
          "annual_profit_projection": 330755.16239999956,
          "margin_percentage": 30.715644131697744
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.052955333333337,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.85"
        ]
      }
    },
    {
      "drug_id": "ndc_24979024706",
      "drug_name": "FORFIVO XL 450 MG TABLET",
      "ndc": 24979024706,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.985596000000003,
        "feasible_range": [
          12.985596000000003,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.739197000000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.2463990000000003,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 32463.99,
          "annual_profit_projection": 389567.88,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.985596000000003,
        "regulatory_headroom": -1.0208221400000053,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.27"
        ]
      }
    },
    {
      "drug_id": "ndc_27437005530",
      "drug_name": "BROVANA 15 MCG/2 ML SOLUTION",
      "ndc": 27437005530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.2144120975,
        "feasible_range": [
          8.4242574,
          11.226943035
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.31819305,
        "profit_projections": {
          "gross_profit_per_unit": 4.212128700000001,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 18954.579150000005,
          "annual_profit_projection": 227454.94980000006,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.4242574,
        "regulatory_headroom": 1.434452109999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_27437005560",
      "drug_name": "BROVANA 15 MCG/2 ML SOLUTION",
      "ndc": 27437005560,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.163861234583338,
        "feasible_range": [
          8.38256596666667,
          11.171381182500005
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.286924475000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.191282983333336,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20956.41491666668,
          "annual_profit_projection": 251476.97900000017,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.38256596666667,
        "regulatory_headroom": 1.4865664016666589,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_27437005601",
      "drug_name": "XOPENEX HFA 45 MCG INHALER",
      "ndc": 27437005601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.288520055000002,
        "feasible_range": [
          4.147858866666668,
          5.527819605000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.110894150000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.0739294333333342,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 20739.294333333342,
          "annual_profit_projection": 248871.53200000012,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.147858866666668,
        "regulatory_headroom": 6.779950276666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_27437006030",
      "drug_name": "BROVANA 15 MCG/2 ML SOLUTION",
      "ndc": 27437006030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.2144120975,
        "feasible_range": [
          8.4242574,
          11.226943035
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.31819305,
        "profit_projections": {
          "gross_profit_per_unit": 4.212128700000001,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 18954.579150000005,
          "annual_profit_projection": 227454.94980000006,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.4242574,
        "regulatory_headroom": 1.434452109999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_27437006060",
      "drug_name": "BROVANA 15 MCG/2 ML SOLUTION",
      "ndc": 27437006060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.163861234583338,
        "feasible_range": [
          8.38256596666667,
          11.171381182500005
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.286924475000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.191282983333336,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20956.41491666668,
          "annual_profit_projection": 251476.97900000017,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.38256596666667,
        "regulatory_headroom": 1.4865664016666589,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_30698006001",
      "drug_name": "LASIX 40 MG TABLET",
      "ndc": 30698006001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1610732249999995,
        "feasible_range": [
          0.9106456666666664,
          1.2136104749999996
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 0.6829842499999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.4553228333333331,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 4553.228333333332,
          "annual_profit_projection": 54638.739999999976,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9106456666666664,
        "regulatory_headroom": 10.826466776666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_30698006701",
      "drug_name": "LASIX 20 MG TABLET",
      "ndc": 30698006701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.8288041450000001,
        "feasible_range": [
          0.6500424666666668,
          0.8663065950000002
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.48753185000000004,
        "profit_projections": {
          "gross_profit_per_unit": 0.3250212333333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 3250.212333333334,
          "annual_profit_projection": 39002.54800000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.6500424666666668,
        "regulatory_headroom": 11.152220776666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_30698045801",
      "drug_name": "LOPRESSOR 50 MG TABLET",
      "ndc": 30698045801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.6746160350000006,
        "feasible_range": [
          2.097738066666667,
          2.7956393850000008
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 1.5733035500000003,
        "profit_projections": {
          "gross_profit_per_unit": 1.0488690333333337,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 10488.690333333338,
          "annual_profit_projection": 125864.28400000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.097738066666667,
        "regulatory_headroom": 9.342601276666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42023011001",
      "drug_name": "DELESTROGEN 50 MG/5 ML VIAL",
      "ndc": 42023011001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 22.040993866666668,
        "feasible_range": [
          22.040993866666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 16.5307454,
        "profit_projections": {
          "gross_profit_per_unit": 5.510248466666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 41326.8635,
          "annual_profit_projection": 495922.36199999996,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 22.040993866666668,
        "regulatory_headroom": -10.07622000666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $15.59"
        ]
      }
    },
    {
      "drug_id": "ndc_42023011101",
      "drug_name": "DELESTROGEN 100 MG/5 ML VIAL",
      "ndc": 42023011101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 31.20294406666666,
        "feasible_range": [
          31.20294406666666,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 23.402208049999995,
        "profit_projections": {
          "gross_profit_per_unit": 7.800736016666665,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 58505.52012499999,
          "annual_profit_projection": 702066.2414999999,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 31.20294406666666,
        "regulatory_headroom": -19.238170206666663,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $27.04"
        ]
      }
    },
    {
      "drug_id": "ndc_42023011201",
      "drug_name": "DELESTROGEN 200 MG/5 ML VIAL",
      "ndc": 42023011201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 51.73376000000001,
        "feasible_range": [
          51.73376000000001,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 38.800320000000006,
        "profit_projections": {
          "gross_profit_per_unit": 12.933440000000004,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 97000.80000000003,
          "annual_profit_projection": 1164009.6000000003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 51.73376000000001,
        "regulatory_headroom": -39.76898614000001,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $52.70"
        ]
      }
    },
    {
      "drug_id": "ndc_42858023401",
      "drug_name": "DILAUDID 4 MG TABLET",
      "ndc": 42858023401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.2856016666666665,
        "feasible_range": [
          3.4284813333333335,
          4.5691107
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 2.571361,
        "profit_projections": {
          "gross_profit_per_unit": 1.7142406666666665,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 12856.804999999998,
          "annual_profit_projection": 154281.65999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.4284813333333335,
        "regulatory_headroom": 7.679172193333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858023450",
      "drug_name": "DILAUDID 4 MG TABLET",
      "ndc": 42858023450,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.2856016666666665,
        "feasible_range": [
          3.4284813333333335,
          4.5691107
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 2.571361,
        "profit_projections": {
          "gross_profit_per_unit": 1.7142406666666665,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 12856.804999999998,
          "annual_profit_projection": 154281.65999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.4284813333333335,
        "regulatory_headroom": 7.679172193333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858033801",
      "drug_name": "DILAUDID 8 MG TABLET",
      "ndc": 42858033801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.8412966666666675,
        "feasible_range": [
          6.273037333333334,
          8.360028600000001
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.704778,
        "profit_projections": {
          "gross_profit_per_unit": 3.1365186666666673,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23523.890000000007,
          "annual_profit_projection": 282286.68000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.273037333333334,
        "regulatory_headroom": 4.12347719333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858040145",
      "drug_name": "APTENSIO XR 10 MG CAPSULE",
      "ndc": 42858040145,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.413602166666665,
        "feasible_range": [
          6.939053333333333,
          9.247622999999999
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 5.204289999999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.469526666666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17347.63333333333,
          "annual_profit_projection": 208171.59999999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.939053333333333,
        "regulatory_headroom": 3.290957193333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858040245",
      "drug_name": "APTENSIO XR 15 MG CAPSULE",
      "ndc": 42858040245,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.377814986666667,
        "feasible_range": [
          6.909538133333334,
          9.208288320000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.1821536,
        "profit_projections": {
          "gross_profit_per_unit": 3.4547690666666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17273.845333333335,
          "annual_profit_projection": 207286.14400000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.909538133333334,
        "regulatory_headroom": 3.3278511933333306,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858040345",
      "drug_name": "APTENSIO XR 20 MG CAPSULE",
      "ndc": 42858040345,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.388270778333336,
        "feasible_range": [
          6.918161466666668,
          9.219780570000005
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.1886211000000015,
        "profit_projections": {
          "gross_profit_per_unit": 3.4590807333333347,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17295.403666666673,
          "annual_profit_projection": 207544.84400000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.918161466666668,
        "regulatory_headroom": 3.3170720266666613,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858040445",
      "drug_name": "APTENSIO XR 30 MG CAPSULE",
      "ndc": 42858040445,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.413441914583338,
        "feasible_range": [
          6.93892116666667,
          9.247446862500004
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 5.204190875000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.469460583333336,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 15612.572625000012,
          "annual_profit_projection": 187350.87150000012,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.93892116666667,
        "regulatory_headroom": 3.2911224016666587,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858040545",
      "drug_name": "APTENSIO XR 40 MG CAPSULE",
      "ndc": 42858040545,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.373144557916666,
        "feasible_range": [
          6.905686233333333,
          9.2031549225
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 5.179264675,
        "profit_projections": {
          "gross_profit_per_unit": 3.452843116666666,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17264.21558333333,
          "annual_profit_projection": 207170.58699999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.905686233333333,
        "regulatory_headroom": 3.3326660683333316,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858040645",
      "drug_name": "APTENSIO XR 50 MG CAPSULE",
      "ndc": 42858040645,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.375847301250001,
        "feasible_range": [
          6.9079153,
          9.2061255825
        ],
        "expected_margin": 0.38144329896907225,
        "estimated_acquisition_cost": 5.180936475,
        "profit_projections": {
          "gross_profit_per_unit": 3.4539576500000004,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17269.78825,
          "annual_profit_projection": 207237.45900000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.9079153,
        "regulatory_headroom": 3.329879734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858040745",
      "drug_name": "APTENSIO XR 60 MG CAPSULE",
      "ndc": 42858040745,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.442317238333334,
        "feasible_range": [
          6.9627358666666685,
          9.279184530000002
        ],
        "expected_margin": 0.3814432989690721,
        "estimated_acquisition_cost": 5.222051900000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.481367933333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17406.83966666667,
          "annual_profit_projection": 208882.07600000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.9627358666666685,
        "regulatory_headroom": 3.2613540266666625,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858051501",
      "drug_name": "MS CONTIN ER 15 MG TABLET",
      "ndc": 42858051501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.866513924999999,
        "feasible_range": [
          3.8168736666666656,
          5.086718174999999
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.862655249999999,
        "profit_projections": {
          "gross_profit_per_unit": 1.9084368333333326,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 19084.368333333325,
          "annual_profit_projection": 229012.4199999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.8168736666666656,
        "regulatory_headroom": 7.193681776666666,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_42858063101",
      "drug_name": "MS CONTIN ER 30 MG TABLET",
      "ndc": 42858063101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.2001852475,
        "feasible_range": [
          7.215831566666666,
          9.6164832225
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.411873675,
        "profit_projections": {
          "gross_profit_per_unit": 3.6079157833333335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 36079.15783333334,
          "annual_profit_projection": 432949.8940000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.215831566666666,
        "regulatory_headroom": 2.944984401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_46287002004",
      "drug_name": "CAROSPIR 25 MG/5 ML SUSPENSION",
      "ndc": 46287002004,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.90785018,
        "feasible_range": [
          3.0649805333333333,
          4.08467598
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.2987354,
        "profit_projections": {
          "gross_profit_per_unit": 1.5324902666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 15324.902666666667,
          "annual_profit_projection": 183898.832,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.0649805333333333,
        "regulatory_headroom": 8.133548193333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49502050001",
      "drug_name": "EPIPEN 0.3 MG AUTO-INJECTOR",
      "ndc": 49502050001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 251.2986666666667,
        "feasible_range": [
          251.2986666666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 188.47400000000002,
        "profit_projections": {
          "gross_profit_per_unit": 62.82466666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 471185.00000000006,
          "annual_profit_projection": 5654220.000000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 251.2986666666667,
        "regulatory_headroom": -239.33389280666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $302.16"
        ]
      }
    },
    {
      "drug_id": "ndc_49502050002",
      "drug_name": "EPIPEN 2-PAK 0.3 MG AUTO-INJCT",
      "ndc": 49502050002,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 251.2986666666667,
        "feasible_range": [
          251.2986666666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 188.47400000000002,
        "profit_projections": {
          "gross_profit_per_unit": 62.82466666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 471185.00000000006,
          "annual_profit_projection": 5654220.000000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 251.2986666666667,
        "regulatory_headroom": -239.33389280666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $302.16"
        ]
      }
    },
    {
      "drug_id": "ndc_49502050101",
      "drug_name": "EPIPEN JR 0.15 MG AUTO-INJECTR",
      "ndc": 49502050101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 252.6198003333333,
        "feasible_range": [
          252.6198003333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 189.46485024999998,
        "profit_projections": {
          "gross_profit_per_unit": 63.15495008333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 473662.12562499987,
          "annual_profit_projection": 5683945.507499998,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 252.6198003333333,
        "regulatory_headroom": -240.6550264733333,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $303.81"
        ]
      }
    },
    {
      "drug_id": "ndc_49502050102",
      "drug_name": "EPIPEN JR 2-PAK 0.15 MG INJCTR",
      "ndc": 49502050102,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 252.6198003333333,
        "feasible_range": [
          252.6198003333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 189.46485024999998,
        "profit_projections": {
          "gross_profit_per_unit": 63.15495008333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 473662.12562499987,
          "annual_profit_projection": 5683945.507499998,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 252.6198003333333,
        "regulatory_headroom": -240.6550264733333,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $303.81"
        ]
      }
    },
    {
      "drug_id": "ndc_49502060530",
      "drug_name": "PERFOROMIST 20 MCG/2 ML SOLN",
      "ndc": 49502060530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.728935620000001,
        "feasible_range": [
          8.414851466666667,
          11.21440782
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 6.3111386,
        "profit_projections": {
          "gross_profit_per_unit": 4.207425733333334,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 37866.831600000005,
          "annual_profit_projection": 454401.97920000006,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.414851466666667,
        "regulatory_headroom": 1.4462095266666637,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49502060561",
      "drug_name": "PERFOROMIST 20 MCG/2 ML SOLN",
      "ndc": 49502060561,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.77175879,
        "feasible_range": [
          8.448438266666665,
          11.25916869
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.336328699999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.224219133333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 42242.191333333336,
          "annual_profit_projection": 506906.29600000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.448438266666665,
        "regulatory_headroom": 1.4042260266666649,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_49702022318",
      "drug_name": "SELZENTRY 150 MG TABLET",
      "ndc": 49702022318,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 24.21072463333333,
        "feasible_range": [
          24.21072463333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 18.158043475,
        "profit_projections": {
          "gross_profit_per_unit": 6.052681158333332,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 60526.81158333332,
          "annual_profit_projection": 726321.7389999998,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 24.21072463333333,
        "regulatory_headroom": -12.245950773333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $18.30"
        ]
      }
    },
    {
      "drug_id": "ndc_49702022418",
      "drug_name": "SELZENTRY 300 MG TABLET",
      "ndc": 49702022418,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 24.287344466666667,
        "feasible_range": [
          24.287344466666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 18.21550835,
        "profit_projections": {
          "gross_profit_per_unit": 6.071836116666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 60718.36116666667,
          "annual_profit_projection": 728620.334,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 24.287344466666667,
        "regulatory_headroom": -12.32257060666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $18.39"
        ]
      }
    },
    {
      "drug_id": "ndc_49708075441",
      "drug_name": "BROMSITE 0.075% EYE DROPS",
      "ndc": 49708075441,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 43.0647854,
        "feasible_range": [
          43.0647854,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 32.29858905,
        "profit_projections": {
          "gross_profit_per_unit": 10.766196350000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 107661.96350000001,
          "annual_profit_projection": 1291943.5620000002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 43.0647854,
        "regulatory_headroom": -31.10001154,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $41.87"
        ]
      }
    },
    {
      "drug_id": "ndc_49884027082",
      "drug_name": "NASCOBAL 500 MCG NASAL SPRAY",
      "ndc": 49884027082,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 148.1015310666667,
        "feasible_range": [
          148.1015310666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 111.07614830000001,
        "profit_projections": {
          "gross_profit_per_unit": 37.02538276666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 370253.8276666668,
          "annual_profit_projection": 4443045.932000002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 148.1015310666667,
        "regulatory_headroom": -136.1367572066667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $173.16"
        ]
      }
    },
    {
      "drug_id": "ndc_50222050106",
      "drug_name": "TACLONEX 0.005%-0.064% SUSPENSION",
      "ndc": 50222050106,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.97900303333333,
        "feasible_range": [
          17.97900303333333,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.484252274999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.494750758333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44947.50758333334,
          "annual_profit_projection": 539370.091,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.97900303333333,
        "regulatory_headroom": -6.014229173333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.51"
        ]
      }
    },
    {
      "drug_id": "ndc_50222050166",
      "drug_name": "TACLONEX 0.005%-0.064% SUSPENSION",
      "ndc": 50222050166,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.95459466666667,
        "feasible_range": [
          17.95459466666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.465946,
        "profit_projections": {
          "gross_profit_per_unit": 4.488648666666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44886.48666666668,
          "annual_profit_projection": 538637.8400000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.95459466666667,
        "regulatory_headroom": -5.989820806666671,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.48"
        ]
      }
    },
    {
      "drug_id": "ndc_50419040201",
      "drug_name": "YASMIN 28 TABLET",
      "ndc": 50419040201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.8704576699999995,
        "feasible_range": [
          3.8199667999999996,
          5.09084037
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.8649750999999997,
        "profit_projections": {
          "gross_profit_per_unit": 1.9099833999999998,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 19099.834,
          "annual_profit_projection": 229198.00799999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.8199667999999996,
        "regulatory_headroom": 7.189815359999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50419040203",
      "drug_name": "YASMIN 28 TABLET",
      "ndc": 50419040203,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.8704576699999995,
        "feasible_range": [
          3.8199667999999996,
          5.09084037
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.8649750999999997,
        "profit_projections": {
          "gross_profit_per_unit": 1.9099833999999998,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 19099.834,
          "annual_profit_projection": 229198.00799999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.8199667999999996,
        "regulatory_headroom": 7.189815359999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50419040501",
      "drug_name": "YAZ 28 TABLET",
      "ndc": 50419040501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.490887682500002,
        "feasible_range": [
          5.090892300000001,
          6.784593007500002
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.818169225000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.545446150000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 25454.46150000001,
          "annual_profit_projection": 305453.5380000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.090892300000001,
        "regulatory_headroom": 5.601158484999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50419040503",
      "drug_name": "YAZ 28 TABLET",
      "ndc": 50419040503,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.490887682500002,
        "feasible_range": [
          5.090892300000001,
          6.784593007500002
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.818169225000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.545446150000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 25454.46150000001,
          "annual_profit_projection": 305453.5380000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.090892300000001,
        "regulatory_headroom": 5.601158484999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50419040701",
      "drug_name": "BEYAZ 28 TABLET",
      "ndc": 50419040701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.223013995000002,
        "feasible_range": [
          7.2337364666666675,
          9.640344945
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.425302350000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.616868233333335,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 32551.814100000014,
          "annual_profit_projection": 390621.76920000016,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.2337364666666675,
        "regulatory_headroom": 2.9226032766666616,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50419040703",
      "drug_name": "BEYAZ 28 TABLET",
      "ndc": 50419040703,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.223013995000002,
        "feasible_range": [
          7.2337364666666675,
          9.640344945
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.425302350000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.616868233333335,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 32551.814100000014,
          "annual_profit_projection": 390621.76920000016,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.2337364666666675,
        "regulatory_headroom": 2.9226032766666616,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50419045101",
      "drug_name": "CLIMARA 0.05 MG/DAY PATCH",
      "ndc": 50419045101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.845027033333336,
        "feasible_range": [
          15.845027033333336,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.883770275000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.9612567583333345,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11883.770275000003,
          "annual_profit_projection": 142605.24330000003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.845027033333336,
        "regulatory_headroom": -3.8802531733333385,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.84"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045104",
      "drug_name": "CLIMARA 0.05 MG/DAY PATCH",
      "ndc": 50419045104,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.845027033333336,
        "feasible_range": [
          15.845027033333336,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.883770275000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.9612567583333345,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11883.770275000003,
          "annual_profit_projection": 142605.24330000003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.845027033333336,
        "regulatory_headroom": -3.8802531733333385,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.84"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045201",
      "drug_name": "CLIMARA 0.1 MG/DAY PATCH",
      "ndc": 50419045201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.881798833333342,
        "feasible_range": [
          15.881798833333342,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.911349125000006,
        "profit_projections": {
          "gross_profit_per_unit": 3.9704497083333354,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11911.349125000006,
          "annual_profit_projection": 142936.18950000007,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.881798833333342,
        "regulatory_headroom": -3.917024973333344,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.89"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045204",
      "drug_name": "CLIMARA 0.1 MG/DAY PATCH",
      "ndc": 50419045204,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.881798833333342,
        "feasible_range": [
          15.881798833333342,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.911349125000006,
        "profit_projections": {
          "gross_profit_per_unit": 3.9704497083333354,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11911.349125000006,
          "annual_profit_projection": 142936.18950000007,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.881798833333342,
        "regulatory_headroom": -3.917024973333344,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.89"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045301",
      "drug_name": "CLIMARA 0.075 MG/DAY PATCH",
      "ndc": 50419045301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.877288700000003,
        "feasible_range": [
          15.877288700000003,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.907966525000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.9693221750000003,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11907.966525000002,
          "annual_profit_projection": 142895.5983,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.877288700000003,
        "regulatory_headroom": -3.9125148400000054,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.88"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045304",
      "drug_name": "CLIMARA 0.075 MG/DAY PATCH",
      "ndc": 50419045304,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.877288700000003,
        "feasible_range": [
          15.877288700000003,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.907966525000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.9693221750000003,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11907.966525000002,
          "annual_profit_projection": 142895.5983,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.877288700000003,
        "regulatory_headroom": -3.9125148400000054,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.88"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045401",
      "drug_name": "CLIMARA 0.025 MG/DAY PATCH",
      "ndc": 50419045401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.797236866666667,
        "feasible_range": [
          15.797236866666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.84792765,
        "profit_projections": {
          "gross_profit_per_unit": 3.9493092166666663,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11847.92765,
          "annual_profit_projection": 142175.1318,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.797236866666667,
        "regulatory_headroom": -3.8324630066666696,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.78"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045404",
      "drug_name": "CLIMARA 0.025 MG/DAY PATCH",
      "ndc": 50419045404,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.797236866666667,
        "feasible_range": [
          15.797236866666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.84792765,
        "profit_projections": {
          "gross_profit_per_unit": 3.9493092166666663,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11847.92765,
          "annual_profit_projection": 142175.1318,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.797236866666667,
        "regulatory_headroom": -3.8324630066666696,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.78"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045601",
      "drug_name": "CLIMARA 0.0375 MG/DAY PATCH",
      "ndc": 50419045601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.88006203333334,
        "feasible_range": [
          15.88006203333334,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.910046525000006,
        "profit_projections": {
          "gross_profit_per_unit": 3.9700155083333346,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11910.046525000003,
          "annual_profit_projection": 142920.55830000003,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.88006203333334,
        "regulatory_headroom": -3.9152881733333427,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.89"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045604",
      "drug_name": "CLIMARA 0.0375 MG/DAY PATCH",
      "ndc": 50419045604,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.88006203333334,
        "feasible_range": [
          15.88006203333334,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.910046525000006,
        "profit_projections": {
          "gross_profit_per_unit": 3.9700155083333346,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11910.046525000003,
          "annual_profit_projection": 142920.55830000003,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.88006203333334,
        "regulatory_headroom": -3.9152881733333427,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.89"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045901",
      "drug_name": "CLIMARA 0.06 MG/DAY PATCH",
      "ndc": 50419045901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.830760400000004,
        "feasible_range": [
          15.830760400000004,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.873070300000004,
        "profit_projections": {
          "gross_profit_per_unit": 3.9576901000000007,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11873.070300000001,
          "annual_profit_projection": 142476.84360000002,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.830760400000004,
        "regulatory_headroom": -3.865986540000007,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.82"
        ]
      }
    },
    {
      "drug_id": "ndc_50419045904",
      "drug_name": "CLIMARA 0.06 MG/DAY PATCH",
      "ndc": 50419045904,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.830760400000004,
        "feasible_range": [
          15.830760400000004,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.873070300000004,
        "profit_projections": {
          "gross_profit_per_unit": 3.9576901000000007,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11873.070300000001,
          "annual_profit_projection": 142476.84360000002,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.830760400000004,
        "regulatory_headroom": -3.865986540000007,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.82"
        ]
      }
    },
    {
      "drug_id": "ndc_50458030001",
      "drug_name": "RISPERDAL 1 MG TABLET",
      "ndc": 50458030001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.850961645833334,
        "feasible_range": [
          4.0850203333333335,
          5.444075175000001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 3.0637652500000003,
        "profit_projections": {
          "gross_profit_per_unit": 2.042510166666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 6127.530500000002,
          "annual_profit_projection": 73530.36600000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.0850203333333335,
        "regulatory_headroom": 6.85849844333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50458030006",
      "drug_name": "RISPERDAL 1 MG TABLET",
      "ndc": 50458030006,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.850961645833334,
        "feasible_range": [
          4.0850203333333335,
          5.444075175000001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 3.0637652500000003,
        "profit_projections": {
          "gross_profit_per_unit": 2.042510166666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 6127.530500000002,
          "annual_profit_projection": 73530.36600000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.0850203333333335,
        "regulatory_headroom": 6.85849844333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50458030201",
      "drug_name": "RISPERDAL 0.5 MG TABLET",
      "ndc": 50458030201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.551702620833335,
        "feasible_range": [
          3.833012733333334,
          5.108226585000001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 2.8747595500000007,
        "profit_projections": {
          "gross_profit_per_unit": 1.9165063666666673,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 5749.519100000002,
          "annual_profit_projection": 68994.22920000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.833012733333334,
        "regulatory_headroom": 7.1735079433333295,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50458030206",
      "drug_name": "RISPERDAL 0.5 MG TABLET",
      "ndc": 50458030206,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.551702620833335,
        "feasible_range": [
          3.833012733333334,
          5.108226585000001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 2.8747595500000007,
        "profit_projections": {
          "gross_profit_per_unit": 1.9165063666666673,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 5749.519100000002,
          "annual_profit_projection": 68994.22920000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.833012733333334,
        "regulatory_headroom": 7.1735079433333295,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50458030503",
      "drug_name": "RISPERDAL 1 MG/ML SOLUTION",
      "ndc": 50458030503,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.4110902354166655,
        "feasible_range": [
          4.556707566666666,
          6.0726891225
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 3.4175306749999996,
        "profit_projections": {
          "gross_profit_per_unit": 2.278353783333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 6835.061349999999,
          "annual_profit_projection": 82020.73619999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.556707566666666,
        "regulatory_headroom": 6.268889401666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50458030611",
      "drug_name": "RISPERDAL CONSTA 25 MG VIAL",
      "ndc": 50458030611,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 535.2894958666665,
        "feasible_range": [
          535.2894958666665,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 401.4671218999999,
        "profit_projections": {
          "gross_profit_per_unit": 133.8223739666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 401467.1218999998,
          "annual_profit_projection": 4817605.462799998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 535.2894958666665,
        "regulatory_headroom": -523.3247220066664,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $657.15"
        ]
      }
    },
    {
      "drug_id": "ndc_50458030711",
      "drug_name": "RISPERDAL CONSTA 37.5 MG VIAL",
      "ndc": 50458030711,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 802.4050805333335,
        "feasible_range": [
          802.4050805333335,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 601.8038104000001,
        "profit_projections": {
          "gross_profit_per_unit": 200.6012701333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 601803.8104000002,
          "annual_profit_projection": 7221645.724800002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 802.4050805333335,
        "regulatory_headroom": -790.4403066733335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $991.04"
        ]
      }
    },
    {
      "drug_id": "ndc_50458030811",
      "drug_name": "RISPERDAL CONSTA 50 MG VIAL",
      "ndc": 50458030811,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 652.8512206666669,
        "feasible_range": [
          652.8512206666669,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 489.6384155000002,
        "profit_projections": {
          "gross_profit_per_unit": 163.21280516666673,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 489638.4155000002,
          "annual_profit_projection": 5875660.986000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 652.8512206666669,
        "regulatory_headroom": -640.8864468066669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $804.10"
        ]
      }
    },
    {
      "drug_id": "ndc_50458032001",
      "drug_name": "RISPERDAL 2 MG TABLET",
      "ndc": 50458032001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.083460937499998,
        "feasible_range": [
          6.807124999999999,
          9.071803125
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 5.105343749999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.4035624999999996,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10210.687499999998,
          "annual_profit_projection": 122528.24999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.807124999999999,
        "regulatory_headroom": 3.4558676099999985,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50458032006",
      "drug_name": "RISPERDAL 2 MG TABLET",
      "ndc": 50458032006,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.083460937499998,
        "feasible_range": [
          6.807124999999999,
          9.071803125
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 5.105343749999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.4035624999999996,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10210.687499999998,
          "annual_profit_projection": 122528.24999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.807124999999999,
        "regulatory_headroom": 3.4558676099999985,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50458033001",
      "drug_name": "RISPERDAL 3 MG TABLET",
      "ndc": 50458033001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.496933875000002,
        "feasible_range": [
          7.997418000000002,
          10.658097450000003
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 5.9980635000000015,
        "profit_projections": {
          "gross_profit_per_unit": 3.9987090000000007,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11996.127000000002,
          "annual_profit_projection": 143953.52400000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.997418000000002,
        "regulatory_headroom": 1.9680013599999953,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50458033006",
      "drug_name": "RISPERDAL 3 MG TABLET",
      "ndc": 50458033006,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.496933875000002,
        "feasible_range": [
          7.997418000000002,
          10.658097450000003
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 5.9980635000000015,
        "profit_projections": {
          "gross_profit_per_unit": 3.9987090000000007,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11996.127000000002,
          "annual_profit_projection": 143953.52400000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.997418000000002,
        "regulatory_headroom": 1.9680013599999953,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50458035001",
      "drug_name": "RISPERDAL 4 MG TABLET",
      "ndc": 50458035001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.745530466666667,
          11.964773859999998
        ],
        "expected_margin": 0.29097585749808796,
        "estimated_acquisition_cost": 8.05914785,
        "profit_projections": {
          "gross_profit_per_unit": 3.905626009999997,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11716.87802999999,
          "annual_profit_projection": 140602.53635999988,
          "margin_percentage": 32.64270646231836
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.745530466666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.47"
        ]
      }
    },
    {
      "drug_id": "ndc_50458035006",
      "drug_name": "RISPERDAL 4 MG TABLET",
      "ndc": 50458035006,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.745530466666667,
          11.964773859999998
        ],
        "expected_margin": 0.29097585749808796,
        "estimated_acquisition_cost": 8.05914785,
        "profit_projections": {
          "gross_profit_per_unit": 3.905626009999997,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11716.87802999999,
          "annual_profit_projection": 140602.53635999988,
          "margin_percentage": 32.64270646231836
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.745530466666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.47"
        ]
      }
    },
    {
      "drug_id": "ndc_50458055001",
      "drug_name": "INVEGA ER 3 MG TABLET",
      "ndc": 50458055001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.40525286666667,
          11.964773859999998
        ],
        "expected_margin": 0.34775702898240957,
        "estimated_acquisition_cost": 7.803939650000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.1608342099999955,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 31206.256574999967,
          "annual_profit_projection": 374475.0788999996,
          "margin_percentage": 34.77570289824096
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.40525286666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.04"
        ]
      }
    },
    {
      "drug_id": "ndc_50458055101",
      "drug_name": "INVEGA ER 6 MG TABLET",
      "ndc": 50458055101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.434341666666665,
          11.964773859999998
        ],
        "expected_margin": 0.34593362636274677,
        "estimated_acquisition_cost": 7.825756249999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.139017609999999,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 31042.63207499999,
          "annual_profit_projection": 372511.5848999999,
          "margin_percentage": 34.593362636274676
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.434341666666665,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.08"
        ]
      }
    },
    {
      "drug_id": "ndc_50458055201",
      "drug_name": "INVEGA ER 9 MG TABLET",
      "ndc": 50458055201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.664560600000003,
        "feasible_range": [
          15.664560600000003,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.748420450000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.9161401500000004,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29371.051125,
          "annual_profit_projection": 352452.61350000004,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.664560600000003,
        "regulatory_headroom": -3.6997867400000057,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.62"
        ]
      }
    },
    {
      "drug_id": "ndc_50458058501",
      "drug_name": "CONCERTA ER 18 MG TABLET",
      "ndc": 50458058501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.7102281,
          11.964773859999998
        ],
        "expected_margin": 0.3286399585156889,
        "estimated_acquisition_cost": 8.032671075,
        "profit_projections": {
          "gross_profit_per_unit": 3.932102784999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29490.770887499984,
          "annual_profit_projection": 353889.2506499998,
          "margin_percentage": 32.86399585156889
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.7102281,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.42"
        ]
      }
    },
    {
      "drug_id": "ndc_50458058601",
      "drug_name": "CONCERTA ER 36 MG TABLET",
      "ndc": 50458058601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.3269156,
          11.964773859999998
        ],
        "expected_margin": 0.2899835133198245,
        "estimated_acquisition_cost": 8.4951867,
        "profit_projections": {
          "gross_profit_per_unit": 3.469587159999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 26021.903699999984,
          "annual_profit_projection": 312262.8443999998,
          "margin_percentage": 28.99835133198245
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.3269156,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.19"
        ]
      }
    },
    {
      "drug_id": "ndc_50458058701",
      "drug_name": "CONCERTA ER 54 MG TABLET",
      "ndc": 50458058701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.320435833333336,
        "feasible_range": [
          12.320435833333336,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.240326875000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.0801089583333336,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23100.8171875,
          "annual_profit_projection": 277209.80625,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.320435833333336,
        "regulatory_headroom": -0.3556619733333388,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.44"
        ]
      }
    },
    {
      "drug_id": "ndc_50458058801",
      "drug_name": "CONCERTA ER 27 MG TABLET",
      "ndc": 50458058801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.977331300000001,
          11.964773859999998
        ],
        "expected_margin": 0.3118968589515822,
        "estimated_acquisition_cost": 8.232998475,
        "profit_projections": {
          "gross_profit_per_unit": 3.731775384999997,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 27988.315387499977,
          "annual_profit_projection": 335859.7846499997,
          "margin_percentage": 31.18968589515822
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.977331300000001,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.76"
        ]
      }
    },
    {
      "drug_id": "ndc_50458063965",
      "drug_name": "TOPAMAX 25 MG TABLET",
      "ndc": 50458063965,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.940883083333335,
        "feasible_range": [
          5.552706466666668,
          7.400049195000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.164529850000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.7763532333333343,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 20822.649250000006,
          "annual_profit_projection": 249871.79100000008,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.552706466666668,
        "regulatory_headroom": 5.023890776666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50458064065",
      "drug_name": "TOPAMAX 50 MG TABLET",
      "ndc": 50458064065,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.048316066666667,
          11.964773859999998
        ],
        "expected_margin": 0.30744724915344096,
        "estimated_acquisition_cost": 8.28623705,
        "profit_projections": {
          "gross_profit_per_unit": 3.678536809999997,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 27589.02607499998,
          "annual_profit_projection": 331068.3128999998,
          "margin_percentage": 30.744724915344097
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.048316066666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.85"
        ]
      }
    },
    {
      "drug_id": "ndc_50458064165",
      "drug_name": "TOPAMAX 100 MG TABLET",
      "ndc": 50458064165,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.105132466666666,
        "feasible_range": [
          15.105132466666666,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.328849349999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.776283116666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28322.123375000003,
          "annual_profit_projection": 339865.48050000006,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.105132466666666,
        "regulatory_headroom": -3.140358606666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.92"
        ]
      }
    },
    {
      "drug_id": "ndc_50458064265",
      "drug_name": "TOPAMAX 200 MG TABLET",
      "ndc": 50458064265,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.712108266666664,
        "feasible_range": [
          17.712108266666664,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 13.2840812,
        "profit_projections": {
          "gross_profit_per_unit": 4.428027066666665,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33210.20299999999,
          "annual_profit_projection": 398522.43599999987,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.712108266666664,
        "regulatory_headroom": -5.747334406666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.18"
        ]
      }
    },
    {
      "drug_id": "ndc_50458064565",
      "drug_name": "TOPAMAX 25 MG SPRINKLE CAP",
      "ndc": 50458064565,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.9305286666666674,
        "feasible_range": [
          6.344422933333334,
          8.45516364
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.7583172000000005,
        "profit_projections": {
          "gross_profit_per_unit": 3.172211466666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23791.586000000003,
          "annual_profit_projection": 285499.032,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.344422933333334,
        "regulatory_headroom": 4.03424519333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50474000148",
      "drug_name": "KEPPRA 100 MG/ML ORAL SOLN",
      "ndc": 50474000148,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.9652963470833338,
        "feasible_range": [
          1.6208629666666667,
          2.1601116075
        ],
        "expected_margin": 0.38144329896907225,
        "estimated_acquisition_cost": 1.215647225,
        "profit_projections": {
          "gross_profit_per_unit": 0.8104314833333337,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 3646.941675000002,
          "annual_profit_projection": 43763.30010000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.6208629666666667,
        "regulatory_headroom": 9.938695151666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50474059440",
      "drug_name": "KEPPRA 250 MG TABLET",
      "ndc": 50474059440,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.345364727916667,
        "feasible_range": [
          6.882775033333334,
          9.172621342500001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.162081275,
        "profit_projections": {
          "gross_profit_per_unit": 3.4413875166666674,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17206.937583333336,
          "annual_profit_projection": 206483.25100000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.882775033333334,
        "regulatory_headroom": 3.36130506833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50474059540",
      "drug_name": "KEPPRA 500 MG TABLET",
      "ndc": 50474059540,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.17322205791667,
        "feasible_range": [
          8.390286233333336,
          11.181669922500003
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 6.292714675000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.195143116666668,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20975.71558333334,
          "annual_profit_projection": 251708.58700000012,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.390286233333336,
        "regulatory_headroom": 1.4769160683333276,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50474059640",
      "drug_name": "KEPPRA 750 MG TABLET",
      "ndc": 50474059640,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.404139933333335,
          11.964773859999998
        ],
        "expected_margin": 0.26303379635524776,
        "estimated_acquisition_cost": 8.553104950000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.411668909999996,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17058.34454999998,
          "annual_profit_projection": 204700.13459999976,
          "margin_percentage": 28.51427824645903
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.404139933333335,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.29"
        ]
      }
    },
    {
      "drug_id": "ndc_50474059766",
      "drug_name": "KEPPRA 1,000 MG TABLET",
      "ndc": 50474059766,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.802298933333333,
        "feasible_range": [
          16.802298933333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 12.6017242,
        "profit_projections": {
          "gross_profit_per_unit": 4.200574733333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21002.873666666666,
          "annual_profit_projection": 252034.484,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.802298933333333,
        "regulatory_headroom": -4.837525073333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $9.04"
        ]
      }
    },
    {
      "drug_id": "ndc_50474059866",
      "drug_name": "KEPPRA XR 500 MG TABLET",
      "ndc": 50474059866,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.22581699541667,
        "feasible_range": [
          7.608921233333336,
          10.140350797500004
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 5.706690925000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.8044606166666686,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19022.303083333343,
          "annual_profit_projection": 228267.6370000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.608921233333336,
        "regulatory_headroom": 2.453622318333327,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_50474059966",
      "drug_name": "KEPPRA XR 750 MG TABLET",
      "ndc": 50474059966,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.418768833333333,
          11.964773859999998
        ],
        "expected_margin": 0.2620884374803548,
        "estimated_acquisition_cost": 8.564076625,
        "profit_projections": {
          "gross_profit_per_unit": 3.4006972349999973,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17003.486174999987,
          "annual_profit_projection": 204041.83409999986,
          "margin_percentage": 28.42257843559442
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.418768833333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.31"
        ]
      }
    },
    {
      "drug_id": "ndc_51248015001",
      "drug_name": "VESICARE 5 MG TABLET",
      "ndc": 51248015001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.667377933333334,
          11.964773859999998
        ],
        "expected_margin": 0.331325978776167,
        "estimated_acquisition_cost": 8.00053345,
        "profit_projections": {
          "gross_profit_per_unit": 3.964240409999997,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 39642.40409999997,
          "annual_profit_projection": 475708.84919999965,
          "margin_percentage": 33.132597877616696
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.667377933333334,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.37"
        ]
      }
    },
    {
      "drug_id": "ndc_51248015101",
      "drug_name": "VESICARE 10 MG TABLET",
      "ndc": 51248015101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.667180333333333,
          11.964773859999998
        ],
        "expected_margin": 0.3313383651364723,
        "estimated_acquisition_cost": 8.000385249999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.9643886099999985,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 39643.88609999999,
          "annual_profit_projection": 475726.63319999987,
          "margin_percentage": 33.13383651364723
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.667180333333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.37"
        ]
      }
    },
    {
      "drug_id": "ndc_51285012570",
      "drug_name": "LOESTRIN FE 1-20 TABLET",
      "ndc": 51285012570,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.2789754775,
        "feasible_range": [
          6.493314099999999,
          8.6535897525
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 4.869985574999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.2466570499999996,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 32466.570499999994,
          "annual_profit_projection": 389598.8459999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.493314099999999,
        "regulatory_headroom": 3.8481312349999985,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_51672211500",
      "drug_name": "FEVERALL 120 MG SUPPOSITORY",
      "ndc": 51672211500,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 1.0182348475,
        "feasible_range": [
          0.7986155666666667,
          1.0643088225000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.598961675,
        "profit_projections": {
          "gross_profit_per_unit": 0.3993077833333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 3993.0778333333337,
          "annual_profit_projection": 47916.93400000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7986155666666667,
        "regulatory_headroom": 10.966504401666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_51672211502",
      "drug_name": "FEVERALL 120 MG SUPPOSITORY",
      "ndc": 51672211502,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 1.0182348475,
        "feasible_range": [
          0.7986155666666667,
          1.0643088225000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.598961675,
        "profit_projections": {
          "gross_profit_per_unit": 0.3993077833333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 3993.0778333333337,
          "annual_profit_projection": 47916.93400000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7986155666666667,
        "regulatory_headroom": 10.966504401666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_52268001201",
      "drug_name": "SUPREP BOWEL PREP KIT",
      "ndc": 52268001201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.3568359925000001,
        "feasible_range": [
          0.27987136666666673,
          0.3729824175000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.20990352500000004,
        "profit_projections": {
          "gross_profit_per_unit": 0.1399356833333334,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 1259.4211500000006,
          "annual_profit_projection": 15113.053800000007,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.27987136666666673,
        "regulatory_headroom": 11.614934651666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_52268010001",
      "drug_name": "GOLYTELY SOLUTION",
      "ndc": 52268010001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.006585799999999998,
        "feasible_range": [
          0.005165333333333332,
          0.006883799999999999
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.003873999999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.0025826666666666663,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 25.826666666666664,
          "annual_profit_projection": 309.91999999999996,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.005165333333333332,
        "regulatory_headroom": 11.95831719333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_52427042990",
      "drug_name": "TENORMIN 25 MG TABLET",
      "ndc": 52427042990,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.057920033333337,
          11.964773859999998
        ],
        "expected_margin": 0.30684523401430974,
        "estimated_acquisition_cost": 8.293440025000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.671333834999995,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 27535.003762499964,
          "annual_profit_projection": 330420.04514999955,
          "margin_percentage": 30.684523401430972
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.057920033333337,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.86"
        ]
      }
    },
    {
      "drug_id": "ndc_52427043090",
      "drug_name": "TENORMIN 50 MG TABLET",
      "ndc": 52427043090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.066556366666667,
          11.964773859999998
        ],
        "expected_margin": 0.306303874012375,
        "estimated_acquisition_cost": 8.299917275,
        "profit_projections": {
          "gross_profit_per_unit": 3.6648565849999972,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 27486.424387499977,
          "annual_profit_projection": 329837.0926499997,
          "margin_percentage": 30.630387401237503
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.066556366666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.87"
        ]
      }
    },
    {
      "drug_id": "ndc_52427044090",
      "drug_name": "ZESTRIL 10 MG TABLET",
      "ndc": 52427044090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.981975333333336,
          11.964773859999998
        ],
        "expected_margin": 0.31160575232133947,
        "estimated_acquisition_cost": 8.236481500000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.7282923599999958,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 37282.92359999996,
          "annual_profit_projection": 447395.0831999995,
          "margin_percentage": 31.160575232133947
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.981975333333336,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.76"
        ]
      }
    },
    {
      "drug_id": "ndc_52427057530",
      "drug_name": "FORFIVO XL 450 MG TABLET",
      "ndc": 52427057530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.985596000000003,
        "feasible_range": [
          12.985596000000003,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.739197000000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.2463990000000003,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 32463.99,
          "annual_profit_projection": 389567.88,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.985596000000003,
        "regulatory_headroom": -1.0208221400000053,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $4.27"
        ]
      }
    },
    {
      "drug_id": "ndc_52427080390",
      "drug_name": "GRALISE ER 300 MG TABLET",
      "ndc": 52427080390,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.297934927500005,
        "feasible_range": [
          8.861125433333337,
          11.809153702500005
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.645844075000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.430562716666669,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44305.627166666694,
          "annual_profit_projection": 531667.5260000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.861125433333337,
        "regulatory_headroom": 0.8883670683333253,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_52427080690",
      "drug_name": "GRALISE ER 600 MG TABLET",
      "ndc": 52427080690,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.26948394,
        "feasible_range": [
          8.838810933333333,
          11.77941534
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.6291082,
        "profit_projections": {
          "gross_profit_per_unit": 4.4194054666666664,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44194.05466666666,
          "annual_profit_projection": 530328.656,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.838810933333333,
        "regulatory_headroom": 0.916260193333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_52544008001",
      "drug_name": "FIORICET 50-300-40 MG CAPSULE",
      "ndc": 52544008001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.874121847499998,
        "feasible_range": [
          6.9600955666666655,
          9.275665822499997
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 5.220071674999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.4800477833333323,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 34800.47783333332,
          "annual_profit_projection": 417605.7339999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.9600955666666655,
        "regulatory_headroom": 3.2646544016666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_52652400101",
      "drug_name": "EPANED 1 MG/ML ORAL SOLUTION",
      "ndc": 52652400101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.73709964,
        "feasible_range": [
          3.7153722666666664,
          4.95144804
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.7865292,
        "profit_projections": {
          "gross_profit_per_unit": 1.8576861333333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 18576.861333333334,
          "annual_profit_projection": 222922.336,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.7153722666666664,
        "regulatory_headroom": 7.320558526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_52652600101",
      "drug_name": "FLEQSUVY 25 MG/5 ML SUSPENSION",
      "ndc": 52652600101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.3768478150000005,
        "feasible_range": [
          5.001449266666667,
          6.665392965
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.75108695,
        "profit_projections": {
          "gross_profit_per_unit": 2.5007246333333337,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 25007.246333333336,
          "annual_profit_projection": 300086.956,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.001449266666667,
        "regulatory_headroom": 5.712962276666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_52652600102",
      "drug_name": "FLEQSUVY 25 MG/5 ML SUSPENSION",
      "ndc": 52652600102,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.352849850000002,
        "feasible_range": [
          4.982627333333334,
          6.64030911923077
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.736970500000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.4913136666666675,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 24913.136666666676,
          "annual_profit_projection": 298957.64000000013,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.982627333333334,
        "regulatory_headroom": 5.736489693333329,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092017112",
      "drug_name": "CARBATROL ER 100 MG CAPSULE",
      "ndc": 54092017112,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.843361000000001,
        "feasible_range": [
          1.4746888000000007,
          1.9653064200000008
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.1060166000000005,
        "profit_projections": {
          "gross_profit_per_unit": 0.7373444000000005,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 5530.083000000003,
          "annual_profit_projection": 66360.99600000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4746888000000007,
        "regulatory_headroom": 10.121412859999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092017212",
      "drug_name": "CARBATROL ER 200 MG CAPSULE",
      "ndc": 54092017212,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.8408828750000004,
        "feasible_range": [
          1.4727063000000002,
          1.9626643575000007
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.1045297250000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.7363531500000002,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 5522.648625000002,
          "annual_profit_projection": 66271.78350000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4727063000000002,
        "regulatory_headroom": 10.123890984999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092017312",
      "drug_name": "CARBATROL ER 300 MG CAPSULE",
      "ndc": 54092017312,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.8377802083333337,
        "feasible_range": [
          1.4702241666666669,
          1.9593564375
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.102668125,
        "profit_projections": {
          "gross_profit_per_unit": 0.7351120833333336,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 5513.340625000002,
          "annual_profit_projection": 66160.08750000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4702241666666669,
        "regulatory_headroom": 10.126993651666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092019112",
      "drug_name": "PENTASA 500 MG CAPSULE",
      "ndc": 54092019112,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.438768147500001,
        "feasible_range": [
          5.050014233333334,
          6.730115122500002
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.7875106750000005,
        "profit_projections": {
          "gross_profit_per_unit": 2.5250071166666674,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 25250.071166666676,
          "annual_profit_projection": 303000.8540000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.050014233333334,
        "regulatory_headroom": 5.65225606833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092038101",
      "drug_name": "ADDERALL XR 5 MG CAPSULE",
      "ndc": 54092038101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.0200482354166684,
        "feasible_range": [
          5.911619566666668,
          7.878369922500002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 4.433714675000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.9558097833333346,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 8867.429350000004,
          "annual_profit_projection": 106409.15220000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.911619566666668,
        "regulatory_headroom": 4.575249401666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092038301",
      "drug_name": "ADDERALL XR 10 MG CAPSULE",
      "ndc": 54092038301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.033786581249999,
        "feasible_range": [
          5.9231887,
          7.8937880174999995
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 4.442391525,
        "profit_projections": {
          "gross_profit_per_unit": 2.9615943500000004,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 8884.783050000002,
          "annual_profit_projection": 106617.39660000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.9231887,
        "regulatory_headroom": 4.5607879849999975,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092038501",
      "drug_name": "ADDERALL XR 15 MG CAPSULE",
      "ndc": 54092038501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.0362926020833365,
        "feasible_range": [
          5.925299033333336,
          7.896600442500003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 4.443974275000002,
        "profit_projections": {
          "gross_profit_per_unit": 2.9626495166666684,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 8887.948550000005,
          "annual_profit_projection": 106655.38260000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.925299033333336,
        "regulatory_headroom": 4.558150068333327,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092038701",
      "drug_name": "ADDERALL XR 20 MG CAPSULE",
      "ndc": 54092038701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.0314267020833325,
        "feasible_range": [
          5.921201433333333,
          7.8911396025
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 4.440901074999999,
        "profit_projections": {
          "gross_profit_per_unit": 2.960600716666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 8881.80215,
          "annual_profit_projection": 106581.6258,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.921201433333333,
        "regulatory_headroom": 4.563272068333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092038901",
      "drug_name": "ADDERALL XR 25 MG CAPSULE",
      "ndc": 54092038901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.032707500000001,
        "feasible_range": [
          5.922280000000001,
          7.892577000000001
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 4.4417100000000005,
        "profit_projections": {
          "gross_profit_per_unit": 2.9611400000000003,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 8883.420000000002,
          "annual_profit_projection": 106601.04000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.922280000000001,
        "regulatory_headroom": 4.561923859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092039101",
      "drug_name": "ADDERALL XR 30 MG CAPSULE",
      "ndc": 54092039101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.0338421562499995,
        "feasible_range": [
          5.9232355,
          7.893850387500001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 4.4424266249999995,
        "profit_projections": {
          "gross_profit_per_unit": 2.9616177500000003,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 8884.85325,
          "annual_profit_projection": 106618.239,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.9232355,
        "regulatory_headroom": 4.560729484999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092046801",
      "drug_name": "MYDAYIS ER 12.5 MG CAPSULE",
      "ndc": 54092046801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.72242608333333,
        "feasible_range": [
          9.377940866666664,
          11.964773859999998
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 7.033455649999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.688970433333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 35167.27824999999,
          "annual_profit_projection": 422007.33899999986,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.377940866666664,
        "regulatory_headroom": 0.2423477766666675,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092047101",
      "drug_name": "MYDAYIS ER 25 MG CAPSULE",
      "ndc": 54092047101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.689643333333334,
        "feasible_range": [
          9.351714666666668,
          11.964773859999998
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 7.0137860000000005,
        "profit_projections": {
          "gross_profit_per_unit": 4.675857333333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 35068.93000000001,
          "annual_profit_projection": 420827.1600000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.351714666666668,
        "regulatory_headroom": 0.27513052666666304,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092047401",
      "drug_name": "MYDAYIS ER 37.5 MG CAPSULE",
      "ndc": 54092047401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.72995525,
        "feasible_range": [
          9.3839642,
          11.964773859999998
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 7.03797315,
        "profit_projections": {
          "gross_profit_per_unit": 4.6919821,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 35189.86575,
          "annual_profit_projection": 422278.38899999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.3839642,
        "regulatory_headroom": 0.23481860999999782,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092047601",
      "drug_name": "LIALDA DR 1.2 GM TABLET",
      "ndc": 54092047601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.734043583333335,
        "feasible_range": [
          7.787234866666668,
          10.377988005000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.840426150000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.8936174333333344,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29202.130750000008,
          "annual_profit_projection": 350425.5690000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.787234866666668,
        "regulatory_headroom": 2.2307302766666623,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092047602",
      "drug_name": "LIALDA DR 1.2 GM TABLET",
      "ndc": 54092047602,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.734043583333335,
        "feasible_range": [
          7.787234866666668,
          10.377988005000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.840426150000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.8936174333333344,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29202.130750000008,
          "annual_profit_projection": 350425.5690000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.787234866666668,
        "regulatory_headroom": 2.2307302766666623,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092047612",
      "drug_name": "LIALDA DR 1.2 GM TABLET",
      "ndc": 54092047612,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.734043583333335,
        "feasible_range": [
          7.787234866666668,
          10.377988005000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.840426150000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.8936174333333344,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 29202.130750000008,
          "annual_profit_projection": 350425.5690000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.787234866666668,
        "regulatory_headroom": 2.2307302766666623,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092047701",
      "drug_name": "MYDAYIS ER 50 MG CAPSULE",
      "ndc": 54092047701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.762511041666668,
        "feasible_range": [
          9.410008833333334,
          11.964773859999998
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 7.057506625000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.705004416666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 35287.533125,
          "annual_profit_projection": 423450.3975,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.410008833333334,
        "regulatory_headroom": 0.20226281833332926,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092051302",
      "drug_name": "INTUNIV ER 1 MG TABLET",
      "ndc": 54092051302,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.162728333333332,
        "feasible_range": [
          8.130182666666665,
          10.835031899999997
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.097636999999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.065091333333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30488.184999999998,
          "annual_profit_projection": 365858.22,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.130182666666665,
        "regulatory_headroom": 1.8020455266666655,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092051502",
      "drug_name": "INTUNIV ER 2 MG TABLET",
      "ndc": 54092051502,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.1008245,
        "feasible_range": [
          8.080659599999999,
          10.769032889999998
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.0604947,
        "profit_projections": {
          "gross_profit_per_unit": 4.0403298,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30302.473500000004,
          "annual_profit_projection": 363629.68200000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.080659599999999,
        "regulatory_headroom": 1.8639493599999977,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092051702",
      "drug_name": "INTUNIV ER 3 MG TABLET",
      "ndc": 54092051702,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.093824541666667,
        "feasible_range": [
          8.075059633333334,
          10.761569857500001
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.056294725,
        "profit_projections": {
          "gross_profit_per_unit": 4.037529816666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30281.473625000002,
          "annual_profit_projection": 363377.68350000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.075059633333334,
        "regulatory_headroom": 1.8709493183333308,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54092051902",
      "drug_name": "INTUNIV ER 4 MG TABLET",
      "ndc": 54092051902,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.07760325,
        "feasible_range": [
          8.062082599999998,
          10.744275465
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.046561949999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.0310413,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30232.80975,
          "annual_profit_projection": 362793.717,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.062082599999998,
        "regulatory_headroom": 1.8871706099999983,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54482014407",
      "drug_name": "CARNITOR 330 MG TABLET",
      "ndc": 54482014407,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.294518333333333,
        "feasible_range": [
          1.0356146666666664,
          1.3801556999999998
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 0.7767109999999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.5178073333333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 3883.554999999999,
          "annual_profit_projection": 46602.65999999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.0356146666666664,
        "regulatory_headroom": 10.670255526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54482014508",
      "drug_name": "CARNITOR 100 MG/ML ORAL SOLN",
      "ndc": 54482014508,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.3680191666666668,
        "feasible_range": [
          0.2944153333333334,
          0.3923650500000001
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 0.22081150000000005,
        "profit_projections": {
          "gross_profit_per_unit": 0.14720766666666674,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 993.6517500000004,
          "annual_profit_projection": 11923.821000000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.2944153333333334,
        "regulatory_headroom": 11.596754693333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54482014509",
      "drug_name": "CARNITOR 1 GM/10 ML ORAL SOLN",
      "ndc": 54482014509,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.3680191666666668,
        "feasible_range": [
          0.2944153333333334,
          0.3923650500000001
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 0.22081150000000005,
        "profit_projections": {
          "gross_profit_per_unit": 0.14720766666666674,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 993.6517500000004,
          "annual_profit_projection": 11923.821000000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.2944153333333334,
        "regulatory_headroom": 11.596754693333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54482014801",
      "drug_name": "CARNITOR SF 100 MG/ML ORAL SOL",
      "ndc": 54482014801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.44643083333333333,
        "feasible_range": [
          0.35714466666666667,
          0.47596395
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.2678585,
        "profit_projections": {
          "gross_profit_per_unit": 0.17857233333333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 1339.2925,
          "annual_profit_projection": 16071.51,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.35714466666666667,
        "regulatory_headroom": 11.518343026666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54766059010",
      "drug_name": "IMURAN 50 MG TABLET",
      "ndc": 54766059010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.5010679075,
        "feasible_range": [
          7.451817966666667,
          9.9309804825
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 5.588863475,
        "profit_projections": {
          "gross_profit_per_unit": 3.7259089833333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 37259.08983333333,
          "annual_profit_projection": 447109.078,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.451817966666667,
        "regulatory_headroom": 2.650001401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54766077245",
      "drug_name": "NAFTIN 2% GEL",
      "ndc": 54766077245,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.645518755000003,
        "feasible_range": [
          9.133740200000002,
          11.964773859999998
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.850305150000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.566870100000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 45668.701000000015,
          "annual_profit_projection": 548024.4120000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.133740200000002,
        "regulatory_headroom": 0.5475986099999943,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_54766077260",
      "drug_name": "NAFTIN 2% GEL",
      "ndc": 54766077260,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605575215000002,
        "feasible_range": [
          9.102411933333334,
          11.964773859999998
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.826808950000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.551205966666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 45512.05966666667,
          "annual_profit_projection": 546144.716,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.102411933333334,
        "regulatory_headroom": 0.5867589433333293,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_55494010010",
      "drug_name": "DICLEGIS DR 10-10 MG TABLET",
      "ndc": 55494010010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.751030100000001,
        "feasible_range": [
          2.157670666666667,
          2.8755111000000007
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 1.6182530000000004,
        "profit_projections": {
          "gross_profit_per_unit": 1.0788353333333338,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 10788.353333333338,
          "annual_profit_projection": 129460.24000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.157670666666667,
        "regulatory_headroom": 9.267685526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_55513007330",
      "drug_name": "SENSIPAR 30 MG TABLET",
      "ndc": 55513007330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 22.394380666666667,
        "feasible_range": [
          22.394380666666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 16.7957855,
        "profit_projections": {
          "gross_profit_per_unit": 5.598595166666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 55985.95166666666,
          "annual_profit_projection": 671831.4199999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 22.394380666666667,
        "regulatory_headroom": -10.42960680666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $16.03"
        ]
      }
    },
    {
      "drug_id": "ndc_55513080060",
      "drug_name": "CORLANOR 5 MG TABLET",
      "ndc": 55513080060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.002066204999998,
        "feasible_range": [
          8.629071533333333,
          11.499897254999999
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.471803649999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.314535766666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 43145.35766666666,
          "annual_profit_projection": 517744.29199999996,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.629071533333333,
        "regulatory_headroom": 1.178434443333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_55513081060",
      "drug_name": "CORLANOR 7.5 MG TABLET",
      "ndc": 55513081060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.008081825,
        "feasible_range": [
          8.633789666666667,
          11.506185075000001
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.47534225,
        "profit_projections": {
          "gross_profit_per_unit": 4.3168948333333335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 43168.948333333334,
          "annual_profit_projection": 518027.38,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.633789666666667,
        "regulatory_headroom": 1.1725367766666643,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_55566260000",
      "drug_name": "DDAVP 0.1 MG TABLET",
      "ndc": 55566260000,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.2635215,
        "feasible_range": [
          6.481193333333333,
          8.6374365
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 4.860894999999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.240596666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 32405.966666666667,
          "annual_profit_projection": 388871.6,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.481193333333333,
        "regulatory_headroom": 3.8632821933333314,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_57844010501",
      "drug_name": "ADDERALL 5 MG TABLET",
      "ndc": 57844010501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.669513100000005,
          11.964773859999998
        ],
        "expected_margin": 0.3619748922209088,
        "estimated_acquisition_cost": 7.252134825000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.712639034999994,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 14137.917104999982,
          "annual_profit_projection": 169655.00525999977,
          "margin_percentage": 39.38761476098634
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.669513100000005,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.12"
        ]
      }
    },
    {
      "drug_id": "ndc_57844011001",
      "drug_name": "ADDERALL 10 MG TABLET",
      "ndc": 57844011001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.705946466666669,
          11.964773859999998
        ],
        "expected_margin": 0.3595709032657407,
        "estimated_acquisition_cost": 7.279459850000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.685314009999996,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 14055.94202999999,
          "annual_profit_projection": 168671.30435999986,
          "margin_percentage": 39.15923581024537
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.705946466666669,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.17"
        ]
      }
    },
    {
      "drug_id": "ndc_57844011501",
      "drug_name": "ADDERALL 15 MG TABLET",
      "ndc": 57844011501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.684001600000004,
          11.964773859999998
        ],
        "expected_margin": 0.36101889509070617,
        "estimated_acquisition_cost": 7.263001200000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.701772659999995,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 14105.317979999985,
          "annual_profit_projection": 169263.81575999982,
          "margin_percentage": 39.296795033617094
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.684001600000004,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.14"
        ]
      }
    },
    {
      "drug_id": "ndc_57844012001",
      "drug_name": "ADDERALL 20 MG TABLET",
      "ndc": 57844012001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.702046033333335,
          11.964773859999998
        ],
        "expected_margin": 0.35982826621381764,
        "estimated_acquisition_cost": 7.2765345250000015,
        "profit_projections": {
          "gross_profit_per_unit": 4.688239334999996,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 14064.718004999988,
          "annual_profit_projection": 168776.61605999985,
          "margin_percentage": 39.18368529031268
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.702046033333335,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.16"
        ]
      }
    },
    {
      "drug_id": "ndc_57844013001",
      "drug_name": "ADDERALL 30 MG TABLET",
      "ndc": 57844013001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.693571766666668,
          11.964773859999998
        ],
        "expected_margin": 0.3603874251753324,
        "estimated_acquisition_cost": 7.270178825000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.694595034999996,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 14083.785104999988,
          "annual_profit_projection": 169005.42125999986,
          "margin_percentage": 39.23680539165658
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.693571766666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.15"
        ]
      }
    },
    {
      "drug_id": "ndc_57844014001",
      "drug_name": "ADIPEX-P 37.5 MG TABLET",
      "ndc": 57844014001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.989969775,
        "feasible_range": [
          2.3450743333333333,
          3.125262525
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 1.7588057499999998,
        "profit_projections": {
          "gross_profit_per_unit": 1.1725371666666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 11725.371666666666,
          "annual_profit_projection": 140704.46,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.3450743333333333,
        "regulatory_headroom": 9.03343094333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_57844014056",
      "drug_name": "ADIPEX-P 37.5 MG TABLET",
      "ndc": 57844014056,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.989969775,
        "feasible_range": [
          2.3450743333333333,
          3.125262525
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 1.7588057499999998,
        "profit_projections": {
          "gross_profit_per_unit": 1.1725371666666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 11725.371666666666,
          "annual_profit_projection": 140704.46,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.3450743333333333,
        "regulatory_headroom": 9.03343094333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151008291",
      "drug_name": "CELEBREX 50 MG CAPSULE",
      "ndc": 58151008291,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.583867166666667,
        "feasible_range": [
          3.860098666666667,
          5.1443238000000004
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 2.895074,
        "profit_projections": {
          "gross_profit_per_unit": 1.9300493333333337,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 5790.148000000001,
          "annual_profit_projection": 69481.77600000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.860098666666667,
        "regulatory_headroom": 7.139650526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151008301",
      "drug_name": "CELEBREX 100 MG CAPSULE",
      "ndc": 58151008301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.844821539583332,
        "feasible_range": [
          8.290376033333333,
          11.048520367499998
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.217782024999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.145188016666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12435.564049999999,
          "annual_profit_projection": 149226.76859999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.290376033333333,
        "regulatory_headroom": 1.601803818333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151008305",
      "drug_name": "CELEBREX 100 MG CAPSULE",
      "ndc": 58151008305,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.844821539583332,
        "feasible_range": [
          8.290376033333333,
          11.048520367499998
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.217782024999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.145188016666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12435.564049999999,
          "annual_profit_projection": 149226.76859999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.290376033333333,
        "regulatory_headroom": 1.601803818333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151008332",
      "drug_name": "CELEBREX 100 MG CAPSULE",
      "ndc": 58151008332,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.844821539583332,
        "feasible_range": [
          8.290376033333333,
          11.048520367499998
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.217782024999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.145188016666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12435.564049999999,
          "annual_profit_projection": 149226.76859999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.290376033333333,
        "regulatory_headroom": 1.601803818333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151008388",
      "drug_name": "CELEBREX 100 MG CAPSULE",
      "ndc": 58151008388,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.844821539583332,
        "feasible_range": [
          8.290376033333333,
          11.048520367499998
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.217782024999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.145188016666666,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12435.564049999999,
          "annual_profit_projection": 149226.76859999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.290376033333333,
        "regulatory_headroom": 1.601803818333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151008401",
      "drug_name": "CELEBREX 200 MG CAPSULE",
      "ndc": 58151008401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.628605033333336,
        "feasible_range": [
          13.628605033333336,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.221453775000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.407151258333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10221.453775000002,
          "annual_profit_projection": 122657.44530000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.628605033333336,
        "regulatory_headroom": -1.6638311733333389,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.07"
        ]
      }
    },
    {
      "drug_id": "ndc_58151008405",
      "drug_name": "CELEBREX 200 MG CAPSULE",
      "ndc": 58151008405,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.628605033333336,
        "feasible_range": [
          13.628605033333336,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.221453775000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.407151258333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10221.453775000002,
          "annual_profit_projection": 122657.44530000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.628605033333336,
        "regulatory_headroom": -1.6638311733333389,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.07"
        ]
      }
    },
    {
      "drug_id": "ndc_58151008488",
      "drug_name": "CELEBREX 200 MG CAPSULE",
      "ndc": 58151008488,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.628605033333336,
        "feasible_range": [
          13.628605033333336,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.221453775000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.407151258333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10221.453775000002,
          "annual_profit_projection": 122657.44530000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.628605033333336,
        "regulatory_headroom": -1.6638311733333389,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.07"
        ]
      }
    },
    {
      "drug_id": "ndc_58151010477",
      "drug_name": "DETROL LA 4 MG CAPSULE",
      "ndc": 58151010477,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.466376566666666,
          11.964773859999998
        ],
        "expected_margin": 0.2812415407406621,
        "estimated_acquisition_cost": 8.599782424999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.3649914349999985,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 25237.43576249999,
          "annual_profit_projection": 302849.2291499999,
          "margin_percentage": 28.12415407406621
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.466376566666666,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.37"
        ]
      }
    },
    {
      "drug_id": "ndc_58151010493",
      "drug_name": "DETROL LA 4 MG CAPSULE",
      "ndc": 58151010493,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.466376566666666,
          11.964773859999998
        ],
        "expected_margin": 0.2812415407406621,
        "estimated_acquisition_cost": 8.599782424999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.3649914349999985,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 25237.43576249999,
          "annual_profit_projection": 302849.2291499999,
          "margin_percentage": 28.12415407406621
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.466376566666666,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.37"
        ]
      }
    },
    {
      "drug_id": "ndc_58151011001",
      "drug_name": "DILANTIN 100 MG CAPSULE",
      "ndc": 58151011001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.7451294250000002,
        "feasible_range": [
          1.4392820000000002,
          1.91812005
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 1.0794615,
        "profit_projections": {
          "gross_profit_per_unit": 0.7196410000000002,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 3598.205000000001,
          "annual_profit_projection": 43178.46000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4392820000000002,
        "regulatory_headroom": 10.165671359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151011032",
      "drug_name": "DILANTIN 100 MG CAPSULE",
      "ndc": 58151011032,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.7451294250000002,
        "feasible_range": [
          1.4392820000000002,
          1.91812005
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 1.0794615,
        "profit_projections": {
          "gross_profit_per_unit": 0.7196410000000002,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 3598.205000000001,
          "annual_profit_projection": 43178.46000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4392820000000002,
        "regulatory_headroom": 10.165671359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151011088",
      "drug_name": "DILANTIN 100 MG CAPSULE",
      "ndc": 58151011088,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.7451294250000002,
        "feasible_range": [
          1.4392820000000002,
          1.91812005
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 1.0794615,
        "profit_projections": {
          "gross_profit_per_unit": 0.7196410000000002,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 3598.205000000001,
          "annual_profit_projection": 43178.46000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4392820000000002,
        "regulatory_headroom": 10.165671359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151012577",
      "drug_name": "EFFEXOR XR 37.5 MG CAPSULE",
      "ndc": 58151012577,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.58510386666667,
        "feasible_range": [
          14.58510386666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 10.938827900000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.6462759666666678,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10938.827900000004,
          "annual_profit_projection": 131265.93480000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.58510386666667,
        "regulatory_headroom": -2.6203300066666717,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.27"
        ]
      }
    },
    {
      "drug_id": "ndc_58151012593",
      "drug_name": "EFFEXOR XR 37.5 MG CAPSULE",
      "ndc": 58151012593,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.58510386666667,
        "feasible_range": [
          14.58510386666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 10.938827900000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.6462759666666678,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10938.827900000004,
          "annual_profit_projection": 131265.93480000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.58510386666667,
        "regulatory_headroom": -2.6203300066666717,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.27"
        ]
      }
    },
    {
      "drug_id": "ndc_58151012677",
      "drug_name": "EFFEXOR XR 75 MG CAPSULE",
      "ndc": 58151012677,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.376915533333335,
        "feasible_range": [
          16.376915533333335,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.282686650000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.094228883333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12282.686649999998,
          "annual_profit_projection": 147392.23979999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.376915533333335,
        "regulatory_headroom": -4.412141673333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.51"
        ]
      }
    },
    {
      "drug_id": "ndc_58151012693",
      "drug_name": "EFFEXOR XR 75 MG CAPSULE",
      "ndc": 58151012693,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.376915533333335,
        "feasible_range": [
          16.376915533333335,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 12.282686650000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.094228883333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12282.686649999998,
          "annual_profit_projection": 147392.23979999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.376915533333335,
        "regulatory_headroom": -4.412141673333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.51"
        ]
      }
    },
    {
      "drug_id": "ndc_58151012777",
      "drug_name": "EFFEXOR XR 150 MG CAPSULE",
      "ndc": 58151012777,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.809430600000002,
        "feasible_range": [
          17.809430600000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.357072950000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.4523576500000015,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13357.072950000005,
          "annual_profit_projection": 160284.87540000008,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.809430600000002,
        "regulatory_headroom": -5.844656740000005,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.30"
        ]
      }
    },
    {
      "drug_id": "ndc_58151014293",
      "drug_name": "INSPRA 25 MG TABLET",
      "ndc": 58151014293,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.279704666666667,
        "feasible_range": [
          12.279704666666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.2097785,
        "profit_projections": {
          "gross_profit_per_unit": 3.069926166666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 30699.26166666667,
          "annual_profit_projection": 368391.14,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.279704666666667,
        "regulatory_headroom": -0.31493080666666984,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.38"
        ]
      }
    },
    {
      "drug_id": "ndc_58151015577",
      "drug_name": "LIPITOR 10 MG TABLET",
      "ndc": 58151015577,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.060003066666667,
          11.964773859999998
        ],
        "expected_margin": 0.28527284652861795,
        "estimated_acquisition_cost": 8.2950023,
        "profit_projections": {
          "gross_profit_per_unit": 3.6697715599999974,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18348.857799999987,
          "annual_profit_projection": 220186.29359999986,
          "margin_percentage": 30.67146611327594
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.060003066666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.86"
        ]
      }
    },
    {
      "drug_id": "ndc_58151015677",
      "drug_name": "LIPITOR 20 MG TABLET",
      "ndc": 58151015677,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.81416026666667,
        "feasible_range": [
          15.81416026666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.860620200000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.953540066666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19767.700333333334,
          "annual_profit_projection": 237212.404,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.81416026666667,
        "regulatory_headroom": -3.8493864066666728,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.80"
        ]
      }
    },
    {
      "drug_id": "ndc_58151015777",
      "drug_name": "LIPITOR 40 MG TABLET",
      "ndc": 58151015777,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.848492400000005,
        "feasible_range": [
          15.848492400000005,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.886369300000004,
        "profit_projections": {
          "gross_profit_per_unit": 3.9621231000000012,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19810.615500000007,
          "annual_profit_projection": 237727.3860000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.848492400000005,
        "regulatory_headroom": -3.8837185400000074,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.85"
        ]
      }
    },
    {
      "drug_id": "ndc_58151015877",
      "drug_name": "LIPITOR 80 MG TABLET",
      "ndc": 58151015877,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.902466666666667,
        "feasible_range": [
          15.902466666666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.92685,
        "profit_projections": {
          "gross_profit_per_unit": 3.9756166666666672,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 19878.083333333336,
          "annual_profit_projection": 238537.00000000003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.902466666666667,
        "regulatory_headroom": -3.9376928066666697,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.91"
        ]
      }
    },
    {
      "drug_id": "ndc_58151023677",
      "drug_name": "LYRICA 25 MG CAPSULE",
      "ndc": 58151023677,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.97887204166667,
        "feasible_range": [
          8.40326066666667,
          11.198960850000004
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.302445500000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.201630333333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12604.891000000005,
          "annual_profit_projection": 151258.69200000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.40326066666667,
        "regulatory_headroom": 1.4606980266666607,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151023732",
      "drug_name": "LYRICA 50 MG CAPSULE",
      "ndc": 58151023732,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.990345779761906,
        "feasible_range": [
          8.412922761904763,
          11.211837450000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.3096920714285725,
        "profit_projections": {
          "gross_profit_per_unit": 4.2064613809523825,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 11357.445728571432,
          "annual_profit_projection": 136289.3487428572,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.412922761904763,
        "regulatory_headroom": 1.4486204076190425,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151023777",
      "drug_name": "LYRICA 50 MG CAPSULE",
      "ndc": 58151023777,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.990345779761906,
        "feasible_range": [
          8.412922761904763,
          11.211837450000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.3096920714285725,
        "profit_projections": {
          "gross_profit_per_unit": 4.2064613809523825,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 11357.445728571432,
          "annual_profit_projection": 136289.3487428572,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.412922761904763,
        "regulatory_headroom": 1.4486204076190425,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151023788",
      "drug_name": "LYRICA 50 MG CAPSULE",
      "ndc": 58151023788,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.990345779761906,
        "feasible_range": [
          8.412922761904763,
          11.211837450000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 6.3096920714285725,
        "profit_projections": {
          "gross_profit_per_unit": 4.2064613809523825,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 11357.445728571432,
          "annual_profit_projection": 136289.3487428572,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.412922761904763,
        "regulatory_headroom": 1.4486204076190425,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151024032",
      "drug_name": "LYRICA 150 MG CAPSULE",
      "ndc": 58151024032,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.97179431547619,
        "feasible_range": [
          8.397300476190475,
          11.19101775
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.297975357142857,
        "profit_projections": {
          "gross_profit_per_unit": 4.198650238095238,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12595.950714285715,
          "annual_profit_projection": 151151.40857142856,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.397300476190475,
        "regulatory_headroom": 1.4681482647619024,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151024077",
      "drug_name": "LYRICA 150 MG CAPSULE",
      "ndc": 58151024077,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.97179431547619,
        "feasible_range": [
          8.397300476190475,
          11.19101775
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.297975357142857,
        "profit_projections": {
          "gross_profit_per_unit": 4.198650238095238,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12595.950714285715,
          "annual_profit_projection": 151151.40857142856,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.397300476190475,
        "regulatory_headroom": 1.4681482647619024,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151024088",
      "drug_name": "LYRICA 150 MG CAPSULE",
      "ndc": 58151024088,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.97179431547619,
        "feasible_range": [
          8.397300476190475,
          11.19101775
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 6.297975357142857,
        "profit_projections": {
          "gross_profit_per_unit": 4.198650238095238,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 12595.950714285715,
          "annual_profit_projection": 151151.40857142856,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.397300476190475,
        "regulatory_headroom": 1.4681482647619024,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151031052",
      "drug_name": "NITROSTAT 0.4 MG TABLET SL",
      "ndc": 58151031052,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6797625000000005,
        "feasible_range": [
          1.3438100000000004,
          1.7908852500000005
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.0078575000000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.6719050000000002,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 5039.287500000001,
          "annual_profit_projection": 60471.45000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3438100000000004,
        "regulatory_headroom": 10.285011359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151031094",
      "drug_name": "NITROSTAT 0.4 MG TABLET SL",
      "ndc": 58151031094,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.6797625000000005,
        "feasible_range": [
          1.3438100000000004,
          1.7908852500000005
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.0078575000000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.6719050000000002,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 5039.287500000001,
          "annual_profit_projection": 60471.45000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.3438100000000004,
        "regulatory_headroom": 10.285011359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151035377",
      "drug_name": "NORVASC 2.5 MG TABLET",
      "ndc": 58151035377,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.460675220833338,
        "feasible_range": [
          7.124779133333337,
          9.495138345000004
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 5.343584350000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.5623895666666687,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10687.168700000006,
          "annual_profit_projection": 128246.02440000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.124779133333337,
        "regulatory_headroom": 3.0587999433333266,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151035430",
      "drug_name": "NORVASC 5 MG TABLET",
      "ndc": 58151035430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.523589208333334,
        "feasible_range": [
          7.177759333333334,
          9.565744650000001
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 5.383319500000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.588879666666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10766.639000000001,
          "annual_profit_projection": 129199.668,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.177759333333334,
        "regulatory_headroom": 2.9925746933333297,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151035432",
      "drug_name": "NORVASC 5 MG TABLET",
      "ndc": 58151035432,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.533506258333333,
        "feasible_range": [
          7.1861105333333315,
          9.576874229999998
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 5.389582899999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.593055266666667,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 9701.249220000002,
          "annual_profit_projection": 116414.99064000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.1861105333333315,
        "regulatory_headroom": 2.9821356933333316,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151035477",
      "drug_name": "NORVASC 5 MG TABLET",
      "ndc": 58151035477,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.523589208333336,
        "feasible_range": [
          7.177759333333335,
          9.565744650000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 5.383319500000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.588879666666668,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 10766.639000000005,
          "annual_profit_projection": 129199.66800000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.177759333333335,
        "regulatory_headroom": 2.992574693333328,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151035488",
      "drug_name": "NORVASC 5 MG TABLET",
      "ndc": 58151035488,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.533506258333333,
        "feasible_range": [
          7.1861105333333315,
          9.576874229999998
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 5.389582899999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.593055266666667,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 9701.249220000002,
          "annual_profit_projection": 116414.99064000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.1861105333333315,
        "regulatory_headroom": 2.9821356933333316,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58151035532",
      "drug_name": "NORVASC 10 MG TABLET",
      "ndc": 58151035532,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.808158533333332,
          11.964773859999998
        ],
        "expected_margin": 0.35282662729476943,
        "estimated_acquisition_cost": 7.356118899999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.608654959999998,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13825.964879999994,
          "annual_profit_projection": 165911.57855999994,
          "margin_percentage": 38.518529593003095
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.808158533333332,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.30"
        ]
      }
    },
    {
      "drug_id": "ndc_58151035577",
      "drug_name": "NORVASC 10 MG TABLET",
      "ndc": 58151035577,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.808158533333332,
          11.964773859999998
        ],
        "expected_margin": 0.35282662729476943,
        "estimated_acquisition_cost": 7.356118899999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.608654959999998,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13825.964879999994,
          "annual_profit_projection": 165911.57855999994,
          "margin_percentage": 38.518529593003095
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.808158533333332,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.30"
        ]
      }
    },
    {
      "drug_id": "ndc_58151035588",
      "drug_name": "NORVASC 10 MG TABLET",
      "ndc": 58151035588,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          9.808158533333332,
          11.964773859999998
        ],
        "expected_margin": 0.35282662729476943,
        "estimated_acquisition_cost": 7.356118899999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.608654959999998,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 13825.964879999994,
          "annual_profit_projection": 165911.57855999994,
          "margin_percentage": 38.518529593003095
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.808158533333332,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.30"
        ]
      }
    },
    {
      "drug_id": "ndc_58151036832",
      "drug_name": "RELPAX 40 MG TABLET",
      "ndc": 58151036832,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 67.01014536666668,
        "feasible_range": [
          67.01014536666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 50.25760902500001,
        "profit_projections": {
          "gross_profit_per_unit": 16.75253634166667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 83762.68170833334,
          "annual_profit_projection": 1005152.1805000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 67.01014536666668,
        "regulatory_headroom": -55.04537150666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $71.80"
        ]
      }
    },
    {
      "drug_id": "ndc_58151036856",
      "drug_name": "RELPAX 40 MG TABLET",
      "ndc": 58151036856,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 67.01014536666668,
        "feasible_range": [
          67.01014536666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 50.25760902500001,
        "profit_projections": {
          "gross_profit_per_unit": 16.75253634166667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 83762.68170833334,
          "annual_profit_projection": 1005152.1805000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 67.01014536666668,
        "regulatory_headroom": -55.04537150666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $71.80"
        ]
      }
    },
    {
      "drug_id": "ndc_58151036896",
      "drug_name": "RELPAX 40 MG TABLET",
      "ndc": 58151036896,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 67.15952273333333,
        "feasible_range": [
          67.15952273333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 50.36964205,
        "profit_projections": {
          "gross_profit_per_unit": 16.78988068333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 83949.40341666665,
          "annual_profit_projection": 1007392.8409999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 67.15952273333333,
        "regulatory_headroom": -55.19474887333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $71.98"
        ]
      }
    },
    {
      "drug_id": "ndc_58151041935",
      "drug_name": "XALATAN 0.005% EYE DROPS",
      "ndc": 58151041935,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 89.73711586666668,
        "feasible_range": [
          89.73711586666668,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 67.30283690000002,
        "profit_projections": {
          "gross_profit_per_unit": 22.434278966666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 224342.78966666668,
          "annual_profit_projection": 2692113.4760000003,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 89.73711586666668,
        "regulatory_headroom": -77.77234200666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $100.21"
        ]
      }
    },
    {
      "drug_id": "ndc_58151057493",
      "drug_name": "ZOLOFT 25 MG TABLET",
      "ndc": 58151057493,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.394581333333337,
        "feasible_range": [
          12.394581333333337,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.295936000000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.0986453333333337,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15493.22666666667,
          "annual_profit_projection": 185918.72000000003,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.394581333333337,
        "regulatory_headroom": -0.429807473333339,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.53"
        ]
      }
    },
    {
      "drug_id": "ndc_58151057693",
      "drug_name": "ZOLOFT 100 MG TABLET",
      "ndc": 58151057693,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.355538000000005,
        "feasible_range": [
          12.355538000000005,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 9.266653500000004,
        "profit_projections": {
          "gross_profit_per_unit": 3.0888845000000007,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 15444.422500000004,
          "annual_profit_projection": 185333.07000000007,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.355538000000005,
        "regulatory_headroom": -0.39076414000000703,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.48"
        ]
      }
    },
    {
      "drug_id": "ndc_58151060135",
      "drug_name": "ZOLOFT 20 MG/ML ORAL CONC",
      "ndc": 58151060135,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.779788975,
        "feasible_range": [
          3.9420939999999995,
          5.25359835
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 2.9565704999999998,
        "profit_projections": {
          "gross_profit_per_unit": 1.9710470000000004,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 8869.711500000001,
          "annual_profit_projection": 106436.53800000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.9420939999999995,
        "regulatory_headroom": 7.037156359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58468013001",
      "drug_name": "RENVELA 800 MG TABLET",
      "ndc": 58468013001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.005148386249999,
        "feasible_range": [
          4.952699699999999,
          6.600424792499999
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 3.7145247749999992,
        "profit_projections": {
          "gross_profit_per_unit": 2.47634985,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 11143.574325,
          "annual_profit_projection": 133722.8919,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.952699699999999,
        "regulatory_headroom": 5.773899234999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58468013101",
      "drug_name": "RENVELA 2.4 GM POWDER PACKET",
      "ndc": 58468013101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.897065733333337,
        "feasible_range": [
          14.897065733333337,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.172799300000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.7242664333333337,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18621.332166666667,
          "annual_profit_projection": 223455.986,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.897065733333337,
        "regulatory_headroom": -2.932291873333339,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.66"
        ]
      }
    },
    {
      "drug_id": "ndc_58468013102",
      "drug_name": "RENVELA 2.4 GM POWDER PACKET",
      "ndc": 58468013102,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.897065733333337,
        "feasible_range": [
          14.897065733333337,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.172799300000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.7242664333333337,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18621.332166666667,
          "annual_profit_projection": 223455.986,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.897065733333337,
        "regulatory_headroom": -2.932291873333339,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.66"
        ]
      }
    },
    {
      "drug_id": "ndc_58468013201",
      "drug_name": "RENVELA 0.8 GM POWDER PACKET",
      "ndc": 58468013201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.869032966666667,
        "feasible_range": [
          14.869032966666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.151774725000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.7172582416666664,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18586.291208333332,
          "annual_profit_projection": 223035.49449999997,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.869032966666667,
        "regulatory_headroom": -2.90425910666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.62"
        ]
      }
    },
    {
      "drug_id": "ndc_58468013202",
      "drug_name": "RENVELA 0.8 GM POWDER PACKET",
      "ndc": 58468013202,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.869032966666667,
        "feasible_range": [
          14.869032966666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.151774725000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.7172582416666664,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 18586.291208333332,
          "annual_profit_projection": 223035.49449999997,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.869032966666667,
        "regulatory_headroom": -2.90425910666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.62"
        ]
      }
    },
    {
      "drug_id": "ndc_58468013301",
      "drug_name": "RENVELA 800 MG TABLET",
      "ndc": 58468013301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.005148386249999,
        "feasible_range": [
          4.952699699999999,
          6.600424792499999
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 3.7145247749999992,
        "profit_projections": {
          "gross_profit_per_unit": 2.47634985,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 11143.574325,
          "annual_profit_projection": 133722.8919,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.952699699999999,
        "regulatory_headroom": 5.773899234999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58809055508",
      "drug_name": "VANACOF DM 18-200-10 MG/15 ML",
      "ndc": 58809055508,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.10779606500000001,
        "feasible_range": [
          0.08454593333333334,
          0.11267371500000001
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 0.06340945,
        "profit_projections": {
          "gross_profit_per_unit": 0.042272966666666675,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 422.72966666666673,
          "annual_profit_projection": 5072.756000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.08454593333333334,
        "regulatory_headroom": 11.85909144333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58914017014",
      "drug_name": "CARAFATE 1 GM/10 ML SUSP",
      "ndc": 58914017014,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.6737472300000001,
        "feasible_range": [
          0.5284292,
          0.7042335300000001
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.3963219,
        "profit_projections": {
          "gross_profit_per_unit": 0.2642146000000001,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 2377.931400000001,
          "annual_profit_projection": 28535.17680000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.5284292,
        "regulatory_headroom": 11.304237359999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58914017110",
      "drug_name": "CARAFATE 1 GM TABLET",
      "ndc": 58914017110,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.263773580000002,
        "feasible_range": [
          4.128449866666668,
          5.5019533800000024
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.0963374000000012,
        "profit_projections": {
          "gross_profit_per_unit": 2.0642249333333345,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 20642.249333333344,
          "annual_profit_projection": 247706.99200000014,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.128449866666668,
        "regulatory_headroom": 6.804211526666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_58914030180",
      "drug_name": "RECTIV 0.4% OINTMENT",
      "ndc": 58914030180,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 17.761152500000005,
        "feasible_range": [
          17.761152500000005,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 13.320864375000005,
        "profit_projections": {
          "gross_profit_per_unit": 4.440288125,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44402.881250000006,
          "annual_profit_projection": 532834.5750000001,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.761152500000005,
        "regulatory_headroom": -5.7963786400000075,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.24"
        ]
      }
    },
    {
      "drug_id": "ndc_58914050156",
      "drug_name": "CANASA 1,000 MG SUPPOSITORY",
      "ndc": 58914050156,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 32.1965475,
        "feasible_range": [
          32.1965475,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 24.147410625000003,
        "profit_projections": {
          "gross_profit_per_unit": 8.049136874999999,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 80491.36874999998,
          "annual_profit_projection": 965896.4249999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 32.1965475,
        "regulatory_headroom": -20.231773640000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $28.28"
        ]
      }
    },
    {
      "drug_id": "ndc_58914060120",
      "drug_name": "PYLERA CAPSULE",
      "ndc": 58914060120,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.6872323725,
        "feasible_range": [
          2.1076332333333334,
          2.8088265975000004
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 1.580724925,
        "profit_projections": {
          "gross_profit_per_unit": 1.0538166166666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 10538.166166666668,
          "annual_profit_projection": 126457.994,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.1076332333333334,
        "regulatory_headroom": 9.33023231833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_59011027160",
      "drug_name": "HYSINGLA ER 20 MG TABLET",
      "ndc": 59011027160,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.622724666666667,
          11.964773859999998
        ],
        "expected_margin": 0.33412502457443005,
        "estimated_acquisition_cost": 7.9670435,
        "profit_projections": {
          "gross_profit_per_unit": 3.9977303599999976,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 39977.30359999998,
          "annual_profit_projection": 479727.6431999997,
          "margin_percentage": 33.412502457443004
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.622724666666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.31"
        ]
      }
    },
    {
      "drug_id": "ndc_59011042010",
      "drug_name": "OXYCONTIN ER 20 MG TABLET",
      "ndc": 59011042010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.931855729166669,
        "feasible_range": [
          8.745484583333335,
          11.655040031250003
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 6.559113437500001,
        "profit_projections": {
          "gross_profit_per_unit": 4.372742291666668,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 29516.01046875001,
          "annual_profit_projection": 354192.1256250001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.745484583333335,
        "regulatory_headroom": 1.0329181308333286,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_59011042020",
      "drug_name": "OXYCONTIN ER 20 MG TABLET",
      "ndc": 59011042020,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.931855729166669,
        "feasible_range": [
          8.745484583333335,
          11.655040031250003
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 6.559113437500001,
        "profit_projections": {
          "gross_profit_per_unit": 4.372742291666668,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 29516.01046875001,
          "annual_profit_projection": 354192.1256250001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.745484583333335,
        "regulatory_headroom": 1.0329181308333286,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_59011044010",
      "drug_name": "OXYCONTIN ER 40 MG TABLET",
      "ndc": 59011044010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.985960708333335,
        "feasible_range": [
          14.985960708333335,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.239470531250001,
        "profit_projections": {
          "gross_profit_per_unit": 3.7464901770833343,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28098.676328125006,
          "annual_profit_projection": 337184.1159375001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.985960708333335,
        "regulatory_headroom": -3.021186848333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.77"
        ]
      }
    },
    {
      "drug_id": "ndc_59011044020",
      "drug_name": "OXYCONTIN ER 40 MG TABLET",
      "ndc": 59011044020,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.985960708333335,
        "feasible_range": [
          14.985960708333335,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 11.239470531250001,
        "profit_projections": {
          "gross_profit_per_unit": 3.7464901770833343,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28098.676328125006,
          "annual_profit_projection": 337184.1159375001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.985960708333335,
        "regulatory_headroom": -3.021186848333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.77"
        ]
      }
    },
    {
      "drug_id": "ndc_59011075004",
      "drug_name": "BUTRANS 5 MCG/HR PATCH",
      "ndc": 59011075004,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 42.47113216666666,
        "feasible_range": [
          42.47113216666666,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 31.853349124999998,
        "profit_projections": {
          "gross_profit_per_unit": 10.617783041666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 79633.37281249999,
          "annual_profit_projection": 955600.4737499999,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 42.47113216666666,
        "regulatory_headroom": -30.506358306666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $41.12"
        ]
      }
    },
    {
      "drug_id": "ndc_59011075104",
      "drug_name": "BUTRANS 10 MCG/HR PATCH",
      "ndc": 59011075104,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 63.980838566666705,
        "feasible_range": [
          63.980838566666705,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 47.98562892500003,
        "profit_projections": {
          "gross_profit_per_unit": 15.995209641666676,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 119964.07231250007,
          "annual_profit_projection": 1439568.8677500007,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 63.980838566666705,
        "regulatory_headroom": -52.01606470666671,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $68.01"
        ]
      }
    },
    {
      "drug_id": "ndc_59011075204",
      "drug_name": "BUTRANS 20 MCG/HR PATCH",
      "ndc": 59011075204,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 113.83029883333337,
        "feasible_range": [
          113.83029883333337,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 85.37272412500003,
        "profit_projections": {
          "gross_profit_per_unit": 28.45757470833334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 213431.81031250005,
          "annual_profit_projection": 2561181.723750001,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 113.83029883333337,
        "regulatory_headroom": -101.86552497333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $130.32"
        ]
      }
    },
    {
      "drug_id": "ndc_59011075704",
      "drug_name": "BUTRANS 7.5 MCG/HR PATCH",
      "ndc": 59011075704,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 59.65207776666668,
        "feasible_range": [
          59.65207776666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 44.73905832500001,
        "profit_projections": {
          "gross_profit_per_unit": 14.91301944166667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 111847.64581250002,
          "annual_profit_projection": 1342171.7497500002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 59.65207776666668,
        "regulatory_headroom": -47.687303906666685,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $62.60"
        ]
      }
    },
    {
      "drug_id": "ndc_59011075804",
      "drug_name": "BUTRANS 15 MCG/HR PATCH",
      "ndc": 59011075804,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 108.24146146666665,
        "feasible_range": [
          108.24146146666665,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 81.18109609999999,
        "profit_projections": {
          "gross_profit_per_unit": 27.06036536666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 202952.74024999994,
          "annual_profit_projection": 2435432.8829999994,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 108.24146146666665,
        "regulatory_headroom": -96.27668760666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $123.34"
        ]
      }
    },
    {
      "drug_id": "ndc_59148000613",
      "drug_name": "ABILIFY 2 MG TABLET",
      "ndc": 59148000613,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.194520333333333,
        "feasible_range": [
          16.194520333333333,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 12.145890249999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.048630083333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20243.15041666667,
          "annual_profit_projection": 242917.80500000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.194520333333333,
        "regulatory_headroom": -4.229746473333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.28"
        ]
      }
    },
    {
      "drug_id": "ndc_59148000713",
      "drug_name": "ABILIFY 5 MG TABLET",
      "ndc": 59148000713,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.232713900000004,
        "feasible_range": [
          16.232713900000004,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 12.174535425000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.058178475000002,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20290.89237500001,
          "annual_profit_projection": 243490.70850000012,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.232713900000004,
        "regulatory_headroom": -4.267940040000006,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.33"
        ]
      }
    },
    {
      "drug_id": "ndc_59148000813",
      "drug_name": "ABILIFY 10 MG TABLET",
      "ndc": 59148000813,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.213933233333336,
        "feasible_range": [
          16.213933233333336,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 12.160449925000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.053483308333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20267.41654166667,
          "annual_profit_projection": 243208.99850000005,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.213933233333336,
        "regulatory_headroom": -4.249159373333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.30"
        ]
      }
    },
    {
      "drug_id": "ndc_59148000913",
      "drug_name": "ABILIFY 15 MG TABLET",
      "ndc": 59148000913,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 16.176818666666673,
        "feasible_range": [
          16.176818666666673,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 12.132614000000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.044204666666669,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20221.023333333345,
          "annual_profit_projection": 242652.28000000014,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 16.176818666666673,
        "regulatory_headroom": -4.212044806666675,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.26"
        ]
      }
    },
    {
      "drug_id": "ndc_59148001013",
      "drug_name": "ABILIFY 20 MG TABLET",
      "ndc": 59148001013,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 22.902340500000005,
        "feasible_range": [
          22.902340500000005,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 17.176755375000003,
        "profit_projections": {
          "gross_profit_per_unit": 5.725585125000002,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 28627.92562500001,
          "annual_profit_projection": 343535.10750000016,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 22.902340500000005,
        "regulatory_headroom": -10.937566640000007,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $16.66"
        ]
      }
    },
    {
      "drug_id": "ndc_59148001113",
      "drug_name": "ABILIFY 30 MG TABLET",
      "ndc": 59148001113,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 22.859839166666678,
        "feasible_range": [
          22.859839166666678,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 17.14487937500001,
        "profit_projections": {
          "gross_profit_per_unit": 5.714959791666669,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 28574.798958333344,
          "annual_profit_projection": 342897.58750000014,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 22.859839166666678,
        "regulatory_headroom": -10.89506530666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $16.61"
        ]
      }
    },
    {
      "drug_id": "ndc_59310081206",
      "drug_name": "AIRDUO RESPICLICK 113-14 MCG",
      "ndc": 59310081206,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 334.2352676000001,
        "feasible_range": [
          334.2352676000001,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 250.67645070000006,
        "profit_projections": {
          "gross_profit_per_unit": 83.55881690000004,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 835588.1690000003,
          "annual_profit_projection": 10027058.028000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 334.2352676000001,
        "regulatory_headroom": -322.2704937400001,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $405.83"
        ]
      }
    },
    {
      "drug_id": "ndc_59310082206",
      "drug_name": "AIRDUO RESPICLICK 232-14 MCG",
      "ndc": 59310082206,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 335.02669199999997,
        "feasible_range": [
          335.02669199999997,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 251.270019,
        "profit_projections": {
          "gross_profit_per_unit": 83.75667299999998,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 837566.7299999997,
          "annual_profit_projection": 10050800.759999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 335.02669199999997,
        "regulatory_headroom": -323.06191814,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $406.82"
        ]
      }
    },
    {
      "drug_id": "ndc_59417010110",
      "drug_name": "VYVANSE 10 MG CAPSULE",
      "ndc": 59417010110,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.727581366666664,
          11.964773859999998
        ],
        "expected_margin": 0.2921601959796232,
        "estimated_acquisition_cost": 8.045686024999998,
        "profit_projections": {
          "gross_profit_per_unit": 3.919087834999999,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11757.263504999997,
          "annual_profit_projection": 141087.16205999997,
          "margin_percentage": 32.75521861806421
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.727581366666664,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.44"
        ]
      }
    },
    {
      "drug_id": "ndc_59417010210",
      "drug_name": "VYVANSE 20 MG CAPSULE",
      "ndc": 59417010210,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.7339817,
          11.964773859999998
        ],
        "expected_margin": 0.29173788170975345,
        "estimated_acquisition_cost": 8.050486274999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.9142875849999985,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11742.862754999995,
          "annual_profit_projection": 140914.35305999994,
          "margin_percentage": 32.71509876242658
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.7339817,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.45"
        ]
      }
    },
    {
      "drug_id": "ndc_59417010310",
      "drug_name": "VYVANSE 30 MG CAPSULE",
      "ndc": 59417010310,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.736699133333333,
          11.964773859999998
        ],
        "expected_margin": 0.2915585768494721,
        "estimated_acquisition_cost": 8.05252435,
        "profit_projections": {
          "gross_profit_per_unit": 3.912249509999997,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11736.748529999992,
          "annual_profit_projection": 140840.9823599999,
          "margin_percentage": 32.69806480069986
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.736699133333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.46"
        ]
      }
    },
    {
      "drug_id": "ndc_59417010410",
      "drug_name": "VYVANSE 40 MG CAPSULE",
      "ndc": 59417010410,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.738463666666668,
          11.964773859999998
        ],
        "expected_margin": 0.2914421473500199,
        "estimated_acquisition_cost": 8.053847750000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.9109261099999966,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11732.77832999999,
          "annual_profit_projection": 140793.3399599999,
          "margin_percentage": 32.687003998251896
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.738463666666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.46"
        ]
      }
    },
    {
      "drug_id": "ndc_59417010510",
      "drug_name": "VYVANSE 50 MG CAPSULE",
      "ndc": 59417010510,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.73931516666667,
          11.964773859999998
        ],
        "expected_margin": 0.2913859626824305,
        "estimated_acquisition_cost": 8.054486375000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.910287484999996,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11730.862454999988,
          "annual_profit_projection": 140770.34945999985,
          "margin_percentage": 32.6816664548309
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.73931516666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.46"
        ]
      }
    },
    {
      "drug_id": "ndc_59417010610",
      "drug_name": "VYVANSE 60 MG CAPSULE",
      "ndc": 59417010610,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.738484466666668,
          11.964773859999998
        ],
        "expected_margin": 0.2914407749001246,
        "estimated_acquisition_cost": 8.05386335,
        "profit_projections": {
          "gross_profit_per_unit": 3.9109105099999972,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11732.731529999992,
          "annual_profit_projection": 140792.7783599999,
          "margin_percentage": 32.68687361551185
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.738484466666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.46"
        ]
      }
    },
    {
      "drug_id": "ndc_59417010710",
      "drug_name": "VYVANSE 70 MG CAPSULE",
      "ndc": 59417010710,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.7330002,
          11.964773859999998
        ],
        "expected_margin": 0.2918026441891884,
        "estimated_acquisition_cost": 8.04975015,
        "profit_projections": {
          "gross_profit_per_unit": 3.915023709999998,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11745.071129999995,
          "annual_profit_projection": 140940.85355999993,
          "margin_percentage": 32.721251197972904
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.7330002,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.45"
        ]
      }
    },
    {
      "drug_id": "ndc_59417011501",
      "drug_name": "VYVANSE 10 MG CHEWABLE TABLET",
      "ndc": 59417011501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.7356028,
          11.964773859999998
        ],
        "expected_margin": 0.29163091639603755,
        "estimated_acquisition_cost": 8.0517021,
        "profit_projections": {
          "gross_profit_per_unit": 3.9130717599999976,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11739.215279999993,
          "annual_profit_projection": 140870.58335999993,
          "margin_percentage": 32.704937057623575
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.7356028,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.45"
        ]
      }
    },
    {
      "drug_id": "ndc_59417011601",
      "drug_name": "VYVANSE 20 MG CHEWABLE TABLET",
      "ndc": 59417011601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.734986600000001,
          11.964773859999998
        ],
        "expected_margin": 0.291671575224186,
        "estimated_acquisition_cost": 8.051239950000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.9135339099999964,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11740.60172999999,
          "annual_profit_projection": 140887.22075999988,
          "margin_percentage": 32.708799646297685
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.734986600000001,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.45"
        ]
      }
    },
    {
      "drug_id": "ndc_59417011701",
      "drug_name": "VYVANSE 30 MG CHEWABLE TABLET",
      "ndc": 59417011701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.733167466666664,
          11.964773859999998
        ],
        "expected_margin": 0.29179160740461374,
        "estimated_acquisition_cost": 8.049875599999998,
        "profit_projections": {
          "gross_profit_per_unit": 3.9148982599999993,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11744.694779999998,
          "annual_profit_projection": 140936.33735999998,
          "margin_percentage": 32.72020270343831
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.733167466666664,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.45"
        ]
      }
    },
    {
      "drug_id": "ndc_59417011801",
      "drug_name": "VYVANSE 40 MG CHEWABLE TABLET",
      "ndc": 59417011801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.738746200000001,
          11.964773859999998
        ],
        "expected_margin": 0.29142350490560853,
        "estimated_acquisition_cost": 8.054059650000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.9107142099999965,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11732.14262999999,
          "annual_profit_projection": 140785.71155999988,
          "margin_percentage": 32.68523296603282
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.738746200000001,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.46"
        ]
      }
    },
    {
      "drug_id": "ndc_59417011901",
      "drug_name": "VYVANSE 50 MG CHEWABLE TABLET",
      "ndc": 59417011901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.741234833333335,
          11.964773859999998
        ],
        "expected_margin": 0.2912592969941758,
        "estimated_acquisition_cost": 8.055926125000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.9088477349999966,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11726.543204999989,
          "annual_profit_projection": 140718.51845999988,
          "margin_percentage": 32.669633214446705
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.741234833333335,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.46"
        ]
      }
    },
    {
      "drug_id": "ndc_59417012001",
      "drug_name": "VYVANSE 60 MG CHEWABLE TABLET",
      "ndc": 59417012001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.366535166999997,
        "feasible_range": [
          10.737989166666667,
          11.964773859999998
        ],
        "expected_margin": 0.29147345636325667,
        "estimated_acquisition_cost": 8.053491875,
        "profit_projections": {
          "gross_profit_per_unit": 3.911281984999997,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11733.845954999992,
          "annual_profit_projection": 140806.1514599999,
          "margin_percentage": 32.68997835450939
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.737989166666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.46"
        ]
      }
    },
    {
      "drug_id": "ndc_59467031801",
      "drug_name": "MITIGARE 0.6 MG CAPSULE",
      "ndc": 59467031801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.524730875000001,
        "feasible_range": [
          5.219784700000001,
          6.956366917500001
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 3.914838525000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.6098923500000004,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 19574.192625000003,
          "annual_profit_projection": 234890.31150000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.219784700000001,
        "regulatory_headroom": 5.440042984999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_59467031810",
      "drug_name": "MITIGARE 0.6 MG CAPSULE",
      "ndc": 59467031810,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.524730875000001,
        "feasible_range": [
          5.219784700000001,
          6.956366917500001
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 3.914838525000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.6098923500000004,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 19574.192625000003,
          "annual_profit_projection": 234890.31150000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.219784700000001,
        "regulatory_headroom": 5.440042984999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_59467031830",
      "drug_name": "MITIGARE 0.6 MG CAPSULE",
      "ndc": 59467031830,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.524730875000001,
        "feasible_range": [
          5.219784700000001,
          6.956366917500001
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 3.914838525000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.6098923500000004,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 19574.192625000003,
          "annual_profit_projection": 234890.31150000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.219784700000001,
        "regulatory_headroom": 5.440042984999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_59630075050",
      "drug_name": "METHYLIN 5 MG/5 ML SOLUTION",
      "ndc": 59630075050,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.16262727000000005,
        "feasible_range": [
          0.12755080000000002,
          0.16998597000000001
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.09566310000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.06377540000000002,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 573.9786000000003,
          "annual_profit_projection": 6887.743200000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.12755080000000002,
        "regulatory_headroom": 11.805335359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_59630075550",
      "drug_name": "METHYLIN 10 MG/5 ML SOLUTION",
      "ndc": 59630075550,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.23199530250000008,
        "feasible_range": [
          0.18195710000000007,
          0.24249282750000004
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.13646782500000004,
        "profit_projections": {
          "gross_profit_per_unit": 0.09097855000000005,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 909.7855000000005,
          "annual_profit_projection": 10917.426000000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.18195710000000007,
        "regulatory_headroom": 11.737327484999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_59676056201",
      "drug_name": "PREZISTA 600 MG TABLET",
      "ndc": 59676056201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.259337333333335,
        "feasible_range": [
          30.259337333333335,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 22.694503,
        "profit_projections": {
          "gross_profit_per_unit": 7.564834333333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 75648.34333333334,
          "annual_profit_projection": 907780.1200000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.259337333333335,
        "regulatory_headroom": -18.294563473333337,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $25.86"
        ]
      }
    },
    {
      "drug_id": "ndc_59676056630",
      "drug_name": "PREZISTA 800 MG TABLET",
      "ndc": 59676056630,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 60.55557473333335,
        "feasible_range": [
          60.55557473333335,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 45.416681050000015,
        "profit_projections": {
          "gross_profit_per_unit": 15.138893683333336,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 151388.93683333337,
          "annual_profit_projection": 1816667.2420000006,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 60.55557473333335,
        "regulatory_headroom": -48.59080087333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $63.73"
        ]
      }
    },
    {
      "drug_id": "ndc_59676057101",
      "drug_name": "INTELENCE 200 MG TABLET",
      "ndc": 59676057101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 21.005422100000004,
        "feasible_range": [
          21.005422100000004,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 15.754066575000003,
        "profit_projections": {
          "gross_profit_per_unit": 5.251355525000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 52513.55525000001,
          "annual_profit_projection": 630162.6630000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 21.005422100000004,
        "regulatory_headroom": -9.040648240000007,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $14.29"
        ]
      }
    },
    {
      "drug_id": "ndc_60505437703",
      "drug_name": "PAXIL CR 12.5 MG TABLET",
      "ndc": 60505437703,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.146657516666668,
        "feasible_range": [
          8.368377333333335,
          11.152472100000004
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 6.276283000000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.1841886666666674,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20920.943333333336,
          "annual_profit_projection": 251051.32000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.368377333333335,
        "regulatory_headroom": 1.504302193333329,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60505437803",
      "drug_name": "PAXIL CR 25 MG TABLET",
      "ndc": 60505437803,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.638268875000003,
        "feasible_range": [
          8.773830000000002,
          11.692815750000003
        ],
        "expected_margin": 0.38144329896907225,
        "estimated_acquisition_cost": 6.580372500000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.386915000000002,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 19741.117500000008,
          "annual_profit_projection": 236893.4100000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.773830000000002,
        "regulatory_headroom": 0.9974863599999946,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60505437903",
      "drug_name": "PAXIL CR 37.5 MG TABLET",
      "ndc": 60505437903,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.954338524999999,
        "feasible_range": [
          9.034505999999999,
          11.964773859999998
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 6.775879499999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.517252999999999,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 22586.264999999996,
          "annual_profit_projection": 271035.17999999993,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.034505999999999,
        "regulatory_headroom": 0.6716413599999989,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60505451703",
      "drug_name": "PAXIL 10 MG TABLET",
      "ndc": 60505451703,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.861072541666669,
        "feasible_range": [
          8.132843333333335,
          10.838577750000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.099632500000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.066421666666668,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20332.108333333337,
          "annual_profit_projection": 243985.30000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.132843333333335,
        "regulatory_headroom": 1.7987196933333287,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60505451803",
      "drug_name": "PAXIL 20 MG TABLET",
      "ndc": 60505451803,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.35291455791667,
        "feasible_range": [
          8.538486233333336,
          11.379174922500004
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.403864675000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.269243116666669,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 19211.59402500001,
          "annual_profit_projection": 230539.1283000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.538486233333336,
        "regulatory_headroom": 1.2916660683333276,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60505451903",
      "drug_name": "PAXIL 30 MG TABLET",
      "ndc": 60505451903,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.631373306666669,
        "feasible_range": [
          8.768142933333335,
          11.685236640000005
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 6.576107200000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.384071466666668,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 21920.357333333337,
          "annual_profit_projection": 263044.28800000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.768142933333335,
        "regulatory_headroom": 1.0045951933333281,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60505452003",
      "drug_name": "PAXIL 40 MG TABLET",
      "ndc": 60505452003,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.183819508333334,
        "feasible_range": [
          9.223768666666667,
          11.964773859999998
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.9178265,
        "profit_projections": {
          "gross_profit_per_unit": 4.611884333333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23059.42166666667,
          "annual_profit_projection": 276713.06000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.223768666666667,
        "regulatory_headroom": 0.4350630266666631,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793011501",
      "drug_name": "CYTOMEL 5 MCG TABLET",
      "ndc": 60793011501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.4077781500000002,
        "feasible_range": [
          0.3198260000000001,
          0.4262296500000001
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.23986950000000007,
        "profit_projections": {
          "gross_profit_per_unit": 0.15991300000000008,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 1439.2170000000008,
          "annual_profit_projection": 17270.60400000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.3198260000000001,
        "regulatory_headroom": 11.564991359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793011601",
      "drug_name": "CYTOMEL 25 MCG TABLET",
      "ndc": 60793011601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.5638240400000003,
        "feasible_range": [
          0.44221493333333356,
          0.5893364400000003
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.33166120000000016,
        "profit_projections": {
          "gross_profit_per_unit": 0.22110746666666675,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 2211.0746666666673,
          "annual_profit_projection": 26532.896000000008,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.44221493333333356,
        "regulatory_headroom": 11.41200519333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085001",
      "drug_name": "LEVOXYL 25 MCG TABLET",
      "ndc": 60793085001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.7388032437500001,
        "feasible_range": [
          0.6221501,
          0.8291346525000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.46661257500000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.3110750500000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 933.2251500000002,
          "annual_profit_projection": 11198.701800000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.6221501,
        "regulatory_headroom": 11.187086234999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085010",
      "drug_name": "LEVOXYL 25 MCG TABLET",
      "ndc": 60793085010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.7388032437500001,
        "feasible_range": [
          0.6221501,
          0.8291346525000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.46661257500000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.3110750500000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 933.2251500000002,
          "annual_profit_projection": 11198.701800000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.6221501,
        "regulatory_headroom": 11.187086234999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085101",
      "drug_name": "LEVOXYL 50 MCG TABLET",
      "ndc": 60793085101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.8395807875000001,
        "feasible_range": [
          0.7070154000000001,
          0.9422339850000002
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.5302615500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.3535077000000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1060.5231000000003,
          "annual_profit_projection": 12726.277200000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7070154000000001,
        "regulatory_headroom": 11.081004609999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085110",
      "drug_name": "LEVOXYL 50 MCG TABLET",
      "ndc": 60793085110,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.8395807875000001,
        "feasible_range": [
          0.7070154000000001,
          0.9422339850000002
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.5302615500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.3535077000000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1060.5231000000003,
          "annual_profit_projection": 12726.277200000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7070154000000001,
        "regulatory_headroom": 11.081004609999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085201",
      "drug_name": "LEVOXYL 75 MCG TABLET",
      "ndc": 60793085201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9258635479166668,
        "feasible_range": [
          0.7796745666666668,
          1.0390662975000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.5847559250000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.38983728333333345,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1169.5118500000003,
          "annual_profit_projection": 14034.142200000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7796745666666668,
        "regulatory_headroom": 10.990180651666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085210",
      "drug_name": "LEVOXYL 75 MCG TABLET",
      "ndc": 60793085210,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9258635479166668,
        "feasible_range": [
          0.7796745666666668,
          1.0390662975000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.5847559250000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.38983728333333345,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1169.5118500000003,
          "annual_profit_projection": 14034.142200000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.7796745666666668,
        "regulatory_headroom": 10.990180651666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085301",
      "drug_name": "LEVOXYL 88 MCG TABLET",
      "ndc": 60793085301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9453240604166671,
        "feasible_range": [
          0.796062366666667,
          1.0609061925000005
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.5970467750000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.39803118333333354,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1194.0935500000005,
          "annual_profit_projection": 14329.122600000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.796062366666667,
        "regulatory_headroom": 10.969695901666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085310",
      "drug_name": "LEVOXYL 88 MCG TABLET",
      "ndc": 60793085310,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9453240604166671,
        "feasible_range": [
          0.796062366666667,
          1.0609061925000005
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.5970467750000003,
        "profit_projections": {
          "gross_profit_per_unit": 0.39803118333333354,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1194.0935500000005,
          "annual_profit_projection": 14329.122600000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.796062366666667,
        "regulatory_headroom": 10.969695901666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085401",
      "drug_name": "LEVOXYL 100 MCG TABLET",
      "ndc": 60793085401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9526517270833335,
        "feasible_range": [
          0.8022330333333335,
          1.0691297925000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.6016747750000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.4011165166666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1203.3495500000001,
          "annual_profit_projection": 14440.194600000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8022330333333335,
        "regulatory_headroom": 10.961982568333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085410",
      "drug_name": "LEVOXYL 100 MCG TABLET",
      "ndc": 60793085410,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.9526517270833335,
        "feasible_range": [
          0.8022330333333335,
          1.0691297925000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.6016747750000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.4011165166666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1203.3495500000001,
          "annual_profit_projection": 14440.194600000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.8022330333333335,
        "regulatory_headroom": 10.961982568333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085501",
      "drug_name": "LEVOXYL 112 MCG TABLET",
      "ndc": 60793085501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1023213770833336,
        "feasible_range": [
          0.9282706333333334,
          1.2370991325000003
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 0.6962029750000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.46413531666666685,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1253.1653550000005,
          "annual_profit_projection": 15037.984260000007,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9282706333333334,
        "regulatory_headroom": 10.80443556833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085510",
      "drug_name": "LEVOXYL 112 MCG TABLET",
      "ndc": 60793085510,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1023213770833336,
        "feasible_range": [
          0.9282706333333334,
          1.2370991325000003
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 0.6962029750000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.46413531666666685,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1253.1653550000005,
          "annual_profit_projection": 15037.984260000007,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9282706333333334,
        "regulatory_headroom": 10.80443556833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085601",
      "drug_name": "LEVOXYL 125 MCG TABLET",
      "ndc": 60793085601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1148787541666665,
        "feasible_range": [
          0.9388452666666666,
          1.251191865
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.7041339499999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.46942263333333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1408.2679,
          "annual_profit_projection": 16899.2148,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9388452666666666,
        "regulatory_headroom": 10.791217276666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085610",
      "drug_name": "LEVOXYL 125 MCG TABLET",
      "ndc": 60793085610,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1148787541666665,
        "feasible_range": [
          0.9388452666666666,
          1.251191865
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.7041339499999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.46942263333333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1408.2679,
          "annual_profit_projection": 16899.2148,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9388452666666666,
        "regulatory_headroom": 10.791217276666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085701",
      "drug_name": "LEVOXYL 137 MCG TABLET",
      "ndc": 60793085701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1300023583333336,
        "feasible_range": [
          0.9515809333333336,
          1.2681645900000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.7136857000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.4757904666666669,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1284.6342600000007,
          "annual_profit_projection": 15415.611120000009,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9515809333333336,
        "regulatory_headroom": 10.77529769333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085710",
      "drug_name": "LEVOXYL 137 MCG TABLET",
      "ndc": 60793085710,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1300023583333336,
        "feasible_range": [
          0.9515809333333336,
          1.2681645900000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.7136857000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.4757904666666669,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1284.6342600000007,
          "annual_profit_projection": 15415.611120000009,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9515809333333336,
        "regulatory_headroom": 10.77529769333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085801",
      "drug_name": "LEVOXYL 150 MCG TABLET",
      "ndc": 60793085801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1465426104166663,
        "feasible_range": [
          0.9655095666666664,
          1.2867271724999998
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 0.7241321749999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.4827547833333332,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1448.2643499999997,
          "annual_profit_projection": 17379.172199999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9655095666666664,
        "regulatory_headroom": 10.757886901666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085810",
      "drug_name": "LEVOXYL 150 MCG TABLET",
      "ndc": 60793085810,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1465426104166663,
        "feasible_range": [
          0.9655095666666664,
          1.2867271724999998
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 0.7241321749999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.4827547833333332,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1448.2643499999997,
          "annual_profit_projection": 17379.172199999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9655095666666664,
        "regulatory_headroom": 10.757886901666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085901",
      "drug_name": "LEVOXYL 175 MCG TABLET",
      "ndc": 60793085901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.3654283500000004,
        "feasible_range": [
          1.1498344000000003,
          1.5323754600000006
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 0.8623758000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.5749172000000002,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1552.2764400000005,
          "annual_profit_projection": 18627.317280000007,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.1498344000000003,
        "regulatory_headroom": 10.527480859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793085910",
      "drug_name": "LEVOXYL 175 MCG TABLET",
      "ndc": 60793085910,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.3654283500000004,
        "feasible_range": [
          1.1498344000000003,
          1.5323754600000006
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 0.8623758000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.5749172000000002,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1552.2764400000005,
          "annual_profit_projection": 18627.317280000007,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.1498344000000003,
        "regulatory_headroom": 10.527480859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793086001",
      "drug_name": "LEVOXYL 200 MCG TABLET",
      "ndc": 60793086001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.326052947916667,
        "feasible_range": [
          1.116676166666667,
          1.4881857375000005
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.8375071250000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.5583380833333336,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1507.5128250000007,
          "annual_profit_projection": 18090.15390000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.116676166666667,
        "regulatory_headroom": 10.568928651666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60793086010",
      "drug_name": "LEVOXYL 200 MCG TABLET",
      "ndc": 60793086010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.326052947916667,
        "feasible_range": [
          1.116676166666667,
          1.4881857375000005
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.8375071250000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.5583380833333336,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 1507.5128250000007,
          "annual_profit_projection": 18090.15390000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.116676166666667,
        "regulatory_headroom": 10.568928651666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846080101",
      "drug_name": "UNITHROID 25 MCG TABLET",
      "ndc": 60846080101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.325778925000001,
        "feasible_range": [
          3.6427612000000007,
          4.854679830000001
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 2.7320709000000005,
        "profit_projections": {
          "gross_profit_per_unit": 1.8213806000000008,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 4917.727620000002,
          "annual_profit_projection": 59012.73144000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.6427612000000007,
        "regulatory_headroom": 7.411322359999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846080201",
      "drug_name": "UNITHROID 50 MCG TABLET",
      "ndc": 60846080201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.326774129166668,
        "feasible_range": [
          3.6435992666666674,
          4.855796715000001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 2.7326994500000006,
        "profit_projections": {
          "gross_profit_per_unit": 1.8217996333333342,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 4918.859010000002,
          "annual_profit_projection": 59026.30812000002,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.6435992666666674,
        "regulatory_headroom": 7.410274776666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846080301",
      "drug_name": "UNITHROID 75 MCG TABLET",
      "ndc": 60846080301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.334816552083333,
        "feasible_range": [
          3.650371833333333,
          4.864822462499999
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 2.7377788749999996,
        "profit_projections": {
          "gross_profit_per_unit": 1.8251859166666669,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 4928.001975,
          "annual_profit_projection": 59136.023700000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.650371833333333,
        "regulatory_headroom": 7.401809068333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846080401",
      "drug_name": "UNITHROID 88 MCG TABLET",
      "ndc": 60846080401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.333976752083333,
        "feasible_range": [
          3.6496646333333334,
          4.8638799825
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 2.737248475,
        "profit_projections": {
          "gross_profit_per_unit": 1.8248323166666665,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 5474.49695,
          "annual_profit_projection": 65693.9634,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.6496646333333334,
        "regulatory_headroom": 7.402693068333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846080501",
      "drug_name": "UNITHROID 100 MCG TABLET",
      "ndc": 60846080501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.3476039479166655,
        "feasible_range": [
          3.661140166666666,
          4.879173337499999
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 2.7458551249999994,
        "profit_projections": {
          "gross_profit_per_unit": 1.830570083333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 5491.710249999999,
          "annual_profit_projection": 65900.52299999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.661140166666666,
        "regulatory_headroom": 7.388348651666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846080601",
      "drug_name": "UNITHROID 112 MCG TABLET",
      "ndc": 60846080601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.355901089583332,
        "feasible_range": [
          3.668127233333333,
          4.888484947499999
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 2.7510954249999995,
        "profit_projections": {
          "gross_profit_per_unit": 1.8340636166666662,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 5502.190849999998,
          "annual_profit_projection": 66026.29019999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.668127233333333,
        "regulatory_headroom": 7.379614818333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846080701",
      "drug_name": "UNITHROID 125 MCG TABLET",
      "ndc": 60846080701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.364872335416667,
        "feasible_range": [
          3.675681966666667,
          4.898553082500001
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 2.7567614750000002,
        "profit_projections": {
          "gross_profit_per_unit": 1.8378409833333338,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 5513.522950000001,
          "annual_profit_projection": 66162.27540000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.675681966666667,
        "regulatory_headroom": 7.3701714016666635,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846080801",
      "drug_name": "UNITHROID 137 MCG TABLET",
      "ndc": 60846080801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.363716581250002,
        "feasible_range": [
          3.674708700000002,
          4.897256017500003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 2.7560315250000014,
        "profit_projections": {
          "gross_profit_per_unit": 1.8373543500000014,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 4960.856745000004,
          "annual_profit_projection": 59530.28094000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.674708700000002,
        "regulatory_headroom": 7.371387984999995,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846080901",
      "drug_name": "UNITHROID 150 MCG TABLET",
      "ndc": 60846080901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.372990916666666,
        "feasible_range": [
          3.6825186666666663,
          4.9076642999999995
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 2.7618889999999996,
        "profit_projections": {
          "gross_profit_per_unit": 1.841259333333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 5523.777999999998,
          "annual_profit_projection": 66285.33599999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.6825186666666663,
        "regulatory_headroom": 7.361625526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846081001",
      "drug_name": "UNITHROID 175 MCG TABLET",
      "ndc": 60846081001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.372054375000001,
        "feasible_range": [
          3.6817300000000004,
          4.906613250000001
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 2.7612975000000004,
        "profit_projections": {
          "gross_profit_per_unit": 1.8408650000000009,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 4970.335500000002,
          "annual_profit_projection": 59644.02600000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.6817300000000004,
        "regulatory_headroom": 7.362611359999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_60846081101",
      "drug_name": "UNITHROID 200 MCG TABLET",
      "ndc": 60846081101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.379990279166667,
        "feasible_range": [
          3.688412866666667,
          4.915519455000001
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 2.76630965,
        "profit_projections": {
          "gross_profit_per_unit": 1.8442064333333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 5532.6193,
          "annual_profit_projection": 66391.43160000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.688412866666667,
        "regulatory_headroom": 7.354257776666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61269038012",
      "drug_name": "PYLERA CAPSULE",
      "ndc": 61269038012,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.6872323725,
        "feasible_range": [
          2.1076332333333334,
          2.8088265975000004
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 1.580724925,
        "profit_projections": {
          "gross_profit_per_unit": 1.0538166166666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 10538.166166666668,
          "annual_profit_projection": 126457.994,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.1076332333333334,
        "regulatory_headroom": 9.33023231833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61269046090",
      "drug_name": "XENICAL 120 MG CAPSULE",
      "ndc": 61269046090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.112183049999999,
        "feasible_range": [
          4.009555333333332,
          5.3435035499999985
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.007166499999999,
        "profit_projections": {
          "gross_profit_per_unit": 2.004777666666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 20047.77666666666,
          "annual_profit_projection": 240573.31999999995,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.009555333333332,
        "regulatory_headroom": 6.9528296933333325,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61269060510",
      "drug_name": "KLONOPIN 0.5 MG TABLET",
      "ndc": 61269060510,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.65350475,
        "feasible_range": [
          2.1228038000000002,
          2.8290442950000005
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.59210285,
        "profit_projections": {
          "gross_profit_per_unit": 1.0614019000000001,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 7960.514250000001,
          "annual_profit_projection": 95526.17100000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.1228038000000002,
        "regulatory_headroom": 9.311269109999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61269061010",
      "drug_name": "KLONOPIN 1 MG TABLET",
      "ndc": 61269061010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.024305916666666,
        "feasible_range": [
          2.4194447333333327,
          3.2243753849999996
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.8145835499999996,
        "profit_projections": {
          "gross_profit_per_unit": 1.2097223666666665,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 9072.917749999999,
          "annual_profit_projection": 108875.01299999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.4194447333333327,
        "regulatory_headroom": 8.940467943333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61269062010",
      "drug_name": "KLONOPIN 2 MG TABLET",
      "ndc": 61269062010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.202607499999999,
        "feasible_range": [
          3.3620859999999992,
          4.480626149999999
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.5215644999999993,
        "profit_projections": {
          "gross_profit_per_unit": 1.6810429999999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 12607.822499999998,
          "annual_profit_projection": 151293.87,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.3620859999999992,
        "regulatory_headroom": 7.762166359999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61269063530",
      "drug_name": "ZYPREXA 20 MG TABLET",
      "ndc": 61269063530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 43.15453133333333,
        "feasible_range": [
          43.15453133333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 32.3658985,
        "profit_projections": {
          "gross_profit_per_unit": 10.788632833333331,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 53943.164166666655,
          "annual_profit_projection": 647317.9699999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 43.15453133333333,
        "regulatory_headroom": -31.189757473333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $41.98"
        ]
      }
    },
    {
      "drug_id": "ndc_61570012001",
      "drug_name": "ALTACE 10 MG CAPSULE",
      "ndc": 61570012001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.220090580000003,
        "feasible_range": [
          6.447129866666668,
          8.592040380000002
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 4.835347400000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.2235649333333347,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 29012.08440000001,
          "annual_profit_projection": 348145.01280000014,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.447129866666668,
        "regulatory_headroom": 3.905861526666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61570013120",
      "drug_name": "SILVADENE 1% CREAM",
      "ndc": 61570013120,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.4597103333333334,
        "feasible_range": [
          0.3677682666666667,
          0.4901219400000001
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.2758262,
        "profit_projections": {
          "gross_profit_per_unit": 0.18388413333333337,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 1379.1310000000003,
          "annual_profit_projection": 16549.572000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.3677682666666667,
        "regulatory_headroom": 11.505063526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61570013125",
      "drug_name": "SILVADENE 1% CREAM",
      "ndc": 61570013125,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.2649833333333334,
        "feasible_range": [
          0.21198666666666668,
          0.282513
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 0.15899000000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.10599333333333338,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 715.4550000000004,
          "annual_profit_projection": 8585.460000000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.21198666666666668,
        "regulatory_headroom": 11.699790526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61570013150",
      "drug_name": "SILVADENE 1% CREAM",
      "ndc": 61570013150,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.23576258333333333,
        "feasible_range": [
          0.18861006666666666,
          0.251359185
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.14145755,
        "profit_projections": {
          "gross_profit_per_unit": 0.09430503333333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 707.2877500000001,
          "annual_profit_projection": 8487.453000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.18861006666666666,
        "regulatory_headroom": 11.729011276666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61570013155",
      "drug_name": "SILVADENE 1% CREAM",
      "ndc": 61570013155,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.23576258333333333,
        "feasible_range": [
          0.18861006666666666,
          0.251359185
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.14145755,
        "profit_projections": {
          "gross_profit_per_unit": 0.09430503333333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 707.2877500000001,
          "annual_profit_projection": 8487.453000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.18861006666666666,
        "regulatory_headroom": 11.729011276666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61570013185",
      "drug_name": "SILVADENE 1% CREAM",
      "ndc": 61570013185,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.2970882352941177,
        "feasible_range": [
          0.23767058823529416,
          0.3167417647058824
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.17825294117647061,
        "profit_projections": {
          "gross_profit_per_unit": 0.1188352941176471,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 891.2647058823532,
          "annual_profit_projection": 10695.176470588238,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.23767058823529416,
        "regulatory_headroom": 11.66768562470588,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_61958040101",
      "drug_name": "VIREAD 300 MG TABLET",
      "ndc": 61958040101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 35.09999696666666,
        "feasible_range": [
          35.09999696666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 26.324997724999996,
        "profit_projections": {
          "gross_profit_per_unit": 8.774999241666663,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 87749.99241666663,
          "annual_profit_projection": 1052999.9089999995,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 35.09999696666666,
        "regulatory_headroom": -23.13522310666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $31.91"
        ]
      }
    },
    {
      "drug_id": "ndc_61958060101",
      "drug_name": "EMTRIVA 200 MG CAPSULE",
      "ndc": 61958060101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.093465400000007,
        "feasible_range": [
          15.093465400000007,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.320099050000005,
        "profit_projections": {
          "gross_profit_per_unit": 3.7733663500000016,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 37733.66350000002,
          "annual_profit_projection": 452803.9620000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.093465400000007,
        "regulatory_headroom": -3.128691540000009,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $6.90"
        ]
      }
    },
    {
      "drug_id": "ndc_61958070101",
      "drug_name": "TRUVADA 200 MG-300 MG TABLET",
      "ndc": 61958070101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 51.53171486666668,
        "feasible_range": [
          51.53171486666668,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 38.648786150000014,
        "profit_projections": {
          "gross_profit_per_unit": 12.882928716666669,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 128829.28716666669,
          "annual_profit_projection": 1545951.4460000002,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 51.53171486666668,
        "regulatory_headroom": -39.56694100666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $52.45"
        ]
      }
    },
    {
      "drug_id": "ndc_61958220101",
      "drug_name": "EPCLUSA 400 MG-100 MG TABLET",
      "ndc": 61958220101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 748.0265481000002,
        "feasible_range": [
          748.0265481000002,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 561.0199110750002,
        "profit_projections": {
          "gross_profit_per_unit": 187.00663702500003,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 1870066.3702500004,
          "annual_profit_projection": 22440796.443000004,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 748.0265481000002,
        "regulatory_headroom": -736.0617742400002,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $923.07"
        ]
      }
    },
    {
      "drug_id": "ndc_62559028001",
      "drug_name": "LITHOBID ER 300 MG TABLET",
      "ndc": 62559028001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.422877833333333,
          11.964773859999998
        ],
        "expected_margin": 0.3466522254019433,
        "estimated_acquisition_cost": 7.817158374999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.147615484999998,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 41476.154849999984,
          "annual_profit_projection": 497713.8581999998,
          "margin_percentage": 34.66522254019433
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.422877833333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.06"
        ]
      }
    },
    {
      "drug_id": "ndc_62559064130",
      "drug_name": "ATACAND 8 MG TABLET",
      "ndc": 62559064130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.805600833333335,
        "feasible_range": [
          6.244480666666668,
          8.321971350000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.683360500000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.122240333333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 23416.802500000005,
          "annual_profit_projection": 281001.63000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.244480666666668,
        "regulatory_headroom": 4.159173026666663,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_62559064230",
      "drug_name": "ATACAND 16 MG TABLET",
      "ndc": 62559064230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.491885458333334,
        "feasible_range": [
          6.793508366666667,
          9.0536563425
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.095131275,
        "profit_projections": {
          "gross_profit_per_unit": 3.396754183333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 25475.656375000006,
          "annual_profit_projection": 305707.8765000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.793508366666667,
        "regulatory_headroom": 3.4728884016666637,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_62559064290",
      "drug_name": "ATACAND 16 MG TABLET",
      "ndc": 62559064290,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.491885458333334,
        "feasible_range": [
          6.793508366666667,
          9.0536563425
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.095131275,
        "profit_projections": {
          "gross_profit_per_unit": 3.396754183333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 25475.656375000006,
          "annual_profit_projection": 305707.8765000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.793508366666667,
        "regulatory_headroom": 3.4728884016666637,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_62559064330",
      "drug_name": "ATACAND 32 MG TABLET",
      "ndc": 62559064330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.70741154166667,
        "feasible_range": [
          8.565929233333335,
          11.415747997500002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.424446925000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.282964616666668,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 32122.23462500001,
          "annual_profit_projection": 385466.8155000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.565929233333335,
        "regulatory_headroom": 1.2573623183333282,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_62559064390",
      "drug_name": "ATACAND 32 MG TABLET",
      "ndc": 62559064390,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.70741154166667,
        "feasible_range": [
          8.565929233333335,
          11.415747997500002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.424446925000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.282964616666668,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 32122.23462500001,
          "annual_profit_projection": 385466.8155000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.565929233333335,
        "regulatory_headroom": 1.2573623183333282,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_62559067030",
      "drug_name": "ARIMIDEX 1 MG TABLET",
      "ndc": 62559067030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 44.86903416666669,
        "feasible_range": [
          44.86903416666669,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 33.65177562500001,
        "profit_projections": {
          "gross_profit_per_unit": 11.217258541666673,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 112172.58541666674,
          "annual_profit_projection": 1346071.0250000008,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 44.86903416666669,
        "regulatory_headroom": -32.904260306666686,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $44.12"
        ]
      }
    },
    {
      "drug_id": "ndc_62856024630",
      "drug_name": "ARICEPT 10 MG TABLET",
      "ndc": 62856024630,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 14.037339333333335,
        "feasible_range": [
          14.037339333333335,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.528004500000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.509334833333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 35093.348333333335,
          "annual_profit_projection": 421120.18000000005,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 14.037339333333335,
        "regulatory_headroom": -2.072565473333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.58"
        ]
      }
    },
    {
      "drug_id": "ndc_62856024730",
      "drug_name": "ARICEPT 23 MG TABLET",
      "ndc": 62856024730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 12.468213333333331,
        "feasible_range": [
          12.468213333333331,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 9.351159999999998,
        "profit_projections": {
          "gross_profit_per_unit": 3.117053333333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 31170.53333333333,
          "annual_profit_projection": 374046.39999999997,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 12.468213333333331,
        "regulatory_headroom": -0.5034394733333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $3.62"
        ]
      }
    },
    {
      "drug_id": "ndc_62856058252",
      "drug_name": "BANZEL 200 MG TABLET",
      "ndc": 62856058252,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.945331800000003,
          11.964773859999998
        ],
        "expected_margin": 0.313902715918109,
        "estimated_acquisition_cost": 8.208998850000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.7557750099999954,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28168.312574999964,
          "annual_profit_projection": 338019.7508999996,
          "margin_percentage": 31.390271591810897
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.945331800000003,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.72"
        ]
      }
    },
    {
      "drug_id": "ndc_62856058352",
      "drug_name": "BANZEL 400 MG TABLET",
      "ndc": 62856058352,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 21.935952999999998,
        "feasible_range": [
          21.935952999999998,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 16.45196475,
        "profit_projections": {
          "gross_profit_per_unit": 5.4839882499999995,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 41129.911875,
          "annual_profit_projection": 493558.9425,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 21.935952999999998,
        "regulatory_headroom": -9.97117914,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $15.46"
        ]
      }
    },
    {
      "drug_id": "ndc_62856058446",
      "drug_name": "BANZEL 40 MG/ML SUSPENSION",
      "ndc": 62856058446,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.9598260000000005,
        "feasible_range": [
          3.1678608,
          4.22178372
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.3758956,
        "profit_projections": {
          "gross_profit_per_unit": 1.5839304000000003,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 11879.478000000003,
          "annual_profit_projection": 142553.73600000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.1678608,
        "regulatory_headroom": 8.004947859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_63395020113",
      "drug_name": "EVOXAC 30 MG CAPSULE",
      "ndc": 63395020113,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.637082711111113,
        "feasible_range": [
          6.7741825185185185,
          9.027900933333333
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 5.080636888888889,
        "profit_projections": {
          "gross_profit_per_unit": 3.38709125925926,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 30483.82133333334,
          "annual_profit_projection": 365805.8560000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 6.7741825185185185,
        "regulatory_headroom": 3.4970457118518485,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_63402030230",
      "drug_name": "LATUDA 20 MG TABLET",
      "ndc": 63402030230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 39.28382553333334,
        "feasible_range": [
          39.28382553333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 29.462869150000007,
        "profit_projections": {
          "gross_profit_per_unit": 9.820956383333336,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 73657.17287500002,
          "annual_profit_projection": 883886.0745000002,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 39.28382553333334,
        "regulatory_headroom": -27.319051673333345,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $37.14"
        ]
      }
    },
    {
      "drug_id": "ndc_63402030430",
      "drug_name": "LATUDA 40 MG TABLET",
      "ndc": 63402030430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 39.29325573333333,
        "feasible_range": [
          39.29325573333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 29.4699418,
        "profit_projections": {
          "gross_profit_per_unit": 9.823313933333331,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 73674.85449999999,
          "annual_profit_projection": 884098.2539999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 39.29325573333333,
        "regulatory_headroom": -27.328481873333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $37.15"
        ]
      }
    },
    {
      "drug_id": "ndc_63402030630",
      "drug_name": "LATUDA 60 MG TABLET",
      "ndc": 63402030630,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 39.33480590000001,
        "feasible_range": [
          39.33480590000001,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 29.50110442500001,
        "profit_projections": {
          "gross_profit_per_unit": 9.833701475000005,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 73752.76106250004,
          "annual_profit_projection": 885033.1327500005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 39.33480590000001,
        "regulatory_headroom": -27.370032040000016,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $37.20"
        ]
      }
    },
    {
      "drug_id": "ndc_63402030830",
      "drug_name": "LATUDA 80 MG TABLET",
      "ndc": 63402030830,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 39.33663023333333,
        "feasible_range": [
          39.33663023333333,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 29.502472675,
        "profit_projections": {
          "gross_profit_per_unit": 9.834157558333331,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 73756.18168749998,
          "annual_profit_projection": 885074.1802499997,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 39.33663023333333,
        "regulatory_headroom": -27.371856373333333,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $37.21"
        ]
      }
    },
    {
      "drug_id": "ndc_63402031230",
      "drug_name": "LATUDA 120 MG TABLET",
      "ndc": 63402031230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 58.49451573333334,
        "feasible_range": [
          58.49451573333334,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 43.8708868,
        "profit_projections": {
          "gross_profit_per_unit": 14.623628933333336,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 109677.21700000002,
          "annual_profit_projection": 1316126.6040000003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 58.49451573333334,
        "regulatory_headroom": -46.529741873333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $61.15"
        ]
      }
    },
    {
      "drug_id": "ndc_63402051001",
      "drug_name": "XOPENEX HFA 45 MCG INHALER",
      "ndc": 63402051001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.288520055000002,
        "feasible_range": [
          4.147858866666668,
          5.527819605000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.110894150000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.0739294333333342,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 20739.294333333342,
          "annual_profit_projection": 248871.53200000012,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.147858866666668,
        "regulatory_headroom": 6.779950276666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_63402091130",
      "drug_name": "BROVANA 15 MCG/2 ML SOLUTION",
      "ndc": 63402091130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.2144120975,
        "feasible_range": [
          8.4242574,
          11.226943035
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.31819305,
        "profit_projections": {
          "gross_profit_per_unit": 4.212128700000001,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 18954.579150000005,
          "annual_profit_projection": 227454.94980000006,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.4242574,
        "regulatory_headroom": 1.434452109999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_63402091164",
      "drug_name": "BROVANA 15 MCG/2 ML SOLUTION",
      "ndc": 63402091164,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.163861234583338,
        "feasible_range": [
          8.38256596666667,
          11.171381182500005
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 6.286924475000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.191282983333336,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 20956.41491666668,
          "annual_profit_projection": 251476.97900000017,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.38256596666667,
        "regulatory_headroom": 1.4865664016666589,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_63459010130",
      "drug_name": "PROVIGIL 100 MG TABLET",
      "ndc": 63459010130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 46.28311740000001,
        "feasible_range": [
          46.28311740000001,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 34.71233805000001,
        "profit_projections": {
          "gross_profit_per_unit": 11.570779350000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 115707.79350000003,
          "annual_profit_projection": 1388493.5220000003,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 46.28311740000001,
        "regulatory_headroom": -34.318343540000015,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $45.89"
        ]
      }
    },
    {
      "drug_id": "ndc_63459020130",
      "drug_name": "PROVIGIL 200 MG TABLET",
      "ndc": 63459020130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 69.63044659999998,
        "feasible_range": [
          69.63044659999998,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 52.22283494999999,
        "profit_projections": {
          "gross_profit_per_unit": 17.407611649999993,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 174076.11649999992,
          "annual_profit_projection": 2088913.397999999,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 69.63044659999998,
        "regulatory_headroom": -57.66567273999999,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $75.07"
        ]
      }
    },
    {
      "drug_id": "ndc_63459021530",
      "drug_name": "NUVIGIL 150 MG TABLET",
      "ndc": 63459021530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.356683500000013,
        "feasible_range": [
          30.356683500000013,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 22.76751262500001,
        "profit_projections": {
          "gross_profit_per_unit": 7.589170875000004,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 56918.78156250003,
          "annual_profit_projection": 683025.3787500004,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.356683500000013,
        "regulatory_headroom": -18.391909640000016,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $25.98"
        ]
      }
    },
    {
      "drug_id": "ndc_63459022030",
      "drug_name": "NUVIGIL 200 MG TABLET",
      "ndc": 63459022030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.191174866666667,
        "feasible_range": [
          30.191174866666667,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 22.64338115,
        "profit_projections": {
          "gross_profit_per_unit": 7.547793716666668,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 56608.45287500001,
          "annual_profit_projection": 679301.4345000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.191174866666667,
        "regulatory_headroom": -18.22640100666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $25.77"
        ]
      }
    },
    {
      "drug_id": "ndc_63459022530",
      "drug_name": "NUVIGIL 250 MG TABLET",
      "ndc": 63459022530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.217986066666665,
        "feasible_range": [
          30.217986066666665,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 22.663489549999998,
        "profit_projections": {
          "gross_profit_per_unit": 7.554496516666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 56658.723875,
          "annual_profit_projection": 679904.6865000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.217986066666665,
        "regulatory_headroom": -18.253212206666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $25.81"
        ]
      }
    },
    {
      "drug_id": "ndc_63459070060",
      "drug_name": "AMRIX ER 15 MG CAPSULE",
      "ndc": 63459070060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 52.244034699999986,
        "feasible_range": [
          52.244034699999986,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 39.18302602499999,
        "profit_projections": {
          "gross_profit_per_unit": 13.061008674999997,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 130610.08674999996,
          "annual_profit_projection": 1567321.0409999995,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 52.244034699999986,
        "regulatory_headroom": -40.27926083999999,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $53.34"
        ]
      }
    },
    {
      "drug_id": "ndc_63459070160",
      "drug_name": "AMRIX ER 30 MG CAPSULE",
      "ndc": 63459070160,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 52.507905666666666,
        "feasible_range": [
          52.507905666666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 39.38092925,
        "profit_projections": {
          "gross_profit_per_unit": 13.126976416666665,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 131269.76416666666,
          "annual_profit_projection": 1575237.17,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 52.507905666666666,
        "regulatory_headroom": -40.543131806666665,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $53.67"
        ]
      }
    },
    {
      "drug_id": "ndc_63481002509",
      "drug_name": "FROVA 2.5 MG TABLET",
      "ndc": 63481002509,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 128.98333630000002,
        "feasible_range": [
          128.98333630000002,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 96.73750222500001,
        "profit_projections": {
          "gross_profit_per_unit": 32.245834075000005,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 322458.34075000003,
          "annual_profit_projection": 3869500.0890000006,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 128.98333630000002,
        "regulatory_headroom": -117.01856244000003,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $149.26"
        ]
      }
    },
    {
      "drug_id": "ndc_63481062370",
      "drug_name": "PERCOCET 5-325 MG TABLET",
      "ndc": 63481062370,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 24.190126566666663,
        "feasible_range": [
          24.190126566666663,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 18.142594924999997,
        "profit_projections": {
          "gross_profit_per_unit": 6.047531641666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 45356.487312499994,
          "annual_profit_projection": 544277.84775,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 24.190126566666663,
        "regulatory_headroom": -12.225352706666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $18.27"
        ]
      }
    },
    {
      "drug_id": "ndc_63481062385",
      "drug_name": "PERCOCET 5-325 MG TABLET",
      "ndc": 63481062385,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 24.190126566666663,
        "feasible_range": [
          24.190126566666663,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 18.142594924999997,
        "profit_projections": {
          "gross_profit_per_unit": 6.047531641666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 45356.487312499994,
          "annual_profit_projection": 544277.84775,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 24.190126566666663,
        "regulatory_headroom": -12.225352706666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $18.27"
        ]
      }
    },
    {
      "drug_id": "ndc_63481062870",
      "drug_name": "PERCOCET 7.5-325 MG TABLET",
      "ndc": 63481062870,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 26.135812733333335,
        "feasible_range": [
          26.135812733333335,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 19.60185955,
        "profit_projections": {
          "gross_profit_per_unit": 6.533953183333335,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 49004.648875000006,
          "annual_profit_projection": 588055.7865,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 26.135812733333335,
        "regulatory_headroom": -14.171038873333337,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $20.70"
        ]
      }
    },
    {
      "drug_id": "ndc_63481062970",
      "drug_name": "PERCOCET 10-325 MG TABLET",
      "ndc": 63481062970,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 34.23389666666666,
        "feasible_range": [
          34.23389666666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 25.675422499999996,
        "profit_projections": {
          "gross_profit_per_unit": 8.558474166666663,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 64188.55624999997,
          "annual_profit_projection": 770262.6749999997,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 34.23389666666666,
        "regulatory_headroom": -22.26912280666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $30.83"
        ]
      }
    },
    {
      "drug_id": "ndc_64764004613",
      "drug_name": "PREVACID DR 30 MG CAPSULE",
      "ndc": 64764004613,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.517020233333334,
          11.964773859999998
        ],
        "expected_margin": 0.25573916768148647,
        "estimated_acquisition_cost": 8.637765175,
        "profit_projections": {
          "gross_profit_per_unit": 3.3270086849999974,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16635.043424999985,
          "annual_profit_projection": 199620.52109999984,
          "margin_percentage": 27.80669926510419
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.517020233333334,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.43"
        ]
      }
    },
    {
      "drug_id": "ndc_64764008060",
      "drug_name": "AMITIZA 8 MCG CAPSULE",
      "ndc": 64764008060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.434959375,
        "feasible_range": [
          5.1479675,
          6.8606566875000015
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.860975625,
        "profit_projections": {
          "gross_profit_per_unit": 2.57398375,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 19304.878125,
          "annual_profit_projection": 231658.53749999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.1479675,
        "regulatory_headroom": 5.5298144849999975,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64764011901",
      "drug_name": "COLCRYS 0.6 MG TABLET",
      "ndc": 64764011901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.6329096025000025,
        "feasible_range": [
          5.986595766666668,
          7.978290127500003
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 4.489946825000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.9932978833333346,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 29932.978833333345,
          "annual_profit_projection": 359195.74600000016,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.986595766666668,
        "regulatory_headroom": 4.4815291516666615,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64764011907",
      "drug_name": "COLCRYS 0.6 MG TABLET",
      "ndc": 64764011907,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.6329096025000025,
        "feasible_range": [
          5.986595766666668,
          7.978290127500003
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 4.489946825000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.9932978833333346,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 29932.978833333345,
          "annual_profit_projection": 359195.74600000016,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.986595766666668,
        "regulatory_headroom": 4.4815291516666615,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64764012530",
      "drug_name": "NESINA 12.5 MG TABLET",
      "ndc": 64764012530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.386041333333338,
          11.964773859999998
        ],
        "expected_margin": 0.2862772752814899,
        "estimated_acquisition_cost": 8.539531000000004,
        "profit_projections": {
          "gross_profit_per_unit": 3.425242859999994,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 34252.42859999994,
          "annual_profit_projection": 411029.1431999993,
          "margin_percentage": 28.627727528148988
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.386041333333338,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.27"
        ]
      }
    },
    {
      "drug_id": "ndc_64764017130",
      "drug_name": "DEXILANT DR 30 MG CAPSULE",
      "ndc": 64764017130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.666243791666668,
        "feasible_range": [
          8.532995033333334,
          11.371856842500002
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 6.399746275,
        "profit_projections": {
          "gross_profit_per_unit": 4.266497516666668,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 28798.858237500008,
          "annual_profit_projection": 345586.2988500001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.532995033333334,
        "regulatory_headroom": 1.2985300683333296,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64764017530",
      "drug_name": "DEXILANT DR 60 MG CAPSULE",
      "ndc": 64764017530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.682384916666665,
        "feasible_range": [
          8.545907933333332,
          11.389065765
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.409430949999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.272953966666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 32047.154749999994,
          "annual_profit_projection": 384565.85699999996,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.545907933333332,
        "regulatory_headroom": 1.2823889433333324,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64764017590",
      "drug_name": "DEXILANT DR 60 MG CAPSULE",
      "ndc": 64764017590,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.682384916666665,
        "feasible_range": [
          8.545907933333332,
          11.389065765
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.409430949999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.272953966666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 32047.154749999994,
          "annual_profit_projection": 384565.85699999996,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.545907933333332,
        "regulatory_headroom": 1.2823889433333324,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64764024060",
      "drug_name": "AMITIZA 24 MCG CAPSULE",
      "ndc": 64764024060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.442148916666666,
        "feasible_range": [
          5.1537191333333325,
          6.8683218450000005
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.8652893499999994,
        "profit_projections": {
          "gross_profit_per_unit": 2.5768595666666663,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 19326.446749999996,
          "annual_profit_projection": 231917.36099999995,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.1537191333333325,
        "regulatory_headroom": 5.522624943333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64764025030",
      "drug_name": "NESINA 25 MG TABLET",
      "ndc": 64764025030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.348553233333334,
          11.964773859999998
        ],
        "expected_margin": 0.28862717970333607,
        "estimated_acquisition_cost": 8.511414925,
        "profit_projections": {
          "gross_profit_per_unit": 3.453358934999997,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 34533.58934999997,
          "annual_profit_projection": 414403.0721999997,
          "margin_percentage": 28.862717970333605
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.348553233333334,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.22"
        ]
      }
    },
    {
      "drug_id": "ndc_64764033560",
      "drug_name": "KAZANO 12.5-500 MG TABLET",
      "ndc": 64764033560,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.280325650000004,
        "feasible_range": [
          5.710059333333336,
          7.609752150000002
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 4.282544500000002,
        "profit_projections": {
          "gross_profit_per_unit": 2.8550296666666686,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 28550.296666666687,
          "annual_profit_projection": 342603.56000000023,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.710059333333336,
        "regulatory_headroom": 4.827199693333327,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64764033760",
      "drug_name": "KAZANO 12.5-1,000 MG TABLET",
      "ndc": 64764033760,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.255590777500003,
        "feasible_range": [
          5.690659433333335,
          7.583898052500001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 4.267994575000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.845329716666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 28453.297166666678,
          "annual_profit_projection": 341439.5660000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.690659433333335,
        "regulatory_headroom": 4.8514495683333285,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64764054311",
      "drug_name": "PREVACID DR 15 MG SOLUTAB",
      "ndc": 64764054311,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.4615371,
          11.964773859999998
        ],
        "expected_margin": 0.25932463702665537,
        "estimated_acquisition_cost": 8.596152824999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.3686210349999985,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16843.105174999993,
          "annual_profit_projection": 202117.26209999993,
          "margin_percentage": 28.154489791585576
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.4615371,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.36"
        ]
      }
    },
    {
      "drug_id": "ndc_64764054330",
      "drug_name": "PREVACID DR 15 MG SOLUTAB",
      "ndc": 64764054330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.4615371,
          11.964773859999998
        ],
        "expected_margin": 0.25932463702665537,
        "estimated_acquisition_cost": 8.596152824999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.3686210349999985,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16843.105174999993,
          "annual_profit_projection": 202117.26209999993,
          "margin_percentage": 28.154489791585576
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.4615371,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.36"
        ]
      }
    },
    {
      "drug_id": "ndc_64764054411",
      "drug_name": "PREVACID DR 30 MG SOLUTAB",
      "ndc": 64764054411,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.477668366666668,
          11.964773859999998
        ],
        "expected_margin": 0.25828219117586676,
        "estimated_acquisition_cost": 8.608251275,
        "profit_projections": {
          "gross_profit_per_unit": 3.356522584999997,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16782.612924999983,
          "annual_profit_projection": 201391.3550999998,
          "margin_percentage": 28.05337254405908
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.477668366666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.38"
        ]
      }
    },
    {
      "drug_id": "ndc_64764054430",
      "drug_name": "PREVACID DR 30 MG SOLUTAB",
      "ndc": 64764054430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.477668366666668,
          11.964773859999998
        ],
        "expected_margin": 0.25828219117586676,
        "estimated_acquisition_cost": 8.608251275,
        "profit_projections": {
          "gross_profit_per_unit": 3.356522584999997,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16782.612924999983,
          "annual_profit_projection": 201391.3550999998,
          "margin_percentage": 28.05337254405908
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.477668366666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.38"
        ]
      }
    },
    {
      "drug_id": "ndc_64764067730",
      "drug_name": "ULORIC 80 MG TABLET",
      "ndc": 64764067730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.6721100275,
        "feasible_range": [
          9.154596100000001,
          11.964773859999998
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 6.865947075,
        "profit_projections": {
          "gross_profit_per_unit": 4.5772980500000005,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 45772.980500000005,
          "annual_profit_projection": 549275.7660000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.154596100000001,
        "regulatory_headroom": 0.5215287349999969,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64764080510",
      "drug_name": "ROZEREM 8 MG TABLET",
      "ndc": 64764080510,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.736031800000001,
          11.964773859999998
        ],
        "expected_margin": 0.3270224791360994,
        "estimated_acquisition_cost": 8.052023850000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.9127500099999963,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 39127.50009999996,
          "annual_profit_projection": 469530.00119999953,
          "margin_percentage": 32.70224791360994
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.736031800000001,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.46"
        ]
      }
    },
    {
      "drug_id": "ndc_64764080530",
      "drug_name": "ROZEREM 8 MG TABLET",
      "ndc": 64764080530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.736031800000001,
          11.964773859999998
        ],
        "expected_margin": 0.3270224791360994,
        "estimated_acquisition_cost": 8.052023850000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.9127500099999963,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 39127.50009999996,
          "annual_profit_projection": 469530.00119999953,
          "margin_percentage": 32.70224791360994
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.736031800000001,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.46"
        ]
      }
    },
    {
      "drug_id": "ndc_64764091830",
      "drug_name": "ULORIC 40 MG TABLET",
      "ndc": 64764091830,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.673303980000005,
        "feasible_range": [
          9.155532533333337,
          11.964773859999998
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.866649400000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.577766266666669,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 45777.662666666685,
          "annual_profit_projection": 549331.9520000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.155532533333337,
        "regulatory_headroom": 0.5203581933333261,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_64896008412",
      "drug_name": "ZOMIG 5 MG NASAL SPRAY",
      "ndc": 64896008412,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 86.66726466666665,
        "feasible_range": [
          86.66726466666665,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 65.00044849999999,
        "profit_projections": {
          "gross_profit_per_unit": 21.666816166666663,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 216668.16166666662,
          "annual_profit_projection": 2600017.9399999995,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 86.66726466666665,
        "regulatory_headroom": -74.70249080666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $96.37"
        ]
      }
    },
    {
      "drug_id": "ndc_64896067410",
      "drug_name": "DEXEDRINE SPANSULE 10 MG",
      "ndc": 64896067410,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.414200000000005,
        "feasible_range": [
          19.414200000000005,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 14.560650000000003,
        "profit_projections": {
          "gross_profit_per_unit": 4.853550000000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 48535.50000000002,
          "annual_profit_projection": 582426.0000000002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.414200000000005,
        "regulatory_headroom": -7.449426140000007,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.30"
        ]
      }
    },
    {
      "drug_id": "ndc_64896068151",
      "drug_name": "ZOMIG 5 MG NASAL SPRAY",
      "ndc": 64896068151,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 82.80343066666667,
        "feasible_range": [
          82.80343066666667,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 62.10257300000001,
        "profit_projections": {
          "gross_profit_per_unit": 20.700857666666664,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 207008.57666666663,
          "annual_profit_projection": 2484102.9199999995,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 82.80343066666667,
        "regulatory_headroom": -70.83865680666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $91.54"
        ]
      }
    },
    {
      "drug_id": "ndc_65597011030",
      "drug_name": "AZOR 5-20 MG TABLET",
      "ndc": 65597011030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.118225733333333,
          11.964773859999998
        ],
        "expected_margin": 0.30306503093406556,
        "estimated_acquisition_cost": 8.3386693,
        "profit_projections": {
          "gross_profit_per_unit": 3.626104559999998,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 27195.784199999987,
          "annual_profit_projection": 326349.4103999998,
          "margin_percentage": 30.306503093406555
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.118225733333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.93"
        ]
      }
    },
    {
      "drug_id": "ndc_65597011330",
      "drug_name": "AZOR 10-40 MG TABLET",
      "ndc": 65597011330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.981562592592594,
        "feasible_range": [
          13.981562592592594,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 10.486171944444445,
        "profit_projections": {
          "gross_profit_per_unit": 3.495390648148149,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 26215.429861111115,
          "annual_profit_projection": 314585.1583333334,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.981562592592594,
        "regulatory_headroom": -2.0167887325925964,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.51"
        ]
      }
    },
    {
      "drug_id": "ndc_65628001605",
      "drug_name": "FIRVANQ 50 MG/ML SOLUTION",
      "ndc": 65628001605,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.2441051350000003,
        "feasible_range": [
          0.9757687333333335,
          1.300399485
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.7318265500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.4878843666666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 4878.843666666668,
          "annual_profit_projection": 58546.12400000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9757687333333335,
        "regulatory_headroom": 10.74506294333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65628020605",
      "drug_name": "FIRVANQ 50 MG/ML SOLUTION",
      "ndc": 65628020605,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.2441051350000003,
        "feasible_range": [
          0.9757687333333335,
          1.300399485
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.7318265500000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.4878843666666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 4878.843666666668,
          "annual_profit_projection": 58546.12400000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9757687333333335,
        "regulatory_headroom": 10.74506294333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65649010302",
      "drug_name": "APRISO ER 0.375 GRAM CAPSULE",
      "ndc": 65649010302,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.5019285675,
        "feasible_range": [
          3.530924366666667,
          4.705635742500001
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 2.648193275,
        "profit_projections": {
          "gross_profit_per_unit": 1.7654621833333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 17654.62183333333,
          "annual_profit_projection": 211855.46199999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.530924366666667,
        "regulatory_headroom": 7.551118401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_65649020175",
      "drug_name": "MOVIPREP POWDER PACKET",
      "ndc": 65649020175,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 104.26937170000004,
        "feasible_range": [
          104.26937170000004,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 78.20202877500003,
        "profit_projections": {
          "gross_profit_per_unit": 26.067342925000005,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 260673.42925000004,
          "annual_profit_projection": 3128081.1510000005,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 104.26937170000004,
        "regulatory_headroom": -92.30459784000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $118.37"
        ]
      }
    },
    {
      "drug_id": "ndc_65649065103",
      "drug_name": "UCERIS 2 MG RECTAL FOAM",
      "ndc": 65649065103,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.132344733333333,
          11.964773859999998
        ],
        "expected_margin": 0.36486400504355193,
        "estimated_acquisition_cost": 7.59925855,
        "profit_projections": {
          "gross_profit_per_unit": 4.3655153099999975,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 43655.153099999974,
          "annual_profit_projection": 523861.8371999997,
          "margin_percentage": 36.486400504355196
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.132344733333333,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.70"
        ]
      }
    },
    {
      "drug_id": "ndc_66302046760",
      "drug_name": "ADCIRCA 20 MG TABLET",
      "ndc": 66302046760,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 58.36511200000001,
        "feasible_range": [
          58.36511200000001,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 43.77383400000001,
        "profit_projections": {
          "gross_profit_per_unit": 14.591278000000003,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 145912.78000000003,
          "annual_profit_projection": 1750953.3600000003,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 58.36511200000001,
        "regulatory_headroom": -46.40033814000002,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $60.99"
        ]
      }
    },
    {
      "drug_id": "ndc_66490069110",
      "drug_name": "MYSOLINE 250 MG TABLET",
      "ndc": 66490069110,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 56.794537366666674,
        "feasible_range": [
          56.794537366666674,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 42.595903025000005,
        "profit_projections": {
          "gross_profit_per_unit": 14.198634341666668,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 141986.3434166667,
          "annual_profit_projection": 1703836.1210000003,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 56.794537366666674,
        "regulatory_headroom": -44.82976350666668,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $59.03"
        ]
      }
    },
    {
      "drug_id": "ndc_66758008570",
      "drug_name": "AZOPT 1% EYE DROPS",
      "ndc": 66758008570,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.481344399999998,
        "feasible_range": [
          30.481344399999998,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 22.861008299999998,
        "profit_projections": {
          "gross_profit_per_unit": 7.620336099999999,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 57152.520749999996,
          "annual_profit_projection": 685830.249,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.481344399999998,
        "regulatory_headroom": -18.51657054,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $26.14"
        ]
      }
    },
    {
      "drug_id": "ndc_66758008585",
      "drug_name": "AZOPT 1% EYE DROPS",
      "ndc": 66758008585,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 30.587078708333333,
        "feasible_range": [
          30.587078708333333,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 22.94030903125,
        "profit_projections": {
          "gross_profit_per_unit": 7.646769677083334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 57350.772578125005,
          "annual_profit_projection": 688209.2709375,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 30.587078708333333,
        "regulatory_headroom": -18.622304848333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $26.27"
        ]
      }
    },
    {
      "drug_id": "ndc_66758008675",
      "drug_name": "DUREZOL 0.05% EYE DROPS",
      "ndc": 66758008675,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 36.87333866666667,
        "feasible_range": [
          36.87333866666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 27.655004,
        "profit_projections": {
          "gross_profit_per_unit": 9.218334666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 92183.34666666668,
          "annual_profit_projection": 1106200.1600000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 36.87333866666667,
        "regulatory_headroom": -24.90856480666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $34.13"
        ]
      }
    },
    {
      "drug_id": "ndc_66758009556",
      "drug_name": "TRAVATAN Z 0.004% EYE DROP",
      "ndc": 66758009556,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 81.56124946666668,
        "feasible_range": [
          81.56124946666668,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 61.17093710000001,
        "profit_projections": {
          "gross_profit_per_unit": 20.39031236666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 152927.34275000004,
          "annual_profit_projection": 1835128.1130000004,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 81.56124946666668,
        "regulatory_headroom": -69.59647560666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $89.99"
        ]
      }
    },
    {
      "drug_id": "ndc_66758009575",
      "drug_name": "TRAVATAN Z 0.004% EYE DROP",
      "ndc": 66758009575,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 81.79181659999999,
        "feasible_range": [
          81.79181659999999,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 61.343862449999996,
        "profit_projections": {
          "gross_profit_per_unit": 20.447954149999994,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 153359.65612499995,
          "annual_profit_projection": 1840315.8734999993,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 81.79181659999999,
        "regulatory_headroom": -69.82704274,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $90.27"
        ]
      }
    },
    {
      "drug_id": "ndc_66758014558",
      "drug_name": "VIVELLE-DOT 0.025 MG PATCH",
      "ndc": 66758014558,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.884483333333337,
        "feasible_range": [
          15.884483333333337,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.913362500000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.971120833333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11913.362500000001,
          "annual_profit_projection": 142960.35,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.884483333333337,
        "regulatory_headroom": -3.9197094733333397,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.89"
        ]
      }
    },
    {
      "drug_id": "ndc_66758014583",
      "drug_name": "VIVELLE-DOT 0.025 MG PATCH",
      "ndc": 66758014583,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.884483333333337,
        "feasible_range": [
          15.884483333333337,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 11.913362500000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.971120833333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11913.362500000001,
          "annual_profit_projection": 142960.35,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.884483333333337,
        "regulatory_headroom": -3.9197094733333397,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.89"
        ]
      }
    },
    {
      "drug_id": "ndc_66758014658",
      "drug_name": "VIVELLE-DOT 0.0375 MG PATCH",
      "ndc": 66758014658,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.943944900000005,
        "feasible_range": [
          15.943944900000005,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.957958675000004,
        "profit_projections": {
          "gross_profit_per_unit": 3.9859862250000013,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11957.958675000003,
          "annual_profit_projection": 143495.50410000005,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.943944900000005,
        "regulatory_headroom": -3.9791710400000078,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.97"
        ]
      }
    },
    {
      "drug_id": "ndc_66758014683",
      "drug_name": "VIVELLE-DOT 0.0375 MG PATCH",
      "ndc": 66758014683,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.943944900000005,
        "feasible_range": [
          15.943944900000005,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.957958675000004,
        "profit_projections": {
          "gross_profit_per_unit": 3.9859862250000013,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11957.958675000003,
          "annual_profit_projection": 143495.50410000005,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.943944900000005,
        "regulatory_headroom": -3.9791710400000078,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.97"
        ]
      }
    },
    {
      "drug_id": "ndc_66758014858",
      "drug_name": "VIVELLE-DOT 0.075 MG PATCH",
      "ndc": 66758014858,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.961581133333333,
        "feasible_range": [
          15.961581133333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.97118585,
        "profit_projections": {
          "gross_profit_per_unit": 3.990395283333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11971.18585,
          "annual_profit_projection": 143654.2302,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.961581133333333,
        "regulatory_headroom": -3.996807273333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.99"
        ]
      }
    },
    {
      "drug_id": "ndc_66758014883",
      "drug_name": "VIVELLE-DOT 0.075 MG PATCH",
      "ndc": 66758014883,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.961581133333333,
        "feasible_range": [
          15.961581133333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.97118585,
        "profit_projections": {
          "gross_profit_per_unit": 3.990395283333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11971.18585,
          "annual_profit_projection": 143654.2302,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.961581133333333,
        "regulatory_headroom": -3.996807273333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $7.99"
        ]
      }
    },
    {
      "drug_id": "ndc_66758014958",
      "drug_name": "VIVELLE-DOT 0.1 MG PATCH",
      "ndc": 66758014958,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.98534513333334,
        "feasible_range": [
          15.98534513333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.989008850000005,
        "profit_projections": {
          "gross_profit_per_unit": 3.996336283333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11989.008850000006,
          "annual_profit_projection": 143868.10620000007,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.98534513333334,
        "regulatory_headroom": -4.020571273333342,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.02"
        ]
      }
    },
    {
      "drug_id": "ndc_66758014983",
      "drug_name": "VIVELLE-DOT 0.1 MG PATCH",
      "ndc": 66758014983,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 15.98534513333334,
        "feasible_range": [
          15.98534513333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 11.989008850000005,
        "profit_projections": {
          "gross_profit_per_unit": 3.996336283333335,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 11989.008850000006,
          "annual_profit_projection": 143868.10620000007,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 15.98534513333334,
        "regulatory_headroom": -4.020571273333342,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $8.02"
        ]
      }
    },
    {
      "drug_id": "ndc_66758021131",
      "drug_name": "LESCOL XL 80 MG TABLET",
      "ndc": 66758021131,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.358091333333334,
          11.964773859999998
        ],
        "expected_margin": 0.2880292933509733,
        "estimated_acquisition_cost": 8.5185685,
        "profit_projections": {
          "gross_profit_per_unit": 3.446205359999997,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 34462.05359999997,
          "annual_profit_projection": 413544.64319999964,
          "margin_percentage": 28.802929335097332
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.358091333333334,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.23"
        ]
      }
    },
    {
      "drug_id": "ndc_66758023501",
      "drug_name": "FOCALIN XR 5 MG CAPSULE",
      "ndc": 66758023501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.847766083333333,
        "feasible_range": [
          4.082329333333333,
          5.4404889
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 3.061747,
        "profit_projections": {
          "gross_profit_per_unit": 2.0411646666666665,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 6123.494,
          "annual_profit_projection": 73481.928,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.082329333333333,
        "regulatory_headroom": 6.861862193333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66758023601",
      "drug_name": "FOCALIN XR 10 MG CAPSULE",
      "ndc": 66758023601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.9184080833333335,
        "feasible_range": [
          4.141817333333333,
          5.5197681
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 3.106363,
        "profit_projections": {
          "gross_profit_per_unit": 2.070908666666667,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 6212.726000000001,
          "annual_profit_projection": 74552.712,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.141817333333333,
        "regulatory_headroom": 6.787502193333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66758023701",
      "drug_name": "FOCALIN XR 15 MG CAPSULE",
      "ndc": 66758023701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.053895816666666,
        "feasible_range": [
          4.255912266666666,
          5.67182154
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 3.1919341999999995,
        "profit_projections": {
          "gross_profit_per_unit": 2.127956133333333,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 6383.868399999999,
          "annual_profit_projection": 76606.42079999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.255912266666666,
        "regulatory_headroom": 6.644883526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66758023801",
      "drug_name": "FOCALIN XR 20 MG CAPSULE",
      "ndc": 66758023801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.04703281875,
        "feasible_range": [
          4.2501329,
          5.6641194225
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 3.1875996749999995,
        "profit_projections": {
          "gross_profit_per_unit": 2.1250664500000003,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 5737.6794150000005,
          "annual_profit_projection": 68852.15298000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.2501329,
        "regulatory_headroom": 6.652107734999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66758023901",
      "drug_name": "FOCALIN XR 25 MG CAPSULE",
      "ndc": 66758023901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.323446916666667,
        "feasible_range": [
          4.482902666666667,
          5.974329900000001
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 3.362177,
        "profit_projections": {
          "gross_profit_per_unit": 2.241451333333334,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 6051.918600000002,
          "annual_profit_projection": 72623.02320000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.482902666666667,
        "regulatory_headroom": 6.361145526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66758024201",
      "drug_name": "FOCALIN XR 40 MG CAPSULE",
      "ndc": 66758024201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.558660899999998,
        "feasible_range": [
          4.6809775999999985,
          6.2383028399999985
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 3.510733199999999,
        "profit_projections": {
          "gross_profit_per_unit": 2.3404887999999993,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 7021.4663999999975,
          "annual_profit_projection": 84257.59679999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.6809775999999985,
        "regulatory_headroom": 6.113551859999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66758025001",
      "drug_name": "FOCALIN 2.5 MG TABLET",
      "ndc": 66758025001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.6666427083333335,
        "feasible_range": [
          0.5613833333333335,
          0.7481512500000002
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.42103750000000006,
        "profit_projections": {
          "gross_profit_per_unit": 0.2806916666666668,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 757.8675000000003,
          "annual_profit_projection": 9094.410000000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.5613833333333335,
        "regulatory_headroom": 11.263044693333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66758025201",
      "drug_name": "FOCALIN 10 MG TABLET",
      "ndc": 66758025201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.3673950874999996,
        "feasible_range": [
          1.1514905999999996,
          1.5345826649999996
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.8636179499999997,
        "profit_projections": {
          "gross_profit_per_unit": 0.5757452999999998,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 1727.2358999999994,
          "annual_profit_projection": 20726.830799999992,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.1514905999999996,
        "regulatory_headroom": 10.525410609999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66758027401",
      "drug_name": "RITALIN 10 MG TABLET",
      "ndc": 66758027401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.1950497000000002,
        "feasible_range": [
          0.9856080000000002,
          1.3135122000000004
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.7392060000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.49280400000000013,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 2464.0200000000004,
          "annual_profit_projection": 29568.240000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.9856080000000002,
        "regulatory_headroom": 10.732763859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66758027501",
      "drug_name": "RITALIN 20 MG TABLET",
      "ndc": 66758027501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.7238080166666672,
        "feasible_range": [
          1.4216973333333336,
          1.8946851000000002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 1.0662730000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.7108486666666669,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 3554.2433333333347,
          "annual_profit_projection": 42650.92000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.4216973333333336,
        "regulatory_headroom": 10.18765219333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66869010490",
      "drug_name": "LIVALO 1 MG TABLET",
      "ndc": 66869010490,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.089289791666667,
        "feasible_range": [
          8.871431833333334,
          11.822888962500002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.653573875,
        "profit_projections": {
          "gross_profit_per_unit": 4.435715916666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33267.869375,
          "annual_profit_projection": 399214.4325,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.871431833333334,
        "regulatory_headroom": 0.8754840683333303,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66869020490",
      "drug_name": "LIVALO 2 MG TABLET",
      "ndc": 66869020490,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.084769583333335,
        "feasible_range": [
          8.867815666666667,
          11.818069725000004
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 6.650861750000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.433907833333334,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 33254.30875000001,
          "annual_profit_projection": 399051.70500000013,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.867815666666667,
        "regulatory_headroom": 0.8800042766666625,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66869040490",
      "drug_name": "LIVALO 4 MG TABLET",
      "ndc": 66869040490,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.07842341666667,
        "feasible_range": [
          8.862738733333336,
          11.811303735000003
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 6.647054050000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.431369366666669,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 29911.743225000013,
          "annual_profit_projection": 358940.91870000015,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.862738733333336,
        "regulatory_headroom": 0.8863504433333276,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_66887000105",
      "drug_name": "TESTIM 1% (50 MG) GEL",
      "ndc": 66887000105,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.184543285000002,
        "feasible_range": [
          3.2819947333333346,
          4.373889135000002
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.461496050000001,
        "profit_projections": {
          "gross_profit_per_unit": 1.6409973666666673,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 16409.973666666672,
          "annual_profit_projection": 196919.68400000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.2819947333333346,
        "regulatory_headroom": 7.862280443333329,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67386031321",
      "drug_name": "ONFI 2.5 MG/ML SUSPENSION",
      "ndc": 67386031321,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          10.840670099999997,
          11.964773859999998
        ],
        "expected_margin": 0.32046333093001733,
        "estimated_acquisition_cost": 8.130502574999998,
        "profit_projections": {
          "gross_profit_per_unit": 3.834271285,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28757.034637499997,
          "annual_profit_projection": 345084.41565,
          "margin_percentage": 32.046333093001735
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 10.840670099999997,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $1.59"
        ]
      }
    },
    {
      "drug_id": "ndc_67386031401",
      "drug_name": "ONFI 10 MG TABLET",
      "ndc": 67386031401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 25.944363466666662,
        "feasible_range": [
          25.944363466666662,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 19.458272599999997,
        "profit_projections": {
          "gross_profit_per_unit": 6.486090866666665,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 48645.681499999984,
          "annual_profit_projection": 583748.1779999998,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 25.944363466666662,
        "regulatory_headroom": -13.979589606666664,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $20.47"
        ]
      }
    },
    {
      "drug_id": "ndc_67386031501",
      "drug_name": "ONFI 20 MG TABLET",
      "ndc": 67386031501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 52.02165106666666,
        "feasible_range": [
          52.02165106666666,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 39.01623829999999,
        "profit_projections": {
          "gross_profit_per_unit": 13.005412766666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 97540.59575,
          "annual_profit_projection": 1170487.149,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 52.02165106666666,
        "regulatory_headroom": -40.056877206666655,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $53.06"
        ]
      }
    },
    {
      "drug_id": "ndc_67618010101",
      "drug_name": "COLACE 100 MG CAPSULE",
      "ndc": 67618010101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.31922845499999997,
        "feasible_range": [
          0.2632812,
          0.35087283
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.1974609,
        "profit_projections": {
          "gross_profit_per_unit": 0.1316406,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 658.203,
          "annual_profit_projection": 7898.436,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.2632812,
        "regulatory_headroom": 11.635672359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618010110",
      "drug_name": "COLACE 100 MG CAPSULE",
      "ndc": 67618010110,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.31922845499999997,
        "feasible_range": [
          0.2632812,
          0.35087283
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.1974609,
        "profit_projections": {
          "gross_profit_per_unit": 0.1316406,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 658.203,
          "annual_profit_projection": 7898.436,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.2632812,
        "regulatory_headroom": 11.635672359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618010130",
      "drug_name": "COLACE 100 MG CAPSULE",
      "ndc": 67618010130,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.31922845499999997,
        "feasible_range": [
          0.2632812,
          0.35087283
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.1974609,
        "profit_projections": {
          "gross_profit_per_unit": 0.1316406,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 658.203,
          "annual_profit_projection": 7898.436,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.2632812,
        "regulatory_headroom": 11.635672359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618010152",
      "drug_name": "COLACE 100 MG CAPSULE",
      "ndc": 67618010152,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.31922845499999997,
        "feasible_range": [
          0.2632812,
          0.35087283
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.1974609,
        "profit_projections": {
          "gross_profit_per_unit": 0.1316406,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 658.203,
          "annual_profit_projection": 7898.436,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.2632812,
        "regulatory_headroom": 11.635672359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618010160",
      "drug_name": "COLACE 100 MG CAPSULE",
      "ndc": 67618010160,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.31922845499999997,
        "feasible_range": [
          0.2632812,
          0.35087283
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 0.1974609,
        "profit_projections": {
          "gross_profit_per_unit": 0.1316406,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 658.203,
          "annual_profit_projection": 7898.436,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.2632812,
        "regulatory_headroom": 11.635672359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618011010",
      "drug_name": "COLACE 2-IN-1 TABLET",
      "ndc": 67618011010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.42793506166666667,
        "feasible_range": [
          0.35293613333333335,
          0.47035527000000005
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 0.2647021,
        "profit_projections": {
          "gross_profit_per_unit": 0.1764680666666667,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 794.1063000000001,
          "annual_profit_projection": 9529.2756,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.35293613333333335,
        "regulatory_headroom": 11.523603693333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618011030",
      "drug_name": "COLACE 2-IN-1 TABLET",
      "ndc": 67618011030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.42793506166666667,
        "feasible_range": [
          0.35293613333333335,
          0.47035527000000005
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 0.2647021,
        "profit_projections": {
          "gross_profit_per_unit": 0.1764680666666667,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 794.1063000000001,
          "annual_profit_projection": 9529.2756,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.35293613333333335,
        "regulatory_headroom": 11.523603693333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618011060",
      "drug_name": "COLACE 2-IN-1 TABLET",
      "ndc": 67618011060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.42793506166666667,
        "feasible_range": [
          0.35293613333333335,
          0.47035527000000005
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 0.2647021,
        "profit_projections": {
          "gross_profit_per_unit": 0.1764680666666667,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 794.1063000000001,
          "annual_profit_projection": 9529.2756,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.35293613333333335,
        "regulatory_headroom": 11.523603693333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618015009",
      "drug_name": "BETADINE 10% SOLUTION",
      "ndc": 67618015009,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.014310854999999999,
        "feasible_range": [
          0.011224199999999998,
          0.014958405
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.00841815,
        "profit_projections": {
          "gross_profit_per_unit": 0.0056121,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 56.121,
          "annual_profit_projection": 673.452,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.011224199999999998,
        "regulatory_headroom": 11.950743609999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618030010",
      "drug_name": "SENOKOT 8.6 MG TABLET",
      "ndc": 67618030010,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.26467945833333334,
        "feasible_range": [
          0.2117435666666667,
          0.28218902250000005
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 0.158807675,
        "profit_projections": {
          "gross_profit_per_unit": 0.10587178333333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 794.038375,
          "annual_profit_projection": 9528.4605,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.2117435666666667,
        "regulatory_headroom": 11.700094401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618030020",
      "drug_name": "SENOKOT 8.6 MG TABLET",
      "ndc": 67618030020,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.26467945833333334,
        "feasible_range": [
          0.2117435666666667,
          0.28218902250000005
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 0.158807675,
        "profit_projections": {
          "gross_profit_per_unit": 0.10587178333333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 794.038375,
          "annual_profit_projection": 9528.4605,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.2117435666666667,
        "regulatory_headroom": 11.700094401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618030050",
      "drug_name": "SENOKOT 8.6 MG TABLET",
      "ndc": 67618030050,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.26467945833333334,
        "feasible_range": [
          0.2117435666666667,
          0.28218902250000005
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 0.158807675,
        "profit_projections": {
          "gross_profit_per_unit": 0.10587178333333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 794.038375,
          "annual_profit_projection": 9528.4605,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.2117435666666667,
        "regulatory_headroom": 11.700094401666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618031001",
      "drug_name": "SENOKOT-S TABLET",
      "ndc": 67618031001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.4411701666666667,
        "feasible_range": [
          0.35293613333333335,
          0.47035527000000005
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 0.2647021,
        "profit_projections": {
          "gross_profit_per_unit": 0.1764680666666667,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 1191.1594500000003,
          "annual_profit_projection": 14293.913400000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.35293613333333335,
        "regulatory_headroom": 11.523603693333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618031030",
      "drug_name": "SENOKOT-S TABLET",
      "ndc": 67618031030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.4411701666666667,
        "feasible_range": [
          0.35293613333333335,
          0.47035527000000005
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 0.2647021,
        "profit_projections": {
          "gross_profit_per_unit": 0.1764680666666667,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 1191.1594500000003,
          "annual_profit_projection": 14293.913400000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.35293613333333335,
        "regulatory_headroom": 11.523603693333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_67618031060",
      "drug_name": "SENOKOT-S TABLET",
      "ndc": 67618031060,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.4411701666666667,
        "feasible_range": [
          0.35293613333333335,
          0.47035527000000005
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 0.2647021,
        "profit_projections": {
          "gross_profit_per_unit": 0.1764680666666667,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 1191.1594500000003,
          "annual_profit_projection": 14293.913400000005,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.35293613333333335,
        "regulatory_headroom": 11.523603693333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68012000316",
      "drug_name": "GLUMETZA ER 1,000 MG TABLET",
      "ndc": 68012000316,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 92.82700223333332,
        "feasible_range": [
          92.82700223333332,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 69.62025167499999,
        "profit_projections": {
          "gross_profit_per_unit": 23.206750558333326,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 232067.50558333326,
          "annual_profit_projection": 2784810.066999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 92.82700223333332,
        "regulatory_headroom": -80.86222837333332,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $104.07"
        ]
      }
    },
    {
      "drug_id": "ndc_68012000450",
      "drug_name": "GLUMETZA ER 500 MG TABLET",
      "ndc": 68012000450,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 42.653396066666666,
        "feasible_range": [
          42.653396066666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 31.99004705,
        "profit_projections": {
          "gross_profit_per_unit": 10.663349016666665,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 106633.49016666664,
          "annual_profit_projection": 1279601.8819999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 42.653396066666666,
        "regulatory_headroom": -30.68862220666667,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $41.35"
        ]
      }
    },
    {
      "drug_id": "ndc_68012005430",
      "drug_name": "ZEGERID 40 MG PACKET",
      "ndc": 68012005430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 92.18676133333332,
        "feasible_range": [
          92.18676133333332,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 69.14007099999999,
        "profit_projections": {
          "gross_profit_per_unit": 23.04669033333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 230466.9033333333,
          "annual_profit_projection": 2765602.8399999994,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 92.18676133333332,
        "regulatory_headroom": -80.22198747333333,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $103.27"
        ]
      }
    },
    {
      "drug_id": "ndc_68012010430",
      "drug_name": "ZEGERID 40 MG CAPSULE",
      "ndc": 68012010430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 91.74925933333334,
        "feasible_range": [
          91.74925933333334,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 68.81194450000001,
        "profit_projections": {
          "gross_profit_per_unit": 22.937314833333332,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 229373.14833333332,
          "annual_profit_projection": 2752477.78,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 91.74925933333334,
        "regulatory_headroom": -79.78448547333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $102.72"
        ]
      }
    },
    {
      "drug_id": "ndc_68012030930",
      "drug_name": "UCERIS 9 MG ER TABLET",
      "ndc": 68012030930,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 49.62278750000001,
        "feasible_range": [
          49.62278750000001,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 37.217090625000004,
        "profit_projections": {
          "gross_profit_per_unit": 12.405696875000004,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 124056.96875000004,
          "annual_profit_projection": 1488683.6250000005,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 49.62278750000001,
        "regulatory_headroom": -37.65801364000001,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $50.06"
        ]
      }
    },
    {
      "drug_id": "ndc_68025006530",
      "drug_name": "DIVIGEL 0.25 MG GEL PACKET",
      "ndc": 68025006530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.835435666666665,
        "feasible_range": [
          4.668348533333332,
          6.221472179999999
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 3.5012613999999993,
        "profit_projections": {
          "gross_profit_per_unit": 2.334174266666666,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 17506.306999999997,
          "annual_profit_projection": 210075.68399999995,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.668348533333332,
        "regulatory_headroom": 6.129338193333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68025006630",
      "drug_name": "DIVIGEL 0.5 MG GEL PACKET",
      "ndc": 68025006630,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.8386379999999996,
        "feasible_range": [
          4.6709103999999995,
          6.224886360000001
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 3.5031828,
        "profit_projections": {
          "gross_profit_per_unit": 2.3354551999999997,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 17515.913999999997,
          "annual_profit_projection": 210190.96799999996,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.6709103999999995,
        "regulatory_headroom": 6.126135859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68025006730",
      "drug_name": "DIVIGEL 1 MG GEL PACKET",
      "ndc": 68025006730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.828262916666667,
        "feasible_range": [
          4.662610333333333,
          6.213824925
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.49695775,
        "profit_projections": {
          "gross_profit_per_unit": 2.3313051666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 17484.78875,
          "annual_profit_projection": 209817.465,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.662610333333333,
        "regulatory_headroom": 6.136510943333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68025008330",
      "drug_name": "DIVIGEL 0.75 MG GEL PACKET",
      "ndc": 68025008330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 5.846477541666666,
        "feasible_range": [
          4.677182033333333,
          6.2332445175
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.5078865249999995,
        "profit_projections": {
          "gross_profit_per_unit": 2.338591016666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 17539.432625,
          "annual_profit_projection": 210473.19150000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.677182033333333,
        "regulatory_headroom": 6.118296318333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68025008630",
      "drug_name": "DIVIGEL 1.25 MG GEL PACKET",
      "ndc": 68025008630,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.668796166666667,
        "feasible_range": [
          3.7350369333333333,
          4.9776549900000004
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.8012777,
        "profit_projections": {
          "gross_profit_per_unit": 1.8675184666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 14006.3885,
          "annual_profit_projection": 168076.66199999998,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.7350369333333333,
        "regulatory_headroom": 7.295977693333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68084057201",
      "drug_name": "MUCINEX ER 600 MG TABLET",
      "ndc": 68084057201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.5858820500000002,
        "feasible_range": [
          0.45951533333333344,
          0.6123925500000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.34463650000000007,
        "profit_projections": {
          "gross_profit_per_unit": 0.2297576666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 2297.576666666667,
          "annual_profit_projection": 27570.920000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.45951533333333344,
        "regulatory_headroom": 11.390379693333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68084057211",
      "drug_name": "MUCINEX ER 600 MG TABLET",
      "ndc": 68084057211,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 0.5858820500000002,
        "feasible_range": [
          0.45951533333333344,
          0.6123925500000001
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.34463650000000007,
        "profit_projections": {
          "gross_profit_per_unit": 0.2297576666666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 2297.576666666667,
          "annual_profit_projection": 27570.920000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.45951533333333344,
        "regulatory_headroom": 11.390379693333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68546014256",
      "drug_name": "AZILECT 0.5 MG TABLET",
      "ndc": 68546014256,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 34.74358246666666,
        "feasible_range": [
          34.74358246666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 26.057686849999996,
        "profit_projections": {
          "gross_profit_per_unit": 8.685895616666663,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 86858.95616666663,
          "annual_profit_projection": 1042307.4739999995,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 34.74358246666666,
        "regulatory_headroom": -22.77880860666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $31.46"
        ]
      }
    },
    {
      "drug_id": "ndc_68546022956",
      "drug_name": "AZILECT 1 MG TABLET",
      "ndc": 68546022956,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 34.77048900000001,
        "feasible_range": [
          34.77048900000001,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 26.07786675000001,
        "profit_projections": {
          "gross_profit_per_unit": 8.692622250000003,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 86926.22250000003,
          "annual_profit_projection": 1043114.6700000004,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 34.77048900000001,
        "regulatory_headroom": -22.805715140000014,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $31.50"
        ]
      }
    },
    {
      "drug_id": "ndc_68546031730",
      "drug_name": "COPAXONE 20 MG/ML SYRINGE",
      "ndc": 68546031730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 199.06643683333334,
        "feasible_range": [
          199.06643683333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 149.299827625,
        "profit_projections": {
          "gross_profit_per_unit": 49.766609208333335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 497666.09208333335,
          "annual_profit_projection": 5971993.105,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 199.06643683333334,
        "regulatory_headroom": -187.10166297333333,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $236.87"
        ]
      }
    },
    {
      "drug_id": "ndc_68546032512",
      "drug_name": "COPAXONE 40 MG/ML SYRINGE",
      "ndc": 68546032512,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 427.6198736333333,
        "feasible_range": [
          427.6198736333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 320.714905225,
        "profit_projections": {
          "gross_profit_per_unit": 106.90496840833333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 1069049.6840833332,
          "annual_profit_projection": 12828596.208999999,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 427.6198736333333,
        "regulatory_headroom": -415.65509977333335,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $522.56"
        ]
      }
    },
    {
      "drug_id": "ndc_68791010104",
      "drug_name": "DERMA-SMOOTHE-FS BODY OIL",
      "ndc": 68791010104,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.3271954724999999,
        "feasible_range": [
          0.25662389999999996,
          0.34200069749999995
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 0.19246792499999996,
        "profit_projections": {
          "gross_profit_per_unit": 0.12831194999999998,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 1283.1194999999998,
          "annual_profit_projection": 15397.433999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.25662389999999996,
        "regulatory_headroom": 11.643993984999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68791010204",
      "drug_name": "DERMA-SMOOTHE-FS SCALP OIL",
      "ndc": 68791010204,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.310954735,
        "feasible_range": [
          0.24388606666666665,
          0.32502508499999994
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.18291454999999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.12194303333333331,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 1219.430333333333,
          "annual_profit_projection": 14633.163999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.24388606666666665,
        "regulatory_headroom": 11.659916276666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68791010320",
      "drug_name": "DERMOTIC OIL 0.01% EAR DROPS",
      "ndc": 68791010320,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.4844277175,
        "feasible_range": [
          1.1642570333333333,
          1.5515963924999998
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 0.8731927749999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.5821285166666668,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 5239.156650000001,
          "annual_profit_projection": 62869.87980000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.1642570333333333,
        "regulatory_headroom": 10.50945256833333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68968555201",
      "drug_name": "DAYTRANA 10 MG/9 HR PATCH",
      "ndc": 68968555201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.050413032083336,
        "feasible_range": [
          4.990031366666669,
          6.650176417500003
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 3.7425235250000015,
        "profit_projections": {
          "gross_profit_per_unit": 2.495015683333335,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 12475.078416666674,
          "annual_profit_projection": 149700.9410000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.990031366666669,
        "regulatory_headroom": 5.727234651666661,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68968555203",
      "drug_name": "DAYTRANA 10 MG/9 HR PATCH",
      "ndc": 68968555203,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.050413032083336,
        "feasible_range": [
          4.990031366666669,
          6.650176417500003
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 3.7425235250000015,
        "profit_projections": {
          "gross_profit_per_unit": 2.495015683333335,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 12475.078416666674,
          "annual_profit_projection": 149700.9410000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.990031366666669,
        "regulatory_headroom": 5.727234651666661,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68968555301",
      "drug_name": "DAYTRANA 15 MG/9 HR PATCH",
      "ndc": 68968555301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.046985739166667,
        "feasible_range": [
          4.987204733333333,
          6.646409385000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 3.74040355,
        "profit_projections": {
          "gross_profit_per_unit": 2.493602366666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 12468.011833333334,
          "annual_profit_projection": 149616.142,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.987204733333333,
        "regulatory_headroom": 5.730767943333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68968555303",
      "drug_name": "DAYTRANA 15 MG/9 HR PATCH",
      "ndc": 68968555303,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.046985739166667,
        "feasible_range": [
          4.987204733333333,
          6.646409385000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 3.74040355,
        "profit_projections": {
          "gross_profit_per_unit": 2.493602366666667,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 12468.011833333334,
          "annual_profit_projection": 149616.142,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.987204733333333,
        "regulatory_headroom": 5.730767943333331,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68968555401",
      "drug_name": "DAYTRANA 20 MG/9 HOUR PATCH",
      "ndc": 68968555401,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.046850707083335,
        "feasible_range": [
          4.9870933666666675,
          6.646260967500002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 3.740320025000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.493546683333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 12467.733416666671,
          "annual_profit_projection": 149612.80100000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.9870933666666675,
        "regulatory_headroom": 5.7309071516666625,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68968555403",
      "drug_name": "DAYTRANA 20 MG/9 HOUR PATCH",
      "ndc": 68968555403,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.046850707083335,
        "feasible_range": [
          4.9870933666666675,
          6.646260967500002
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 3.740320025000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.493546683333334,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 12467.733416666671,
          "annual_profit_projection": 149612.80100000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.9870933666666675,
        "regulatory_headroom": 5.7309071516666625,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68968555503",
      "drug_name": "DAYTRANA 30 MG/9 HOUR PATCH",
      "ndc": 68968555503,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.062650511666668,
        "feasible_range": [
          5.000124133333334,
          6.663626970000002
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 3.750093100000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.5000620666666675,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 12500.310333333338,
          "annual_profit_projection": 150003.72400000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.000124133333334,
        "regulatory_headroom": 5.714618693333329,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_68968661001",
      "drug_name": "MINIVELLE 0.1 MG PATCH",
      "ndc": 68968661001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.195421699999994,
        "feasible_range": [
          19.195421699999994,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 14.396566274999996,
        "profit_projections": {
          "gross_profit_per_unit": 4.7988554249999975,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23994.277124999986,
          "annual_profit_projection": 287931.3254999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.195421699999994,
        "regulatory_headroom": -7.230647839999996,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.03"
        ]
      }
    },
    {
      "drug_id": "ndc_68968661008",
      "drug_name": "MINIVELLE 0.1 MG PATCH",
      "ndc": 68968661008,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.195421699999994,
        "feasible_range": [
          19.195421699999994,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 14.396566274999996,
        "profit_projections": {
          "gross_profit_per_unit": 4.7988554249999975,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23994.277124999986,
          "annual_profit_projection": 287931.3254999998,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.195421699999994,
        "regulatory_headroom": -7.230647839999996,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.03"
        ]
      }
    },
    {
      "drug_id": "ndc_68968662501",
      "drug_name": "MINIVELLE 0.025 MG PATCH",
      "ndc": 68968662501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.19486703333333,
        "feasible_range": [
          19.19486703333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 14.396150274999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.798716758333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23993.583791666664,
          "annual_profit_projection": 287923.00549999997,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.19486703333333,
        "regulatory_headroom": -7.230093173333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.03"
        ]
      }
    },
    {
      "drug_id": "ndc_68968662508",
      "drug_name": "MINIVELLE 0.025 MG PATCH",
      "ndc": 68968662508,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.19486703333333,
        "feasible_range": [
          19.19486703333333,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 14.396150274999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.798716758333333,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23993.583791666664,
          "annual_profit_projection": 287923.00549999997,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.19486703333333,
        "regulatory_headroom": -7.230093173333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.03"
        ]
      }
    },
    {
      "drug_id": "ndc_68968663701",
      "drug_name": "MINIVELLE 0.0375 MG PATCH",
      "ndc": 68968663701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.1884836,
        "feasible_range": [
          19.1884836,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 14.3913627,
        "profit_projections": {
          "gross_profit_per_unit": 4.797120900000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23985.604500000005,
          "annual_profit_projection": 287827.2540000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.1884836,
        "regulatory_headroom": -7.223709740000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.02"
        ]
      }
    },
    {
      "drug_id": "ndc_68968663708",
      "drug_name": "MINIVELLE 0.0375 MG PATCH",
      "ndc": 68968663708,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.1884836,
        "feasible_range": [
          19.1884836,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 14.3913627,
        "profit_projections": {
          "gross_profit_per_unit": 4.797120900000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23985.604500000005,
          "annual_profit_projection": 287827.2540000001,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.1884836,
        "regulatory_headroom": -7.223709740000004,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.02"
        ]
      }
    },
    {
      "drug_id": "ndc_68968665001",
      "drug_name": "MINIVELLE 0.05 MG PATCH",
      "ndc": 68968665001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.164656766666663,
        "feasible_range": [
          19.164656766666663,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 14.373492574999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.791164191666665,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23955.820958333326,
          "annual_profit_projection": 287469.85149999993,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.164656766666663,
        "regulatory_headroom": -7.199882906666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.99"
        ]
      }
    },
    {
      "drug_id": "ndc_68968665008",
      "drug_name": "MINIVELLE 0.05 MG PATCH",
      "ndc": 68968665008,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.164656766666663,
        "feasible_range": [
          19.164656766666663,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 14.373492574999998,
        "profit_projections": {
          "gross_profit_per_unit": 4.791164191666665,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 23955.820958333326,
          "annual_profit_projection": 287469.85149999993,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.164656766666663,
        "regulatory_headroom": -7.199882906666666,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.99"
        ]
      }
    },
    {
      "drug_id": "ndc_68968667501",
      "drug_name": "MINIVELLE 0.075 MG PATCH",
      "ndc": 68968667501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.21434753333334,
        "feasible_range": [
          19.21434753333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 14.410760650000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.803586883333335,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 24017.934416666674,
          "annual_profit_projection": 288215.2130000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.21434753333334,
        "regulatory_headroom": -7.249573673333341,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.05"
        ]
      }
    },
    {
      "drug_id": "ndc_68968667508",
      "drug_name": "MINIVELLE 0.075 MG PATCH",
      "ndc": 68968667508,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 19.21434753333334,
        "feasible_range": [
          19.21434753333334,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 14.410760650000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.803586883333335,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 24017.934416666674,
          "annual_profit_projection": 288215.2130000001,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 19.21434753333334,
        "regulatory_headroom": -7.249573673333341,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $12.05"
        ]
      }
    },
    {
      "drug_id": "ndc_69547035302",
      "drug_name": "NARCAN 4 MG NASAL SPRAY",
      "ndc": 69547035302,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 51.63414533333335,
        "feasible_range": [
          51.63414533333335,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 38.72560900000001,
        "profit_projections": {
          "gross_profit_per_unit": 12.908536333333338,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 129085.36333333337,
          "annual_profit_projection": 1549024.3600000003,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 51.63414533333335,
        "regulatory_headroom": -39.66937147333336,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $52.58"
        ]
      }
    },
    {
      "drug_id": "ndc_69547062702",
      "drug_name": "NARCAN 4 MG NASAL SPRAY",
      "ndc": 69547062702,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "OTC"
      },
      "pricing_optimization": {
        "optimal_price": 17.844944433333332,
        "feasible_range": [
          17.844944433333332,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 13.383708324999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.461236108333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 44612.36108333333,
          "annual_profit_projection": 535348.333,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 17.844944433333332,
        "regulatory_headroom": -5.880170573333334,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $10.34"
        ]
      }
    },
    {
      "drug_id": "ndc_69784042012",
      "drug_name": "LOVAZA 1 GM CAPSULE",
      "ndc": 69784042012,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 8.92507395,
        "feasible_range": [
          7.000057999999999,
          9.32892345
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.250043499999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.5000290000000005,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 31500.261000000006,
          "annual_profit_projection": 378003.1320000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.000057999999999,
        "regulatory_headroom": 3.2147013599999976,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69809012605",
      "drug_name": "CLOZARIL 25 MG TABLET",
      "ndc": 69809012605,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.74630125,
        "feasible_range": [
          5.291216666666666,
          7.0515637500000015
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.9684125,
        "profit_projections": {
          "gross_profit_per_unit": 2.645608333333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 26456.083333333332,
          "annual_profit_projection": 317473.0,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.291216666666666,
        "regulatory_headroom": 5.3507530266666645,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_69809012705",
      "drug_name": "CLOZARIL 100 MG TABLET",
      "ndc": 69809012705,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.60840086666667,
        "feasible_range": [
          13.60840086666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 10.206300650000003,
        "profit_projections": {
          "gross_profit_per_unit": 3.4021002166666676,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 34021.00216666667,
          "annual_profit_projection": 408252.02600000007,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.60840086666667,
        "regulatory_headroom": -1.643627006666673,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.05"
        ]
      }
    },
    {
      "drug_id": "ndc_70839015030",
      "drug_name": "TEKTURNA 150 MG TABLET",
      "ndc": 70839015030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          9.637080266666665,
          11.964773859999998
        ],
        "expected_margin": 0.3959091676472354,
        "estimated_acquisition_cost": 7.227810199999999,
        "profit_projections": {
          "gross_profit_per_unit": 4.736963659999999,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 47369.63659999999,
          "annual_profit_projection": 568435.6391999999,
          "margin_percentage": 39.59091676472354
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 9.637080266666665,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $0.08"
        ]
      }
    },
    {
      "drug_id": "ndc_70839030030",
      "drug_name": "TEKTURNA 300 MG TABLET",
      "ndc": 70839030030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.952060466666666,
          11.964773859999998
        ],
        "expected_margin": 0.25079692647028423,
        "estimated_acquisition_cost": 8.96404535,
        "profit_projections": {
          "gross_profit_per_unit": 3.0007285099999983,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 30007.285099999983,
          "annual_profit_projection": 360087.4211999998,
          "margin_percentage": 25.079692647028423
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.952060466666666,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.98"
        ]
      }
    },
    {
      "drug_id": "ndc_70842011002",
      "drug_name": "TOPROL XL 25 MG TABLET",
      "ndc": 70842011002,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.4342683333333333,
        "feasible_range": [
          1.1474146666666665,
          1.5291507
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.8605609999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.5737073333333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 4302.805,
          "annual_profit_projection": 51633.66,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.1474146666666665,
        "regulatory_headroom": 10.530505526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_70842011102",
      "drug_name": "TOPROL XL 50 MG TABLET",
      "ndc": 70842011102,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.4345283333333332,
        "feasible_range": [
          1.1476226666666665,
          1.5294279
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 0.8607169999999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.5738113333333333,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 4303.585,
          "annual_profit_projection": 51643.020000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.1476226666666665,
        "regulatory_headroom": 10.530245526666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_70842011202",
      "drug_name": "TOPROL XL 100 MG TABLET",
      "ndc": 70842011202,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 2.1540133333333342,
        "feasible_range": [
          1.7232106666666673,
          2.2965096000000007
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 1.2924080000000004,
        "profit_projections": {
          "gross_profit_per_unit": 0.8616053333333338,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 6462.040000000004,
          "annual_profit_projection": 77544.48000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.7232106666666673,
        "regulatory_headroom": 9.810760526666662,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_70842011302",
      "drug_name": "TOPROL XL 200 MG TABLET",
      "ndc": 70842011302,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.4286525,
        "feasible_range": [
          2.742922,
          3.65547105
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.0571915,
        "profit_projections": {
          "gross_profit_per_unit": 1.371461,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 10285.9575,
          "annual_profit_projection": 123431.49,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.742922,
        "regulatory_headroom": 8.536121359999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305002530",
      "drug_name": "EUTHYROX 25 MCG TABLET",
      "ndc": 72305002530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.13574914166666668,
        "feasible_range": [
          0.11431506666666669,
          0.15234681000000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.08573630000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.057157533333333344,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 171.47260000000003,
          "annual_profit_projection": 2057.6712,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.11431506666666669,
        "regulatory_headroom": 11.821880026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305002590",
      "drug_name": "EUTHYROX 25 MCG TABLET",
      "ndc": 72305002590,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.13574914166666668,
        "feasible_range": [
          0.11431506666666669,
          0.15234681000000003
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.08573630000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.057157533333333344,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 171.47260000000003,
          "annual_profit_projection": 2057.6712,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.11431506666666669,
        "regulatory_headroom": 11.821880026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305005030",
      "drug_name": "EUTHYROX 50 MCG TABLET",
      "ndc": 72305005030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.14775076875,
        "feasible_range": [
          0.12442170000000001,
          0.16581584250000003
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.093316275,
        "profit_projections": {
          "gross_profit_per_unit": 0.06221085000000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 186.63255000000004,
          "annual_profit_projection": 2239.5906000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.12442170000000001,
        "regulatory_headroom": 11.809246734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305005090",
      "drug_name": "EUTHYROX 50 MCG TABLET",
      "ndc": 72305005090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.14775076875,
        "feasible_range": [
          0.12442170000000001,
          0.16581584250000003
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.093316275,
        "profit_projections": {
          "gross_profit_per_unit": 0.06221085000000001,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 186.63255000000004,
          "annual_profit_projection": 2239.5906000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.12442170000000001,
        "regulatory_headroom": 11.809246734999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305007530",
      "drug_name": "EUTHYROX 75 MCG TABLET",
      "ndc": 72305007530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.15644516875000003,
        "feasible_range": [
          0.13174330000000004,
          0.17557328250000007
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.09880747500000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.06587165000000002,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 197.61495000000005,
          "annual_profit_projection": 2371.3794000000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.13174330000000004,
        "regulatory_headroom": 11.800094734999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305007590",
      "drug_name": "EUTHYROX 75 MCG TABLET",
      "ndc": 72305007590,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.15644516875000003,
        "feasible_range": [
          0.13174330000000004,
          0.17557328250000007
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.09880747500000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.06587165000000002,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 197.61495000000005,
          "annual_profit_projection": 2371.3794000000007,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.13174330000000004,
        "regulatory_headroom": 11.800094734999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305008830",
      "drug_name": "EUTHYROX 88 MCG TABLET",
      "ndc": 72305008830,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.16042083958333334,
        "feasible_range": [
          0.13509123333333334,
          0.18003504750000002
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.101318425,
        "profit_projections": {
          "gross_profit_per_unit": 0.06754561666666668,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 202.63685000000004,
          "annual_profit_projection": 2431.6422000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.13509123333333334,
        "regulatory_headroom": 11.795909818333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305008890",
      "drug_name": "EUTHYROX 88 MCG TABLET",
      "ndc": 72305008890,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.16042083958333334,
        "feasible_range": [
          0.13509123333333334,
          0.18003504750000002
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.101318425,
        "profit_projections": {
          "gross_profit_per_unit": 0.06754561666666668,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 202.63685000000004,
          "annual_profit_projection": 2431.6422000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.13509123333333334,
        "regulatory_headroom": 11.795909818333332,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305010030",
      "drug_name": "EUTHYROX 100 MCG TABLET",
      "ndc": 72305010030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.16160695416666665,
        "feasible_range": [
          0.13609006666666665,
          0.18136618499999999
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 0.10206754999999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.06804503333333334,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 183.72159000000002,
          "annual_profit_projection": 2204.6590800000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.13609006666666665,
        "regulatory_headroom": 11.794661276666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305010090",
      "drug_name": "EUTHYROX 100 MCG TABLET",
      "ndc": 72305010090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.16160695416666665,
        "feasible_range": [
          0.13609006666666665,
          0.18136618499999999
        ],
        "expected_margin": 0.36842105263157904,
        "estimated_acquisition_cost": 0.10206754999999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.06804503333333334,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 183.72159000000002,
          "annual_profit_projection": 2204.6590800000004,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.13609006666666665,
        "regulatory_headroom": 11.794661276666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305011230",
      "drug_name": "EUTHYROX 112 MCG TABLET",
      "ndc": 72305011230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.17967346041666665,
        "feasible_range": [
          0.15130396666666665,
          0.20164163249999997
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.11347797499999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.07565198333333334,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 204.260355,
          "annual_profit_projection": 2451.12426,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.15130396666666665,
        "regulatory_headroom": 11.775643901666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305011290",
      "drug_name": "EUTHYROX 112 MCG TABLET",
      "ndc": 72305011290,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.17967346041666665,
        "feasible_range": [
          0.15130396666666665,
          0.20164163249999997
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.11347797499999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.07565198333333334,
          "estimated_monthly_volume": 2700,
          "monthly_gross_profit": 204.260355,
          "annual_profit_projection": 2451.12426,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.15130396666666665,
        "regulatory_headroom": 11.775643901666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305012530",
      "drug_name": "EUTHYROX 125 MCG TABLET",
      "ndc": 72305012530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.18189182916666669,
        "feasible_range": [
          0.1531720666666667,
          0.20413123500000002
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 0.11487905000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.07658603333333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 229.75810000000004,
          "annual_profit_projection": 2757.0972000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.1531720666666667,
        "regulatory_headroom": 11.773308776666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305012590",
      "drug_name": "EUTHYROX 125 MCG TABLET",
      "ndc": 72305012590,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.18189182916666669,
        "feasible_range": [
          0.1531720666666667,
          0.20413123500000002
        ],
        "expected_margin": 0.36842105263157887,
        "estimated_acquisition_cost": 0.11487905000000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.07658603333333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 229.75810000000004,
          "annual_profit_projection": 2757.0972000000006,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.1531720666666667,
        "regulatory_headroom": 11.773308776666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305013730",
      "drug_name": "EUTHYROX 137 MCG TABLET",
      "ndc": 72305013730,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.18092852916666666,
        "feasible_range": [
          0.15236086666666665,
          0.20305015499999998
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.11427064999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.07618043333333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 228.5413,
          "annual_profit_projection": 2742.4956,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.15236086666666665,
        "regulatory_headroom": 11.774322776666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305013790",
      "drug_name": "EUTHYROX 137 MCG TABLET",
      "ndc": 72305013790,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.18092852916666666,
        "feasible_range": [
          0.15236086666666665,
          0.20305015499999998
        ],
        "expected_margin": 0.368421052631579,
        "estimated_acquisition_cost": 0.11427064999999999,
        "profit_projections": {
          "gross_profit_per_unit": 0.07618043333333334,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 228.5413,
          "annual_profit_projection": 2742.4956,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.15236086666666665,
        "regulatory_headroom": 11.774322776666665,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305015030",
      "drug_name": "EUTHYROX 150 MCG TABLET",
      "ndc": 72305015030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.18831897499999997,
        "feasible_range": [
          0.1585844,
          0.21134421
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.11893829999999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.0792922,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 237.87659999999997,
          "annual_profit_projection": 2854.5191999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.1585844,
        "regulatory_headroom": 11.766543359999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305015090",
      "drug_name": "EUTHYROX 150 MCG TABLET",
      "ndc": 72305015090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.18831897499999997,
        "feasible_range": [
          0.1585844,
          0.21134421
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.11893829999999998,
        "profit_projections": {
          "gross_profit_per_unit": 0.0792922,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 237.87659999999997,
          "annual_profit_projection": 2854.5191999999997,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.1585844,
        "regulatory_headroom": 11.766543359999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305017530",
      "drug_name": "EUTHYROX 175 MCG TABLET",
      "ndc": 72305017530,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.23150383750000006,
        "feasible_range": [
          0.19495060000000006,
          0.25980916500000006
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.14621295000000004,
        "profit_projections": {
          "gross_profit_per_unit": 0.09747530000000004,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 292.4259000000001,
          "annual_profit_projection": 3509.1108000000013,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.19495060000000006,
        "regulatory_headroom": 11.721085609999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305017590",
      "drug_name": "EUTHYROX 175 MCG TABLET",
      "ndc": 72305017590,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.23150383750000006,
        "feasible_range": [
          0.19495060000000006,
          0.25980916500000006
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.14621295000000004,
        "profit_projections": {
          "gross_profit_per_unit": 0.09747530000000004,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 292.4259000000001,
          "annual_profit_projection": 3509.1108000000013,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.19495060000000006,
        "regulatory_headroom": 11.721085609999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305020030",
      "drug_name": "EUTHYROX 200 MCG TABLET",
      "ndc": 72305020030,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.23776065625000004,
        "feasible_range": [
          0.20021950000000002,
          0.2668309875
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.15016462500000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.10010975000000003,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 300.32925000000006,
          "annual_profit_projection": 3603.951000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.20021950000000002,
        "regulatory_headroom": 11.714499484999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72305020090",
      "drug_name": "EUTHYROX 200 MCG TABLET",
      "ndc": 72305020090,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 0.23776065625000004,
        "feasible_range": [
          0.20021950000000002,
          0.2668309875
        ],
        "expected_margin": 0.3684210526315789,
        "estimated_acquisition_cost": 0.15016462500000002,
        "profit_projections": {
          "gross_profit_per_unit": 0.10010975000000003,
          "estimated_monthly_volume": 3000,
          "monthly_gross_profit": 300.32925000000006,
          "annual_profit_projection": 3603.951000000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances aggressive pricing due to intense competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 0.20021950000000002,
        "regulatory_headroom": 11.714499484999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_72989037230",
      "drug_name": "PROMETRIUM 100 MG CAPSULE",
      "ndc": 72989037230,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 13.884834600000003,
        "feasible_range": [
          13.884834600000003,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 10.413625950000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.4712086500000012,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 34712.08650000001,
          "annual_profit_projection": 416545.0380000002,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 13.884834600000003,
        "regulatory_headroom": -1.9200607400000056,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $5.39"
        ]
      }
    },
    {
      "drug_id": "ndc_72989037330",
      "drug_name": "PROMETRIUM 200 MG CAPSULE",
      "ndc": 72989037330,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 26.42482006666667,
        "feasible_range": [
          26.42482006666667,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 19.818615050000002,
        "profit_projections": {
          "gross_profit_per_unit": 6.606205016666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 66062.05016666667,
          "annual_profit_projection": 792744.602,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 26.42482006666667,
        "regulatory_headroom": -14.460046206666672,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $21.07"
        ]
      }
    },
    {
      "drug_id": "ndc_75854060203",
      "drug_name": "BALCOLTRA TABLET",
      "ndc": 75854060203,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.757373900000005,
        "feasible_range": [
          8.437156000000003,
          11.244132900000004
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.327867000000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.218578000000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 42185.78000000002,
          "annual_profit_projection": 506229.3600000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.437156000000003,
        "regulatory_headroom": 1.4183288599999937,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_75854060228",
      "drug_name": "BALCOLTRA TABLET",
      "ndc": 75854060228,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.757373900000005,
        "feasible_range": [
          8.437156000000003,
          11.244132900000004
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 6.327867000000002,
        "profit_projections": {
          "gross_profit_per_unit": 4.218578000000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 42185.78000000002,
          "annual_profit_projection": 506229.3600000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.437156000000003,
        "regulatory_headroom": 1.4183288599999937,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_75987001003",
      "drug_name": "DUEXIS 800-26.6 MG TABLET",
      "ndc": 75987001003,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 22.7474,
        "feasible_range": [
          22.7474,
          11.964773859999998
        ],
        "expected_margin": 0.25,
        "estimated_acquisition_cost": 17.06055,
        "profit_projections": {
          "gross_profit_per_unit": 5.68685,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 56868.5,
          "annual_profit_projection": 682422.0,
          "margin_percentage": 25.0
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 22.7474,
        "regulatory_headroom": -10.782626140000001,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $16.47"
        ]
      }
    },
    {
      "drug_id": "ndc_75987004005",
      "drug_name": "PENNSAID 2% PUMP",
      "ndc": 75987004005,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 18.56581133333334,
        "feasible_range": [
          18.56581133333334,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 13.924358500000004,
        "profit_projections": {
          "gross_profit_per_unit": 4.641452833333336,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 46414.52833333336,
          "annual_profit_projection": 556974.3400000003,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 18.56581133333334,
        "regulatory_headroom": -6.601037473333342,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $11.24"
        ]
      }
    },
    {
      "drug_id": "ndc_78206011801",
      "drug_name": "CELESTONE SOLUSPAN 30 MG/5 ML",
      "ndc": 78206011801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.19756695,
        "feasible_range": [
          7.2137780000000005,
          9.61374645
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.4103335,
        "profit_projections": {
          "gross_profit_per_unit": 3.6068890000000007,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 36068.89000000001,
          "annual_profit_projection": 432826.68000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.2137780000000005,
        "regulatory_headroom": 2.9475513599999967,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206012101",
      "drug_name": "COZAAR 25 MG TABLET",
      "ndc": 78206012101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.4726900000000005,
        "feasible_range": [
          2.7781520000000004,
          3.7024218
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.0836140000000003,
        "profit_projections": {
          "gross_profit_per_unit": 1.3890760000000002,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 10418.070000000002,
          "annual_profit_projection": 125016.84000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.7781520000000004,
        "regulatory_headroom": 8.492083859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206012201",
      "drug_name": "COZAAR 50 MG TABLET",
      "ndc": 78206012201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.657445000000002,
        "feasible_range": [
          3.7259560000000014,
          4.965552900000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.794467000000001,
        "profit_projections": {
          "gross_profit_per_unit": 1.862978000000001,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 13972.335000000006,
          "annual_profit_projection": 167668.02000000008,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.7259560000000014,
        "regulatory_headroom": 7.307328859999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206012202",
      "drug_name": "COZAAR 50 MG TABLET",
      "ndc": 78206012202,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.657445000000002,
        "feasible_range": [
          3.7259560000000014,
          4.965552900000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 2.794467000000001,
        "profit_projections": {
          "gross_profit_per_unit": 1.862978000000001,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 13972.335000000006,
          "annual_profit_projection": 167668.02000000008,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.7259560000000014,
        "regulatory_headroom": 7.307328859999996,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206012301",
      "drug_name": "COZAAR 100 MG TABLET",
      "ndc": 78206012301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.354324166666669,
        "feasible_range": [
          5.083459333333335,
          6.774687150000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.812594500000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.5417296666666678,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 19062.972500000007,
          "annual_profit_projection": 228755.6700000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.083459333333335,
        "regulatory_headroom": 5.6104496933333285,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206012302",
      "drug_name": "COZAAR 100 MG TABLET",
      "ndc": 78206012302,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.354324166666669,
        "feasible_range": [
          5.083459333333335,
          6.774687150000002
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 3.812594500000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.5417296666666678,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 19062.972500000007,
          "annual_profit_projection": 228755.6700000001,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.083459333333335,
        "regulatory_headroom": 5.6104496933333285,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206013501",
      "drug_name": "FOSAMAX 70 MG TABLET",
      "ndc": 78206013501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 31.968152666666672,
        "feasible_range": [
          31.968152666666672,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 23.976114500000005,
        "profit_projections": {
          "gross_profit_per_unit": 7.992038166666667,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 79920.38166666667,
          "annual_profit_projection": 959044.5800000001,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 31.968152666666672,
        "regulatory_headroom": -20.003378806666674,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $28.00"
        ]
      }
    },
    {
      "drug_id": "ndc_78206013901",
      "drug_name": "HYZAAR 50-12.5 TABLET",
      "ndc": 78206013901,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.978081224999999,
        "feasible_range": [
          4.105633999999999,
          5.471546849999999
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 3.0792254999999993,
        "profit_projections": {
          "gross_profit_per_unit": 2.0528169999999997,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 10264.085,
          "annual_profit_projection": 123169.01999999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.105633999999999,
        "regulatory_headroom": 6.832731359999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206013902",
      "drug_name": "HYZAAR 50-12.5 TABLET",
      "ndc": 78206013902,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.978081224999999,
        "feasible_range": [
          4.105633999999999,
          5.471546849999999
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 3.0792254999999993,
        "profit_projections": {
          "gross_profit_per_unit": 2.0528169999999997,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 10264.085,
          "annual_profit_projection": 123169.01999999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.105633999999999,
        "regulatory_headroom": 6.832731359999999,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206014001",
      "drug_name": "HYZAAR 100-12.5 TABLET",
      "ndc": 78206014001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.802622125000002,
        "feasible_range": [
          5.610410000000002,
          7.476950250000002
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 4.207807500000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.805205000000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 14026.025000000005,
          "annual_profit_projection": 168312.30000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.610410000000002,
        "regulatory_headroom": 4.9517613599999954,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206014002",
      "drug_name": "HYZAAR 100-12.5 TABLET",
      "ndc": 78206014002,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.802622125000002,
        "feasible_range": [
          5.610410000000002,
          7.476950250000002
        ],
        "expected_margin": 0.38144329896907214,
        "estimated_acquisition_cost": 4.207807500000001,
        "profit_projections": {
          "gross_profit_per_unit": 2.805205000000001,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 14026.025000000005,
          "annual_profit_projection": 168312.30000000005,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.610410000000002,
        "regulatory_headroom": 4.9517613599999954,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206014101",
      "drug_name": "HYZAAR 100-25 TABLET",
      "ndc": 78206014101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.820013416666667,
        "feasible_range": [
          5.6247533333333335,
          7.496065500000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 4.218565,
        "profit_projections": {
          "gross_profit_per_unit": 2.812376666666667,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 12655.695000000002,
          "annual_profit_projection": 151868.34000000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.6247533333333335,
        "regulatory_headroom": 4.9338321933333305,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206014102",
      "drug_name": "HYZAAR 100-25 TABLET",
      "ndc": 78206014102,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.820013416666667,
        "feasible_range": [
          5.6247533333333335,
          7.496065500000001
        ],
        "expected_margin": 0.3814432989690722,
        "estimated_acquisition_cost": 4.218565,
        "profit_projections": {
          "gross_profit_per_unit": 2.812376666666667,
          "estimated_monthly_volume": 4500,
          "monthly_gross_profit": 12655.695000000002,
          "annual_profit_projection": 151868.34000000003,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.6247533333333335,
        "regulatory_headroom": 4.9338321933333305,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206014201",
      "drug_name": "MAXALT 10 MG TABLET",
      "ndc": 78206014201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 36.793787333333334,
        "feasible_range": [
          36.793787333333334,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 27.595340500000002,
        "profit_projections": {
          "gross_profit_per_unit": 9.198446833333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 68988.35124999999,
          "annual_profit_projection": 827860.2149999999,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 36.793787333333334,
        "regulatory_headroom": -24.829013473333337,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $34.03"
        ]
      }
    },
    {
      "drug_id": "ndc_78206014299",
      "drug_name": "MAXALT 10 MG TABLET",
      "ndc": 78206014299,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 36.793787333333334,
        "feasible_range": [
          36.793787333333334,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 27.595340500000002,
        "profit_projections": {
          "gross_profit_per_unit": 9.198446833333332,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 68988.35124999999,
          "annual_profit_projection": 827860.2149999999,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 36.793787333333334,
        "regulatory_headroom": -24.829013473333337,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $34.03"
        ]
      }
    },
    {
      "drug_id": "ndc_78206014301",
      "drug_name": "MAXALT MLT 10 MG TABLET",
      "ndc": 78206014301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 36.65097799999999,
        "feasible_range": [
          36.65097799999999,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 27.488233499999993,
        "profit_projections": {
          "gross_profit_per_unit": 9.162744499999995,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 68720.58374999996,
          "annual_profit_projection": 824647.0049999995,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 36.65097799999999,
        "regulatory_headroom": -24.68620413999999,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $33.85"
        ]
      }
    },
    {
      "drug_id": "ndc_78206014399",
      "drug_name": "MAXALT MLT 10 MG TABLET",
      "ndc": 78206014399,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 36.65097799999999,
        "feasible_range": [
          36.65097799999999,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 27.488233499999993,
        "profit_projections": {
          "gross_profit_per_unit": 9.162744499999995,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 68720.58374999996,
          "annual_profit_projection": 824647.0049999995,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 36.65097799999999,
        "regulatory_headroom": -24.68620413999999,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $33.85"
        ]
      }
    },
    {
      "drug_id": "ndc_78206014601",
      "drug_name": "NUVARING VAGINAL RING",
      "ndc": 78206014601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 135.28697910000002,
        "feasible_range": [
          135.28697910000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 101.46523432500001,
        "profit_projections": {
          "gross_profit_per_unit": 33.82174477500001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 338217.4477500001,
          "annual_profit_projection": 4058609.3730000015,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 135.28697910000002,
        "regulatory_headroom": -123.32220524000003,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $157.14"
        ]
      }
    },
    {
      "drug_id": "ndc_78206014603",
      "drug_name": "NUVARING VAGINAL RING",
      "ndc": 78206014603,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 135.28697910000002,
        "feasible_range": [
          135.28697910000002,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 101.46523432500001,
        "profit_projections": {
          "gross_profit_per_unit": 33.82174477500001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 338217.4477500001,
          "annual_profit_projection": 4058609.3730000015,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 135.28697910000002,
        "regulatory_headroom": -123.32220524000003,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $157.14"
        ]
      }
    },
    {
      "drug_id": "ndc_78206015201",
      "drug_name": "PROPECIA 1 MG TABLET",
      "ndc": 78206015201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 4.190955600000002,
        "feasible_range": [
          3.287024000000001,
          4.380591600000002
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 2.465268000000001,
        "profit_projections": {
          "gross_profit_per_unit": 1.6435120000000012,
          "estimated_monthly_volume": 9000,
          "monthly_gross_profit": 14791.608000000011,
          "annual_profit_projection": 177499.29600000015,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.287024000000001,
        "regulatory_headroom": 7.855993859999995,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206015202",
      "drug_name": "PROPECIA 1 MG TABLET",
      "ndc": 78206015202,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.7658731499999996,
        "feasible_range": [
          2.9536259999999994,
          3.9362746499999997
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 2.2152194999999995,
        "profit_projections": {
          "gross_profit_per_unit": 1.476813,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 14768.13,
          "annual_profit_projection": 177217.56,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.9536259999999994,
        "regulatory_headroom": 8.272741359999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206015301",
      "drug_name": "PROSCAR 5 MG TABLET",
      "ndc": 78206015301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.0228246,
        "feasible_range": [
          4.723783999999999,
          6.295350599999999
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.5428379999999997,
        "profit_projections": {
          "gross_profit_per_unit": 2.361892,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 23618.920000000002,
          "annual_profit_projection": 283427.04000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.723783999999999,
        "regulatory_headroom": 6.060043859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206015302",
      "drug_name": "PROSCAR 5 MG TABLET",
      "ndc": 78206015302,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.0228246,
        "feasible_range": [
          4.723783999999999,
          6.295350599999999
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 3.5428379999999997,
        "profit_projections": {
          "gross_profit_per_unit": 2.361892,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 23618.920000000002,
          "annual_profit_projection": 283427.04000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 4.723783999999999,
        "regulatory_headroom": 6.060043859999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206016001",
      "drug_name": "REMERON 15 MG TABLET",
      "ndc": 78206016001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.83410455,
        "feasible_range": [
          5.360081999999999,
          7.14334005
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 4.0200615,
        "profit_projections": {
          "gross_profit_per_unit": 2.680041,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 26800.41,
          "annual_profit_projection": 321604.92,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.360081999999999,
        "regulatory_headroom": 5.264671359999998,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206016101",
      "drug_name": "REMERON 30 MG TABLET",
      "ndc": 78206016101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 7.0465629000000005,
        "feasible_range": [
          5.526716,
          7.365411900000002
        ],
        "expected_margin": 0.4117647058823529,
        "estimated_acquisition_cost": 4.145037,
        "profit_projections": {
          "gross_profit_per_unit": 2.763358,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 27633.58,
          "annual_profit_projection": 331602.96,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.526716,
        "regulatory_headroom": 5.056378859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206016801",
      "drug_name": "SINEMET 25-100 MG TABLET",
      "ndc": 78206016801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.4983910500000004,
        "feasible_range": [
          1.1752086666666668,
          1.5661915500000003
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.8814065000000001,
        "profit_projections": {
          "gross_profit_per_unit": 0.5876043333333335,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 5876.043333333335,
          "annual_profit_projection": 70512.52000000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.1752086666666668,
        "regulatory_headroom": 10.495763026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206017201",
      "drug_name": "SINGULAIR 10 MG TABLET",
      "ndc": 78206017201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.552573333333331,
        "feasible_range": [
          7.642058666666665,
          10.184512799999998
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.731543999999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.8210293333333327,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28657.719999999994,
          "annual_profit_projection": 343892.6399999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.642058666666665,
        "regulatory_headroom": 2.412200526666666,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206017202",
      "drug_name": "SINGULAIR 10 MG TABLET",
      "ndc": 78206017202,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.552573333333331,
        "feasible_range": [
          7.642058666666665,
          10.184512799999998
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 5.731543999999999,
        "profit_projections": {
          "gross_profit_per_unit": 3.8210293333333327,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 28657.719999999994,
          "annual_profit_projection": 343892.6399999999,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.642058666666665,
        "regulatory_headroom": 2.412200526666666,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206017301",
      "drug_name": "SINGULAIR 5 MG TABLET CHEW",
      "ndc": 78206017301,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.568520000000001,
        "feasible_range": [
          7.654816,
          10.2015144
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 5.741112,
        "profit_projections": {
          "gross_profit_per_unit": 3.827408000000001,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 25835.004000000008,
          "annual_profit_projection": 310020.04800000007,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.654816,
        "regulatory_headroom": 2.3962538599999963,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206017501",
      "drug_name": "VYTORIN 10-20 MG TABLET",
      "ndc": 78206017501,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.450954666666668,
          11.964773859999998
        ],
        "expected_margin": 0.2600085023391278,
        "estimated_acquisition_cost": 8.588216000000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.3765578599999966,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16882.789299999982,
          "annual_profit_projection": 202593.4715999998,
          "margin_percentage": 28.2208247268954
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.450954666666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.35"
        ]
      }
    },
    {
      "drug_id": "ndc_78206017502",
      "drug_name": "VYTORIN 10-20 MG TABLET",
      "ndc": 78206017502,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.450954666666668,
          11.964773859999998
        ],
        "expected_margin": 0.2600085023391278,
        "estimated_acquisition_cost": 8.588216000000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.3765578599999966,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16882.789299999982,
          "annual_profit_projection": 202593.4715999998,
          "margin_percentage": 28.2208247268954
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.450954666666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.35"
        ]
      }
    },
    {
      "drug_id": "ndc_78206017601",
      "drug_name": "VYTORIN 10-40 MG TABLET",
      "ndc": 78206017601,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.430163333333335,
          11.964773859999998
        ],
        "expected_margin": 0.2613520942351368,
        "estimated_acquisition_cost": 8.572622500000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.392151359999996,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16960.75679999998,
          "annual_profit_projection": 203529.08159999977,
          "margin_percentage": 28.35115314080827
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.430163333333335,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.32"
        ]
      }
    },
    {
      "drug_id": "ndc_78206017602",
      "drug_name": "VYTORIN 10-40 MG TABLET",
      "ndc": 78206017602,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.430163333333335,
          11.964773859999998
        ],
        "expected_margin": 0.2613520942351368,
        "estimated_acquisition_cost": 8.572622500000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.392151359999996,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 16960.75679999998,
          "annual_profit_projection": 203529.08159999977,
          "margin_percentage": 28.35115314080827
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.430163333333335,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.32"
        ]
      }
    },
    {
      "drug_id": "ndc_78206017701",
      "drug_name": "VYTORIN 10-80 MG TABLET",
      "ndc": 78206017701,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.398772666666668,
          11.964773859999998
        ],
        "expected_margin": 0.26338064356708535,
        "estimated_acquisition_cost": 8.549079500000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.4156943599999963,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17078.47179999998,
          "annual_profit_projection": 204941.66159999976,
          "margin_percentage": 28.547922426007283
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.398772666666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.28"
        ]
      }
    },
    {
      "drug_id": "ndc_78206017702",
      "drug_name": "VYTORIN 10-80 MG TABLET",
      "ndc": 78206017702,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.605830644199997,
        "feasible_range": [
          11.398772666666668,
          11.964773859999998
        ],
        "expected_margin": 0.26338064356708535,
        "estimated_acquisition_cost": 8.549079500000001,
        "profit_projections": {
          "gross_profit_per_unit": 3.4156943599999963,
          "estimated_monthly_volume": 5000,
          "monthly_gross_profit": 17078.47179999998,
          "annual_profit_projection": 204941.66159999976,
          "margin_percentage": 28.547922426007283
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "high",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.398772666666668,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.28"
        ]
      }
    },
    {
      "drug_id": "ndc_78206017801",
      "drug_name": "ZETIA 10 MG TABLET",
      "ndc": 78206017801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 11.964773859999998,
        "feasible_range": [
          11.516838666666667,
          11.964773859999998
        ],
        "expected_margin": 0.2780783739777258,
        "estimated_acquisition_cost": 8.637629,
        "profit_projections": {
          "gross_profit_per_unit": 3.327144859999997,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 33271.448599999974,
          "annual_profit_projection": 399257.3831999997,
          "margin_percentage": 27.807837397772577
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 11.516838666666667,
        "regulatory_headroom": 0.0,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $2.43"
        ]
      }
    },
    {
      "drug_id": "ndc_78206018101",
      "drug_name": "ZOCOR 20 MG TABLET",
      "ndc": 78206018101,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.189454166666668,
        "feasible_range": [
          8.151563333333334,
          10.863525750000003
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 6.113672500000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.075781666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30568.362500000003,
          "annual_profit_projection": 366820.35000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.151563333333334,
        "regulatory_headroom": 1.77531969333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206018102",
      "drug_name": "ZOCOR 20 MG TABLET",
      "ndc": 78206018102,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.189454166666668,
        "feasible_range": [
          8.151563333333334,
          10.863525750000003
        ],
        "expected_margin": 0.39999999999999997,
        "estimated_acquisition_cost": 6.113672500000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.075781666666667,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 30568.362500000003,
          "annual_profit_projection": 366820.35000000003,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.151563333333334,
        "regulatory_headroom": 1.77531969333333,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206018201",
      "drug_name": "ZOCOR 40 MG TABLET",
      "ndc": 78206018201,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.099895000000002,
        "feasible_range": [
          8.079916,
          10.768041900000002
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 6.059937000000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.039958000000001,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 27269.71650000001,
          "annual_profit_projection": 327236.5980000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.079916,
        "regulatory_headroom": 1.8648788599999957,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206018202",
      "drug_name": "ZOCOR 40 MG TABLET",
      "ndc": 78206018202,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 10.099895000000002,
        "feasible_range": [
          8.079916,
          10.768041900000002
        ],
        "expected_margin": 0.4000000000000001,
        "estimated_acquisition_cost": 6.059937000000001,
        "profit_projections": {
          "gross_profit_per_unit": 4.039958000000001,
          "estimated_monthly_volume": 6750,
          "monthly_gross_profit": 27269.71650000001,
          "annual_profit_projection": 327236.5980000001,
          "margin_percentage": 40.00000000000001
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 8.079916,
        "regulatory_headroom": 1.8648788599999957,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206018801",
      "drug_name": "CLARINEX 5 MG TABLET",
      "ndc": 78206018801,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.349382900000004,
        "feasible_range": [
          7.3328493333333356,
          9.772431900000003
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.499637000000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.6664246666666678,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 36664.24666666668,
          "annual_profit_projection": 439970.9600000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.3328493333333356,
        "regulatory_headroom": 2.798712193333328,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78206019001",
      "drug_name": "SINEMET 25-100 MG TABLET",
      "ndc": 78206019001,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 1.4983910500000002,
        "feasible_range": [
          1.1752086666666666,
          1.56619155
        ],
        "expected_margin": 0.41176470588235303,
        "estimated_acquisition_cost": 0.8814065,
        "profit_projections": {
          "gross_profit_per_unit": 0.5876043333333334,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 5876.043333333334,
          "annual_profit_projection": 70512.52,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 1.1752086666666666,
        "regulatory_headroom": 10.495763026666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_78670005036",
      "drug_name": "LUCEMYRA 0.18 MG TABLET",
      "ndc": 78670005036,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 20.18536,
        "feasible_range": [
          20.18536,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 15.139019999999999,
        "profit_projections": {
          "gross_profit_per_unit": 5.046340000000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 50463.40000000001,
          "annual_profit_projection": 605560.8,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 20.18536,
        "regulatory_headroom": -8.220586140000002,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $13.27"
        ]
      }
    },
    {
      "drug_id": "ndc_78670005096",
      "drug_name": "LUCEMYRA 0.18 MG TABLET",
      "ndc": 78670005096,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 20.18536,
        "feasible_range": [
          20.18536,
          11.964773859999998
        ],
        "expected_margin": 0.25000000000000006,
        "estimated_acquisition_cost": 15.139019999999999,
        "profit_projections": {
          "gross_profit_per_unit": 5.046340000000001,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 50463.40000000001,
          "annual_profit_projection": 605560.8,
          "margin_percentage": 25.000000000000007
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 20.18536,
        "regulatory_headroom": -8.220586140000002,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $13.27"
        ]
      }
    },
    {
      "drug_id": "ndc_80005015218",
      "drug_name": "E.E.S. 200 MG/5 ML SUSPENSION",
      "ndc": 80005015218,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.983105100000001,
        "feasible_range": [
          3.1240040000000007,
          4.1633361
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.3430030000000004,
        "profit_projections": {
          "gross_profit_per_unit": 1.5620020000000006,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 15620.020000000006,
          "annual_profit_projection": 187440.24000000008,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 3.1240040000000007,
        "regulatory_headroom": 8.059768859999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_80005015518",
      "drug_name": "ERYPED 400 MG/5 ML SUSPENSION",
      "ndc": 80005015518,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 6.832843333333334,
        "feasible_range": [
          5.466274666666667,
          7.284862200000001
        ],
        "expected_margin": 0.4,
        "estimated_acquisition_cost": 4.099706,
        "profit_projections": {
          "gross_profit_per_unit": 2.7331373333333335,
          "estimated_monthly_volume": 7500,
          "monthly_gross_profit": 20498.530000000002,
          "annual_profit_projection": 245982.36000000004,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances balanced pricing considering moderate competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 5.466274666666667,
        "regulatory_headroom": 5.131930526666664,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_82584060430",
      "drug_name": "COSOPT PF EYE DROPS",
      "ndc": 82584060430,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 3.6508277325000003,
        "feasible_range": [
          2.8633943,
          3.8160235575
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 2.147545725,
        "profit_projections": {
          "gross_profit_per_unit": 1.4316971500000002,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 14316.971500000001,
          "annual_profit_projection": 171803.65800000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 2.8633943,
        "regulatory_headroom": 8.385530984999997,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_82584060510",
      "drug_name": "COSOPT EYE DROPS",
      "ndc": 82584060510,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 20.168633333333336,
        "feasible_range": [
          20.168633333333336,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999994,
        "estimated_acquisition_cost": 15.126475000000003,
        "profit_projections": {
          "gross_profit_per_unit": 5.042158333333333,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 50421.58333333333,
          "annual_profit_projection": 605059.0,
          "margin_percentage": 24.999999999999993
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 20.168633333333336,
        "regulatory_headroom": -8.203859473333338,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $13.25"
        ]
      }
    },
    {
      "drug_id": "ndc_82584060930",
      "drug_name": "ZIOPTAN 0.0015% EYE DROP",
      "ndc": 82584060930,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 9.399764270000004,
        "feasible_range": [
          7.372364133333336,
          9.825092970000004
        ],
        "expected_margin": 0.411764705882353,
        "estimated_acquisition_cost": 5.529273100000002,
        "profit_projections": {
          "gross_profit_per_unit": 3.6861820666666683,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 36861.82066666668,
          "annual_profit_projection": 442341.8480000002,
          "margin_percentage": 40.0
        },
        "regulatory_status": "compliant",
        "risk_level": "low",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and full regulatory compliance maintained."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 7.372364133333336,
        "regulatory_headroom": 2.7493186933333273,
        "compliance_issues": []
      }
    },
    {
      "drug_id": "ndc_82667070003",
      "drug_name": "VIGAMOX 0.5% EYE DROPS",
      "ndc": 82667070003,
      "classification": {
        "brand_generic": "Brand",
        "otc_rx": "Prescription"
      },
      "pricing_optimization": {
        "optimal_price": 27.314516666666666,
        "feasible_range": [
          27.314516666666666,
          11.964773859999998
        ],
        "expected_margin": 0.24999999999999997,
        "estimated_acquisition_cost": 20.4858875,
        "profit_projections": {
          "gross_profit_per_unit": 6.828629166666666,
          "estimated_monthly_volume": 10000,
          "monthly_gross_profit": 68286.29166666666,
          "annual_profit_projection": 819435.4999999999,
          "margin_percentage": 24.999999999999996
        },
        "regulatory_status": "requires_adjustment",
        "risk_level": "medium",
        "pricing_rationale": "Optimal price balances premium pricing opportunity with limited competition and pricing adjusted for regulatory constraints."
      },
      "constraint_analysis": {
        "regulatory_ceiling": 11.964773859999998,
        "regulatory_floor": 27.314516666666666,
        "regulatory_headroom": -15.349742806666669,
        "compliance_issues": [
          "Target price exceeds regulatory ceiling by $22.18"
        ]
      }
    }
  ],
  "processing_status": {
    "optimization_success": true,
    "drugs_processed": 1184,
    "compliance_rate": 0.5633445945945946
  }
}